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Abstract 
 
Allelic expression imbalance, or AEI, is the term given to differences in the 
expression levels of the two alleles of a gene. AEI has been previously identified in a 
number of species using various techniques. Here, the genome-wide extent of allelic 
expression imbalance in the pathogenic yeast species, Candida albicans, was 
examined through use of RNA sequencing in combination with a novel computational 
pipeline based around the diploid reference genome. Techniques for validating these 
results were investigated, and the difficulties surrounding specificity and 
quantification are discussed.  
 
As C. albicans is a highly heterozygous species, it was hypothesised that 
polymorphisms within alleles lead to differences in allele expression, which are 
further linked to differences in allele function. The functional consequences of AEI 
were therefore interrogated through investigation of Gene Ontology, identification of 
condition specific responses in AEI, and targeted construction and phenotypic 
screening of heterozygous knockout strains. Together, these results strongly suggest 
that divergence in allele expression is not linked to differences in allele function. 
 
Investigations of the possible control mechanisms behind the differences in allele 
expression were considered, with a focus upon structural factors such as 
chromosomal location, GC content, allele length and codon usage. However, issues 
with establishing causality are present, and difficulties lie in distinguishing between 
functional differences and consequences of bias in sequencing technologies.   
 
This piece of research has advanced the understanding of gene expression 
mechanisms within a medically important pathogen, paving the way for further 
investigations into the functional consequences of allelic expression imbalance in 
Candida albicans.  
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bp  Base pairs 
BSA  Bovine serum albumin 
 
CAI  Codon adaptation index 
cAMP  Cyclic adenosine monophosphate 
CBI  Codon bias index 
cDNA  Complementary DNA 
cells/ml Cells per millilitre  
cfu  Colony forming units 
CGD  Candida genome database 
Ct  Threshold value 
 
dATP  Deoxyadenosine triphosphate 
dCTP  Deoxycytidine triphosphate 
DEPC  Diethylpyrocarbonate  
d.f.  Degrees of freedom 
dGTP  Deoxyguanosine triphosphate 
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DIG  Digoxigenin 
DMR  Differentially methylated region  
DNA  Deoxyribonucleic acid  
dNTP  Deoxyribonucleotide triphosphate 
dN/dS Ratio of substitution rates at non-synonymous vs. synonymous 
sites 
d.p.  Decimal places 
DTT  Dithiothreitol 
dTTP  Deoxythymidine triphosphate 
 
EDTA  Ethylenediaminetetraacetic acid 
et al.  and others 
etc.  Etcetera  
EtOH  Ethanol 
 
FISH  Fluorescence in situ hybridisation  
FUMP  5-fluorouridylic acid 
 
GFP  Green fluorescent protein 
GCB  Measure of codon usage bias 
GO  Gene Ontology 
 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HIV  Human immunodeficiency virus  
HPLC  High performance liquid chromatography  
HRP  Horseradish peroxidase 
 
INCA  Interactive codon usage analysis 
INDEL Insertion or deletion 
IPTG  Isopropyl β-D-1-thiogalactopyranoside 
 
kb  Kilobase 
kDa  Kilodalton 
KO  Knockout 
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LiAc  Lithium acetate 
LB  Luria-Bertani (media) 
LOH  Loss of heterozygosity 
 
M  Molar  
m/s  Metres per second 
MAE  Autosomal monoallelic expression  
MAPK  Mitogen activated protein kinase 
Mb  Megabase 
mg   Milligram 
mg/ml  Milligram per millilitre 
MIC  Minimum inhibitory concentration 
ml  Millilitre 
MLST  Multi-locus sequence typing 
mM  Millimolar 
mm  Millimetre 
MOPS  3-(N-morpholino)propanesulfonic acid 
MTL  Mating-type like locus 
 
NaOH  Sodium hydroxide 
NAT  Nourseothricin 
ng  Nanogram 
ng/µl  Nanogram per microlitre 
nl  Nanolitre 
nm  Nanometre 
nM  Nanomolar 
NMD  Nonsense-mediated decay 
 
OPC  Oral pseudomembranous candidiasis 
ORF  Open reading frame 
OSCC  Oral squamous cell carcinoma 
 
pBS  pBluescript 
PBS  Phosphate buffered saline 
PCR  Polymerase chain reaction  
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PEG  Polyethylene glycol 
PKA  Protein kinase  
pmol/µl Picomoles per microlitre 
pH  Measure of acidity or basicity of a solution 
PVDF  Polyvinylidene fluoride 
 
QconCAT Quantification concatamer 
qPCR  Quantitative real time polymerase chain reaction 
QTL  Quantitative trait loci 
 
RBT  Repressed by TUP1  
RNA  Ribonucleic acid 
RNAi  RNA interference 
RNA-seq RNA sequencing 
RPKM  Reads per kilobase per million mapped reads 
rpm  Revolutions per minute 
RPMI  Roswell Park Memorial Institute Media 
RT PCR Reverse transcription polymerase chain reaction 
 
SAM  Sequence alignment/map 
SAP  Secreted aspartic proteinase  
SC  Synthetic complete media 
SDS  Sodium dodecyl sulphate  
SDS-PAGE Sodium dodecyl sulphate polyacrylamide agarose gel 
electrophoresis 
siRNA  Small interfering ribonucleic acid 
SNP  Single nucleotide polymorphism 
spp.  Species 
SSC  Sodium chloride sodium citrate buffer 
 
TAE  Tris-acetate-EDTA 
tBOOH tert-Butyl hydroperoxide 
TE  Tris-EDTA  
TMM  Trimmed mean of M 
tRNA  Transfer ribonucleic acid 
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U  Units 
U/µl  Units per microlitre 
U.S.  United States of America 
UTR  Untranslated region 
 
VVC  Vulvovaginal candidiasis  
v/cm  volts per centimetre 
v/v  volume to volume ratio 
 
w/v  weight to volume ratio 
 
X-Gal  5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside 
XTT 2,3-Bis(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-
carboxanilide 
 
YE  Yeast extract 
YCB  Yeast carbon base 
YNB  Yeast nitrogen base 
YPD  Yeast extract peptone glucose media  
YPE  Yeast extract peptone ethanol media 
 
µg  Microgram 
µg/ml  Microgram per millilitre 
µl  Microlitre 
µM  Micromolar 
µm  Micrometre 
°C  Degrees Celsius  
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Chapter 1: Introduction 
 
This body of work aims to investigate the functional consequences of allelic 
expression imbalance (AEI) in the pathogenic yeast Candida albicans, 
examining the simple hypothesis that alleles which differ in expression level 
may also differ in function. Here, as an introduction, C. albicans will be 
described alongside its notable pathogenesis related characteristics. 
Heterozygosity and examples of differing allele function in C. albicans will be 
detailed. Allelic expression imbalance will then be overviewed, with examples 
from numerous species including C. albicans. Finally, suggested control 
mechanisms of AEI will be discussed. 
 
1.1 Candida albicans and Related Candida Species – An Overview 
The pathogen Candida albicans is a commensal ascomycetous yeast which 
causes both superficial infections in healthy individuals and life-threatening 
disseminated candidiasis in immune compromised patients (Calderone, 2002b). 
In healthy patients, C. albicans occupies various body cavities including the oral 
cavity, gastrointestinal tract and vaginal cavity (Soll, 2002). In response to 
physiological changes in the host, especially compromise of the immune 
system, C. albicans becomes an opportunistic pathogen which can invade a 
number of human tissues including mucosal tissues and organs. Resultantly, a 
broad spectrum of diseases are associated with Candida infection. At risk 
groups can be identified based on four predisposing factors: natural, dietary, 
mechanical and iatrogenic (Calderone, 2002a). Natural predisposing factors 
include diabetes, microbial infections, pregnancy, infancy, old age and 
lymphocyte defects. Mechanical predisposing factors include physical changes 
to the patient such as trauma, burns, wounds or prosthetic devices. A high 
proportion of infections are within the urinary tract due to the ability of C. 
albicans to form a biofilm upon catheters (Jarvis, 1995). Dietary factors are the 
least well studied predisposing factor but can include excess of food groups, 
such as carbohydrates, or deficiencies in vitamins. Iatrogenic factors are due to 
medical treatment. For example, immunosuppressive treatment given to 
transplant patients increases their risk of Candida infection due to depletion of 
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lymphocyte cells (Calderone, 2002a). As another example, although anti-
microbial drugs prevent bacterial infections, they lead to a drastic change in the 
microbial flora of the gastrointestinal tract allowing Candida species to flourish 
(Jarvis, 1995). Patients often display a combination of these factors, as an 
example, a high incidence of Candida infections are seen in patients with acute 
lymphoid leukaemia (ALL) due to a combination of neutropenia in the patient 
and administration of anti-microbial drugs (Jarvis, 1995). Survival statistics in 
immune compromised individuals are low; even with rapid administration of 
antifungal drugs, hematogenously disseminated candidiasis has a mortality rate 
of 47% (Gudlaugsson et al., 2003).  
 
Candidiasis has emerged as a relatively recent medical condition, with 
increasing prevalence over the last 50 years (Pfaller and Diekema, 2007). This 
has coincided with an increase in the number of AIDS patients (Rex et al., 
1995) and a general increase in life expectancy (Pfaller and Diekema, 2007). 
Although more recent reports suggest that the incidence rates may now be 
declining (Hobson, 2003), this theory is often contested (Pfaller and Diekema, 
2007). As Candida species are able to infect various body cavities within a wide 
range of patients, different types of candidiasis are clinically presented. Oral 
candidiasis is one of the earliest reported Candida infections, with oral 
pseudomembranous candidiasis (OPC) as the most common form (Ruhnke, 
2002). Oesophageal candidiasis tends to be seen in patients with chronic 
disorders and is characterised by ulcers and lesions of the oesophagus 
(Ruhnke, 2002). Vulvovaginal candidiasis (VVC) is estimated to affect 75% of 
all women during their lifetime, with recurrent VVC occurring in a smaller 
population (Ruhnke, 2002). Infections can also be observed upon skin and 
nails, often referred to as cutaneous candidiasis (Ruhnke, 2002). Skin and 
mucosal infections can occur in patients who are either immunocompromised or 
non-immunocompromised. On the other hand, invasive candidiasis is only 
observed in patients with severe defects in the immune system (Ruhnke, 2002). 
Invasive candidiasis is used as a broad term which covers several forms of 
infection, blood stream infections are known as candidemia, hematogenously 
disseminated candidiasis occurs when infection spreads from candidemia to 
one or more organs and can be both acute or chronic, less frequently observed 
is a non-haematogenous infection of a single organ (Kullberg and Filler, 2002).  
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The most common cause of candidiasis is the species Candida albicans, 
although infections have been reported from a total of 17 different Candida 
species including C. parapsilosis, C. tropicalis, C. krusei and the distantly 
related species C. glabrata (Pfaller and Diekema, 2007). Accurately determining 
the current prevalence of Candidiasis is difficult as reports often only detail 
specific infection types or patient groups (Calderone, 2002a). In 1995, Candida 
infections were the sixth most common nosocomial pathogen (Jarvis, 1995), 
with higher occurrences of commonly reported bacterial infections such as 
Escherichia coli and Staphylococcus aureus observed. In the same study, 
Candida species made up 72.1% of all fungal species found, with Candida 
albicans being the most prominent of these species (76% of Candida spp.). By 
1999, this statistic had risen with Candida species identified as the fourth most 
common hospital acquired infection in the U.S. (Edmond et al., 1999), 
overtaking E. coli in its prevalence. Estimations of the cost of nosocomial 
candidiasis just in the U.S. have approached $1 billion per year (Miller et al., 
2001). It should be noted that these infection statistics have all been recorded in 
the U.S. and that rates have been suggested to be lower in other countries, 
especially within Europe (Hobson, 2003). 
 
These factors of high occurrence, high mortality and high cost make 
understanding the fundamental mechanics of C. albicans infections ever more 
important so that new therapeutic methods can be developed.  
 
Several phenotypic characteristics are associated with pathogenesis in Candida 
species and their ability to cause infections. A brief description of these 
characteristics follow. 
 
1.1.1 Morphology 
As a pleomorphic organism, C. albicans can be found in numerous distinct 
morphological forms. In laboratory conditions, growth is most commonly found 
in the unicellular budding yeast (blastospore) form, which readily switches to 
either long hyphae with parallel sides or elongated pseudohyphae which remain 
attached to the mother cell and form chains (Figure 1.1) (Berman, 2006). The 
switch between the yeast and hyphal form is well characterised as a link to 
virulence (Biswas et al., 2007). Interestingly, although the switch between yeast  
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Figure 1.1 Common morphologies of Candida albicans a) yeast cells which form both 
b) pseudohyphal cells and c) hyphal cells. The switch between pseudohyphae and 
hyphae is less frequent. Figure adapted from (Berman, 2006).   
 
and hyphae occurs readily, the transition between hyphal and pseudohyphal 
forms is less common (Berman, 2006). As well as observable morphological 
differences, yeast, pseudohyphae and hyphae differ in other characteristics 
such as cell cycle, gene expression and the mechanism of polarized growth 
(Berman, 2006, Kim and Sudbery, 2011). In addition to these morphological 
forms, under certain nutrient poor growth conditions, C. albicans will also form 
chlamydospores, very large spherical cells with thick cell walls (Figure 1.2). 
These structures are commonly observed in vitro but are rarely observed in vivo 
(Palige et al., 2013). Although the biological purpose of this structure is still 
unknown, characteristics of this morphology include large liquid droplets and 
high amounts of RNA (Staib and Morschhäuser, 2007). Interestingly, this 
phenotypic form is only seen in C. albicans and C. dubliniensis and not 
observed in other Candida species. A recent study using RNA sequencing of C. 
albicans and C. dubliniensis chlamydospores has identified two genes, CSP1 
and CSP2, as potential chlamydospore specific cell wall proteins (Palige et al., 
2013). Taken together, these morphological characteristics demonstrate the 
adaptability of C. albicans to the ever-changing host environment during the 
infection process.  
 
 
  
a) Yeast 
 
  
 
  
b) Pseudohyphal c) Hyphal 
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Figure 1.2. Micrograph of chlamydospores in C. albicans SC5314 cells after 4 days of 
growth at 25 °C on rice Tween-80 agar with the use of coverslips to generate 
microaerophilic conditions. Chlamydospores can clearly be seen as spherical cells at 
the end of filaments. Figure adapted from (Staib and Morschhäuser, 2007). 
 
The rapid switch in phenotypic morphology is often triggered by changes in 
environmental cues, such as carbon source or pH. Changes in these 
environmental signals triggers a rapid switch in the expression of genes, leading 
to alterations in morphology. This process involves a complex network of 
interconnected signalling pathways, all triggered by different environmental 
cues, as demonstrated by Figure 1.3 (Biswas et al., 2007). Two main pathways 
are utilised in C. albicans to trigger morphological changes; the MAPK pathway 
and the cAMP-PKA pathway. The MAPK pathway acts through a cascade of 
protein kinases, CST20, HST7 and CEK1. The final protein kinase, CEK1, then 
activates the transcription factor CPH1, leading to expression of hyphal specific 
genes. Alternatively the cAMP-PKA pathway involves activation of the protein 
kinases TPK1 and TPK2, by cAMP and the gene BCY1. The TPK genes then in 
turn activate the transcription factor EFG1. Interestingly these pathways are not 
exclusive and crosstalk may occur between them. Evidence suggests that both 
of these pathways are also under the control of the “master regulator” gene 
RAS1. As well as activation of hyphal specific genes, under certain conditions 
the gene TUP1 acts as a hyphal repressor, ensuring that cells remain in the 
yeast form. TUP1 is recruited to many genes including the RBT (repressed by 
TUP1) family, HWP1 and WAP1. This recruitment is carried out by NRG1 and 
RFG1 and resultantly leads to the repression of these seven genes. The 
receptors to environmental cues are highly specialised for each condition. For 
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example amino acid sensing is controlled by the gene CSY1, which in turn 
activates the genes GAP1 and GPR1, triggering the cAMP-PKA pathway, 
whereas sensing of ammonium occurs through Mep2 which activates the MAPK 
pathway (Biswas et al., 2007). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3 The complex network of multiple signalling pathways involved in phenotypic 
switching in C. albicans. Figure adapted from Biswas et al., (2007). 
 
1.1.2 White-Opaque Switching and Mating 
A reversible switch from a white to opaque form is an additional phenotypic 
characteristic seen in certain strains of C. albicans on agar at 25 °C, which was 
first observed in the strain WO-1 (Slutsky et al., 1987). When observed as a 
colony, the most common phase is a white, smooth dome. Upon microscopic 
examination these cells appear as normal unicellular yeasts. However after 
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switching to opaque phase the colony appears grey in colour, often flatter and 
the cells themselves are elongated and larger (Figure 1.4) (Slutsky et al., 1987) 
(Kim and Sudbery, 2011). Other differences between the phases include length 
of generation time, sensitivity to temperature, and an inability to form hyphae in 
the opaque phase (Slutsky et al., 1987). 
 
Interestingly mating in C. albicans was first demonstrated both in vivo (Hull et 
al., 2000) and in vitro (Magee and Magee, 2000) using strains that undergo 
white-opaque switching. C. albicans contains a mating-type like (MTL) locus 
which contains orthologues of S. cerevisiae mating genes alongside other 
genes whose functions have diverged. In C. albicans two distinct alleles of MTL 
(a and α) are present in either homozygous or heterozygous combinations, 
reminiscent of a/α strains in S. cerevisiae.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4 Examples of colony and cell morphology in the white-opaque transition from 
strain WO-1. a) Opaque sector (Op) from a white colony (W). b) Differing cell 
morphologies with white phase cells showing the common yeast form whereas opaque 
cells appear elongated. Figures adapted from (Slutsky et al., 1987) and (Zordan et al., 
2007). 
a 
b 
Page | 29  
 
In an examination of 120 clinical isolates, it was found that the heterozygous 
strain is the most frequent at 108, with just 12 homozygous strains: seven MTLa 
and five MTLα (Legrand et al., 2004). Strains homozygous for MTL, such as 
WO-1, undergo white-opaque switching.  
 
It has been elucidated that this switch in appearance is under the control of the 
gene WOR1. In heterozygous strains, the dimer formed by the a1/α2 gene 
products represses the expression of WOR1 preventing the switch to opaque 
phase (Kim and Sudbery, 2011). In homozygous strains this repression is lifted, 
allowing a shift in phenotype to an opaque phase which is concurrent with the 
strain’s ability to mate through a parasexual cycle. Opaque cells of opposite 
mating-type form long conjugation tubes which fuse to form tetraploid cells. 
However unlike a conventional sexual cycle, nuclear fusion does not happen. 
From the bridge formed by the joined conjugation tubes a new daughter cell is 
formed. Again as opposed to conventional meiosis, the two nuclei divide 
asynchronously with one or two nuclei moving to the new daughter cell and one 
or two nuclei returning to the mother cell (Figure 1.5) (Johnson, 2003). This is 
then followed by a process of random chromosome loss to return cells to a 
diploid, or near diploid, state (Bennett and Johnson, 2003). 
 
As this process of concerted chromosome loss is random, formation of genetic 
diversity can still be achieved despite a lack of meiosis. The strains resulting 
from this process can contain chromosomes from either parental strain and are 
often associated with differing levels of aneuploidy. Further genetic diversity is 
also achieved through homologous recombination of the chromosomes during 
the parasexual cycle, under the control of the re-programmed meiosis gene 
SPO11, resulting in gene conversion events (Forche et al., 2008). Although this 
process has been observed under in vivo conditions (Lachke et al., 2003, 
Dumitru et al., 2007), it is a rare event, explaining why Candida albicans is 
found naturally in genetically distinct clades. This is further discussed later in 
section 1.2. 
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Figure 1.5 The model of nuclear dynamics during the parasexual cycle of Candida 
albicans. Vacuoles are light brown, and nuclei are dark brown. B, bud; S, septum; DC, 
daughter cell. Figure adapted from Lockhart et al., (2003). 
 
1.1.3 Resistance to Antifungal Drugs 
Resistance to antifungal drug treatments is commonly reported in Candida 
species, especially with regards to long-term use of azole-based therapeutics 
such as fluconazole (Odds, 1993, Rex et al., 1995). Azoles act as a fungistatic 
drug inhibiting synthesis of an integral constituent of the cell membrane, 
ergosterol. Most azoles act via inhibition of the 14α-demethylase enzyme, 
however some earlier azole derivatives such as ketoconazole have a more 
complex mode of action against various membrane-bound enzymes. The 
subsequent increase in sterol precursors modifies the structure and function of 
the plasma membrane (Ghannoum and Rice, 1999). Resistance to azoles has 
largely been attributed to the activity of efflux transporters, such as the ATP-
binding cassette multidrug transporter genes CDR1 and CDR2, which prevent 
the accumulation of azoles in the cell (Sanglard et al., 1995). Interactions of 
trans modifiers with these genes also further complicate the mechanism of 
antifungal drug resistance. The transcription factor, TAC1, up regulates 
expression of these ABC-transporter genes, with varying levels of efficacy 
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dependent upon the sequence of the TAC1 gene. Azole resistant strains have 
been shown to have a more active variant of TAC1 (Coste et al., 2006). Other 
mechanisms of azole resistance have also been reported including 
modifications of the affinity of 14α-demethylase (White, 1997). Fluconazole 
resistance is most commonly reported in C. albicans with resistance to other 
azole derivatives, such as ketoconazole and itraconazole, more commonly 
reported in related Candida species such as C. glabrata and C. tropicalis (Odds, 
1993, Pfaller and Diekema, 2007).   
 
Antifungal resistance isn’t restricted to azoles; resistance to the fluorinated 
pyrimidine, 5-flucytosine, has also been reported. Upon entrance to the cell, 5-
flucytosine is converted to 5-fluorouracil. From here, 5-fluorouracil can operate 
in two separate manners. 5-fluorouracil is converted to 5-fluorouridylic acid 
(FUMP). FUMP undergoes further phosphorylation and is incorporated within 
RNA resulting in inhibition of macromolecular synthesis (Ghannoum and Rice, 
1999). Alternatively, 5-fluorouracil can also be converted to 5-fluorodeoxyuridine 
monophosphate, which inhibits the biosynthesis of DNA through blocking 
production of thymidine (Vermes et al., 2000). Resistance is attributed to 
mutations in the enzymes of the pyrimidine salvage pathway which convert 5-
flucytosine to FUMP (Hope et al., 2004). Other examples of antifungal 
resistance, such as resistance to both the fungicidal polyene drug, amphotericin 
B, and the echinocandin antifungal drugs, such as caspofungin, are relatively 
rare in C. albicans but decreased susceptibility has been reported in C. glabrata 
and C. krusei for amphotericin B and in C. guilliermondii and C. parapsilosis for 
echinocandins (Pfaller and Diekema, 2007). Treatment with antibiotics has also 
been linked to a significantly increased infection risk, especially in the case of C. 
glabrata infections (Pfaller and Diekema, 2007). This has been attributed to the 
alteration of bowel flora and an increase of Candida growth in intestinal tracts 
(Jarvis, 1995). 
 
1.1.4 Biofilm Formation 
In a clinical setting, both superficial and systemic Candida albicans infections 
can be found in the form of a biofilm. Most commonly these infections are 
associated with chronic in-dwelling devices such as catheters and dentures. 
Mortality rates in patients with catheter-associated candidiasis are higher than 
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that seen for disseminated candidiasis at 41% compared to 34% (Nguyen et al., 
1995).  
 
Biofilm formation occurs in three distinct stages termed early, intermediate, and 
maturation (Chandra et al., 2001). At the early stage, primarily yeast cells and 
some hyphal cells are present which begin binding to the surface and forming 
microcolonies. The intermediate stage is characterised by the increase in 
noncellular material, similar to the polysaccharides found in the cell wall, which 
form a haze-like film over the microcolonies; and the maturation stage sees this 
film developing to encase the C. albicans cells (Chandra et al., 2001, Ramage 
et al., 2001).  
 
Several transcription factors which control formation of biofilms have previously 
been identified; BCR1 and the hyphal regulator TEC1 have been shown to 
genetically interact and influence biofilm formation (Nobile and Mitchell, 2005); 
and the hyphal regulatory gene EFG1 has also been identified as an important 
regulator (Ramage et al., 2002). These studies all underpin the importance of 
the morphological switch to hyphae during the process of biofilm formation. In 
2012, a complete network of regulatory genes responsible for control of biofilm 
formation was identified through transcriptional studies of homozygous 
knockout mutants of transcription factors which are unable to form biofilms 
(Nobile et al., 2012). Six main regulatory genes were identified including BCR1, 
TEC1, EFG1 and the newly identified regulators NDT80, ROB1 and BRG1. 
Together, these transcription factors impact upon the expression of over a 1000 
target genes, with eight core genes being identified us up-regulated by all six 
regulators, including the adhesion gene ALS1 and the hyphal cell wall gene 
HWP1 (Nobile et al., 2012). 
 
Treatment of biofilm infections is often complicated by various factors. For 
example denture stomatitis is a superficial infection attributed to biofilm 
formation on dentures. Even with antifungal treatment, the infection is 
persistence and is often re-established quickly after cessation of treatment 
(Chandra et al., 2001). Although the suggested form of treatment is removal of 
the in-dwelling device, especially in the case of catheters, this option isn’t 
always possible leaving treatment with antifungal therapies the only choice 
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(Chandra et al., 2012). Antifungal resistance of biofilm infections has also been 
identified as problematic (Chandra et al., 2012), with some evidence suggesting 
that resistance levels, particularly to azole based treatments, is significantly 
higher in biofilms when compared to planktonic cells with MICs ranging from 1 
µg/ml in planktonic cells to 128 µg/ml in biofilms (Chandra et al., 2001). The 
mechanisms of resistance change as the biofilm develops, with early phase 
resistance being attributed to efflux pumps, similar to resistance in planktonic 
cells, whereas mature biofilm resistance has been shown to be due to 
reductions in the production of ergosterol intermediates (Mukherjee et al., 
2003). Drug resistance is also not restricted to a single group of antifungal 
drugs; observations of resistance have been seen with exposure to fluconazole 
and related azoles, 5-flucytosine, amphotericin B (Hawser and Douglas, 1995, 
Ramage et al., 2001), nystatin and chlorhexidine (Chandra et al., 2001). 
Research is now being undertaken to investigate the efficacy of drug treatments 
used in combination with each other and with other agents that target proteins 
such as cyclosporine A and FK 506, which target the protein phosphatase, 
calcineurin (Uppuluri et al., 2008, Shinde et al., 2012), and geldanamycin which 
targets the heat shock protein Hsp90 (Robbins et al., 2011). Recently, it has 
been shown that the efficacy of fluconazole against Candida tropicalis is 
increased by addition of flavonoids such as catechin and quercetin (da Silva et 
al., 2013). 
 
1.2 Phylogeny and Clades 
Candida albicans falls into the Ascomycota phylum of the fungal kingdom, and 
then under the sub-phylum Saccharomycotina (otherwise known as the 
hemiascomycetes) (Scannell et al., 2007). The Saccharomycotina can be split 
into three “clusters”; C. albicans forms part of the Candida clade. This consists 
of closely related infective Candida species including C. parapsilosis, C. 
tropicalis and C. guilliermondii (Figure 1.6). A distinctive feature shared by all 
species within the Candida clade is the alternative use of the CUG codon, which 
codes for serine instead of leucine (Butler et al., 2009). However other traits are 
not well conserved within the clade. The level of ploidy varies with some diploid 
organisms: C. albicans, C. dubliniensis, C. tropicalis, C. parapsilosis and 
Lodderomyces elongisporus, and some haploid organisms: C. guilliermondii, C. 
lusitaniae and Debaryomyces hansenii (Butler et al., 2009). The ability to mate 
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Figure 1.6. Phylogenetic relationships among the sequenced fungal genomes. The 
yeast species phylogeny recovered from concatenation analysis of 1,070 genes using 
maximum likelihood. Asterisks denote internodes that received 100% bootstrap support 
by the concatenation analysis. Values near internodes correspond to gene-support 
frequency and internode certainty, respectively. The scale bar is in units of amino-acid 
substitutions per site. Figure adapted from (Salichos and Rokas, 2013). 
 
is also not well conserved; C. albicans is primarily a clonal organism with an 
infrequent parasexual cycle (see section 1.1.2). A similar mating behaviour is 
observed in C. tropicalis (Porman et al., 2011). However L. elongisporus is a 
sexual homothallic organism (Butler et al., 2009). Although C. glabrata has 
historically been named as a Candida species and causes a highly similar 
infection, this species is in fact very distantly related to the other Candida 
species with a genome far more similar to Saccharomyces cerevisiae. 
Interestingly though, unlike S. cerevisiae, C. glabrata is also a clonal organism 
with no known sexual cycle.   
 
Candida 
Clade 
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C. albicans strains are generally grouped into genetically distinct groups 
historically termed clades. Different typing methods have been used for this 
analysis including geographical origins (Odds and Jacobsen, 2008), restriction 
fragment length polymorphism analysis (A, B, C genotypes) (Scherer and 
Stevens, 1987, Xu et al., 1999), the presence of an intron within the ribosomal 
DNA gene ITS1 (McCullough et al., 1999) and MLST (Odds and Jacobsen, 
2008). However the most commonly used criteria for grouping isolates is Ca3 
fingerprinting. Five separate genetically distinct groups have been identified; I, 
II, III (Pujol et al., 1997), SA (Blignaut et al., 2002) and E (Pujol et al., 2002). 
Different typing methods produce results with some similarities of groupings and 
some differences (Odds et al., 2007). Although all genetic groups are equally 
successful as pathogens (Soll, 2002), they have been shown to differ in many 
phenotypic characteristics including growth rate and growth under salt stress 
(MacCallum et al., 2009). These phenotypic differences are elucidated to be 
due to differences in gene sequences. for example a non-synonymous SNP in 
the FUR1 gene confers resistance to 5-flucytosine in clade I (Pujol et al., 2004, 
Odds et al., 2007).  
 
1.3 Genome Architecture 
The full diploid genome sequence for Candida albicans was completed in 2004 
(Jones et al., 2004). Although haploid genome sequencing is commonly carried 
out on many organisms, the diploid genome has only been assembled for a 
handful of organisms, mostly humans (Levy et al., 2007, Wang et al., 2008), 
making C. albicans an important model organism for diploid genetics. 
 
Sequencing of the lab strain SC5314 revealed that the haploid genome is 
14851 kb in length, containing 6419 open reading frames over 100 codons in 
length, distributed across eight chromosomes. A gene density of one ORF 
every 2342 bp is observed. Splicing has been identified in C. albicans and 
therefore 224 genes were identified as containing introns, with most located at 
5’ ends (Braun et al., 2005). Although some variations are observed, these 
results are similar to those identified in other closely related species from the 
Candida group (Butler et al., 2009). 20% of the ORFs identified have no 
counterpart in other genome sequences (Odds et al., 2004). These C. albicans 
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specific genes may be of particular interest during investigation of 
pathogenesis-related characteristics only seen in C. albicans.  
 
Genes which confer similar functions or have similar sequences are grouped 
into gene families. In total 23% of all genes were identified as members of a 
gene family, with 451 families identified computationally (Braun et al., 2005). 
Virulence-associated gene families include the secreted aspartic proteinase 
(SAP) family (Monod et al., 1994), and the agglutinin-like sequence (ALS) family 
which are involved in adhesion to the host surface (Hoyer, 2001).  
 
1.4 Diploid Nature, Heterozygosity and Divergence in Allele Function  
Initially, Candida albicans was thought to be a haploid species (Whelan and 
Magee, 1981). Preliminary studies which suggested that C. albicans is a diploid 
species with heterozygosity used UV exposure and auxotrophic markers to 
identify strains heterozygous for genes which produce amino acids such as 
methionine andcysteine, and genes coding for the nucleobase, adenine. At the 
time it was unclear whether the species was truly diploid or if aneuploidy was 
present (Whelan et al., 1980, Whelan and Magee, 1981).  
 
As mentioned in section 1.3, the full diploid genome sequence for Candida 
albicans was completed in 2004. The results indicated a high level of 
polymorphism at a frequency of one SNP approximately every 237 base pairs. 
This heterozygosity is not distributed evenly across the eight chromosomes, 
with high levels seen on chromosome five and six covering genes such as the 
mating type like-locus and the ALS gene family. Conversely regions of low 
heterozygosity/near homozygosity are also present on chromosome three and 
chromosome seven. These polymorphisms between alleles are not restricted to 
SNPs, with various numbers of tandem repeat sequences also observed (Jones 
et al., 2004). 
 
This level of heterozygosity is much higher than that observed in the most 
closely related species from the Candida clade. Lodderomyces elongisporus 
has a similar rate of polymorphisms with one SNP seen every 222 bp, but C. 
tropicalis has one SNP every 576 bp and C. parapsilosis has the lowest rate 
with one SNP observed every 15,553 bp (Butler et al., 2009). This is also higher 
Page | 37  
 
than the levels of heterozygosity observed in the human genome (Jones et al., 
2004).  
 
Although the wild-type strain SC5314 remains the most widely studied strain of 
C. albicans, investigation of other clinical isolates and strains has shown that a 
high number of different alleles are present for genes. For example, differing 
numbers of microsatellites are found in the promoter regions of elongation 
factor 3 (EF3). Each of these differences were identified as a different allele and 
across 29 reference strains eight alleles were discovered (Bretagne et al., 
1997). 
 
1.4.1 Functional Polymorphisms 
Due to the high levels of heterozygosity reported in C. albicans, SNPs are often 
observed within coding regions of genes. As a consequence of this, there have 
been numerous reports of alleles of a single gene differing in function. This 
concept is a key idea being investigated throughout this work, with the 
suggestion that both proteins produced by an allele, and therefore that 
heterozygosity, is fundamental to phenotypes involved in pathogenicity and 
virulence.  
 
A study using the clinical isolate CA12 found the adenine gene ADE2 has two 
alleles, one functional and one non-functional. The non-functional allele has a 
1.3 kb deletion which spans the promoter and coding region. Homozygosity of 
this non-functional allele results in an auxotrophic strain which can no longer 
produce adenine (Tsang et al., 1999). It is unclear how this clinical isolate, 
obtained from oral infections of HIV patients, relates to the wild-type strain 
SC5314, but demonstrates that variability in allele function occurs in vivo. In 
SC5314, a similar case of functional differences in auxotrophic genes is seen in 
the histidine gene HIS4 where a single SNP renders allele one inactive 
(Gómez-Raja et al., 2008).  
 
A number of genes from the ALS family span a region of high heterozygosity on 
chromosome six. These genes encode cell-wall glycoproteins which are 
involved in adhesion to host cell surfaces (Hoyer, 2001). This family of genes 
has been reported to have variability in the sequences of alleles, especially 
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within repeated regions. ALS9 was discovered to have divergence in allele 
sequences, both within and outside of the repeated regions. The majority of 
these differences lie within the N terminal domain and result in amino acid 
sequences of the two alleles being only 87% identical (Zhao et al., 2003). 
Mutants of ALS9 have shown that only allele two can complement function. This 
suggests that the sequence differences between the alleles leads to differences 
in function (Zhao et al., 2007).     
 
Variability in allele function has been reported in numerous examples relating to 
antifungal drug resistance. TAC1 is the transcription factor responsible for up-
regulation of the ABC-transporter genes CDR1 and CDR2 (Coste et al., 2006). 
These genes act as multi-drug transporters and up-regulation confers 
resistance to azole based antifungals (see section 1.1.3). Investigation of both 
azole resistant and azole susceptible clinical isolates of C. albicans revealed 
that the alleles of TAC1 differ in sequence and function impacting upon the 
resistance status of the isolate. A single amino acid change from asparagine to 
aspartic acid in the C-terminal activation domain creates a hyperactive allele. 
Azole resistant strains occur when this allele is homozygous and the CDR 
genes are therefore constitutively expressed (Coste et al., 2006). Interestingly, it 
has been shown that the CDR genes themselves also have differential allele 
functions. Over-expression of each CDR2 allele separately showed that allele 
two has better pumping efficiency than allele one conferring to differences in 
susceptibility to azoles (Holmes et al., 2006). 
 
A single amino acid mutation in ERG16, encoding the lanosterol 14α-
demethylase, results in a decreased affinity of the enzyme for azoles and 
confers resistance to azole drug treatment. Resistance is associated with “loss 
of allelic variation” with strains homozygous for the mutation demonstrating the 
most resistance (White, 1997). 
 
Similar results have been found with regards to resistance to the antifungal 5-
flucytosine. Homozygous mutations in the pyrimidine salvage pathway enzyme, 
uracil phosphoribosyltransferase, which lead to an arginine residue becoming a 
cysteine residue, have been shown to confer resistance. When this mutation is 
seen in a heterozygous strain, an intermediate phenotype is observed with a 
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reduced susceptibility to 5-flucytosine but not complete resistance (Dodgson et 
al., 2004, Hope et al., 2004). 
 
Three genes are present in the MTL-locus in C. albicans which are not present 
in the mating type locus in S. cerevisiae: a gene for poly(A) polymerase, a gene 
for an oxysterol binding protein, and a gene for phosphoinositol kinase. Due to 
high levels of heterozygosity across the MTL-locus, the amino acid similarity 
between the two alleles of these genes is low with an average of just 60%. 
Therefore different MTL-loci might encode genes with different functions 
(Johnson, 2003), although this observation is currently speculative. 
 
The impact of heterozygosity on the phenotype of C. albicans is apparent from 
the above examples, but conversely homozygosity is also suggested to have 
important functions. Despite the existence of a parasexual cycle, C. albicans is 
primarily a clonal organism; recombination doesn’t occur during meiosis as in 
other sexual species. A potential mechanism to introduce genetic variation in C. 
albicans is mitotic recombination leading to loss of heterozygosity (LOH).  
 
LOH has been shown to readily occur at the GAL1 locus in SC5314 during 
passage through a mouse infection model (Forche et al., 2005) and LOH also 
occurs when cells are exposed to in vitro stress conditions (Forche et al., 2011). 
Genetic variation produced by LOH events may be used as a mechanism to 
adapt to a changing host environment.  Conversely large regions of LOH may 
actually be detrimental to fitness and cause increased doubling times (Abbey et 
al., 2011).  
 
Recent work into C. albicans mating has disproved the long standing idea that 
the species is an obligate diploid. Rare haploid strains have been identified both 
in vitro and in vivo. The exact mechanism under which the haploid cells are 
produced is still unclear; conventional meiosis has been ruled out as 
chromosomes appear to be from one diploid parent with very little crossover. A 
possible suggested mechanism is concerted chromosome loss, similar to that 
seen during the parasexual cycle (Hickman et al., 2013).  
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As haploid strains are produced, this paper initially disproves the theories of 
heterozygosity being essential to function. This finding is surprising, as it has 
been believed that the diploid state of cells may be masking lethal mutations. 
However certain homologue biases were observed suggesting that some alleles 
are favoured over others in the haploid state. Haploid strains also have reduced 
fitness and reduced cell size. Interestingly these phenotypes were also 
observed in homozygous diploid strains which were produced from auto-
diploidisation of haploid cells indicating that not just the diploid state but 
heterozygosity itself is important. Fitness levels were restored when haploid 
strains were mated (through a parasexual cycle) to form heterozygous diploid 
strains (Hickman et al., 2013).  
 
1.5 Differences in Allele Expression 
Following on from the idea that alleles may differ in function is the idea that 
alleles of a single gene may differ in expression levels. This phenomenon can 
include situations where one allele of a gene is not expressed (monoallelic 
expression) or the expression levels of alleles are uneven. Commonly these 
situations are referred to as allelic expression imbalance (AEI). There are a 
small number of examples of AEI in Candida albicans which will be discussed at 
the end of this section. More generally AEI is widely reported in higher 
eukaryotic species which will be the main focus of the section.  
 
1.5.1 Monoallelic Expression, Imprinting and X Chromosome Inactivation 
Monoallelic expression is an area which has been extensively investigated in 
higher eukaryotes. It is observed in a number of forms and is generally 
characterised by one allele in a pair being subjected to silencing.  
 
1.5.1.1 Monoallelic Expression 
Monoallelic expression within autosomal cells is where the paternal allele is 
silenced in some cells, whereas in other cells of the same type, the maternal 
allele is silenced. This is termed autosomal monoallelic expression (MAE) and 
has been observed across a large fraction of cell populations. One of the 
earliest and most widely reported cases of monoallelic expression is seen in the 
olfactory system in humans. Over 1000 genes are present for odorant receptors 
but only a single receptor is expressed per neuron. To achieve this fine-tuned 
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selection of expression, single allele expression and random cis-regulation are 
employed (Chess et al., 1994). A similar system of monoallelic expression is 
also reported in receptors upon the surface of T cells, where again only a single 
receptor is expressed per cell.   
 
Despite these two examples of monoallelic expression being within receptor 
cells, it is a phenomenon that is not restricted to specific cell types. It is also 
seen across a wide range of formal gene categories (ontologies), but notably 
there is an excess of genes which encode cell surface markers and thus 
contribute to unique cellular identities (Chess, 2012).  
 
Monoallelic expression has been seen to have functional consequences 
through haploinsufficiency. In mice, the toll-like receptor 4 gene (Tlr4) is 
expressed from just one allele in lymphocytes. Heterozygous mice have two 
types of lymphocyte cells, ones which express a functional copy and therefore 
respond to lipopolysaccharides, and others which express the non-functional 
copy and are therefore not responsive, causing the mice to be more sensitive to 
infections by Gram-negative bacteria (Pereira et al., 2003).  
 
As well as humans and mice, monoallelic expression has been found in more 
simple eukaryotes species as reviewed by Borst and Chaves (1999). Two 
examples based upon antigenic variation include the var gene in the malarial 
species Plasmodium falciparum and surface glycoproteins in Trypanosoma 
brucei. P. falciparum have around 50 var genes, responsible for antigenic 
variation. To ensure that only one var gene is expressed per cell, a system of 
selective transcription similar to that seen in the olfactory system in humans is 
adopted (Scherf et al., 1998). T. brucei encode a large number of surface 
glycoproteins but again only one is expressed per cell. This is achieved by 
some alleles containing a modified DNA base, beta-D-glucosyl-
hydroxymethyluracil or J, rendering some inactive and others active (van 
Leeuwen et al., 1997).  
 
1.5.1.2 Imprinting 
Parent of origin specific monoallelic expression, also known as imprinting, 
occurs when just one allele is expressed based on the parental origin. Currently 
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there are around 50 genes in the human genome which are classically defined 
as imprinted (Morison et al., 2005). A commonly cited example of imprinting in 
the human genome is the H19/Igf2 locus. The H19/Igf2 locus is made up of two 
genes which are 7 kb apart on chromosome 11p15.5. Each gene is expressed 
from opposite chromosomes. Expression is under control of a region of the H19 
promoter which contains differentially methylated regions (DMRs). H19 is 
expressed from the unmethylated maternal allele. Lack of methylation allows a 
zinc finger protein, CTCF, to bind and suppress expression of Igf2 and activate 
expression of H19. Whereas on the paternal allele, the H19 promoter is 
methylated, causing silencing of H19 and prevention of binding of CTCF leading 
to Igf2 expression (Pidsley et al., 2012) (Figure 1.7).   
 
A more complex example of imprinting in mice is Mest. Here only the paternal 
allele is active, with differential methylation of the promoter CpG island 
rendering the maternal allele silent (Figure 1.8a). Expression of an additional 
longer form of the gene, termed MestXL, has been found in cells of the central 
nervous system. The longer RNA occurs due to alternative polyadenylation. 
Imprinting in these cells is then further complicated by the longer MestXL 
transcript. As well as Mest being only transcribed from the paternal allele,  
 
 
 
 
 
 
 
 
 
 
 
Figure 1.7 A simplified schematic map of the human H19/Igf2 locus on chromosome 
11p15.5, with paternal allele (♂) on the top and maternal allele (♀) on the bottom. 
Expression of H19 is repressed in the paternal allele due to methylation (filled black 
triangles), allowing activation of Igf2. Conversely expression of H19 is active in the 
unmethylated maternal allele, allowing CTCF to bind and repress Igf2.  
IGF2 
IGF2 
H19 
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MestXL overlaps with the RNA of the adjacent antisense gene Copg2 causing 
paternal suppression via transcriptional interference, leaving Copg2 expression 
only from the maternal allele (Figure 1.8b) (MacIsaac et al., 2011).  
 
Imprinting on a genome-wide scale in eukaryotes has been investigated in 
mouse brains using RNA sequencing. In total, divergence in allele expression 
levels was found at 1308 loci, with the expressed allele showing inconsistencies 
across different developmental stages (Gregg et al., 2010). A conclusion from 
this study was that imprinting wasn’t solely due to monoallelic expression and 
that AEI also has a role to play. However, DeVeale et al., (2012) argued that the 
results found by Gregg et al., (2010) were a massive over representation of 
monoallelic expression and they could not be repeated. False positives were  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.8 A simplified schematic map of the mouse Mest locus. a) Shows “normal” 
regulation with paternal allele (♂) on the top being expressed and maternal allele (♀) 
on the bottom being silenced due to methylation (filled black triangles). Copg2 is 
expressed from both alleles. b) Shows expression of the longer MestXL transcript from 
the paternal allele (♂) leading to repression of Copg2. The maternal allele (♀) has Mest 
silenced but Copg2 is expressed.  
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attributed to technical and biological variation as well as systemic errors in the 
sequencing (DeVeale et al., 2012).  
 
Imprinting has also been identified on a genome-wide scale in various plant 
species. RNA sequencing has been used to examine triploid maize endosperm 
to identify genes with at least a fivefold difference between the two paternal 
alleles and single maternal allele. On this basis, a total of 179 genes were 
identified as imprinted (Zhang et al., 2011). However this study only identified 
imprinting in early endosperm and suggested that this was lost after 12 days 
post pollination and therefore cannot be used to determine imprinting levels in 
all cell types and at all life cycle stages.  
 
1.5.1.3 X-chromosome Inactivation 
X-chromosome inactivation is adopted by female mammals to prevent gene 
dosage effects caused by females carrying a second X chromosome. 
Heteropyknosis (condensation) of one X chromosome occurs in female cells, 
resulting in gene inactivation across that chromosome (Lyon, 1961). Therefore 
this mechanism could be seen as large scale monoallelic expression. The 
process of lyonization or silencing renders one X chromosome active and 
condenses the second X chromosome into a transcriptionally silent structure 
known as a Barr body. This silencing is achieved using the non-coding RNA 
XIST which binds to the inactive X chromosome, recruiting the Polycomb 
repressive complex 2 (PRC2) which triggers inactivation (Simon et al., 2013). 
The exact mechanisms of silencing are still unclear but suggestions have been 
made that both DNA methylation and histone deacetylation are involved (Boumil 
and Lee, 2001). In most mammals, the silenced X-chromosome is determined 
randomly in each cell during embryo development, with approximately half of 
cells inactivating the paternal X and the other half inactivating the maternal X. 
This can lead to differential expression of phenotypes across an organism, 
accounting for phenomena such as the coat colour mosaicism seen in 
tortoiseshell cats. 
 
X-chromosome inactivation has been shown to have functional consequences 
on cell phenotype. In women who are heterozygous for the X-linked tumour 
suppressor gene FOXP3, breast cancer arises from cells where the X-
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chromosome containing the functional copy of FOXP3 is inactivated, leaving 
expression of a non-functional allele (Zuo et al., 2007).  
 
1.5.2 Genome-Wide Allelic Expression Imbalance 
AEI is not restricted to imprinted genes or to cases of monoallelic expression. 
There are now a large number of studies showing that both alleles of a gene 
can have significantly different levels of expression. The recent development of 
microarrays and sequencing technologies has allowed for the identification of 
genes with significant AEI on a genome-wide scale.  
 
For example, Lo et al. (2003) used microarray analysis based upon known SNP 
locations to investigate the variability of human allele expression. Here it was 
demonstrated that at least 326 genes in the human genome showed preference 
for the expression of one allele. Similar studies in humans include use of the 
Illumina Allele-specific Expression BeadArray platform which identified that 20% 
of 1380 genes exhibit AEI across 2968 SNPS (Serre et al., 2008), and use of 
the Affymetrix Human Mapping 500 K array set revealed that 2.2% of genes 
have monoallelic expression across multiple SNPs (Gimelbrant et al., 2007). 
Outside of humans, a study using SNP chip arrays with Drosophila simulans, 
found AEI in 37% of the probe sets tested (Yang et al., 2011). 
 
RNA sequencing has also been used to identify genes with AEI on a genome-
wide scale in humans. Using CD4+ T cells, it was found that 4.6% of 
heterozygous SNP-sample pairs have evidence of imbalance in allele 
expression levels, which was validated for four genes using bacterial cloning 
(Heap et al., 2010). Other methods employed to identify genes with AEI in 
humans include use of expression sequence tags (Ge et al., 2005), and use of 
allele-specific serial analysis of gene expression where 25% of human genes 
were identified as having AEI (Vidal et al., 2011). These studies don’t discuss in 
detail the functional consequences of this AEI, but instead focus upon the 
increased complexity of gene expression observed.  
 
Contrary to the above examples in humans, (Yan et al., 2002b) developed an 
RT-PCR based method which could detect a 20% difference in allele 
expression. Although the study only investigated 13 genes, expression levels 
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were assessed across 96 individuals with this RT-PCR method and very little 
AEI was identified. Interestingly, a genome-wide study using chip based 
methods identified only five genes with monoallelic expression and a further 125 
genes with AEI, but did not identify any known imprinted genes (Song et al., 
2011).  
 
It should be noted here that all of these papers identified different percentages 
of genes with AEI. A review by Pastinen et al. (2006) found that correlations 
between different studies of AEI were low, possibly due to differential probe 
location in array-based studies. This demonstrates the lack of consistency in the 
methods used. In most cases, different cell types or cell lines have been used, 
adding a level of uncertainty. There are also inconsistencies in the reference 
genome used across studies. The downstream bioinformatic analysis of 
expression lacks uniformity, with the criteria for a gene with AEI often differing. 
Teare et al. (2011) discusses the discrepancies between different methods 
used to identify AEI, including restriction fragment length polymorphism, RT 
PCR, differential hybridisation to oligo arrays and RNA sequencing. However a 
study by Cheung et al. (2010) looking at the regulation of gene expression 
identified AEI using both microarrays and RNA sequencing and found a 
significant strong positive correlation between the methods (Cheung et al., 
2010). 
 
AEI has also been exploited as an alternative method to quantitative trait loci 
(QTL) in human genetic studies for use in identifying cis-acting polymorphisms 
and regions of regulatory DNA which cause genetic variation (Teare et al., 
2011). This method works on the principle that alleles with expression 
imbalance must differ by at least one regulatory SNP which is in linkage 
disequilibrium. However this method requires knowledge of haplotypes and 
therefore can be prone to phasing errors, especially where regulatory regions 
are far from the transcript. A study by Lefebvre et al. (2012) developed a 
genotype-based method to negate the need for haplotype information in these 
type of studies and improved reliability of results for regulatory regions with 
increasing distances from the transcript (Lefebvre et al., 2012). A general 
comment about using AEI in this way is that the method assumes that the 
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disparity in expression of alleles is solely due to cis-acting polymorphisms and 
that no other elements, such as differences in genome structure, contribute. 
  
Plants have been used as model organisms for genome-wide identification of 
AEI with further discussion upon functional impact. The highly heterozygous 
maize Zea mays showed AEI in 11 of 15 genes analysed using a method which 
combined RT-PCR and denaturing HPLC. This study linked AEI to the 
functional response to abiotic stresses such as drought and density (Guo et al., 
2004). Similar results have been seen in the tomato species Solanum 
peruvianum and Solanum chilense where AEI was suggested to have a role in 
adaptation to abiotic stress (Mboup et al., 2012). Other higher eukaryotic 
species where allelic expression imbalance has been identified include the 
identification of AEI in two species of pig using RNA sequencing (Esteve-
Codina et al., 2011) and in a wild population of yellow baboons (Tung et al., 
2011). 
 
Allelic expression imbalance in constructed diploid hybrid strains has been used 
with numerous species for various purposes. In yeast, detection of AEI by RNA 
sequencing of a hybrid of Saccharomyces cerevisiae and Saccharomyces 
bayanus was used to identify genes whose expression was favoured in each of 
the parental species (Bullard et al., 2010b). Whereas a study by Tirosh et al. 
(2009) used a hybrid of S. cerevisiae and S. paradoxus to identify the 
contribution of cis and trans regulatory factors on genes. Cis factors can be 
identified using AEI, whereas trans factors are identified by comparing the level 
of AEI in a diploid hybrid to the ratio of gene expression between parental 
strains. Similar work has also been carried out in S. cerevisiae strains BY4716 
and RM11-1a, with AEI identified through pyrosequencing (Sung et al., 2009), 
and in Drosophila using hybrid strains of D. melanogaster and D. simulans 
(Wittkopp et al., 2004, Main et al., 2009). The use of a constructed “super-
hybrid” of rice species demonstrated that levels of AEI can significantly change 
between developmental stages, in this case tillering and heading (Zhai et al., 
2013). 
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1.6 Mechanisms of Control of AEI 
The exact regulatory mechanisms behind allelic expression imbalance are yet 
to be fully determined and it is unknown if it is controlled by a single mechanism 
or combination of several. Many different factors have been suggested to play a 
role including CpG methylation patterns, heterochromatin blocks, distances to 
enhancers, and replication asynchrony (reviewed by Ohlsson et al. (1998)). 
Differences in promoter sequences, inter-chromosomal interactions, and post-
translational histone modifications may also play a role. There are suggestions 
from some groups that epigenetic mechanisms are the most influential factors 
(Pastinen and Hudson, 2004), but this is still speculative. Examples of the 
contributions of some of these factors are discussed below.  
 
1.6.1 Regulation of AEI via Methylation 
Methylation of DNA is an epigenetic marker generally associated with gene 
silencing. Repression is achieved through association of methylated DNA at 
CpG dinucleotides with methyl-CpG-binding proteins. In humans, these proteins 
are known as MBD1-4 and MeCP2. These proteins further recruit other 
enzymes, such as histone deacetylases, which leads to modification of the 
chromatin structure and therefore silencing of the gene (Newell-Price et al., 
2000). Methylation is commonly associated with imprinting as a mechanism of 
silencing just one allele. All but one imprinted gene in humans has been shown 
to exhibit allele-specific methylation (Brannan and Bartolomei, 1999). 
 
For example in the case of the H19/Igf2 locus in mice (discussed in section 
1.5.1.2), the lack of methylation on the H19 maternal allele causes the DNA to 
bind to the transcriptional repressor CTCF. This changes the three-dimensional 
arrangement of the DNA preventing enhancers accessing Igf2 and ensuring 
only H19 is expressed (Hou and Corces, 2011).  
 
Lister et al. (2008) studied the relationship between the genome-wide 
methylome (methyl-seq) and transcriptome (RNA-seq) in Arabidopsis thaliana 
showing that methylation was associated with altered transcript abundance of 
hundreds of genes. However, a smaller scale study of methylation in maize 
found that not all imprinted genes have methylation differences (Zhang et al., 
2011). Little information is available on genome-wide levels of allele-specific 
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methylation patterns due to difficulties in using standard bisulphite sequencing 
methods. As methylcytosines occur at higher frequencies than SNPs, it is often 
difficult to identify which allele is associated with the methylation pattern using 
conventional next generation sequencing techniques. Due to the fragmentation 
used in library preparation, reads which contain methylcytosines may not 
contain a SNP and therefore cannot be assigned to a specific allele.  
 
1.6.2 Regulation of AEI via Promoter Region Differences   
As promoters are directly linked to gene expression levels, it can be speculated 
that differences in promoter regions of alleles may cause differential allele 
expression. Definitions of exact promoter regions are often unclear, especially 
within non-human species. Therefore the role of SNPs in upstream regions 
adjacent to genes with AEI has often been investigated.  
 
On a genome-wide level, Gagneur et al. (2009) found a significant positive 
correlation between the polymorphism density in the promoter region and the 
level of AEI observed. However, these polymorphisms are yet to be determined 
as the sole cis-acting factor contributing to AEI.   
 
On a single gene basis, a study on the human RPTOR gene showed that a 
SNP in the upstream region of one allele was associated with people originating 
from cooler climates. The SNP (T to C) affected the binding ability of the 
transcription factor POU2F1 and therefore lead to a decrease in expression of 
the RPTOR allele (Sun et al., 2010).  
 
1.6.3 Regulation of AEI via Other Mechanisms 
As well as DNA methylation and promoter differences, other mechanisms have 
been suggested to play a role in the control of allele-specific expression. In 
cases of imprinting, a possible role for inter-chromosomal interactions has been 
put forward. Imprinted loci are overrepresented in regions of chromosomal 
interactions, and X-chromosomes interact through an unknown mechanism 
during X-chromosome inactivation (Gartler and Goldman, 2005). Positioning of 
the DNA within the cell itself may also impact upon expression levels. It has 
been shown that in S. cerevisiae regions of heterochromatic DNA, especially 
telomeric regions, are tethered to the nuclear envelope leading to transcriptional 
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silencing (Andrulis et al., 1998). Although this mechanism has not been linked 
to allelic expression imbalance, it is sensible to infer that if alleles differ in their 
perinuclear tethering, the expression levels may also differ.  
 
Evidence has been gathered which suggests that chromatin structure and 
therefore gene expression rates do differ between homologous chromosomes in 
the same cell (Gaur et al., 2013). How these chromatin differences are achieved 
is yet to be fully determined, but this could link back to differences in DNA 
methylation patterns as mentioned in section 1.6.1. 
   
Fluorescent in situ hybridisation analysis was used with the monoallelic odorant 
receptor genes (see section 1.5.1.1) to show that the active and inactive alleles 
replicate asynchronously; a trend commonly reported in imprinting and X 
chromosome inactivation (Chess et al., 1994). Although asynchronous 
replication has been shown to occur in every case of human monoallelic 
expression, there is no actual link between whether an allele is replicated early 
or late and whether is it expressed or not (Gimelbrant et al., 2007) and there is 
yet to be an explanation of how asynchronous replication controls the 
expression levels of alleles directly.  
 
These examples demonstrate the complexity of the control mechanisms behind 
AEI and how there is still a long way to go before this phenomenon is clearly 
understood.  
 
1.7 AEI and Disease 
AEI has been implicated as a causative factor in various human diseases, most 
significantly cancer. For example loss of imprinting at the H19/Igf2 locus 
resulting in biallelic expression has been seen in many cancer types (Feinberg, 
1993), and a complete switch in monoallelic expression at this locus has been 
observed in oral squamous cell carcinoma (OSCC) (Tuch et al., 2010a). In 
addition, the OSCC tissues demonstrated that genes with AEI were enriched for 
cancer related functions and were associated with copy number mutations, 
implying a role for allelic expression imbalance in cancer aetiology (Tuch et al., 
2010a). A study using TaqMan qPCR showed that AEI levels of BRCA1 were 
significantly increased in lymphocytes from familial breast cancer patients when 
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compared to cancer free patients, but the exact mechanisms and contributions 
to disease phenotypes are yet to be determined (Chen et al., 2008). SNP chips 
have been used to monitor AEI in colorectal cancer cells. Differences in the 
patterns of expression were also observed between cancer cells and non-
cancerous B cells suggesting colorectal cancer-specific AEI occurs (Lee et al., 
2013). Examples in non-cancer related diseases include (not exclusively) 
reduction in the expression of one allele of the APC gene which has been linked 
to familial adenomatous polyposis (Yan et al., 2002a). 
 
Imprinting associated congenital disorders in humans such as Prader-Willi, 
Angelman, Beckwith-Wiedemann and Silver-Russell syndromes are caused by 
both genetic mutations and epigenetic alterations, which contribute to changes 
in the methylation status of either the imprinted gene or the control region. Each 
syndrome is associated with unique phenotypes dependent upon the imprinted 
gene affected. For example, Silver-Russell syndrome causes postnatal growth 
retardation due to loss of methylation at the H19/Igf2 locus, and subsequent 
loss of Igf2 expression. Conversely, postnatal overgrowth is observed in 
Beckwith-Wiedemann syndrome due to hypermethylation at the H19/Igf2 locus 
which leads to increased expression of Igf2 (Girardot et al. 2013). Prader-Willi 
and Angelman syndromes are both associated with loss of imprinting at 
chromosome 15. Prader-Willi is due to maternal uniparental disomy (both 
copies of the chromosome are from the mother) whereas Angelman syndrome 
is due to loss of maternal expression. This implies that both maternal and 
paternal copies of chromosome 15 are required for normal development in 
humans (Girardot et al., 2013).  
 
1.8 AEI and Candida albicans  
Although AEI has been identified in some Saccharomyces yeast species 
hybrids (see section 1.5.2), investigations on a genome-wide scale in Candida 
albicans are still in their rudimentary stages. Muzzey et al. (2013) demonstrated 
the advantages of using a phased diploid genome reference whilst investigating 
AEI on a genome-wide scale using existing RNA sequencing data, but did not 
look into the functional consequences of the AEI discovered. In a follow up 
study, the level of AEI at both the transcriptional and translational level in C. 
albicans was assessed. Again, very little functional inference was made to 
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explain the levels of allelic expression imbalance, although an over-
representation of genes with mitochondrial functions was observed (Muzzey et 
al., 2014). However some examples of the functional impact of allelic 
expression imbalance in C. albicans have been seen on a gene-by-gene basis. 
 
Staib et al. (2002) identified differences in promoter regions of the SAP2 alleles 
resulting in differential regulation in expression of the two alleles. In the case of 
the drug-resistance gene MDR1, it has been found that the promoters of the 
alleles differ in DNA sequence conferring to a difference in expression level 
(Bruzual and Kumamoto, 2011). A similar study into the chitin synthesis gene 
CHS7 found that although the alleles themselves did not differ in sequence, the 
promoter regions differed in length. This directly impacted upon the allele 
expression levels. A heterozygous knockout containing just the allele with the 
shorter promoter had similar characteristics to the wild-type whereas a knockout 
strain with only the allele with the long promoter remaining suffered from 
reduced chitin and moderate morphological differences during hyphal growth 
(Sanz et al., 2007). 
 
As previously described in section 1.4.1, evidence has been gathered showing 
that the alleles of a gene can differ in function, for example the ADE2 gene has 
a functional and non-functional allele (Tsang et al., 1999), and phenotypic 
differences in the knockout of the ALS9 gene can only be complemented by 
allele two (Zhao et al., 2007). During the sequencing of the C. albicans diploid 
genome, SNPs were identified in 3579 ORFs, just over approximately half of all 
genes. In 78% of these genes, the SNPs lead to an alteration in predicted 
protein sequence (Jones et al., 2004). This suggests that differences in function 
may occur at a high rate across the genome. Although differences in allele 
function have not yet been linked to differences in the expression levels, it 
would be logical to suggest that this may be the case.  
 
The above examples have shown that SNPs within promoter regions are 
leading to AEI. However, the epigenetic control factors mentioned in section 1.6 
may also be impacting upon AEI in C. albicans. The genome-wide extent of 
DNA methylation, and the subsequent impact upon expression, has been 
identified in C. albicans. Unlike other fungal species, where DNA methylation 
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occurs at the highest frequency over repeat sequences, in C. albicans 
methylation is centred on 150 genes with an over representation of genes 
involved in environmentally cued pathways such as the switch to hyphae and 
drug resistance. It was shown that methylation levels are fluid and vary 
significantly between the yeast and hyphal form, and that this methylation is 
directly causing transcriptional repression in a set of these genes (Mishra et al., 
2011).  
 
1.9 Aims and Objectives 
The body of work presented here aims to investigate the functional 
consequences of allelic expression imbalance in Candida albicans. Due to the 
high levels of heterozygosity identified during genome sequencing, it is sensible 
to infer that both coding regions and regulatory regions of alleles may differ in 
sequence. Dependent upon the extent of these polymorphisms, alleles of a 
single gene may therefore be divergent in virulence-related functions. A striking 
example of this can be seen when observing the 149 genes with the Gene 
Ontology (GO) term “pathogenesis”. 48.3% of these genes contain non-
synonymous substitutions, in comparison to just 23.1% seen across all genes. 
As function plays a role in determining gene expression levels, genes with 
differing allele function may also experience a difference in allele expression.  
 
As mentioned above, to date, there has been little evidence of genome-wide 
allelic expression imbalance in C. albicans, although examples have been 
demonstrated on a gene-by-gene basis. Here RNA sequencing has been used 
to identify the extent of AEI in wild-type C. albicans grown under common 
laboratory conditions. Unlike previous studies which use SNP identification with 
RNA sequencing to investigate AEI, here the availability of the diploid reference 
genome enabled reads to be aligned directly to each allele in a novel manner.  
 
From the subsequent list of genes with significant AEI, the functional and 
phenotypic consequences of differing allele expression levels were investigated. 
The contribution of each allele to pathogenesis-related phenotypes, such as 
morphology and antifungal drug resistance, was tested by comparing 
constructed heterozygous knockout strains where only one allele remains. 
Using genes within this list, attempts were made to verify the AEI using various 
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methods including allele-specific qPCR and western blotting. Due to 
complications in the methods surrounding the issue of allele-specificity, this was 
unfortunately not achieved, but has presented an opportunity to discuss the 
difficulties presented whilst studying allele-specific expression. 
 
Structural factors, such as chromosomal location, GC content, gene length and 
codon usage, have previously been shown to impact upon gene expression 
levels. However, the role of these structural factors in control of AEI is yet to be 
investigated. Therefore, in this study, the contribution of each factor to allele-
specific expression levels was explored.  
 
Finally, the method of computational analysis used to identify AEI was critically 
assessed and therefore modified to identify genes with allele-specific 
expression from existing RNA sequencing data which is publically available. 
This enabled a consideration of AEI in a condition specific manner. The 
functional consequences of which were again investigated through the use of 
heterozygous knockout strains.   
 
1.9.1 Aims and Objectives Summarised 
The main research objectives which are investigated in this piece of work are as 
follows: 
 Identification of AEI in the wild-type strain of Candida albicans, SC5314, 
using RNA sequencing.  
 Analysis of the impact of structural factors upon levels of AEI. 
 Development of an alternative method to identify and verify AEI. 
 Construction and phenotypic screening of heterozygous knockout 
mutants to assess the functional consequence of AEI.  
 Development of a computational pipeline to allow for condition-specific 
identification of significant AEI using RNA sequencing data. 
 Further construction and phenotypic screening of heterozygous knockout 
mutants to assess the functional consequences of condition-specific AEI. 
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Chapter 2: General Materials and 
Methods 
 
2.1 Strains Used 
Strains used in this study are listed in Table 2.1 and Table 2.2. All strains were 
stored in 50% (v/v) glycerol at -80 °C. Strains were streaked onto appropriate 
solid media (see section 2.3) and stored at 4 °C for no longer than one month.   
 
2.2 Plasmids Used 
Plasmids used in this study are listed in Table 2.3.  
 
2.3 Growth Conditions 
Yeast strains were grown in YPD media (2% (w/v) Bacto-peptone, 2% (w/v) 
glucose, 1% (w/v) yeast extract) unless otherwise stated. When grown on solid 
media, 2% (w/v) agar was added. For nourseothricin selection, Sabouraud 
dextrose agar (Melford laboratories) was used (65 mg/ml) with nourseothricin 
(Werner Bioagents) at 100 µg/ml, filter sterilised using a 0.2 µm filter disc 
(Sartorius Stedim). Media were autoclaved at 121 °C for 15 minutes. All strains 
were grown at 30 °C unless otherwise stated. 90 mm diameter sterile plastic 
Petri dishes (triple-vented) (Sterilin) were used as standard. 
 
Escherichia coli strains were grown in LB (Luria-Bertani) media (1% (w/v) bacto-
tryptone, 0.5% (w/v) yeast extract, 1% (w/v) sodium chloride, pH 7.5). When 
grown on solid media 2% (w/v) agar was added. For selection of ampicillin 
resistant strains, ampicillin (Sigma Aldrich) was added to the media at 100 
μg/ml, filter sterilised using a 0.2 µm filter disc (Sartorius Stedim). Media were 
autoclaved at 121 °C for 15 minutes. All strains were grown at 37 °C unless 
otherwise stated. 90 mm diameter sterile plastic Petri dishes (triple-vented) 
(Sterilin) were used as standard. 
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Table 2.1 Yeast strains used in this study 
Strain Name Species Genotype Source 
SC5314 C. albicans Ura
+
 ancestor of CAI4 Gillum et al., 
1984 
SC3 C. albicans SC5314 rbt4-1::NAT1 RBT4-2 This Study 
SC4 C. albicans SC5314 RBT4-1 rbt4-2::NAT1 This Study 
SC5 C. albicans SC5314 RBT4-1 rbt4-2::NAT1 This Study 
SC6 C. albicans SC5314 vps1-1::NAT1 VPS1-2 This Study 
SC7 C. albicans SC5314 VPS1-1 vps1-2::NAT1 This Study 
SC8 C. albicans SC5314 CDC6-1 cdc6-2::NAT1 This Study 
SC9 C. albicans SC5314 cdc6-1::NAT1 CDC6-2 This Study 
SC10 C. albicans SC5314 cdc6-1::NAT1 CDC6-2 This Study 
SC12 C. albicans SC5314 RPS1-1 rps1-2::CIp10-NAT1 This Study 
SC13 C. albicans SC5314 VPS1-1::V5-6xHis-NAT1 VPS1-2 This Study 
SC14 C. albicans SC5314 VPS1-1::V5-6xHis-NAT1 VPS1-2 This Study 
SC16 C. albicans SC5314 vps1-1::NAT1 VPS1-2 This Study 
SC17 C. albicans SC5314 vps1-1::NAT1 VPS1-2 This Study 
SC18  C. albicans SC5314 VPS1-1 vps1-2::NAT1 This Study 
SC27 C. albicans SC5314 VPS1-1 VPS1-2-V5-6xHis-NAT1 This Study 
SC28 C. albicans SC5314 VPS1-1 VPS1-2-V5-6xHis-NAT1 This Study 
SC30 C. albicans SC5314 SMI1-1 smi1-2::NAT1 This Study 
SC32 C. albicans SC5314 VPS1-1 vps1-2::NAT1 This Study 
SC33 C. albicans SC5314 smi1-1::NAT1 SMI1-2 This Study 
SC34 C. albicans SC5314 rck2-1::NAT1 RCK2-2 This Study 
SC35 C. albicans SC5314 CDC6-1-V5-6xHis-NAT1 CDC6-2 This Study 
SC36 C. albicans SC5314 CDC6-1-V5-6xHis-NAT1 CDC6-2 This Study 
SC41 C. albicans SC5314 CDC6-1 CDC6-2-V5-6xHis-NAT1 This Study 
SC42 C. albicans SC5314 erb1-1::NAT1 ERB1-2 This Study 
SC44 C. albicans SC5314 rck2-1::NAT1 RCK2-2 This Study 
SC45 C. albicans SC5314 rck2-1::NAT1 RCK2-2 This Study 
SC46 C. albicans SC5314 erb1-1::NAT1 ERB1-2 This Study 
SC47 C. albicans SC5314 ERB1-1 erb1-2::NAT1 This Study 
SC48 C. albicans SC5314 ERB1-1 erb1-2::NAT1 This Study 
SC49 C. albicans SC5314 erb1-1::NAT1 ERB1-2 This Study 
SC51 C. albicans SC5314 rck2-1::NAT1 RCK2-2 This Study 
SC52 C. albicans SC5314 rck2-1::NAT1 RCK2-2 This Study 
SC53 C. albicans SC5314 rck2-1::NAT1 RCK2-2 This Study 
SC54 C. albicans SC5314 rck2-1::NAT1 RCK2-2 This Study 
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SC55 C. albicans SC5314 rck2-1::NAT1 RCK2-2 This Study 
SC56 C. albicans SC5314 ERB1-1 erb1-2::NAT1 This Study 
SC61 C. albicans SC5314 CDC6-1 CDC6-2-V5-6xHis-NAT1 This Study 
SC62 C. albicans SC5314 CDC6-1 CDC6-2-V5-6xHis-NAT1 This Study 
SC66 C. albicans SC5314 ADH2-1 adh2-2::NAT1 This Study  
SC67 C. albicans SC5314 ADH2-1 adh2-2::NAT1 This Study  
SC68 C. albicans SC5314 ADH2-1 adh2-2::NAT1 This Study 
SC69 C. albicans SC5314 adh2-1::NAT1 ADH2-2 This Study 
SC70 C. albicans SC5314 rps7a-1::NAT1 RPS7A-2 This Study 
SC71 C. albicans SC5314 orf19.5648-1 orf19.5648-2::NAT1 This Study 
SC72 C. albicans SC5314 orf19.5648-1 orf19.5648-2::NAT1 This Study 
SC73 C. albicans SC5314 orf19.5648-1 orf19.5648-2::NAT1 This Study 
SC74 C. albicans SC5314 gpx1-1::NAT1 GPX1-2  This Study 
SC75 C. albicans SC5314 gpx1-1::NAT1 GPX1-2 This Study 
SC76 C. albicans SC5314 gpx1-1::NAT1 GPX1-2 This Study 
SC81 C. albicans SC5314 GPX1-1 gpx1-2::NAT1  This Study 
SC85 C. albicans SC5314 orf19.5648-1 orf19.5648-2::NAT1 This Study 
SC86 C. albicans SC5314 orf19.5648-1 orf19.5648-2::NAT1 This Study 
SC87 C. albicans SC5314 orf19.5648-1 orf19.5648-2::NAT1 This Study 
SC88 C. albicans SC5314 orf19.5648-1 orf19.5648-2::NAT1 This Study  
SC90 C. albicans SC5314 adh2-1::NAT1 ADH2-2 This Study 
SC92 C. albicans SC5314 adh2-1::NAT1 ADH2-2 This Study 
SC93 C. albicans SC5314 rps7a-1::NAT1 RPS7A-2 This Study 
SC94 C. albicans SC5314 rps7a-1::NAT1 RPS7A-2 This Study 
SC96 C. albicans SC5314 rps7a-1::NAT1 RPS7A-2 This Study 
SC97 C. albicans SC5314 rps7a-1::NAT1 RPS7A-2 This Study 
SC98 C. albicans SC5314 rps7aA-1::NAT1 RPS7A-2 This Study 
SC99 C. albicans SC5314 orf19.5648-1 orf19.5648-2::NAT1 This Study 
SC100 C. albicans SC5314 orf19.5648-1 orf19.5648-2::NAT1 This Study 
SC101 C. albicans SC5314 orf19.5648-1 orf19.5648-2::NAT1 This Study 
SC102 C. albicans SC5314 orf19.5648-1 orf19.5648-2::NAT1 This Study 
SC107 C. albicans SC5314 GPX1-1 gpx1-2::NAT1 This Study  
SC108 C. albicans SC5314 GPX1-1 gpx1-2::NAT1 This Study  
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Table 2.2 Escherichia coli strains used in this study  
Strain Name Genotype Source 
DH5α F- Φ80lacZΔM15 Δ(lacZYA-argF) 
U169 recA1 endA1 hsdR17 (rK-
,mK+) phoA supE44 λ- thi-1 
gyrA96 relA1 
Lab Stock 
DH5α (pJK795) NAT1 cassette pBS  Shen et al., 2005 
DH5α (CIp10-
NAT1) 
CIp10 + AgTEF1p-CaNAT1-
AgTEF1t  
Bates, S., Personal 
Communication 
topo(SB168) V5-6xHis-NAT1 cassette  Milne et al., 2011 
 
Table 2.3 Plasmids used in this study  
Plasmid Description  Source 
pJK795 NAT1 cassette pBS  Shen et al., 2005 
CIp10-NAT1 CIp10 + AgTEF1p-CaNAT1-
AGTEF1t  
Bates, S., Personal 
Communication 
SB168 V5-6xHis-NAT1 cassette  Milne et al., 2011 
pGEM-T  Promega 
 
2.4 Purification of Plasmid DNA from E. coli   
A single colony of E. coli was inoculated in 5 ml of LB medium in a 30 ml 
universal tube (Greiner Bio-One) with ampicillin and grown overnight at 37 °C, 
180 rpm. Plasmids were then extracted using either an NBS Biologicals mini 
prep kit, a Promega plasmid mini prep kit or an Omega EZNA plasmid mini prep 
kit, as per manufacturer’s instructions. Plasmids were resuspended in 1 x TE 
buffer (10 mM Tris-HCl pH 7.5, 1 mM EDTA pH 8.0), separated by gel 
electrophoresis (see section 2.5) to check the size and purity of constructs, and 
stored at -20 °C until use. DNA concentrations were subsequently measured 
using a NanoDrop Spectrophotometer.  
 
2.5 DNA Gel Electrophoresis 
Gel electrophoresis was carried out using 1% (w/v) agarose in TAE buffer (40 
mM Tris, 20 mM acetic acid, 1 mM EDTA, pH 8.0) containing 15 nl/ml ethidium 
bromide. For loading, samples were diluted in a 5:1 ratio in DNA loading buffer 
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(0.25% (w/v) bromophenol blue, 0.25% (w/v) xylene cyanol, 30% (v/v) glycerol). 
Results were visualised using a G:Box system (SynGene) set with a UV filter for 
use with ethidium bromide. 
 
2.6 Gel Extraction  
Extraction and purification of DNA fragments from an agarose gel was carried 
out using either an NBS DNA purification spin column kit or a Qiagen QIAquick 
gel extraction kit following the manufacturer’s instructions.  
 
2.7 Polymerase Chain Reaction 
Polymerase chain reactions (PCR) were set up as follows: 1 x Thermostart PCR 
mastermix (0.625 U ThermoPrime Taq DNA polymerase, 75 mM Tris-HCl (pH 
8.8 at 25 °C), 20 mM ammonium sulphate, 1.5 mM magnesium chloride, 0.01% 
(v/v) Tween® 20, 0.2 mM each of dATP, dCTP, dGTP and dTTP; Thermo 
scientific), 10 µM forward primer, 10 µM reverse primer and 1 µl of template 
DNA.  
 
Thermal cycling conditions were as follows: 
 Initial denaturation:  94 °C for 3 minutes 
 Denaturation: 94 °C for 1 minute 
 Annealing:  52 °C for 1 minute    30 cycles 
 Extension:  72 °C for 1 minute per 1 kb amplified 
 Final Extension: 72 °C for 10 minutes 
 Hold:   4 °C 
 
2.8 Cloning 
2.8.1 PCR Amplification of Gene 
The desired gene for cloning was amplified using polymerase chain reaction as 
described in section 2.7. For a full list of oligonucleotides (Invitrogen) used to 
amplify the genes of interest see Table 2.4. The correct band was isolated using 
gel extraction as described in section 2.6 and quantified using a NanoDrop 
Spectrophotometer.  
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Table 2.4 Oligonucleotides used to amplify genes of interest for cloning 
 Name Sequence 5’ – 3’ Position
1
 Strain Sequenced 
RCK2-F AGCTTTTATTCGACATGGGAAG 18 – 39  SC5314 
RCK2-R GCTGCTTTGAATAGGAATCTGTT 1746 – 1767  SC5314 
RPS7A-F CCAAGGATCAAGCTTCATC -26 – -8  SC5314 
RPS7A-R CAAATTCTCTTCTGACGGATG 598 – 618  SC5314 
5648-F GTATGATAAACAGTGGTAATGG -2 – 22  SC5314 
5648-R CATATCTGCTTCATTTGCC 640 – 658  SC5314 
1. Relative to A bp of ATG codon = 1. Negative numbers represent primers 
placed before the gene start position.  
 
2.8.2 Ligation 
DNA fragments were ligated into the pGEM-T vector (Promega); a linear vector 
that allows for easy insertion of Taq-polymerase amplified PCR products with 
no prior enzymatic digest. The plasmid backbone allows for two levels of 
selection based on both ampicillin resistance and use of the lacZ operon 
(successful colonies are white). Ligation reactions were set up as follows: 5 µl of 
2x Rapid Ligation Buffer (Promega), 1 µl of pGEM-T vector, 1 µl of T4 DNA 
ligase, an appropriate volume of gel extracted PCR product (see below), or for 
the positive control 2 µl of control DNA, or for the negative control 2 µl of sterile 
water. The volume was then made up to 10 µl using sterile water and incubated 
overnight at 4 °C.  
 
Appropriate volumes of PCR fragment were calculated as follows: 
 
ng of insert= 
ng of vector ×size of insert (kb)
size of vector (kb)
 ×insert:vector molar ratio 
 
In all cases, the insert:vector molar ratio was always 3:1.  
 
2.8.3 Preparation of Competent E. coli Cells 
E. coli cells competent for transformation were prepared as follows with all 
centrifugations carried out at 4 °C. A single colony of the appropriate E. coli 
strain was grown overnight in 5 ml of LB at 37 °C, 180 rpm. The culture was 
diluted 1:20 in 100 ml of pre-warmed LB and grown at 37 °C, 180 rpm, until the 
optical density at 550 nm reached 0.48. The culture was then chilled on ice for 
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five minutes, split into two 50 ml falcon tubes and pelleted at 4000 rpm for five 
minutes. Each pellet was resuspended in 20 ml of ice cold TfbI solution (30 mM 
potassium acetate, 100 mM potassium chloride, 10 mM calcium chloride, 50 
mM manganese chloride, 15% glycerol, pH 5.8). Cell suspensions were cooled 
on ice for five minutes and then pelleted at 4000 rpm for five minutes. Each 
pellet was resuspended in 2 ml of ice-cold TfbII solution (10 mM MOPS, 75 mM 
calcium chloride, 10 mM potassium chloride, 15% glycerol, pH 6.5) and left to 
cool on ice for 15 minutes. Cells were then stored in 100 µl aliquots at -80 °C.  
 
2.8.4 Transformation of E. coli Cells 
The protocol for transformation of plasmid DNA into E. coli cells was taken from 
the manufacturer’s instructions for the pGEM-T vector. 2 µl of ligation reactions 
were combined with 50 µl of competent E. coli cells, flicked to mix, and 
incubated on ice for 20 minutes. The cells were then heat shocked at 42 °C for 
45 seconds followed by two minutes on ice. 950 µl of SOC media (2 % (w/v) 
tryptone, 0.5% (w/v) yeast extract, 10 mM sodium chloride, 10 mM potassium 
chloride, 40 mM magnesium solution (1 M magnesium sulphate heptahydrate, 
1.7 M magnesium sulphate), 20 mM glucose) was added and the cells were left 
to incubate at 37 °C, 180 rpm, for 1.5 hours. 100 µl was then taken and plated 
onto LB agar plates containing 100 µg/ml ampicillin, 0.1 mM IPTG and 40 µg/ml 
X-Gal. Plates were incubated at 37 °C overnight. 
 
Transformation efficiencies of the competent cells were calculated using the 
control DNA supplied with the vector as a positive control and the following 
calculation: 
 
Transformation efficiency= 
cfu on control plate
ng of vector used
 × final dilution plated 
 
2.8.5 Screening Successful Transformants 
Colonies which had the ability to grow on the selective media showed 
successful transformation of the plasmid due to the resistance to ampicillin. 
Colonies which were white also showed a further level of selection 
demonstrating that the lacZ operon has been interrupted, and therefore the 
insert DNA has been successful ligated into the plasmid. These successful 
Page | 62  
 
colonies were checked using colony PCR with the same oligonucleotides used 
for initial gene amplification (see section 2.7 and section 2.11). Plasmids were 
extracted as described in section 2.4 and stored at -20 °C.  
 
2.9 Construction of DNA Cassettes for Transformation  
DNA cassettes for transformation into C. albicans were constructed using PCR 
as described in section 2.7 with a modification of the annealing temperature to 
55 °C. 1 µl of Plasmid DNA (200 ng/µl) containing an appropriate cassette (see 
Table 2.3) was used as the DNA template. Oligonucleotides (Invitrogen) were 
designed containing 60 bp – 100 bp of target gene sequence and 18 bp – 20 bp 
of cassette (Figure 2.1). For a full list of oligonucleotides and template plasmid 
DNA combinations used see Table 2.5. Reactions were checked using DNA gel 
electrophoresis (see section 2.5). This was followed by precipitation as follows: 
four separate PCR reactions per cassette were combined and added to 15 µl of 
3M sodium acetate and 450 µl of 100% ethanol and frozen at -20 °C for 30 
minutes. DNA was pelleted at 13,000 rpm for 15 minutes, washed in 70% 
ethanol, pelleted at 13,000 rpm for three minutes and resuspended in 10 µl of 
sterile water. Cassettes were stored at -20 °C until required for Candida 
albicans transformations (see section 2.10).  
 
 
 
Figure 2.1 Construction of DNA cassette for transformation into Candida albicans. 
Each primer contains 60 – 100 bp of DNA corresponding to the gene of interest and 18 
– 20 bp of DNA corresponding to the cassette.  
CASSETTE 
Plasmid Template 
18-20bp  
60-100bp 
of target 
gene 
18-20bp  60-100bp 
of target 
gene 
Forward 
 Primer 
Reverse 
Primer  
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Table 2.5 Oligonucleotides used to construct DNA cassettes  
Name Sequence1 5’ – 3’ Position2 Plasmid 
Template 
CDC6-KO-F GGTCCACCAGGGACGGGTAAGACTGCTCAAGTTCAATTAATCCTACAACCTT
ATCAACAGAATTCAAGAATACGGCGGGATATCAAGCTTGC 
375 – 448 pJK795 
CDC6-KO-R CCCGATATCTTGAAACCATATTCCGCGGGTACTTTTTTGGTATTGTTTTGAAA
GTCACCGTGGGTACCGAATTCGAGC 
1545 – 1604  pJK795 
ERB1-KO-F CAGTGATGATGATGATGATGACGATGATGATGACGATGACAACAACTCAGAA
GCAGATTCTGGCGGGATATCAAGCTTGC 
219 – 280  pJK795 
ERB1-KO-R TATTCATCTATGTAGTCCAAAGACGAGCAGTTCCATCAGCACCAGCACTAAAT
AACCAAGGTGGGTACCGAATTCGAGC 
2497 – 2557  pJK795 
RBT4-KO-F CGCCTATGTCACCCAGACTCGTGGTGTTACTGTTGGTGAAACTGCCACCGTT
GCTACAACTGTTACCGGCGGGATATCAAGCTTGC 
63 – 130  pJK795 
RBT4-KO-R GCCATATAAGATTTACCAGTCTTTGGATCAGTACCCATAACGTTACCAGCTG
GGTCGTAGGAACAAACAACGTGGGTACCGAATTCGAGC 
982 – 1053 pJK795 
RCK2-KO-F CGACATGGGAAGCAAGCCAATGATATGAAAAGAAAGCAACAACAGCAGCCA
CAGCAATATCAACAACCGCGGGATATCAAGCTTGC 
28 – 95  pJK795 
RCK2-KO-R GATGTCTATGACGATGAGTTCTTAGGACTTGGTTGTAGGTATCCTGTACAACT
CTGCCATCCTGGGTACCGAATTCGAGC 
1605 – 1666  pJK795 
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SMI1-KO-F GACGATAATGAACCAATTGGTACCAATTCTCATAGGTCATCAACTAATGACTC
AGCATTACCGCGGGATATCAAGCTTGC 
88 – 149  pJK795 
SMI1-KO-R GCGTATCCACTTTGTCATGGTCTTGTAGATGATTTTGAAAACCAGCCACTAGT
CTCGTTGCTGGGTACCGAATTCGAGC 
1959 – 2019  pJK795 
VPS1-KO-F GGCTCCTTTAGGTGGAGGGTCATCCTCGCCAGTAGATTTGCCTCAAATCACT
GTTGTTGGATCCCGCGGGATATCAAGCTTGC 
48 – 112  pJK795 
VPS1-KO-R CTTCGGTTTCCATAGTTTCTCTTTCACTCATAGTACCTGTGGCTCTCAATACT
GGAGGTGGGGCTGGGTACCGAATTCGAGC 
1762 – 1825 pJK795 
CDC6-V5-F TTGATATAGTGAAAAGTGTTGAAAATATTGGAATCTTGAAAAAAATTTTACAAA
AACCAAATAAGGGCGAGCTTCGAGGTCA 
1384 – 1445  SB168 
CDC6-NAT1-R CCTACTATCTATCTATCTCTGTCTATCTATTTGTCTGTCTATTTACTTGTATCAT
TAATCGTTAGTATCGAATCGACAG 
1452 – 1510  SB168 
VPS1-V5-F AAGGAATGTGTTAGAATGGTTGAGGTGTTGAGAAATGCTAGTGAAATTGTTT
CTAGTGTTAAGGGCGAGCTTCGAGGTCA 
2020 – 2079  SB168 
VPS1-NAT1-R AAGAAGATAAATATATACCACCGACTTTCTGAAATAAAAAGAATTACTCTACT
CTATAATACGTTAGTATCGAATCGACAG 
2086 – 2146  SB168 
ADH2-KO-F CTATAATCACGAATCAATTGATACTTACCCACTTTTTATTAAATCTAACTCAAT
TACACCATGTCTGTCGCGGGATATCAAGCTTGC 
-60 – 9  pJK795 
ADH2-KO-R CACTCATTATTATCGTACTTGGCATGAATGCGCTTATTTGTCGTTGTCCAAGA
CATATCTATGGGTACCGAATTCGAGC 
1020 – 1080  pJK795 
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RPS7A-KO-F GGAATAGTCAACCAACAGCAAATAGCCAAGGATCAAGCTTCATCATTAATCAT
GTCCTCTAAGATCGCGGGATATCAAGCTTGC 
-51 – 15  pJK795 
RPS7A-KO-R GACGGATGATGAAATGGAAAGGTTATTTTTGGGGGGATGTTAATCTAATGAG
ATTCACCTGGTGGGTACCGAATTCGAGC 
544 – 605  pJK795 
5648-KO-F GAATCTGAATAATCTAATAATTCTTCTTGACCTTCGTGAGACATGATTGGTTG
TATGTTTGTATGATAAACAGGCGGGATATCAAGCTTGC 
-62 – 11  pJK795 
5648-KO-R GGATTAAGAAGTGCTATTGCTAGAGGTGTTGAAGAGGCTGCTAACATATCTG
CTTCATTTGCCTGGGTACCGAATTCGAGC 
640 – 702  pJK795 
GPX1-KO-F CTAAATATGGTGAAAAGCAACGTCGAGCTGGCATGGGAAACCATGGAAGATA
CATTTCTGGCGGGATATCAAGCTTGC 
-6 – 54  pJK795 
GPX1-KO-R CTATGTCTAGCTTTCTAGCAACTGTTCAATCCTTGGTGTTATTGCCACGGGTC
TAGTAAACGTATGGGTACCGAATTCGAGC 
633 – 696  pJK795 
1. Red indicates sequence of plasmid template. 
2. Relative to A base pair of ATG codon = 1. Negative numbers represent primers placed before the gene start position.  
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2.10 Candida albicans Transformation  
Transformation of exogenous DNA into C. albicans was performed using a 
modified protocol from Cheetham (2008). DNA cassettes were inserted into the 
genomic DNA via a process of homologous recombination. The sites of 
recombination were selected during cassette construction (see section 2.9). 
 
To summarise, a single colony of the appropriate C. albicans strain was grown 
overnight in 150 ml of YPD at 30 °C, 180 rpm in a 250 ml conical flask. 50 ml 
was taken and cells were pelleted at 2500 rpm for two minutes, washed in 20 ml 
LiAc/TE solution (100 mM LiAc pH 7.0, 1 x TE (10 mM Tris-HCl pH 7.5, 1 mM 
EDTA pH 8.0)), pelleted at 2500 rpm for two minutes, and resuspended in 1 ml 
LiAc/TE. 10 µl of salmon sperm carrier DNA (10 mg/ml, Invitrogen) was heated 
to 100 °C for five minutes and allowed to cool. This was then added to 10 µl of 
transforming DNA and 100 µl of prepared C. albicans cells. 750 µl of 
PEG/LiAc/TE solution (50% PEG 3350, 0.1 mM LiAc pH 7.0, 1 x TE) was added 
and vortexed to mix. This was followed by a minimum of four hours incubation 
at 30 °C, 180 rpm. The cell mixture was then heat-shocked at 42 °C for one 
hour. Cells were pelleted at 8000 rpm for 15 seconds, resuspended in 300 µl 
sterile water and spread onto selective media. Plates were incubated for 2 days 
at 30 °C. Colonies that developed on the selective media were further streaked 
onto selective plates and incubated at 30 °C for a further 24 hours to fully 
ensure the presence of the antibiotic resistance cassette. Single colonies were 
then checked for correct insertion and positioning of transformed DNA using 
colony PCR (see section 2.11).  
 
In the case of heterozygous knockout construction, the remaining allele was 
amplified via colony PCR (see section 2.11) and sent for sequencing (see 
section 2.12) to identify the genotype of the knockout constructed. Alternately, 
in the case of allele tagging, the tagged allele was amplified via colony PCR and 
sequenced for identification.  
 
2.11 Colony PCR  
Colony polymerase chain reaction (PCR) was used to check for correct 
insertion of DNA cassettes and for amplification of DNA for sequencing. A 
single colony of the correct strain was put into 10 µl of sterile water and 2 µl of 
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lyticase solution (25 U/µl lyticase (Sigma Aldrich), 0.1M sodium phosphate 
buffer at pH 7.5, 10% glycerol). This was incubated at 37 °C for 10 minutes 
followed by freeze fracturing at -80 °C for 10 minutes. 2 µl of this mixture was 
then used as the DNA template in a polymerase chain reaction as described in 
section 2.7. Reactions were checked using DNA gel electrophoresis (see 
section 2.5). 
 
When designing primers to verify genotypes, oligonucleotides (Invitrogen) of 
around 18 – 25 bp in length were used to amplify fragments of around 500 bp in 
length. For a full list of oligonucleotides used for checking insertion of DNA 
cassettes see Table 2.6 and oligonucleotides used for sequencing DNA see 
Table 2.7.  
 
2.12 Sequencing 
PCR fragments of amplified regions were diluted 1:10 in sterile water and sent, 
alongside the appropriate the primer (diluted to 3.2 pmol/µl), to either Source 
Bioscience Lifesciences or GATC Biotech for sequencing.  
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Table 2.6 Oligonucleotides used to check correct insertion of DNA cassette 
Name Sequence 5’ – 3’ Position
1
 Strain Checked 
NAT1-CH-R CCGTAATTTTTGCTTCGCG 190 – 208  SC1 – SC11, SC16 – SC18, SC30, SC32 – SC34, SC42, SC44 – SC49, 
SC51 – SC56, SC66 – SC76, SC81, SC85 – SC90, SC92 – SC94, SC96 – 
SC102, SC107 
CDC6-CH-F ACTGGGAACCCTTCATGTGT 128 – 147  SC8 – SC10 
ERB1-CH-F GAGATGAGGTTGGCGCACA -143 – -125  SC42, SC46 – SC49, SC56 
RBT4-CH-F TCCCATCAACTGTCCATCC -224 – -206    SC3 – SC5 
RCK2-CH-F GAGCGTGTGTGTGAAGAGAGAA -282 – -261  SC34, SC44 – SC45, SC51 – SC55 
SMI1-CHSEQ-F GACGACGACGATGGAAAAAC -254 – -235  SC30, SC33 
VPS1-CH-F CAGTCTAGTTCAATGGAGGCTGG -276 – -254  SC6 – SC7, SC16 – SC18, SC32 
CIp10-IS GATATCGAATTCACGCGTAG 2936 – 2955  SC12 
RP10-GS GTACATTCCTACTCCGTTCG 1376 – 1395  SC12 
V5-S GAGGGCGTGAATGTAAGCG 140 – 158   SC13 – SC14, SC27 – SC28, SC35 – SC37, SC41, SC57 – SC58, SC60 – 
SC61, SC65, SC95, SC104 – SC106 
VPS1-HIS-C GCTGGACGTGTCATCCCAT 739 – 757  SC13 – SC14, SC27 – SC28 
CDC6-SEQ-F GGCTAGTATAAATTGCATCCC 686 – 706  SC35 – SC36, SC41, SC61 
ERB1-SEQ-F CCCGATAGTAAAAACACTGCG 1963 – 1983  SC65, SC95 
ADH2-CHSEQ-F GATCACTCTTGCAAGCTAATCTCC -221 – -198   SC66 – SC69, SC90, SC92 
RPS7A-CH-F GCATGCATCGGAATTCTTTC -331 – -312   SC70, SC93, SC94, SC96 – SC98 
5648-CH-F CGCCCTCCTTTAGTCTATTCAC -272 – -251  SC71 – SC73, SC85 – SC88, SC99 – 102  
GPX1-CH-F CCCACTACACCACAAAGGAAAG -305 – -284  SC74 – SC76, SC81, SC107 
1. Relative to A bp of ATG codon = 1. Negative numbers represent primers placed before the gene start position.  
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Table 2.7 Oligonucleotides used to amplify DNA for sequencing 
 Name Sequence 5’ – 3’ Position1 Strain Sequenced 
CDC6-SEQ-F GGCTAGTATAAATTGCATCCC 686 – 706  SC8 – SC10, SC35 – SC36, SC41, SC61 
CDC6-SEQ-R CCGTAAGAGTGGTAGTAGTAGC 1179 – 1200  SC8 – SC10  
ERB1-SEQ-F CCCGATAGTAAAAACACTGCG 1963 – 1983  SC42, SC46 – SC49, SC56, SC65, SC95 
ERB1-SEQ-R GCCAAATTAAATCCAATATCCC 2464 – 2485  SC42, SC46 – SC49, SC56 
RBT4-SEQ-F CCCAGACTCTACTAAAGACGC 534 – 554  SC3 – SC5 
RBT4-SEQ-R CCCAGTTTTGAGCACGAC 957 – 974  SC3 – SC5  
RCK2-SEQ-F TGTGGGCGTTAGGATGTGTA 1082 – 1101  SC34, SC44 – SC45, SC51 – SC55 
RCK2-SEQ-R CAAACCTTCAATTGGGGCTT 1544 – 1563  SC34, SC44 – SC45, SC51 – SC55 
SMI1-CHSEQ-F GACGACGACGATGGAAAAAC -254 – -235  SC30, SC33 
SMI1-SEQ-R CCCTGCTGCACCAGTAGAAT 191 – 210  SC30, SC33 
VPS1-SEQ-F TGTCAACGCTGCTAATACGG 597 – 616  SC6 – SC7, SC16 – SC18, SC32 
VPS1-SEQ-R GGATCAATGGCATTAACCCC 1186 – 1205  SC6 – SC7, SC16 – SC18, SC32 
V5-S GAGGGCGTGAATGTAAGCG 115 – 133   SC13 – SC14, SC27 – SC28, SC35 – SC37, SC41, SC57 – SC58, 
SC60 – SC61, SC65, SC95, SC104 – SC106 
VPS1-HIS-C GCTGGACGTGTCATCCCAT 739 – 757  SC13 – SC14, SC27 – SC28 
VPS1-F-1 TGAGTCGGACCAGCCAAATA -618 – -599  SC6, SC7 
VPS1-R-1 CCACTTACACACGACCATCG -220 – -201  SC6, SC7 
VPS1-F-2 CGATGGTCGTGTGTAAGTGG -220 – -201  SC6, SC7 
VPS1-R-2 CAAGGGCCTTCTGGTAACAA 182 – 201   SC6, SC7 
VPS1-F-3 TTGTTACCAGAAGGCCCTTG 182 – 201   SC6, SC7 
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VPS1-R-3 CCGTATTAGCAGCGTTGACA 597 – 616  SC6, SC7 
VPS1-F-5 GGGGTTAATGCCATTGATCC 1186 – 1205  SC6, SC7 
VPS1-R-5 GGGGCTTCCATTTGTTGTAA 1747 – 1766  SC6, SC7 
VPS1-F-6 TTACAACAAATGGAAGCCCC 1747 – 1766 SC6, SC7 
VPS1-R-6 CAGGCCCACTTACTCTACGC 2210 – 2229  SC6, SC7 
ADH2-CHSEQ-F GATCACTCTTGCAAGCTAATCTCC -221 – -198   SC66 – SC69, SC90, SC92 
ADH2-SEQ-R GCACCTGATTGACAGTATTCACAG 300 – 323  SC66 – SC69, SC90, SC92 
RPS7A-SEQ-F CCACCACCAAGTTTACAAGCTTAC 175 – 198  SC70, SC93 – SC94, SC96 – SC98 
RPS7A-SEQ-R TGAATCTTTAGAATCCAACAAGAC 442 – 465  SC70, SC93 – SC94, SC96 – SC98 
5648-SEQ-F ATCGTCGATTTACCACTACCC 269 – 289  SC71 – SC73, SC85 – SC88, SC99 – 102  
5648-SEQ-R GCTTGTTGACCATGGAAGATC 705 – 725  SC71 – SC73, SC85 – SC88, SC99 – 102 
GPX1-SEQ-F CTGATGATTCGACACTCTCAG 152 – 172  SC74 – SC76, SC81, SC107 
GPX1-SEQ-R CTGGATCTGCTTGTTCACC 502 – 520  SC74 – SC76, SC81, SC107 
1. Relative to A bp of ATG codon = 1. Negative numbers represent primers placed before the gene start position.  
Page | 71  
 
2.13 Genomic DNA Extraction for Candida albicans 
A modified protocol taken from Hoffman and Winston (1987) was used to 
extract genomic DNA from Candida albicans cells. A colony of the appropriate 
strain was grown overnight in 10 ml of YPD at 30 °C, 180 rpm. Cells were 
pelleted at 4000 rpm for five minutes, resuspended in 1 ml of sterile water and 
transferred to a screw-capped microfuge tube. Cells were then pelleted at 
13,000 rpm for one minute and resuspended in 200 µl of glass bead buffer (10 
mM Tris-HCl pH 8, 100 mM sodium chloride, 1 mM EDTA, 2% Triton X-100, 1% 
SDS). 200 µl of phenol/chloroform/isoamyl alcohol (25:24:1) and 300 µl of 0.4 – 
0.6 mm acid-washed glass beads were added, followed by cell disruption by 
vortexing for three minutes. 200 µl of 1x TE buffer (10 mM Tris-HCl pH 8.0, 
1mM EDTA) was added and mixed by inversion. Cell debris was pelleted at 
13,000 rpm for five minutes and the aqueous phase was then transferred to a 
fresh tube. To this, 1 ml of 100% ethanol was added and mixed by inversion. 
The precipitate was pelleted at 13,000 rpm for five minutes and resuspended in 
400 µl 1x TE buffer. To remove any contaminating RNA, 10 µl of DNAse-free 
RNase A (10 mg/ml) was added and the solution was incubated at 37 °C for 
one hour. To this, 10 µl of 3 M sodium acetate, pH 5.2, and 1 ml of 100% 
isopropanol was added and mixed by inversion. This was incubated at room 
temperature for 10 minutes, followed by pelleting of the DNA at 13,000 rpm for 
10 minutes. The pellet was air-dried before resuspension in 50 µl 10 mM Tris-
HCl pH 8.  
 
DNA quality was checked via DNA gel electrophoresis (see section 2.5) and 
concentrations were checked using a NanoDrop spectrophotometer. Samples 
were stored at -20 °C until use.  
 
2.14 Phenotypic Screening 
The following sections list the phenotypic assays used in both chapter four and 
chapter five. 
 
2.14.1 Constructing an RPS1::NAT1 strain 
As a control to show the effect of the nourseothricin cassette alone on 
phenotypes of Candida albicans, a strain was constructed where the RPS1 
locus was replaced by the nourseothricin cassette (Murad et al., 2000). To do 
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this the appropriate strain of E. coli (see Table 2.2) was grown up in 5 ml of LB 
with ampicillin overnight at 37 °C, 180 rpm. The plasmid DNA was extracted as 
described in section 2.4.  
 
25 µl of plasmid DNA was digested at 37 °C for two hours with the restriction 
enzyme StuI (Promega) according to the manufacturer’s instructions. Correct 
digestion was checked using DNA gel electrophoresis (see section 2.5). The 
product was then precipitated by addition of 15 µl 3 M sodium acetate and 450 
µl 100% ethanol, followed by freezing at -20 °C for 30 minutes. The DNA was 
pelleted at 13,000 rpm for five minutes, washed with 70% ethanol, pelleted 
again at 13,000 rpm for three minutes and resuspended in 10 µl of sterile water. 
The plasmid DNA was then transformed into Candida albicans (see section 
2.10) at the RPS1 locus. Correct insertion was checked using colony PCR (see 
section 2.11) with primers CIp10-IS and RP10-GS (see Table 2.6).   
 
2.14.2 Growth Rate 
Growth rates of Candida albicans strains were measured using a liquid assay in 
a 96-well plate format. A single colony of the appropriate strain was grown 
overnight in 10 ml of YPD at 30 °C, 180 rpm. 10 µl of this was taken and diluted 
into 1 ml of fresh YPD. 100 µl as this solution was then transferred to a single 
well of the 96-well plate. Each strain was plated in technical quadruplicate and 
sterile YPD was used as a control. The experiment was then carried out in 
either biological duplicate or triplicate.  
 
Optical density at 650 nm was measured every 3½ minutes using a kinetic 
spectrophotometer held at either 30 °C or 37 °C for a total of 24 hours 
(Molecular Devices VersaMax Microplate Reader). Plates were shaken for three 
minutes in between reads.  
 
For each strain three measurements were calculated: an average end-point 
optical density (taken at 16 hours), time to maximum inflection (OD at 650 nm > 
0.3), and generation time. ANOVA followed by Dunnett’s post-hoc test was 
used to statistically compare these measures. Generation times were calculated 
as follows: 
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g=
Log
10
NT1-Log10NT0
Log
10
2
 
 
generation time (minutes)= (
T1-T0
g
)  ×60 
  
Where: 
g = generations in T1 – T0 
T0 = First time point 
T1 = Second time point 
NT0 = Optical density at first time point 
NT1 = Optical density at second time point 
 
2.14.3 Antifungal Sensitivity 
Sensitivity to the antifungal compounds fluconazole (Sigma Aldrich), 5-
flucytosine (Sigma Aldrich) and amphotericin B (solubilized, Sigma Aldrich) was 
tested using a liquid assay in a 96-well format. Drug stocks were prepared in 
sterile water and stored at -20 °C until use.  
 
The appropriate Candida albicans strain was grown overnight in 5 ml of YPD at 
30 °C, 180 rpm. Cells were counted using a haemocytometer and then diluted 
to a concentration of 1 x 106 cells/ml. 20 µl of cells were taken and added to a 
well containing 160 µl of YPD and 20 µl of the appropriate drug at a final 
concentration ranging from 1 – 1024 µg/ml. The plate contained drug 
concentrations increasing two fold in each column, with sterile water as a 
control.  
 
Plates were incubated at 30 °C, 180 rpm, and growth was assayed by 
measuring optical density at 595 nm using a spectrophotometer (Bio-Rad iMark 
Microplate Reader) at 0, 24 and 48 hours. Assays were carried out in technical 
quadruplicate and biological duplicate or triplicate.   
 
2.14.4 Growth Under Stress Conditions 
To test the ability of strains to grow under stress conditions, serial dilutions on 
solid media containing different compounds were used. A full list of conditions 
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used and strains tested are listed in Table 2.8. The appropriate strains were 
grown overnight in 5 ml of YPD at 30 °C, 180 rpm. Cell concentrations were 
counted with a haemocytometer and adjusted to 10x fold dilutions in YPD 
ranging from 1 x 107 cells/ml to 1 x 103 cells/ml. A 48-pronge replicator was 
used in a sterile fashion to spot the strains onto the correct media. Suitable 
concentrations of compounds were selected by pre-screening SC5314 on a 
range of concentrations. Plates were incubated for three days at 30 °C and 
observed every 24 hours.  
 
2.14.5 Hyphal Induction 
To test the ability of a strain to switch from the yeast to the hyphal form, a single 
colony was first grown for a minimum of 24 hours in 5 ml of YPD at 30 °C, 180 
rpm, to ensure that cells were in stationary phase. Medium containing 45 ml of 
YPD + 5 ml foetal calf serum was pre-warmed at 37 °C for a minimum of one 
hour. 1 ml of the stationary phase culture was then taken and added to the pre-
warmed YPD + foetal calf serum and the combined solution was incubated at 
37 °C for a maximum of three hours. Every 15 minutes 80 µl was taken and 
combined with 20 µl of 70% ethanol, in technical triplicate. This fixed the sample 
and allowed for storage at 4 °C. To quantify the induction of hyphae, cells were 
pelleted at 13,000 rpm for five minutes and resuspended in 10 µl of sterile 
water. Using a light microscope, observations were made as to the ability of a 
strain to induce hyphae. For strains which appeared to have hyphal induction 
defects, the experiment was repeated in biological triplicate.  
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Table 2.8 Stress conditions tested 
Condition Compound (and final 
concentration) 
Functional Implication1 Gene Strain 
Ethanol sensitivity Ethanol (6 %) General protein defect  
SMI1  
ADH2 
SC5314, SC12  
SC30, SC33 
SC66, SC67, SC68, SC69, SC90, SC92 
Cell wall damaging Calcofluor white  
(40 µg/ml) 
Defects in cell wall 
biogenesis 
 
SMI1 
SC5314, SC12 
 SC30, SC33 
Hygromycin B Hygromycin B  
(100 mg/ml) 
Antifungal sensitivity  
SMI1 
SC5314, SC12, 
SC30, SC33 
Divalent Cation 
sensitivity 
Calcium chloride  
(0.5 M) 
Altered expression of 
plasma membrane 
ATPases and defects in 
other biological processes 
 
SMI1 
SC5314, SC12 
SC30, SC33 
Cell membrane 
targeting 
SDS (0.1%) Defects in cell membrane 
and cell wall 
 
SMI1 
SC5314, SC12 
SC30, SC33 
Respiration inhibitor Antimycin A (1 µg/ml)   
ADH2 
SC5314, SC12 
SC42, SC46, SC47, SC48, SC49, SC56 
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Oxidative Stress Hydrogen peroxide 
(2 mM) 
Oxidative stress sensitivity  
ADH2 
GPX1 
SC5314, SC12 
SC42, SC46, SC47, SC48, SC49, SC56 
SC74, SC75, SC76, SC81, SC107 
Oxidative Stress Menadione (50 µM) Oxidative stress sensitivity  
ADH2 
GPX1 
SC5314, SC12 
SC42, SC46, SC47, SC48, SC49, SC56 
SC74, SC75, SC76, SC81, SC107 
tBOOH (1 mM) Oxidative stress sensitivity  
ADH2 
GPX1 
SC5314, SC12 
SC42, SC46, SC47, SC48, SC49, SC56 
SC74, SC75, SC76, SC81, SC107 
Fluconazole Fluconazole (64 µg/ml) Antifungal sensitivity  
VPS1 
ADH2 
GPX1 
SC5314, SC12 
SC6, SC7, SC16, SC17, SC18, SC32 
SC42, SC46, SC47, SC48, SC49, SC56 
SC74, SC75, SC76, SC81, SC107 
Flucytosine 5-Flucytosine  
(32 µg/ml) 
Antifungal sensitivity  
VPS1 
SC5314, SC12 
SC6, SC7, SC16, SC17, SC18, SC32 
Amphotericin B Amphotericin B  
(1 µg/ml) 
Antifungal sensitivity  
GPX1 
SC5314, SC12 
SC74, SC75, SC76, SC81, SC107 
1. Functional implications as stated in (Hampsey, 1997) 
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2.14.6 Buccal Epithelial Cell Adhesion 
To measure the adhesive capabilities of Candida albicans strains, buccal 
epithelial cells (BECs) were used as described by Odds and Webster (1988). 
BECs were isolated from the inner cheek using a sterile cotton bud and 
suspended in 10 ml of PBS. Cells were then pelleted at 3000 rpm for five 
minutes, washed twice in 10 ml of PBS, and resuspended in 1 ml of PBS. This 
produced an appropriate number to test.  
 
A single colony of the appropriate Candida albicans strain was grown overnight 
in 10 ml of YPD at 30 °C, 180 rpm. Cells were pelleted at 3000 rpm for 5 
minutes, washed twice in 10 ml PBS and resuspended in 5 ml of PBS.  
 
200 µl of BECs were then combined with 200 µl of C. albicans cells and 
incubated at 30 °C for one hour. At this point, 40 µl of 37% formaldehyde was 
added to crosslink any adhesion and the number of C. albicans cells adhered to 
150 different BECs was calculated using a light microscope. Three 
measurements were calculated from these results:; percentage of BECs 
adhered to C. albicans cells, number of C. albicans cells per BEC, and number 
of C. albicans cells per BEC discounting BEC with no cells adhered. These 
measurements were statistically compared to the wild-type strain SC5314 using 
a Student’s t-test. The analysis was performed in biological triplicate. 
 
2.14.7 Virulence with Galleria mellonella Model 
Galleria mellonella (Greater Wax Moth) larvae are commonly used as a model 
for virulence of Candida albicans. The results have been shown to be consistent 
with those found using mammalian models, but G. mellonella are cheaper, 
easier to manipulate, and avoid unnecessary mammalian suffering (Cotter et 
al., 2000).  
 
A single colony of the appropriate strain of C. albicans was grown overnight in 5 
ml of YPD at 30 °C, 180 rpm. The cells were pelleted at 4000 rpm for 5 minutes, 
washed with 10 ml of PBS, and resuspended in 5 ml of PBS. Cell numbers 
estimated using a haemocytometer and were diluted in PBS to 1 x 107, 2 x 107 
and 5 x 107 cells/ml. 10 µl of cell suspension was injected into the right pro-leg 
of G. mellonella, before incubation at 37 °C. Survival rates were monitored 
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every 24 hours for a total of 72 hours. PBS alone was used as a control to 
monitor natural survival rates. Kaplan-Meier survival statistics were then 
calculated using IBM SPSS version 21 (IBM, 2012). Galleria larvae were 
injected in batches of 10 and repeated in biological triplicate.  
 
2.15 Southern Blotting 
Southern blotting was used to check that all heterozygous knockout strains had 
just one copy of the NAT1 cassette integrated into the genomic DNA and that 
this copy was in the correct position. The full protocol was based upon the 
methodology in Southern (1975): genomic DNA is digested using restriction 
enzymes, DNA is separated using gel electrophoresis, transferred to a blot, 
hybridised with a specific probe and then an antibody, and finally the blot is 
developed and visualised. Details of each step follow. 
 
2.15.1 Synthesis of Digoxigenin Probe 
For non-radioactive Southern blotting, digoxigenin (DIG) probes were 
synthesised using PCR DIG Probe Synthesis kit (Roche). Reactions were 
prepared as follows: 0.75 µl of Vial 1 enzyme mix, 5 µl of Vial 2 DIG probe 
synthesis mix, 5 µl of Vial 3 PCR buffer without magnesium chloride, 1 µl of 
forward primer, 1 µl of reverse primer, 1 µl of template DNA, 36.25 µl of sterile 
water. For a list of oligonucleotides (Invitrogen) used see Table 2.9.  
 
Thermal cycling conditions were set as follows: 
 Initial denaturation:  95 °C for 2 minutes 
 Denaturation: 95 °C for 30 seconds 
 Annealing:  50 °C for 30 seconds   30 cycles 
 Extension:  72 °C for 40 seconds 
 Final Extension: 72 °C for 7 minutes 
 Hold:   4 °C 
 
Successful reactions were checked using DNA gel electrophoresis (see section 
2.5).  
 
  
Page | 79  
 
Table 2.9 Oligonucleotides used to amplify NAT1 probe for Southern 
blotting 
Name Sequence 5’ – 3’ Position1 Plasmid 
Template 
NAT1-S-F CTGCTACTGGTGATGGTTTC 524 – 542  pJK795 
NAT1-S-R AAACCACACAAAGTGAAACC 889 – 907  pJK795 
1. Relative to gene start position = 1.  
 
2.15.2 Restriction Enzyme Digests 
Restriction enzyme digests were used to fragment genomic DNA into fragments 
of known size predicted from the sequence of the C. albicans genome. This 
information was sourced from the Candida genome database 
(www.candidagenome.org) (Inglis et al. 2012). A list of restriction enzymes used 
for each heterozygous knockout can be found in Table 2.10. Genomic DNA was 
extracted from the appropriate strain as described in section 2.13. Digests were 
set up as follows: 3 µg of DNA, 3 µl of the appropriate buffer (See Table 2.10), 3 
µl of restriction enzyme and 23 µl of sterile water. Reactions were incubated at 
37 °C for 24 hours and separated using DNA gel electrophoresis (see section 
2.5) with a 0.7% (w/v) agarose gel without ethidium bromide. Staining was 
carried out after the gel had run by washing with 1x TAE containing 15 nl/ml 
ethidium bromide with gentle agitation for 30 minutes. 
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Table 2.10 Restriction enzymes used to digest genomic DNA for Southern 
blotting 
Restriction 
Enzyme1 
Buffer Gene Fragment Size (bp) Strains Checked 
BglII 3 SMI1 4588 SC30, SC33 
BsaHI 4 GPX1 5342 SC74 – SC76, SC81, 
SC107 
BspHI 4 VPS1 2931 SC6 – SC17, SC16 – 
SC18, SC32 
BsrGI 2 RBT4 3635 SC3 – SC5 
ClaI 4 ADH2 7145 (allele 1) 
1910 (allele 2) 
SC66 – SC69, SC90, 
SC92 
MspA1I 4 CDC6 2758 SC8 – SC10 
PciI 3 ERB1 2573 SC42, SC46 – SC49, 
SC56 
1. All restriction enzymes were purchased from New England BioLabs UK.  
 
2.15.3 Blotting 
After visualisation of the digested DNA, the gel was depurinated in 250 mM 
hydrochloric acid for 15 minutes with gentle agitation, followed by washing in 
sterile water for 10 minutes. The gel was then denatured twice in denaturation 
solution (1.5 M sodium chloride, 500 mM sodium hydroxide) for 15 minutes with 
gentle agitation, followed by washing in sterile water for 10 minutes. 
Neutralisation was then carried out twice in neutralisation solution (500 mM Tris, 
1.5 M sodium chloride, 4.3% (v/v) hydrochloric acid, pH 7.2) for 15 minutes with 
gentle agitation, followed by washing in sterile water for 10 minutes. The gel 
was then equilibrated in 20x SSC buffer (2 M sodium chloride, 300 mM sodium 
citrate, pH 7.0) for 10 minutes with gentle agitation. The blot was then set up in 
10x SSC buffer (1M sodium chloride, 150 mM sodium citrate, pH 7.0) and left 
overnight to transfer the DNA from the gel to a positively charged nylon 
membrane (Roche).  
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2.15.4 Hybridisation 
The nylon membrane was placed DNA side up in 2x SSC (200 mM sodium 
chloride, 30 mM sodium citrate, pH 7.0). The DNA was cross-linked to the 
membrane using exposure to ultraviolet light (HL-2000 Hybrilinker, UVP).  
 
The range of appropriate hybridisation temperatures (° C) for the probe was 
determined using the following calculations: 
 
Low Thyb=(49.82+0.41(GC content))- 
600
Length (bp)
- 25 
High T
hyb
=(49.82+0.41(GC content))- 
600
Length (bp)
- 20 
Optimal Thyb= 
Low Thyb+ High Thyb
2
 
 
30 ml of DIG Easy Hyb solution (Roche) was heated to the required 
temperature. The membrane was then pre-hybridised in 20 ml of this warmed 
solution at the optimal hybridisation temperature using a hybridisation oven (HL-
2000 Hybrilinker, UVP) for a minimum of 30 minutes to a maximum of 3 hours. 
20 µl of the Digoxigenin probe (as prepared in section 2.15.1) was taken, 
combined with 50 µl of sterile water, heated at 100 °C for five minutes, and then 
added to the remaining 10 ml of warmed DIG Easy Hyb solution (Roche). (In 
the instance of probe re-use, the probe hybridisation buffer was prepared by 
heating to 68 °C for 10 minutes). The pre-hybridisation buffer was removed from 
the membrane and replaced with the DIG Easy Hyb solution (Roche) containing 
the probe. The membrane was then hybridised overnight at the optimal 
hybridisation temperature using a hybridisation oven (HL-2000 Hybrilinker, 
UVP). 
 
2.15.5 Development of the Blot 
The membrane was taken and washed twice in low stringency wash buffer (2x 
SSC (200 mM sodium chloride, 30 mM sodium citrate, pH 7.0), 0.1% (v/v) SDS) 
for five minutes with gentle agitation. This was followed by washing twice in high 
stringency wash buffer (0.5x SSC (50 mM sodium chloride, 7.5 mM sodium 
citrate, pH 7.0), 0.1% (v/v) SDS) for 15 minutes at 65 °C in a hybridisation oven 
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(HL-2000 Hybrilinker, UVP). The membrane was washed in washing buffer 
(0.3% (v/v) Tween-20 in maleic acid buffer (0.1 M maleic acid, 0.15 M sodium 
chloride, pH 7.5)) for two minutes with gentle agitation before blocking in 
blocking reagent (1% (w/v) blocking reagent, Roche, in maleic acid buffer) for a 
minimum of 30 minutes to a maximum of 3 hours with gentle agitation. The 
antibody (anti-digoxigenin-AP, Roche) was prepared by centrifugation at 10000 
rpm for five minutes. 1 µl of antibody per 10 ml of fresh blocking reagent was 
taken from the top layer. The membrane was then incubated with the blocking 
reagent containing antibody at room temperature for 30 minutes with gentle 
agitation.  This was followed by washing twice in washing buffer for 15 minutes 
with gentle agitation. The membrane was equilibrated in detection buffer (0.1 M 
Tris, 0.1 M sodium chloride, pH 9.5) for three minutes with gentle agitation 
before being moved to a development cassette. Chemiluminescence substrate 
(CDP-star, Roche) was added to the membrane and left in the dark for five 
minutes before development and visualisation using a G:Box system (SynGene) 
set with a chemiluminescence filter for detection of ECL substrates. 
 
2.15.6 Stripping the Blot 
To store and re-use the membrane, any bound antibody was removed. This 
was done by washing the blot twice with stripping buffer (0.2 M sodium chloride, 
1% (v/v) SDS) at 37 °C in a hybridisation oven (HL-2000 Hybrilinker, UVP). The 
membrane was then washed in 2x SSC (200 mM sodium chloride, 30 mM 
sodium citrate, pH 7.0) for 10 minutes with gentle agitation and stored in 2x 
SSC at -20 °C. For re-use the protocol was restarted from the hybridisation 
stage after UV crosslinking.   
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Chapter 3: Identification of Allelic 
Expression Imbalance 
 
3.1 Introduction 
In this chapter, RNA sequencing techniques have been used to identify genes 
with significant levels of allelic expression imbalance in the wild-type Candida 
albicans strain SC5314. From here, the list of significant genes is investigated 
for trends which may be of biological relevance such as Gene Ontology and 
chromosomal location, with a focus upon alleles that may have divergent 
functions. Expanding upon this point, structural factors which have previously 
been shown to influence gene expression levels, such as GC content and gene 
length, are explored in relation to AEI. The patterns observed within these 
structural factors are then discussed alongside a brief description of other 
factors such as DNA methylation and RNA decay rates, which are outside of the 
scope of this project, but may still be of importance. Finally, validation of AEI 
identified through RNA sequencing is attempted using qPCR, restriction 
enzyme digests and western blotting. Since these methods proved to be largely 
unsuccessful a discussion of issues surrounding allele specificity and sensitivity 
is presented. Firstly, a brief introduction to gene expression analysis with RNA 
sequencing technologies is given, followed by an introduction into the 
relationship between structural factors and gene expression levels.   
 
3.1.1 RNA sequencing  
The development of next generation sequencing technologies has paved the 
way for advances in RNA sequencing; a technique which uses quantification of 
mRNA levels to determine gene expression patterns. This is achieved through a 
simple process in which RNA is extracted from the tissue of interest and then, 
according to the first RNA sequencing workflows, converted from RNA to cDNA 
followed by fragmentation of the cDNA and library preparation (Nagalakshmi et 
al., 2008). More modern techniques directly fragment the RNA and the next 
generation sequencing is undertaken and reads are aligned to a reference 
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genome with quantification at each gene location. The resulting information on 
gene expression is termed the transcriptome (Figure 3.1) (Wang et al., 2009).  
 
RNA sequencing as a method to monitor gene expression levels has distinct 
advantages over existing methods. Approaches such as northern blotting and 
qPCR determine expression levels on a gene-by-gene basis whereas RNA 
sequencing and microarrays provide information on a genome-wide scale, 
allowing for a much more in depth analysis of overall patterns of gene 
expression. Sequencing of RNA also has benefits over the use of microarrays 
including a higher sensitivity than microarray hybridisation allowing for 
identification of genes with the lowest expression levels (Wang et al., 2009, 
Tuch et al., 2010a), greater specificity, low background noise with no upper limit 
for detection, high accuracy (Wang et al., 2009),  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1. Schematic of key steps in RNA sequencing process. RNAs are extracted 
and converted into a library of cDNA fragments through either RNA fragmentation or 
DNA fragmentation. Sequencing adaptors (blue) are added to each cDNA fragment, 
creating the cDNA library. Short sequences are obtained from each cDNA using high-
throughput sequencing technology. Figure adapted from Wang et al. 2009.  
AAAAAAA 
mRNA 
TTTTTTT 
AAAAAAA 
cDNA RNA Fragments 
or 
Library with adaptors 
Next generation sequencing 
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and high levels of reproducibility (Marioni et al., 2008, Wang et al., 2009). 
Validation of expression levels determined by RNA sequencing is seen through 
a high correlation between RNA sequencing and qPCR in various species 
including yeast and human tissues (Marioni et al., 2008, Nagalakshmi et al., 
2008, Bloom et al., 2009, Bruno et al., 2010, Tuch et al., 2010a) as well as a 
high correlation in results observed between RNA sequencing and microarrays 
(Marioni et al., 2008, Bloom et al., 2009, Esteve-Codina et al., 2011, Guida et 
al., 2011). Unlike microarrays, RNA sequencing assumes no prior knowledge of 
coding sequence, creating the possibility for identification of novel transcripts 
and introns. With the recent development of de novo transcriptome assembly, 
the need for a reference genome is also overcome, vastly increasing the 
number of organisms in which RNA sequencing can be undertaken (Wang et 
al., 2009). As microarrays are susceptible to cross-hybridisation of homologous 
DNA fragments, such as those produced by pairs of alleles or paralogous genes 
(Tuch et al., 2010a), RNA sequencing has a distinct advantage for detection of 
events such as allelic expression imbalance (AEI).  
 
This study aims to exploit these advantages of RNA sequencing to determine 
allelic expression imbalance in the yeast Candida albicans. As detailed in 
section 1.5, RNA sequencing has been used in numerous species to identify 
allele-specific expression. This includes identification of imprinting within mouse 
brain tissue (Gregg et al., 2010) and within triploid maize endosperm (Zhang et 
al., 2011), identification of AEI in human T cells (Heap et al., 2010), human 
cancer cells (Tuch et al., 2010a), in two pig species (Esteve-Codina et al., 
2011), in yellow baboons (Tung et al., 2011) and determination of cis-acting 
polymorphisms in hybrid yeast strains (Bullard et al., 2010b). 
 
Throughout these studies, a lack of consistency is seen with respect to the 
exact method used to determine AEI. Although all studies use RNA sequencing, 
the downstream processing of the results varies dramatically, from the choice of 
alignment software, to the choice of a control, to the statistical analysis of allele 
expression levels. One consistent factor is that all studies have used a haploid 
reference genome and incorporated SNP identification into their analysis. Using 
this method for identification of AEI has proven to be problematic, as mapping 
bias towards the reference genome, and against the alternative SNP, even with 
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SNP masking, is often reported (Degner et al., 2009, Stevenson et al., 2013). 
For Candida albicans, a diploid reference genome is available. Therefore this 
allows us to take a new approach and align reads directly to each allele at 
unique SNP positions, avoiding issues of bias towards the reference genome.  
 
RNA sequencing has been used in numerous yeast species to determine 
overall expression levels including the fission yeast Schizosaccharomyces 
pombe (Wilhelm et al., 2008), where expression of more than 90% of the 
genome was detected; and S. cerevisiae (Nagalakshmi et al., 2008), where a 
lower level of gene expression, at 74.5% of the genome, was detected. In C. 
albicans, various studies have used RNA sequencing to explore gene 
expression levels. In 2010, Bruno et al. investigated the differential 
transcriptional response of the wild-type C. albicans strain SC5314 to nine 
different infection specific in vitro conditions. Haploid alignments were carried 
out and expression was detected for 97% of previously annotated ORFs plus 
602 newly identified transcripts. Analysis of the UTRs was also carried out 
alongside intron discovery using TopHat (Bruno et al., 2010). Other RNA 
sequencing reports in C. albicans include a study of the transcriptional profile of 
C. albicans cells and bone marrow derived dendritic cells from mice (Tierney et 
al., 2012), a study looking at the transcriptional control of biofilm formation 
(Nobile et al., 2012), a comparison of the transcriptome of C. albicans and C. 
dubliniensis chlamydospores to identify chlamydospore specific genes (Palige 
et al., 2013), and a strand-specific RNA sequencing study looking at the 
transcriptional differences between white and opaque cells (Tuch et al., 2010b). 
Closely related Candida species have also undergone RNA sequencing 
including C. parapsilosis under both normal and hypoxic growth conditions 
(Guida et al., 2011). 
 
As mentioned in section 1.8, a recent paper by Muzzey et al. used the RNA 
sequencing data published by Bruno et al. (2010) alongside an improved 
phased reference genome to demonstrate that identification of allelic expression 
imbalance in Candida albicans is achievable (Muzzey et al., 2013). As 
mentioned above, the diploid reference genome negated the need for SNP 
identification before AEI is determined. However, this paper only investigated 
the levels of AEI from a single growth condition and very little biological or 
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functional inference was made from the results. In a follow up study, the 
genome-wide extent of allelic expression imbalance at both the transcriptional 
and translational levels in C. albicans was evaluated (Muzzey et al., 2014). In 
the work presented here, a similar method of identification of AEI has been 
adopted, but with a focus upon the biological impact of these expression levels.   
 
3.1.2 The Relationship Between Structural Factors and Gene Expression 
Levels  
Gene expression levels are often attributed to the control of promoters and 
transcription factors. However, there is evidence that structural factors of the 
genome may have an impact upon transcription. These factors include 
chromosomal location (Muller, 1930, Gottschling et al., 1990), overlap with a 
neighbouring open reading frame (Cullen et al., 1984, MacIsaac et al., 2011), 
GC content (Goncalves et al., 2000, Urrutia and Hurst, 2003, Versteeg et al., 
2003), gene length (Coghlan and Wolfe, 2000, Jansen and Gerstein, 2000, 
Marín et al., 2003) and codon usage (Sharp and Li, 1987, Morton, 1993, Merkl, 
2003). 
 
3.1.2.1 Chromosomal Location 
The chromosomal location of a gene has been shown to impact upon 
expression levels due to the uneven distribution of heterochromatin across 
chromosomes. This concept was first identified in the early 1930s by Muller, 
who showed that the phenotypic characteristics of Drosophila melanogaster 
change when a gene is relocated to a region of denser heterochromatin. This 
phenomenon was titled ‘Position Effect Variegation’ (Muller, 1930). Dense 
heterochromatin is associated with silent regions of DNA due to the 
inaccessibility of DNA binding factors and transcriptional machinery.    
 
In some yeast species, silencing of expression due to heterochromatin is seen 
in genes located in sub-telomeric regions. In S. cerevisiae, it has been shown 
that repositioning of genes to telomeric regions results in disruption of 
expression (Gottschling et al., 1990) and in C. glabrata a group of paralogous 
adhesin genes known as the EPA genes are transcriptionally repressed due to 
their sub-telomeric positioning. This silencing is achieved through recruitment of 
silencing machinery to the chromatin structure (Castaño et al., 2005). In 
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Candida albicans some cases of genes from within a gene family that cluster to 
the same chromosomal locations have been observed (Braun et al., 2005), 
however little evidence has been seen for sub-telomeric silencing.   
 
Contradictory evidence has been seen for the relationship between 
chromosomal location and allelic expression imbalance. Savova et al. (2013) 
claim that there is little clustering in terms of autosomal monoallelic genes, 
however some special cases, such as the olfactory genes, do cluster to a 
specific chromosomal location. On the other hand, a study in maize showed that 
imprinted genes do cluster in location when compared to the overall frequency 
of genes across the entire genome, where a definition of at least two genes 
within 1 Mb of each other was used (Zhang et al., 2011). In mammals, allele-
specific heterochromatin patterns have been observed, along with allele-specific 
DNA methylation. In this case, these factors have been elucidated as the 
control mechanism behind imprinting of genes (Singh et al., 2011). Looking at 
allelic expression imbalance as opposed to imprinting, Lo et al. (2003) showed 
that some genes with AEI clustered in chromosomal location but most were 
randomly distributed across the genome.  
 
3.1.2.2 Overlapping Genes 
The distance between neighbouring open reading frames has been shown to 
influence expression levels of both of the genes. Studies in various organisms 
have shown that when genes on the same strand with the same orientation 
overlap with each other, transcriptional interference occurs where the 
transcription of one gene is repressed by the overlapping gene (Cullen et al., 
1984, Bateman and Paule, 1988, Irniger et al., 1992). Although these studies 
detailed the impact of overlapping genes on the same strand, transcriptome 
analysis of the yeast S. cerevisiae revealed that overlapping of transcripts on 
either strand could contribute to observed impacts upon gene expression 
(Nagalakshmi et al., 2008).   
 
In terms of allelic expression imbalance, the impact of overlapping transcripts 
has been examined using strand specific microarrays in a heterozygous strain 
of S. cerevisiae. In total 196 pairs of transcripts overlapped on opposite strands 
(sense-antisense), and 36 of these demonstrated AEI. Both symmetric and 
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asymmetric patterns of AEI were observed in terms of the strands. For example 
FET4 showed symmetric expression with both sense and antisense strands 
being expressed on one chromosome and silenced upon the other. Conversely 
DAP2 showed asymmetric expression with one chromosome showing strong 
expression of the sense strand and weak antisense expression whereas the 
other chromosome had the opposite expression pattern (Gagneur et al., 2009). 
However, it should be noted here that 335 genes with AEI showed no evidence 
of overlap with their neighbouring open reading frame, suggesting that overlap 
is not the sole cause of allelic expression imbalance.   
 
Another example of overlapping transcripts influencing AEI is the imprinted 
gene Mest (as described in section 1.5.1.2). Mest has two different transcripts, 
Mest and the longer transcript MestXL. In both cases the paternal allele is 
expressed and the maternal allele is silenced. Additionally as MestXL is longer, 
overlap with the antisense gene Copg2 occurs causing silencing of the paternal 
allele via transcriptional interference (MacIsaac et al., 2011). The exact 
mechanism of transcriptional interference is unclear but possible suggestions 
include collision of the elongation complexes of both mRNAs, overlapping 
causing RNA editing of adenosine to inosine marking the Copg2 RNA for 
degradation, or the termination complex of MestXL directly interfering with the 
chromatin of the Copg2 promoter.   
 
3.1.2.3 GC Content and Gene Length 
GC content and gene length are structural factors determined by the DNA 
sequence of the genes themselves. These factors have been correlated with 
gene expression in humans (Urrutia and Hurst, 2003, Versteeg et al., 2003) and 
yeast (Marín et al., 2003) with mixed results.  
 
Some studies have found a negative correlation between GC content and gene 
expression (Goncalves et al., 2000). The causal relationship is not yet 
determined, but this correlation supports the hypothesis that a sequence with 
higher GC content requires more energy to unwind and is therefore transcribed 
less efficiently. Alternatively, this negative correlation between GC content and 
gene length may be due to chromatin organisation. It has been demonstrated in 
S. cerevisiae that low GC content tracts of dA:dT are rigid and therefore unable 
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to bend around and bind nucleosomes. These nucleosome free regions are 
then associated with increased accessibility for the transcriptional machinery 
and have higher gene expression (Mavrich et al., 2008). On the other hand, 
some studies have also indicated a positive relationship, with expression 
increasing as GC content is increased (Urrutia and Hurst, 2003, Versteeg et al., 
2003). Contrarily it has been suggested that differences in chromatin structure 
in GC low areas result in lower transcription levels (Marín et al., 2003). The 
relationship between ORF length and expression is far more straightforward 
with the general conclusion being that shorter genes are more transcriptionally 
efficient and are therefore expressed to higher levels (Coghlan and Wolfe, 
2000, Jansen and Gerstein, 2000, Marín et al., 2003). 
 
Although the relationships between GC content, gene lengths and gene 
expression levels have been investigated, it has yet to be elucidated what 
impact these structural factors have upon allelic expression imbalance.  
 
3.1.2.4 Codon Usage 
Codon usage is another structural factor which has been linked to gene 
expression. In yeast, it was discovered that genes with higher expression levels 
tend to use codons corresponding to the most abundant tRNA species 
(Bennetzen and Hall, 1982). Since then, various measures of codon usage 
have been developed which claim to predict gene expression levels including 
the Codon Adaptation Index (CAI) (Sharp and Li, 1987), the Codon Bias Index 
(CBI) (Morton, 1993), and GCB (Merkl, 2003). Another factor which complicates 
codon usage in Candida albicans is the CUG codon. Typically this is translated 
as a leucine, but in certain Candida species, including C. albicans, the CUG 
codon is now translated as serine (as discussed in section 1.2) (Ohama et al., 
1993).  
 
3.1.3 Aims of this Chapter 
This chapter aims to address three main research questions: 
 
1. Does AEI occur on a genome-wide scale in SC5314, the wild-type strain 
of C. albicans? 
2. Are patterns present in the structural factors of genes identified with AEI? 
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3. Can a method be developed to validate AEI identified by RNA 
sequencing? 
 
3.2 Materials and Methods 
3.2.1 RNA Sequencing 
3.2.1.1 Cell Harvests 
Colonies of SC5314 were inoculated in 10 ml of YPD and grown overnight at  
30 °C, 180 rpm, in biological triplicate. Cells were then diluted to an optical 
density at 600 nm of 0.25 in 10 ml fresh YPD.  Cell cultures were incubated at 
30 °C, 180 rpm, until the optical density at 600 nm equaled 1.0.  Cell density 
was then estimated using a haemocytometer (mean 5 x 107 cells/ml) and cells 
from each replicate were harvested by centrifugation at 4000 rpm for one 
minute before re-suspension in 200 µl of sterile water, cells were then frozen in 
liquid nitrogen and stored at -80 °C. 
 
3.2.1.2 RNA Preparation 
Total RNA samples were obtained using a Qiagen RNeasy mini-kit according to 
the manufacturer’s instructions for yeast using mechanical disruption including 
an on column DNase digestion using RNase-free DNase set (Qiagen). 5 x 107 
cells were disrupted with 0.4 – 0.6 mm glass beads using a FASTPREP-24 
bead beater (MP) (3 x 20 seconds at 6 m/s). RNA was quantified using a 
NanoDrop spectrophotometer and purity assessed using an Agilent 2100 
Bioanalyser (samples prepared according to the manufacturer’s instructions). 
Double stranded cDNA was created using reverse transcription with random 
hexamers using a Thermoscript™ RT-PCR system. Samples were sonicated 
(bioruptor sonicator) and prepared for Illumina GA2 sequencing using standard 
NEB protocols by the University of Exeter Sequencing Service.  
 
3.2.1.3 Illumina Base Calling and Pipeline 
The Illumina 1.4 pipeline was used to analyse images from the GA2 instrument. 
Base calling was carried out using the Bustard module with a standard chastity 
filter applied. 76 bp reads were obtained and trimmed to 60 bp to minimise 
overall error rates. This yielded 16,166,757 reads for replicate 1, 17,369,675 for 
replicate 2 and 16,853,362 for replicate 3. Raw sequence data is available from 
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the NCBI Gene Expression Omnibus (www.ncbi.nlm.nih.gov/geo/) accession 
number [GEO:GSE35233].  
 
3.2.1.4 Alignment and Identification of Allelic Expression Imbalance 
CLCBio software (www.clcibio.com) was used to align reads to the reference 
Assembly 19 diploid genome sequence (Jones et al., 2004). Standard 
parameters were set to allow up to two mismatches per read. Non-unique reads 
were discarded so that only reads which could unambiguously differentiate 
between alleles were counted.  From this data, the normalised measure of 
expression, RPKM (reads per kilobase per million mapped reads) (Mortazavi et 
al., 2008) was calculated for each allele. Allele expression of a single gene was 
compared using Fisher’s-Exact test, with a cut off of 2x fold difference in 
expression at a p-value of <0.0000077 (set using Bonferroni correction).  
Alongside this, a haploid alignment against Assembly 21 (Van Het Hoog et al., 
2007) was undertaken based on both unique and non-unique reads indicating 
overall gene expression levels. Methods from 3.2.1.1 to 3.2.1.4 were kindly 
carried out by the University of Exeter Sequencing Service.  
 
3.2.2 Gene Ontology (GO) Analysis 
Analysis for over representation of Gene Ontology (GO) terms within genes 
identified to have AEI was carried out using “CGD GO Term Finder” at the 
Candida genome database (www.candidagenome.org) (Inglis et al., 2012). Lists 
of GO terms were created using “CGD Gene Ontology Slim Mapper” also 
available from the Candida genome database.  
 
3.2.3 Calculation of Differences in Promoter Sequence 
As promoter sequences in C. albicans are currently undefined, the 1000 bp of 
DNA sequence upstream of each allele were downloaded from the Candida 
Genome Database (www.candidagenome.org) (Inglis et al., 2012). If the 
neighbouring open reading frames were within the 1000 bp upstream, the 
sequence up to the neighbouring ORF was taken. Sequences of each pair of 
alleles of a gene were aligned used ClustalW 
(http://www.genome.jp/tools/clustalw/) (Kyoto University Bioinformatics Center, 
2010) and sequences were recorded as different if one of more SNPs or 
INDELs were observed. For comparison, an equivalent set of genes with equal 
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allele expression (fold difference ≈ 1) (Appendix I Table II) were also analysed. 
The probability of observing SNPs across a region of 1000 bp was calculated 
based upon the observed average level of heterozygosity of one SNP in every 
237 bp (Jones et al., 2004). The observed and expected number of promoter 
sequences with SNPs was compared statistically using a chi-square test.  
 
3.2.4 Calculation of Percentage Protein Identity 
Protein sequences for all genes with allelic expression imbalance identified in 
this study and for an equivalent set of genes with equal allele expression (fold 
difference ≈ 1) (Appendix I Table II) were downloaded from the Candida 
Genome Database (www.candidagenome.org) (Inglis et al., 2012).  
 
To assess if AEI could have a link to differences in allele function, percentage 
protein identity comparisons between alleles were carried out using a 
Needleman-Wunsch algorithm for global alignment (Rose and Eisenmenger, 
1991). Arc-sine transformations were carried out to normalise the data 
(Osborne, 2005) before statistical analysis was undertaken, using a Student’s t-
test, to compare the percentage protein identities of genes with AEI and genes 
with equal allele expression.  
 
3.2.5 Analysis of Structural Factors 
3.2.5.1 Chromosomal Locations and Identification of Overlapping Genes 
Chromosomal coordinates and strand information were obtained from the 
‘Chromosomal Features File’ available from the Candida genome database 
(www.candidagenome.org) (Inglis et al., 2012). Gene locations were calculated 
by converting start coordinates to a percentage of overall chromosome length. 
Clusters were identified by a significant deviation from a Poisson distribution. 
Over- or under-representation of genes with AEI on each chromosome was 
statistically analysed using a chi-square test. As the ‘Chromosomal Features 
File’ only lists the chromosomal coordinates for “allele one” of an allele pair, this 
was carried out for just one allele, with the assumption that the second allele will 
have the same chromosomal location and strand orientation.  
 
Chromosomal coordinates were also used to calculate the number of genes 
across the entire genome which overlap with the neighbouring open reading 
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frame. Stop coordinates of a feature were subtracted from the start coordinate 
of the next feature to determine the distance between the features in base pairs. 
If this number was negative, the features were classified as overlapping. This 
included all features of the C. albicans genome, therefore centromeres, repeat 
regions etc. were included as well as ORFs. Over- or under-representation of 
features which overlap on each chromosome was statistically analysed using a 
chi-square test. The RPKM values, and therefore expression levels, of a pair of 
overlapping genes were statistically compared using a Fisher’s Exact test in R 
version 2.12.0 (The R Foundation for Statistical Computing, 2010) at a p-value  
< 0.000568 (set using Bonferroni correction). The relationship between strand 
and expression difference in a pair of overlapping genes was statistically 
compared using a chi-square test.  
 
For comparison of overlapping genes between pairs of alleles with AEI, 
chromosomal coordinates were manually obtained for both alleles and 
neighbouring alleles using “GBrowse for C. albicans SC5314 Assembly 19” 
available from the Candida genome database (www.candidagenome.org) (Inglis 
et al., 2012). Hypergeometric distribution analysis was used to statistically 
assess the frequency of genes with AEI which overlap with their neighbouring 
open reading frame.  
 
3.2.5.2 GC Content, Gene Length and Codon Usage 
FASTA files containing the genomic open reading frame sequences, as 
annotated in Assembly 19 (Jones et al., 2004), were downloaded from the 
Candida Genome Database (www.candidagenome.org) (Inglis et al., 2012).  
  
Open reading frame lengths were obtained from the ‘Chromosomal Features 
File’ available from the Candida genome database (www.candidagenome.org) 
(Inglis et al., 2012) for “allele one” and calculated manually for “allele two”. GC 
content was calculated using the gene sequences and BioEdit version 7.0.9.0 
(Hall, 1999). Codon usage frequencies for the entire genome were calculated 
using INCA version 2.1 (Supek and Vlahovi ek, 2004). Two codon usage 
measures were used in this study, GCB (Merkl, 2003) and the Codon 
Adaptation Index (CAI) (Sharp and Li, 1987). CAI values for each allele were 
calculated manually based on the formulae in Sharp and Li (1987) using the 
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codon usage frequencies calculated by INCA. CUG usage for each ORF was 
calculated using in-house PERL scripts (Appendix II.I). 
 
Before the analysis of the impact of each structural factor upon AEI was 
undertaken, overall gene expression levels were correlated with each structural 
factor to assess the relationship between each factor and expression. Overall 
gene expression levels were determined by alignment of reads against the 
haploid reference genome, as described in section 3.2.1.4, and normalised to 
RPKM values. For each gene, the GC content, ORF length, CAI value, GCB 
value and CUG usage was calculated as the average of the measure from each 
allele. Correlations were statistically analysed using a Spearman’s correlation in 
SPSS version 21 (IBM, 2012). 
  
To determine the contribution of each structural factor on AEI, the values 
obtained from the allele with the lowest and highest expression were statistically 
compared using a Student’s t-test. Equivalent comparisons were undertaken 
using a set of 210 genes with equal allele expression (fold difference ≈ 1) 
(Appendix I Table II) to reveal if any effects were restricted to genes with AEI. 
ORF lengths were normalised using a logarithmic transformation prior to 
statistical analysis so that a more stringent parametric test could be used 
(Osborne, 2005). 
 
In general, for genes with AEI and genes with equal allele expression, the 
difference in the values obtained from each allele for all structural factors was 
calculated by subtracting the allele one value from the allele two. However for 
ORF length the fold difference was calculated by dividing the length of the 
longest allele by the length of the shortest allele. The difference in variance 
between the data obtained from genes with AEI and genes with equal allele 
expression was statistically analysed using an F-test. Correlations between 
differences in structural factors and percentage protein identities (section 3.2.3), 
and between fold difference in ORF length and all other structural factors were 
statistically analysed using a Spearman’s correlation in SPSS version 21 (IBM, 
2012). 
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3.2.6 Validation of Allelic Expression Imbalance 
3.2.6.1 Allele-Specific qPCR 
3.2.6.1.1 Cell Extractions 
To accurately validate expression levels, cells were grown and harvested in the 
same manner as when obtained for RNA sequencing, as follows. A single 
colony of the wild-type strain SC5314 was grown overnight in 5 ml of YPD at   
30 °C, 180 rpm. Cell concentrations were calculated using a haemocytometer 
and 5 x 106 cells/ml were inoculated, in triplicate, in 50 ml of YPD and grown at 
30 °C, 180 rpm, until optical density at 600 nm was equal to one.  
 
To harvest the cells, an amount equal to an optical density at 600 nm of 0.2 
were taken, pelleted at 4000 rpm for five minutes and resuspended in 1 ml of 
PBS. Cells were transferred to a 1.5 ml screw-topped microfuge top and again 
pelleted at 13000 rpm for five minutes. The supernatant was removed, cells 
were flash frozen using liquid nitrogen and stored at – 80 °C until use. The cells 
were then immediately ready for RNA extraction with the correct cell number.  
 
3.2.6.1.2 RNA Extractions 
Total RNA was extracted using the RNeasy Mini Kit (Qiagen) as per 
manufacturer’s instructions for yeast, using mechanical disruption including an 
on column DNase digestion using RNase-free DNase set (Qiagen). RNA 
concentration and quality was quantified using a NanoDrop Spectrophotometer, 
formaldehyde agarose gel electrophoresis (see section 3.2.6.1.3) and an 
Agilent 2100 Bioanalyser (samples prepared as per manufacturer’s 
instructions).  
 
3.2.6.1.3 Formaldehyde Agarose Gel Electrophoresis 
To assess the integrity of RNA samples, formaldehyde agarose gel 
electrophoresis was used. To summarise, 1.2% (w/v) agarose was melted in 
10% (v/v) formaldehyde agarose gel buffer (200 mM MOPS, 50 mM sodium 
acetate, 10 mM EDTA, pH 7.0). 1.8% (v/v) 37% formaldehyde and 1 µl of 
ethidium bromide were added and mixed. The gel was then poured, allowed to 
set and equilibrated in 1x formaldehyde agarose gel running buffer (10% (v/v) 
formaldehyde agarose gel buffer, 2% (v/v) 37% formaldehyde) for 30 minutes. 
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RNA samples were diluted in a 4:1 ratio in 5x RNA loading buffer (16 µl 
saturated aqueous bromophenol blue solution, 80 µl 500 mM EDTA, pH 8.0, 
720 µl 37% formaldehyde, 2 ml 100% glycerol, 3.084 ml formamide, 4 ml 
formaldehyde agarose gel buffer, 100 µl RNase-free water). This was followed 
by heating to 65 °C for five minutes before cooling on ice. Samples were then 
run at 5 v/cm in 1x formaldehyde agarose gel running buffer for four hours.   
 
3.2.6.1.4 cDNA Preparation 
cDNA was prepared using the Superscript VILO cDNA synthesis kit (Invitrogen). 
Reactions were prepared as follows: 4 µl of 5x VILO reaction mix, 2 µl of 10x 
Superscript enzyme mix and 2.5 µg of total RNA. Diethylpyrocarbonate (DEPC) 
-treated water was used to make the final volume of the reaction 20 µl. The 
reactions were carried out using a PCR machine with the following cycle: 25 °C 
for 10 minutes, 42 °C for 2 hours, 85 °C for 5 minutes, and then stored at – 20 
°C.  
 
3.2.6.1.5 qPCR using TaqMan Probes 
Allele-specific qPCR was attempted using TaqMan Genotyping Assays-By-
Design (Applied Biosystems) with two genes, CDC6 and VPS1. The probes 
consisted of a pair of forward and reverse oligonucleotides which amplified a 
region of 150-200 bp and two fluorophore tagged oligonucleotides which bound 
in between this region, one FAM tagged and specific to one allele, the other VIC 
tagged and specific to the other allele. This technique had previously been 
proved successful by Harries et al. (2006) and Tuch et al. (2010a). For a full list 
of oligonucleotides used see Table 3.1. These probes were diluted to a 20x 
working concentration using 1 x TE buffer and stored in 20 µl aliquots at -20 °C.  
 
To analyse the specificity and efficiency of the probes, the qPCRs were first 
tested using genomic DNA (see section 2.13) from the wild-type strain SC5314, 
where both probes should be equally detected, and from appropriate 
heterozygous knockout strains (see Table 2.1), where only one probe should be 
detected. Heterozygous strains were constructed using transformation and 
homologous recombination of a cassette as detailed in sections 2.8 – 2.11. 
DNA was tested in 10x fold dilutions ranging from 100 ng to 0.0001 ng in 
triplicate. Sterile water was used as a negative control.  
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Reactions were set up as follows: 5 µl of TaqMan Universal PCR mastermix 
(Applied Biosystems), 0.5 µl of 20x TaqMan Assay (Applied Biosystems) and 
4.5 µl of DNA diluted in 1 x TE buffer.  
 
qPCR was carried out using a Stratagene Mx3005P set to detect fluorescence 
from FAM and HEX (equivalent to VIC) fluorophores. The cycle was set as 
follows: 
95 °C for 10 minutes  
92 °C for 15 seconds       40 cycles 
60 °C for 1 minute  
 
To calculate the efficiency of the primer sets, ΔCt values were plotted against 
the concentration of DNA standards from SC5314. Efficiency was calculated 
using the gradient of this line (Δx/Δy) and the following calculation taken from 
Applied Biosystems: 
Efficiency= ((10
-
1
gradient) -1) ×100 
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Table 3.1 TaqMan genotyping assay-by-design oligonucleotides used for 
allele-specific qPCR 
Name Sequence 5’ – 3’ Assay Position
1
 Probe 
CDC6_F TTTGCCATACAATGCTGATCAAATTAAATC
A 
CDC6 1 818 – 838  - 
CDC6_R TGTATAGCACCCGGGTGGAA 888 – 907  -  
CDC6_V 
ALLELE 1 
ATTATCTAATCTTAAACAAGAAAT 863 – 886  VIC 
CDC6_M 
ALLELE 2 
ATTATCTAATCTTAAACAAGAGAT 863 – 886  FAM 
VPS1_F AGAGTACTTTACCTGACATCAAGATGAGA VPS1 1 
 
947 – 975  - 
VPS1_R AGATGCCAGTGTAATCTTTGGAGAAAT 1073 – 
1099  
- 
VPS1_V 
ALLELE 1 
AAGCATTGATAATTCCTG 1003 – 
1020  
VIC 
VPS1_M 
ALLELE 2 
AGCATTGATAATTCTTG 1003 – 
1019  
FAM 
CDC6_F_2 GGTGATTTGAGAAAGGCATTTGATATATG CDC6 2 
 
939 – 967  - 
CDC6_R_2 TGATTTTCATTATTGCCAAAAGATGTCATA
CAAA 
1051 – 
1084  
- 
CDC6_V_2 
ALLELE 1 
AGTTGTCAAGGTACTGATACG 996 – 
1016  
VIC 
CDC6_M_2 
ALLELE 2 
TTGTCAAGGTACCGATACG 998 – 
1016  
FAM 
VPS1_F_2 ACCCATCATACAGAGCCAAAGC VPS1 2 
 
863 – 884  - 
VPS1_R_2 CTTGATGTCAGGTAAAGTACTCTTGATGT 941 – 969  - 
VPS1_V_2 
ALLELE 1 
CTGTGGTACGCCTTAC 891 – 906  VIC 
VPS1_M_2 
ALLELE 2 
TTCTGTGGTACTCCTTAC 889 – 906  FAM 
VPS1_F_3 AAAGTCCCCGTTGGTGATCAG VPS1 3 
 
502 – 522  - 
VPS1_R_3 TGACAGACAAGATAATGGCGTTAGG 577 – 601  - 
VPS1_V_3 
ALLELE 1 
AAGATATTGAAAGGCAAATC 527 – 546  VIC 
VPS1_M_3 
ALLELE 2 
AGATATTGAAAGACAAATC 528 – 546  FAM 
1. Relative to gene start position = 1.  
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3.2.6.1.6 qPCR using SYBR® Green 
Allele-specific qPCR was attempted using a conventional SYBR® green 
technique with primers which amplify each allele specifically. 
 
Oligonucleotides were designed for three genes: VPS1, CDC6 and RBT4. 
Specificity for each allele was achieved by designing the oligonucleotides to 
bind at SNP positions. Specificity of a range of oligonucleotide combinations 
were first computationally tested using BLASTn 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi) before testing using PCR (as described 
in section 2.7). Table 3.2 lists all of the oligonucleotides tested. Genomic DNA 
extracted from either the wild-type strain SC5314 or from an appropriate 
heterozygous knockout strain (see Table 2.1) was used as template DNA. 
Heterozygous strains were constructed using transformation and homologous 
recombination of a cassette as detailed in sections 2.8 – 2.11. PCR products 
were analysed for specificity using DNA gel electrophoresis (see section 2.5).  
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Table 3.2 Oligonucleotides analysed for allele-specificity for use in allele-
specific qPCR 
Name Sequence 5’ – 3’ Position
1
 Gene 
VPS1-F CAGGGACGCATTGAAAGA 822 – 839  VPS1 
VPS1-1-R GAGATTCGGCCATTTCTG 1025 – 1042  VPS1 
VPS1-2-R GGAGACTCAGCCATTTCAG 1025 – 1043  VPS1 
VPS1-2-R-2 AGGAGACTCAGCCATTTCA 1026 – 1044  VPS1 
VPS1-F1-1A GGTGGAGGGTCATCCTCG 58 – 75  VPS1 
VPS1-F1-2A GGGGGAGGATCATCCTCG 58 – 75  VPS1 
VPS1-R1-1A TTCCCTGGCAAATGCAAA 327 – 344  VPS1 
VPS1-R1-2A TTCCCCGGCAAATGCA 329 – 344  VPS1 
VPS1-F23-1A TTGCATTTGCCAGGGAA 328 – 344  VPS1 
VPS1-F23-2A TGCATTTGCCGGGGA 329 – 343  VPS1 
VPS1-R2-1A CTTTGATTTGCCTTTCAATATC 479 – 500  VPS1 
VPS1-R2-2A CATATCTTTGATTTGTCTTTCAATATC 479 – 505  VPS1 
VPS1-R3-1A GGCGTTAGGCTTGGAAA 569 – 585  VPS1 
VPS1-R3-2A AATGGCGTTAGGCTTAGAAATA 567 – 590  VPS1 
VPS1-F45-12A CTATCAGGGACGCATTGAAAG 818 – 838  VPS1 
VPS1-R4-1A ATTTCTTCAATGAATGTTCGATTC 974 – 997  VPS1 
VPS1-R4-2A ACTTCTTCAATGAATGCTCAATTC 974 – 997  VPS1 
VPS1-R5-1A GATTCGGCCATTTCTGGTC 1022 – 1040  VPS1 
VPS1-R5-2A GACTCAGCCATTTCAGGTCC 1021 – 1040  VPS1 
VPS1-F6-1A GAATCGAACATTCATTGAAGAAAT 974 – 997  VPS1 
VPS1-F6-2A GAATTGAGCATTCATTGAAGAAGT 974 – 997 VPS1 
VPS1-R678-12A TGGCATTAACCCCATTCTTG 1179 – 1198  VPS1 
VPS1-F7-1A CCAGAAATGGCCGAATCTC 1024 – 1042 VPS1 
VPS1-F7-2A CCTGAAATGGCTGAGTCTCC 1024 – 1043  VPS1 
VPS1-F8-1A TACCAACAGGAATTATCAATGCTT 997 – 1020  VPS1 
VPS1-F8-2A TATCAACAAGAATTATCAATGCTTG 997 – 1021  VPS1 
CDC6-F1-1A CCAATAACTCACGAGTAGATAAT 89 – 111 CDC6 
CDC6-F1-2A TCCAAAAAACTCAAAATAGATAAT 90 – 111  CDC6 
CDC6-R12-1A CATTAGAATAGTTCACGTTGG 256 – 276  CDC6 
CDC6-R12-2A CATTAGAATGACTCACGTTGG 256 – 276  CDC6 
CDC6-F2-1A TCTGTTGACTACTGGGAACC 118 – 137  CDC6 
CDC6-F2-2A CTCTTTTGATACAGGGAAACC 117 – 138  CDC6 
CDC6-F3-1A CCAAAATACCTTCAACTTCAC 180 – 200  CDC6 
CDC6-F3-2A CCAAAAAACCTTCAACTTCAC 180 – 200  CDC6 
CDC6-R3-1A GCAGTCTTACCCGTCCC 384 – 400 CDC6 
CDC6-R3-2A GCAGTTTTACCAGTGCCTGG 381 – 400  CDC6 
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CDC6-F4-1A CCAAGATTAGTGAGAAATAATATTC 774 – 798  CDC6 
CDC6-F4-2A CCAAGATTAGTTAGAAATAATATTC 774 – 798  CDC6 
CDC6-R4-1A CAAATCACCAGATATTGATGC 927 – 947  CDC6 
CDC6-R4-2A ATCACCGGATATTGATGC 927 – 944  CDC6 
CDC6-F5-1A CAAGAAATTTTCCACCCG 879 – 896  CDC6 
CDC6-F5-2A CAAGAGATCTTCCACCCG 879 – 896   CDC6 
CDC6-R5-1A TTTGCCACATGTTGAATCA 1030 – 1048  CDC6 
CDC6-R5-2A TTTAGCCACATGTTGAATCA 1030 – 1049  CDC6 
CDC6-F6-1A AATATCTGGTGATTTGAGAAAG 932 – 953  CDC6 
CDC6-F6-2A AATATCCGGTGATTTGAGAAAG 932 – 953  CDC6 
CDC6-R6-1A AGTTTTGTTGGAACATTTCG 1156 – 1175  CDC6 
CDC6-R6-2A AGTTTTGTTGGAACGTTTCG 1156 – 1175  CDC6 
CDC6-F7-1A CAAGGTACTGATACGATTAATAAA 1002 – 1025  CDC6 
CDC6-F7-2A CAAGGTACCGATACGATTAATAAA 1002 – 1025  CDC6 
CDC6-R7-1A TTTTAACAGTCCAATCAAATTA 1244 – 1265 CDC6 
CDC6-R7-2A TTTCAACAGTCCAATCAAATCA 1244 – 1265  CDC6 
CDC6-F8-1A CGAAATGTTCCAACAAAACT 1156 – 1175  CDC6 
CDC6-F8-2A CGAAACGTTCCAACAAAACT 1156 – 1175  CDC6 
CDC6-R8-12A CAACAAAATACAACTACTACTTTCC 1248 – 1272  CDC6 
CDC6-R1M-1A AGTTCACGTTGGATCCAC 250 – 267  CDC6 
CDC6-R1M-2A GACTCACGTTGGATCCAC 250 – 267  CDC6 
CDC6-F5M-1A AATTTTCCACCCGGGT 884 – 899 CDC6 
CDC6-F5M-2A GATCTTCCACCCGGGT 884 – 899  CDC6 
CDC6-R7M-2A CAACAGTCCAATCAAATCAT 1243 – 1262  CDC6 
RBT4-F1-1A CAACTGTCACTGGTGGTGAC 137 – 156  RBT4 
RBT4-F1-2A ACTGTCACAGGTGGTGGC 139 – 156  RBT4 
RBT4-R1-12A CCATTACCACCATCAGCAT 278 – 296  RBT4 
RBT4-F2-1A GCTGGTGATATTCAACAATC 196 – 215  RBT4 
RBT4-F2-2A GCTGATGATATCCAACAATC 196 – 215  RBT4 
RBT4-R2-12A CCATAACTGTAATAAACACCG 354 – 374 RBT4 
RBT4-F3-1A CAGCTGTTCCAGAAGCTG 248 – 265 RBT4 
RBT4-F3-2A CAGTTGTTCCAGAAGCTGA 248 – 266 RBT4 
RBT4-R3-12A GGATATTGGTCATCTGAAGG 436 – 455  RBT4 
RBT4-F4-1A CCAATTTGCTCAACAAATC 627 – 645 RBT4 
RBT4-F4-2A CAAATTTGCTCAACAAATTT 627 – 646 RBT4 
RBT4-R4-1A CAAAGTTTCACCATATGTACC 776 – 796 RBT4 
RBT4-R4-2A CAAGTTTTCACCATATTTACC 776 – 796 RBT4 
RBT4-F5-1A CTACTGGTTACGAATATGCTC 704 – 724 RBT4 
RBT4-F5-2A CTACTGTTTACCAATATGCTCA 704 – 725 RBT4 
RBT4-R56-12A GATTTCCAGACAACTTGAGT 905 – 924 RBT4 
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RBT4-F6-1A CGTGATCAATCAAGTTGTC 733 – 751  RBT4 
RBT4-F6-2A GCTGATCAATACAGTTGTTCT 733 – 753 RBT4 
RBT4-F7-1A CTGCACACTCTGAGTGGTACA 760 – 781  RBT4 
RBT4-F7-2A TTGCAACACTCTGGTGGTAA 760 – 780 RBT4 
RBT4-R78-12A CCAGTTTTGAGCACGACAA 955 – 973 RBT4 
RBT4-F8-1A CATATGGTGAAACTTTGGCT 780 – 799 RBT4 
RBT4-F8-2A AATATGGTGAAAACTTGGCT 780 – 799  RBT4 
RBT4-R4M-2A GTTTTCACCATATTTACCACC 772 – 793  RBT4 
1. Relative to gene start position = 1. Negative numbers represent primers 
placed before the gene start position.  
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Oligonucleotide pairs indicating possible allele specificity (Table 3.3) were taken 
forward and tested using gradient PCR under a range of annealing 
temperatures to optimise specificity: 50.1 °C, 50.4 °C, 51.0 °C, 52.2 °C, 53.5 °C, 
55.1 °C, 56.6 °C, 58.3 °C, 60.1 °C, 61.2 °C, 61.8 °C and 62.2 °C.  
 
Table 3.3 Oligonucleotides optimised for allele-specificity using gradient 
PCR 
Name Sequence 5’ – 3’ Position1 Gene 
CDC6-F7-1A CAAGGTACTGATACGATTAATAAA 1001 – 1025  CDC6 
CDC6-F7-2A CAAGGTACCGATACGATTAATAAA 1001 – 1025  CDC6 
CDC6-R7-1A TTTTAACAGTCCAATCAAATTA 1244 – 1265 CDC6 
CDC6-R7-2A TTTCAACAGTCCAATCAAATCA 1244 – 1265  CDC6 
RBT4-F4-1A CCAATTTGCTCAACAAATC 627 – 645 RBT4 
RBT4-F4-2A CAAATTTGCTCAACAAATTT 627 – 646 RBT4 
RBT4-R4-1A CAAAGTTTCACCATATGTACC 776 – 796 RBT4 
RBT4-R4-2A CAAGTTTTCACCATATTTACC 776 – 796 RBT4 
 
Efficiency of the allele-specific oligonucleotide combinations were then tested 
using 2 x SYBR® Green Jumpstart Taq Ready Mix (Sigma Aldrich) with 10x fold 
dilutions of genomic DNA from either the wild-type strain SC5314 or from an 
appropriate heterozygous knockout strain (see Table 2.1). To ensure that the 
polymerase was working optimally, genomic DNA extraction using phenol was 
avoided. Instead DNA was extracted using a Masterpure™ Yeast DNA 
Purification Kit (Epicentre Biotechnologies) according to the manufacturer’s 
instructions, followed by further purification as follows. The final product from 
the extraction with the kit was added to 0.1 volumes of 3 M sodium acetate, 
three volumes of 100% ethanol and vortexed. Samples were frozen at -80 °C 
for one hour before centrifugation at 4 °C and 12000 rpm for 15 minutes. Pellets 
were washed in 3 volumes of 70% ethanol and centrifuged at 4 °C and 12000 
rpm for 10 minutes. The pellets were air dried at 37 °C for 15 minutes before 
resuspension in 1 x TE buffer. Concentrations were determined using a 
NanoDrop spectrophotometer.  
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Reactions were set up as follows: 25 µl of 2 x SYBR® Green Jumpstart Taq 
Ready Mix (Sigma Aldrich), 1 µl of forward primer, 1 µl of reverse primer, 0.5 µl 
of reference dye, 0.7 µl of DNA diluted in 1 x TE buffer, with the final volume 
made up to 50 µl with water. Reactions without DNA were used as negative 
controls. Technical triplicates were prepared.  
 
Reactions were carried out using a Stratagene Mx3005P set to detect 
fluorescence from SYBR® Green with a ROX reference dye. The cycle was set 
as follows: 
94 °C for 2 minutes  
94 °C for 15 seconds       40 cycles 
* °C for 1 minute  
* Appropriate annealing temperature as determined by previous gradient PCR. 
 
To calculate the efficiency of the primer sets, the average ΔCt values of the 
replicates were plotted against the concentration of DNA standards from 
SC5314. Efficiency was calculated using the gradient of this line (Δx/Δy) and 
the following calculation taken from Applied Biosystems: 
 
Efficiency= ((10
-
1
gradient) -1) ×100 
 
3.2.6.2 Restriction Enzyme Verification 
Verification of the RNA sequencing results was attempted with an allele-specific 
restriction enzyme digest (for the gene VPS1) as has been previously used for 
verification of AEI in maize (Zhang et al., 2011). As the genes of interest were 
present in such low abundance in cDNA samples, a PCR step was introduced 
prior to digestion to amplify the signal. This was carried out as described in 
section 2.7 using a selection of appropriate oligonucleotides from Table 2.7. 
PCR products were checked using DNA gel electrophoresis (see section 2.5) 
and gel extracted as described in section 2.6.  
 
PCR products amplified from genomic DNA from appropriate heterozygous 
knockout strains (see Table 2.1) and from the wild-type strain SC5314 were 
used as controls. Heterozygous strains were constructed using transformation 
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and homologous recombination of a cassette as detailed in sections 2.8 – 2.11. 
The wild-type genomic DNA should produce bands of the same intensity for 
both alleles, whereas the cDNA will have bands of varying intensity depending 
on the ratio of expression between allele 1 and allele 2.  
 
Restriction digest reactions were prepared as follows: 8 µl of the PCR product 
or genomic DNA (from the wild-type strain SC5314 or from an appropriate 
heterozygous knockout as described in Table 2.1) was combined with 1 µl of 
restriction enzyme (see Table 3.4), 2 µl of appropriate buffer and 9 µl of sterile 
water. The reaction was incubated at 37 °C for 3 and a half hours and the entire 
reaction was separated using DNA gel electrophoresis (see section 2.5).  
 
Table 3.4 Restriction enzymes used for allele-specific PCR fragment 
digestion 
Restriction Enzyme1 Buffer Gene Fragment Size (bp) 
HaeIII 4 VPS1 Allele 1 314 
123 
172 
Allele 2 26 
288 
295 
1. All restriction enzymes were purchased from New England BioLabs UK.  
 
3.2.6.3 Western Blotting 
To monitor the protein expression of individual alleles, strains were constructed 
with each individual allele tagged with a V5-6xHis marker (Milne et al., 2011). 
Strain construction was achieved using transformation and homologous 
recombination of a cassette as detailed in sections 2.8 – 2.11. All strains used 
are listed in Table 2.1. Expression of each allele was detected using an Anti-V5 
antibody (Invitrogen) and normalised against expression of the actin protein 
detected using an Anti-Actin antibody (Thermoscientific).  
 
3.2.6.3.1 Soluble Protein Extract 
To extract total soluble proteins, cells were grown to an optical density at 600 
nm of 1, as described in section 3.2.6.1.1, to make conditions comparable to the 
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RNA sequencing. Unless otherwise stated, all further steps were carried out on 
ice and centrifugation was carried out at 4 °C, Cells were then pelleted at 4000 
rpm for five minutes, washed in 10 ml of ice-cold sterile water and resuspended 
in 1 ml of ice-cold breaking buffer (100 mM Tris pH 7.5, 0.01% SDS, 1 mM DTT, 
10% (v/v) glycerol, 1 M EDTA, 100 µl protease inhibitor cocktail (Melford 
Laboratories)). Cells were then transferred to screw top microfuge tubes, 
pelleted at 13000 rpm for five minutes and resuspended in 250 µl of ice-cold 
breaking buffer. Acid-washed 0.4 – 0.6 mm glass beads were added to the 
meniscus layer and cells were broken open using a FASTPREP-24 bead beater 
(MP) four times at 6.5 m/s for 20 seconds with one minute intervals on ice. Cell 
debris and glass beads were pelleted at 13000 rpm for 10 minutes. The 
supernatant containing the protein was transferred to a fresh tube, clarified by 
centrifugation at 13000 rpm for 10 minutes and stored at -20 °C. Protein 
concentrations were determined using a Bradford Assay (Sigma Aldrich) 
following the manufacturer’s instructions. 
 
3.2.6.3.2 SDS-PAGE and Protein Transfer 
Approximately 50 µg of each protein sample (section 3.2.6.3.1) were combined 
with 1x protein sample buffer and 25 mM DTT before incubation at 70 °C for 10 
minutes. Samples were run on NuPAGE gels (4 – 12% gradient) in running 
buffer (1.21% (w/v) Tris, 2.38 % (w/v) HEPES, 0.1% (w/v) SDS) at 110 volts for 
approximately one hour. PVDF membrane (Invitrogen) was activated in 
methanol for 10 minutes. The proteins were then transferred to the activated 
membrane in transfer buffer (5 % (v/v) Transfer solution (Invitrogen), 10% 
methanol) at 30 volts for 90 minutes using an X Cell II™ Blot Module 
(Invitrogen). The membrane was then washed in TBS solution (10 mM Tris pH 
8.0, 137 mM sodium chloride). To ensure sufficient transfer of proteins, the 
membrane was stained with Ponceau S (0.1% Ponceau S, 5% acetic acid) for 
five minutes. Excess stain was rinsed away with deionised water and the 
membrane was photographed. The stain was then removed using 100 mM 
sodium hydroxide and the membrane was washed thoroughly in TBS solution.  
 
3.2.6.3.3 Detection of Protein Expression 
Membranes were blocked in 10 ml TBS-T + 5% BSA (TBS solution (10 mM Tris 
pH 8.0, 137 mM sodium chloride) + 0.1% Tween-20 + 5% BSA) overnight at 4 
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°C with gentle agitation. The primary antibody (Anti-V5 or Anti-Actin) was 
appropriately diluted in TBS-T + 5% BSA. Anti-V5 (Invitrogen) was diluted in a 
1:5000 ratio and Anti-Actin (Thermoscientific) was diluted in a 1:1000 ratio. The 
membrane was incubated in this solution for one hour with gentle agitation and 
then washed three times in 10 ml TBS-T for five minutes. The appropriate 
secondary antibody (Anti-mouse linked to horseradish peroxidase (HRP), 
Molecular probes) was diluted in a 1:10000 ratio in TBS-T + 5% BSA and the 
membrane was incubated in this solution for one hour with gentle agitation. 
Again, the membrane was washed three times in 10 ml TBS-T for five minutes. 
The membrane was then developed using an ECL Plus kit (Pierce Antibodies) 
following the manufacturer’s instructions and imaged using a G:Box system 
(SynGene) set with a chemiluminescence filter for detection of ECL substrates. 
 
For detection with multiple primary antibodies the blot was stripped after the first 
detection. The blot was washed in 20 ml pre-warmed western stripping buffer 
(2% SDS, 100 mM β-mercaptoethanol, 50 mM Tris pH 6.8) for 30 minutes at 65 
°C in a hybridisation oven (HL-2000 Hybrilinker, UVP). This was followed by 
washing five times in 10 ml TBS-T for five minutes with gentle agitation. The 
protocol was then repeated with the new antibody from the point of adding the 
primary antibody.    
 
3.3 Results 
3.3.1 Identification of Genes with AEI and the Structural Trends 
Associated with These Genes  
3.3.1.1 Genes with Allelic Expression Imbalance 
RNA sequencing of the C. albicans wild-type strain SC5314, grown in standard 
laboratory conditions in triplicate (YPD at 30 °C, OD at 600 nm = 1), yielded 
16,166,757 reads for replicate 1, 17,369,675 for replicate 2 and 16,853,362 for 
replicate 3. 26,125,364 sequence tags mapped to 5,807 ORFs, producing a 
median count of 320 tags per ORF (average per base coverage, 117x). To 
identify genes with allelic expression imbalance, only reads which aligned 
uniquely to the diploid reference genome (Jones et al., 2004) were used. Reads 
were normalised to produce a RPKM value (Mortazavi et al., 2008) for each 
allele and statistically compared using a Fisher’s Exact Test with a cut off of 2x 
fold difference in expression at a p-value of <0.0000077 (set using Bonferroni 
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correction). These criteria identified a total of 152 genes with significant allelic 
expression imbalance and a further 81 genes with monoallelic expression 
(Appendix I Table Ia and Ib).   
 
3.3.1.2 Gene Ontology (GO) Analysis 
Gene Ontology (GO) term analysis was carried out, using the GO Term Finder 
tool available from the Candida Genome Database (www.candidagenome.org) 
(Inglis et al., 2012), to identify any functional patterns present within genes with 
allelic expression imbalance. No significant over representation was observed in 
process, component or function. This suggests that AEI is present in a random 
selection of genes and that there is no strong selection for AEI to operate in any 
concerted manner in specific biological processes. Therefore reasons behind 
the phenomenon of AEI need to be considered on a gene-by-gene basis. 
 
Identification of the GO terms associated with these 233 genes, using the GO 
Slim Mapper tool available from the Candida Genome Database 
(www.candidagenome.org) (Inglis et al., 2012), shows that some genes with 
AEI are however associated with virulence attributes (Table 3.5).  
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Table 3.5 GO Process Terms found in the set of genes with allelic expression imbalance. Identified using “CGD Gene Ontology 
Slim Mapper” (www.candidagenome.org)  
GOID GO term Frequency Background Frequency Gene(s) 
50789 
“regulation of 
biological 
process” 
49 out of 233 
genes, 21.0% 
1328 out of 6712 genes, 
19.8% 
ALS1 ARP4 BCY1 CAR1 CDC6 CST5 ECM25 HGT1 IFH1 LTP1 MDN1 MSS4 NUP84 
POR1 RCK2 RFG1 RPN4 RPS23A SFL2 SMI1 SNF4 SRR1 SSK2 SSY1 TAC1 TBF1 
VID21 VMA7 ZCF6 orf19.1185 orf19.1196 orf19.1212 orf19.1643 orf19.1694 orf19.2309 
orf19.232 orf19.2458 orf19.2743 orf19.3792 orf19.3920 orf19.3954 orf19.4295 
orf19.4488 orf19.4728 orf19.48 orf19.5221 orf19.6080 orf19.643 orf19.748 
8150 
“biological 
process” 
48 out of 233 
genes, 20.6% 
1699 out of 6712 genes, 
25.3% 
BMT6 EMC9 FAV3 HIT1 IFF9 PGA45 PGA57 PHM7 WSC1 orf19.1152 orf19.1219 
orf19.1246 orf19.1266 orf19.1383 orf19.1440 orf19.1637 orf19.1725 orf19.1736 
orf19.1948 orf19.1953 orf19.2051 orf19.2381 orf19.246 orf19.2521 orf19.254 orf19.2724 
orf19.2731 orf19.2742 orf19.310 orf19.3353 orf19.3448 orf19.3607 orf19.3644 
orf19.4068 orf19.4332 orf19.4349 orf19.4398 orf19.4470 orf19.4749 orf19.4880 
orf19.4952 orf19.4959 orf19.5103 orf19.5626 orf19.5648 orf19.6235 orf19.6351 
orf19.6556 
6810 “transport” 
41 out of 233 
genes, 17.6% 
1001 out of 6712 genes, 
14.9% 
ATP1 CHS6 DAL4 ECM1 ECM21 EXO84 FCY21 HGT1 IFC1 ITR1 MSN5 MTR10 
NUP84 PIR1 PLD1 POR1 SAC3 SEO1 SNX4 SSY1 SUL2 TFP1 TPO3 VMA11 VMA7 
VPS1 YDJ1 orf19.1356 orf19.1386 orf19.1536 orf19.2002 orf19.3556 orf19.4184 
orf19.4337 orf19.4466 orf19.5095 orf19.5534 orf19.6020 orf19.6346 orf19.6555 
orf19.748 
6996 
“organelle 
organization” 
35 out of 233 
genes, 15.0% 
913 out of 6712 genes, 
13.6% 
ARP4 ATS1 BBC1 CDL1 IFM1 MDN1 MSS4 NUP84 POR1 SAC3 SNF4 SSK2 TBF1 
VID21 VPS1 YDJ1 orf19.1185 orf19.1212 orf19.1386 orf19.1646 orf19.2002 orf19.2309 
orf19.2743 orf19.3161 orf19.4184 orf19.4295 orf19.4488 orf19.4728 orf19.48 orf19.5221 
orf19.5534 orf19.6020 orf19.643 orf19.6555 orf19.748 
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16070 
“RNA 
metabolic 
process” 
30 out of 233 
genes, 12.9% 
723 out of 6712 genes, 
10.8% 
ATS1  CDL1 EDC3 ERB1 EXO84 IFH1 MDN1 MPP10 POL5 PUS4 PWP1 RPS23A 
SAC3 SES1 SGD1 TAC1 TBF1 TIF4631 orf19.1356 orf19.1646 orf19.1938 orf19.2309 
orf19.3103 orf19.3161 orf19.3792 orf19.4295 orf19.48 orf19.494 orf19.518 orf19.581 
6950 
“response to 
stress” 
26 out of 233 
genes, 11.2% 
794 out of 6712 genes, 
11.8% 
ARP4 BCY1 CHT2 ECM25 EDC3 HGT1 HSP12 NUP84 OCA1 PLD1 RCK2 RFG1 
RPN4 SAC3 SGD1 SNF4 SRR1 SSK2 TAC1 VID21 VMA7 orf19.2458 orf19.3954 
orf19.5221 orf19.6020 orf19.748 
30447 
“filamentous 
growth” 
22 out of 233 
genes, 9.4% 
555 out of 6712 genes, 
8.3% 
ALS1 BCY1 CHT2 CST5 ECM25 EDC3 HGT1 LMO1 PLD1 RCK2 RFG1 SFL2 SNF4 
SRR1 SSY1 TAC1 VMA7 VPS1 orf19.1536 orf19.3524 orf19.3954 orf19.583 
6464 
“cellular 
protein 
modification 
process” 
19 out of 233 
genes, 8.2% 
535 out of 6712 genes, 
8% 
ARP4 LTP1 OCA1 PPT1 RCK2 SNF4 SSK2 VID21 orf19.1092 orf19.1185 orf19.1196 
orf19.1557 orf19.261 orf19.2743 orf19.3524 orf19.3996 orf19.4466 orf19.4728 
orf19.6020 
42221 
“response to 
chemical 
stimulus” 
18 out of 233 
genes, 7.7% 
637 out of 6712 genes, 
9.5% 
CST5 ERB1 FCY21 HGT1 OCA1 PLD1 RBT4 RCK2 RPN4 SMI1 SRR1 SSK2 SSY1 
TAC1 TPO3 orf19.3954 orf19.4488 orf19.583 
42254 
“ribosome 
biogenesis” 
17 out of 233 
genes, 7.3% 
281 out of 6712 genes, 
4.2% 
CDL1 ECM1 ERB1 MDN1 MPP10 PWP1 RPS23A RPS7A SAC3 SGD1 TIF4631 
orf19.1646 orf19.2002 orf19.3161 orf19.3797 orf19.494 orf19.6346  
7010 
“cytoskeleton 
organization” 
11 out of 233 
genes, 4.7% 
180 out of 6712 genes, 
2.7% 
ARP4 ATS1 BBC1 MSS4 SSK2 VPS1 YDJ1 orf19.1185 orf19.5221 orf19.5534 
orf19.643 
16192 
“vesicle-
mediated 
transport” 
11 out of 233 
genes, 4.7% 
308 out of 6712 genes, 
4.6% 
CHS6 ECM21 EXO84 PLD1 SNX4 TFP1 VPS1 orf19.1386 orf19.4184 orf19.5095 
orf19.5534 
7049 “cell cycle” 
9 out of 233 
genes, 3.9% 
407 out of 6712 genes, 
6.1% 
ARP4 CDC6 SAC3 orf19.1185 orf19.3411 orf19.3556 orf19.5534 orf19.6240 orf19.643 
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6629 
“lipid metabolic 
process” 
9 out of 233 
genes, 3.9% 
252 out of 6712 genes, 
3.8% 
MSS4 PDX3 PLD1 orf19.1092 orf19.1212 orf19.273 orf19.3954 orf19.3996 orf19.4122 
6412 “translation” 
9 out of 233 
genes, 3.9% 
320 out of 6712 genes, 
4.8% 
IFM1 RPL20B RPL24A RPS23A RPS7A SES1 orf19.3792 orf19.4751 orf19.48 
9405 “pathogenesis” 
9 out of 233 
genes, 3.9% 
215 out of 6712 genes, 
3.2% 
ALS1 PLD1 RBT4 RCK2 RFG1 SFL2 SRR1 VMA7 orf19.3524 
7165 
“signal 
transduction” 
8 out of 233 
genes, 3.4% 
189 out of 6712 genes, 
2.8% 
BCY1 CST5 ECM25 MSS4 RCK2 SRR1 SSK2 orf19.1196 
6259 
“DNA 
metabolic 
process” 
8 out of 233 
genes, 3.4% 
371 out of 6712 genes, 
5.5% 
ARP4 CDC6 NUP84 SAC3 TBF1 VID21 orf19.4295 orf19.748 
5975 
“carbohydrate 
metabolic 
process” 
7 out of 233 
genes, 3.0% 
251 out of 6712 genes, 
3.7% 
CHS6 CHT2 SMI1 orf19.1092 orf19.261 orf19.3996 orf19.4488 
71555 
“cell wall 
organization” 
7 out of 233 
genes, 3.0% 
168 out of 6712 genes, 
2.5% 
ECM1 ECM21 ECM25 LMO1 PIR1 RCK2 orf19.5221 
42493 
“response to 
drug” 
7 out of 233 
genes, 3.0% 
357 out of 6712 genes, 
5.3% 
ERB1 FCY21 HGT1 RBT4 SMI1 TAC1 TPO3 
42710 
“biofilm 
formation” 
5 out of 233 
genes, 2.1% 
125 out of 6712 genes, 
1.9% 
ALS1 CST5 IFD6 SMI1 VPS1 
30163 
“protein 
catabolic 
process” 
5 out of 233 
genes, 2.1% 
196 out of 6712 genes, 
2.9% 
APE3 RPN4 RPN6 YDJ1 orf19.6630 
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19725 
“cellular 
homeostasis” 
5 out of 233 
genes, 2.1% 
152 out of 6712 genes, 
2.3% 
POR1 TFP1 VMA7 orf19.1536 orf19.3920  
746 “conjugation” 
4 out of 233 
genes, 1.7% 
92 out of 6712 genes, 
1.4% 
CST5 ITR1 PLD1 SSY1  
16044 
“cellular 
membrane 
organization” 
4 out of 233 
genes, 1.7% 
179 out of 6712 genes, 
2.7% 
SNX4  orf19.1386 orf19.4184 orf19.6020 
48468 
“cell 
development” 
4 out of 233 
genes, 1.7% 
108 out of 6712 genes, 
1.6% 
ITR1 MSS4 PLD1 orf19.4466 
910 “cytokinesis” 
3 out of 233 
genes, 1.3% 
120 out of 6712 genes, 
1.8% 
CYK3 orf19.3411 orf19.6240 
45333 
“cellular 
respiration” 
3 out of 233 
genes, 1.3% 
98 out of 6712 genes, 
1.5% 
RIB3 orf19.2309 orf19.4468 
6457 
“protein 
folding” 
3 out of 233 
genes, 1.3% 
98 out of 6712 genes, 
1.5% 
YDJ1 orf19.2828 orf19.3920 
6091 
“generation of 
precursor 
metabolites 
and energy” 
3 out of 233 
genes, 1.3% 
138 out of 6712 genes, 
2.1% 
RIB3 orf19.2309 orf19.4468 
6997 
“nucleus 
organization” 
3 out of 233 
genes, 1.3% 
46 out of 6712 genes, 
0.7% 
NUP84 orf19.2002 orf19.748 
6766 
“vitamin 
metabolic 
process” 
3 out of 233 
genes, 1.3% 
37 out of 6712 genes, 
0.6% 
PDX3 RIB3 orf19.3411 
Page | 114  
 
30448 
“hyphal 
growth” 
2 out of 233 
genes, 0.9% 
60 out of 6712 genes, 
0.9% 
ALS1 orf19.3524 
44419 
“interspecies 
interaction 
between 
organisms” 
2 out of 233 
genes, 0.9% 
126 out of 6712 genes, 
1.9% 
ALS1 SMI1 
7155 “cell adhesion” 
1 out of 233 
genes, 0.4% 
49 out of 6712 genes, 
0.7% 
ALS1 
7114 “cell budding” 
1 out of 233 
genes, 0.4% 
36 out of 6712 genes, 
0.5% 
ATS1 
70783 
“growth of 
unicellular 
organism as a 
thread of 
attached cells” 
1 out of 233 
genes, 0.4% 
76 out of 6712 genes, 
1.1% 
CST5 
7124 
“pseudohyphal 
growth” 
0 out of 233 
genes, 0.0% 
39 out of 6712 genes, 
0.6%  
32196 “transposition” 
0 out of 233 
genes, 0.0% 
4 out of 6712 genes, 0.1% 
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Seven genes (ERB1, FCY21, HGT1, RBT4, SMI1, TAC1 and TPO3) are 
associated with the “response to antifungal drugs”. This includes TAC1, the 
transcription factor which activates the drug resistance genes CDR1 and CDR2. 
This gene has already been identified as having functionally distinct ‘normal’ 
and ‘hyperactive’ alleles which can be found together in a heterozygous strain 
(Coste et al., 2006). 
  
There are also nine genes under the category of “pathogenesis” (ALS1, PLD1, 
RBT4, RCK2, RFG1, SFL2, SRR1, VMA7 and orf19.3524). ALS1 (an adhesin-
like mannoprotein) is involved in adhesion to host epithelial cells. Other 
members of this gene family, for example ALS9, have also been found to have 
functionally distinct alleles (Zhao et al., 2003, Zhao et al., 2007). RFG1 is a 
transcriptional regulator of filamentous growth (Kadosh and Johnson, 2001). 
Defects in virulence in mice are seen in both the heterozygous and 
homozygous knockout strains. Interestingly, this paper shows differences in 
virulence phenotypes between a heterozygous knockout and a heterozygous 
reintegrant strain, with suggestions of difference in allele expression or activity 
(Kadosh and Johnson, 2001).  
   
22 genes are associated with “filamentous growth” (ALS1, BCY1, CHT2, CST5, 
ECM25, EDC3, HGT1, LMO1, PLD1, RCK2, RFG1, SFL2, SNF4, SRR1, SSY1, 
TAC1, VMA7, VPS1, orf19.1536, orf19.3524, orf19.3954 and orf19.583). The 
morphological switch between yeast and hyphal form has been associated with 
the virulence of C. albicans strains (Biswas et al., 2007). The gene ECM25, 
which has been highlighted as a gene with AEI, has been shown to be 
important during this transition. Homozygous knockout strains of ECM25 have 
reduced virulence in mice associated with defects in filamentous growth, cell 
morphology and cell growth (Zhang et al., 2008). Other genes which fall under 
this category of filamentous growth associated include TAC1, ALS1 and the 
protein kinase A regulatory subunit BCY1. 
 
Five genes that display AEI are associated with “biofilm formation” (ALS1, 
CST5, IFD6, SMI1, and VPS1). Biofilms are a clinically relevant phenotype, 
which form on medically implanted devices such as catheters and dentures, and 
often show increased resistance to antifungals (Ramage et al., 2004). Alongside 
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ALS1, inducible homozygous knockouts of the vacuolar sorting protein VPS1 
have been identified as defective in biofilm formation and filamentous growth 
(Bernardo et al., 2008).  
 
A further seven genes with AEI that exhibit with “cell wall organisation” (ECM1, 
ECM21, ECM25, LMO1, PIR1, RCK2 and orf19.5221) including the 
aforementioned gene ECM25. The cell wall is an integral structure with 
involvement in adhesion to host cells, drug resistance and response to stress. 
Additionally, PIR1 has a role in cell wall assembly. This gene produces two 
distinct alleles that differ in length. Heterozygous knockouts of either allele have 
shown hypersensitivity to various drugs (Martínez et al., 2004). 
 
No significant differences are observed in the percentages of genes within GO 
terms between the 152 genes with AEI and the 81 genes with monoallelic 
expression (Figure 3.2). But it should be noted that there are a much larger 
proportion of genes associated with “transport” and “protein catabolic” 
processes in monoallelic genes (24.7% monoallelic vs. 13.8% AEI). Additionally 
there are no monoallelic genes involved with “cytokinesis”, “cell budding”, “cell 
adhesion” and “hyphal growth” suggesting that C. albicans may require both 
alleles of a gene to be expressed to maintain these vital processes.  
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Figure 3.2 Percentage of genes with AEI (blue) and monoallelic expression (red) within 
each Gene Ontology term. As defined by CGD Gene Ontology Slim Mapper 
www.candidagenome.org.  
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3.3.1.3 Differences in Promoter Sequences of Genes with AEI 
As promoter sequences are undefined in C. albicans, the 1000 bp upstream (or 
the region up to the neighbouring open reading frame) of an allele were 
compared for a gene as described in section 3.2.3 to assess if differences in  
promoter sequences are the driving force behind AEI. Of the 233 genes 
identified with AEI, the upstream DNA sequences were available for 190 genes. 
75% of these genes with AEI were found to have a difference of at least one 
base pair in this region. However, when analysis was carried out on an 
equivalent data-set of genes with equal allele expression (fold difference ≈ 1) 
(Appendix I Table II), 78% of genes were also found to have differences in the 
upstream region. Therefore it cannot be concluded that differences in promoter 
sequences are leading to differences in allele expression levels. Based upon 
the observed level of heterozygosity being one SNP in every 237 bp (Jones et 
al., 2004), the probability that 1000 bp region is homozygous can be calculated 
as follows: 
236
237
1000
= 0.015 
 
Therefore, based on this probability, it would be expected that just 3 promoter 
regions (1.5%) out of the 190 would be homozygous. However, a significantly 
larger proportion of promoter sequences were found to be homozygous at 25% 
(chi-square test, d.f. = 1, p = 4.91 x 10-165). From this it can be inferred that 
differences in promoter regions are not leading to differences in allele 
expression, and in fact mutations within these regions, of both genes with AEI 
and genes with equal allele expression, are selected against, possibly to ensure 
that gene expression levels are not altered. It should be noted that this 
probability has been calculated for the simplest model where 1000 bp upstream 
were compared for each in gene. In reality, upstream regions varied in length 
dependent upon the distance to the adjacent open reading frame which may 
impact upon this statistical measure.   
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3.3.1.4 Genes with AEI Show Significantly Lower Percentage Protein 
Identity 
To examine the hypothesis that genes with allelic expression imbalance have 
alleles with differing functions, the difference in the amino acid sequences of 
alleles with AEI was calculated with the assumption that a larger difference in 
protein sequence could indicate a functional difference. Percentage protein 
identity comparisons were carried out using the Needleman-Wunsch algorithm 
for global alignment (Rose and Eisenmenger, 1991). Each gene was assigned a 
percentage indicating the similarity of proteins produced by each allele. The 
genes with AEI were found to have significantly lower percentage protein 
identities when compared to a cohort of genes with equal allele expression (fold 
difference ≈ 1) (Appendix I Table II) (two-sample t-test, p < 0.001; Figure 3.3). A 
total of 34 genes have a protein identity of less than 50% (Table 3.6). The 
majority of these genes have unknown functions, however the list includes the 
transcription factor TAC1 which has previously been identified as having 
functionally distinct alleles (Coste et al., 2006). This provides support for the 
idea that functional differences in protein sequences could be the driving force 
behind allelic expression imbalance.  
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Figure 3.3. The distribution of percentage protein identities after arc sine transformation 
of genes with AEI (blue) and equally expressed alleles (red). The percentage protein 
identities of genes with AEI are significantly lower than that of equally expressed alleles 
(two sample t-test, p < 0.001). Black line shows fitted distribution assuming normal 
distribution.  
  
Allelic Expression Imbalance 
Equally Expressed 
Percentage Protein Identity (arc sine transformed) 
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Table 3.6 Genes with AEI and less than 50% protein identity between 
alleles 
Allele with Lowest 
Expression 
Allele with Highest 
Expression 
Gene Name Percentage Protein 
Identity (2 d.p.) 
orf19.2053 orf19.9599  11.05 
orf19.8215 orf19.583  15.13 
orf19.3188 orf19.10698 TAC1 18.55 
orf19.1694 orf19.9261  18.62 
orf19.4466 orf19.11946 ERP1 19.41 
orf19.4697 orf19.12167 MDN1 23.52 
orf19.4880 orf19.12344 YFW5 23.90 
orf19.10309 orf19.2791 BBC1 24.40 
orf19.6894 orf19.14182  27.09 
orf19.2665 orf19.10182 MSN5 29.36 
orf19.5624 orf19.13069  29.84 
orf19.4770 orf19.12233  30.10 
orf19.2127 orf19.9674 CST5 30.21 
orf19.11605 orf19.4122  30.89 
orf19.1383 orf19.8963  31.32 
orf19.9015 orf19.1440  33.33 
orf19.9130 orf19.1557  35.22 
orf19.4332 orf19.11806  35.64 
orf19.10590 orf19.3077 VID21 36.82 
orf19.5150 orf19.12615  37.34 
orf19.4887 orf19.12352 ECM21 37.54 
orf19.5615 orf19.13060 AYR2 38.25 
orf19.6389 orf19.13747  38.44 
orf19.10346 orf19.2828  38.52 
orf19.11191 orf19.3706  43.07 
orf19.8671 orf19.1069 RPN4 43.20 
orf19.5145 orf19.12610 SSP96 43.26 
orf19.7862 orf19.232  43.27 
orf19.1230 orf19.8815  43.58 
orf19.13020 orf19.5574  43.86 
orf19.1151 orf19.8744  45.11 
orf19.11826 orf19.4349  46.60 
orf19.11082 orf19.3599 TIF4631 47.27 
orf19.3524 orf19.11006  48.46 
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3.3.2 The Contribution of Structural Factors to AEI 
The impact of various structural factors upon AEI was investigated to determine 
any potential associations. These structural factors include chromosomal 
location, GC content, gene length and codon usage, and are influenced both by 
gene sequence and gene location. From the set of 233 genes with allelic 
expression imbalance, 22 were removed due to lack of information or deletion 
from the more recent C. albicans genome Assembly 21 (Van Het Hoog et al., 
2007) leaving 210 genes for analysis.  
 
3.3.2.1 Chromosomal Location 
An initial question to be addressed when looking at the consequence of 
structural factors upon allelic expression imbalance is gene location. Are there 
any significant patterns seen in the location or clustering of genes with AEI? 
The distribution of genes with AEI across chromosomes was analysed to see if 
there are any over-representations on certain chromosomes (Figure 3.4). The 
overall distribution of genes with allelic expression imbalance on each 
chromosome differs significantly from the expected percentage based upon that 
seen throughout the entire genome (Chi-square test, 7 d.f., p = 0.013; Table 
3.7). This significant difference is likely to be due to Chromosome R which has 
significantly fewer genes with AEI than expected (Chi-square test, 1 d.f., p = 
0.043; Table 3.7). Although Chromosome 7 actually has a smaller percentage 
of genes with AEI than Chromosome R, this did not result in a statistically 
significant difference to the distribution across the entire genome due to the 
smaller overall number of genes on Chromosome 7. However, the p value was 
very close to being significantly different (Chi-square test, 1 d.f., p = 0.073; 
Table 3.7).  
 
Table 3.7 Percentage of features across the entire C. albicans genome and 
within each chromosome that have AEI  
Chromosome Genome 1 2 3 4 5 6 7 R 
Percentage of 
features with AEI  
3.10 3.16 3.33 2.25 4.17 4.36 4.56 1.61 2.04
1
 
1. Chromosome R (highlighted red) has significantly less genes with AEI 
than expected (Chi-squared, 1 d.f., p = 0.043). 
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In Figure 3.4, clusters which are statistically unlikely to occur by chance are 
highlighted with arrows (Poisson distribution, p < 0.05; Figure 3.4). No patterns 
are obvious, with only a few clusters appearing, all of which are at different 
places across the chromosomes with no association to either centromeric or 
telomeric regions. However on chromosome 3, genes with AEI are restricted to 
just one small section. To see if this is significant clustering of genes with allelic 
expression imbalance, the location of all polymorphic genes on each 
chromosome was calculated and overlaid with the position of genes with AEI 
(Figure 3.5). The distribution of polymorphic genes are similar to those recorded 
during the sequencing of the diploid genome (Jones et al., 2004). In accordance 
with previous observations chromosome 3 is highly homozygous with 
significantly less polymorphic genes than expected when compared to the entire 
genome (Chi-square test, 1 d.f., p < 0.001; Table 3.8). These polymorphic 
genes are at the same locations as the genes with AEI suggesting that there is 
no significant clustering and that allelic expression imbalance is not influenced 
by the location of the gene.  
 
During determination of the location of all polymorphic genes, it was noted that 
chromosomes 1, 7 and R also have significantly less polymorphic genes than 
expected when compared to distribution across the entire genome (Chi-square 
test, 1 d.f. p = 0.002, p < 0.001 and p < 0.001 respectively; Table 3.8), whilst 
chromosome 6 has significantly more polymorphic genes than expected (Chi-
square test, 1 d.f., p < 0.001; Table 3.8). This may be a possible explanation as 
to why chromosome R has a significantly smaller percentage of genes with AEI. 
Clusters of polymorphic genes that are unlikely to happen by chance are 
highlighted in Figure 3.5 (Poisson distribution, p < 0.05). Surprisingly, as well as 
chromosomes 3, 7 and R having less polymorphisms than expected, the 
majority of these polymorphic genes are on one side of the centromere. This 
suggests that one arm is almost entirely homozygous. The advantage of this to 
C. albicans is not clear and needs further investigation. These findings support 
previous observations by (Odds et al., 2004) that heterozygosity within the C. 
albicans genome is unevenly distributed. Chromosome 5 and 6 were stated as 
highly homozygous, which is echoed within these results (Odds et al., 2004).  
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Figure 3.4 Distribution of genes with AEI across each chromosome. Genes with AEI 
are blue. Centromeres are red. The x-axis shows start coordinates as a percentage of 
the total length of the chromosome. The y-axis shows the number of differentially 
expressed polymorphic alleles. Clusters which are unlikely to happen by chance are 
highlighted with an arrow (Poisson distribution, p < 0.05).  
1
2
3
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5
6
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R 
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Figure 3.5 Distribution of polymorphic genes (green) and genes with AEI (blue) across 
each chromosome. Centromeres are shown in red. The x-axis shows start coordinates 
as a percentage of the total length of the chromosome. The y-axis shows the number 
of polymorphic alleles. Clusters which are unlikely to happen by chance are highlighted 
with an arrow (Poisson distribution, p < 0.05).  
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Table 3.8 Percentage of polymorphic genes present across the entire C. 
albicans genome and on each chromosome 
Chromosome Genome 1 2 3 4 5 6 7 R 
Percentage 
of 
polymorphic 
genes 
25.65 22.17
1
 23.87 11.89
1
 25.69 27.09 40.13
2
 7.59
1
 16.00
1
 
1. Highlighted blue as have fewer polymorphic genes than expected (Chi-
square test, 1 d.f., Chromosome 1 - p = 0.002, Chromosomes 3, 7, R – p 
< 0.001).  
2. Highlighted red as have more polymorphic genes than expected (Chi-
square test, 1 d.f., Chromosome 6 – p < 0.001). 
 
3.3.2.2 Overlapping Genes 
Transcript expression levels have been shown to be altered when the coding 
sequences of genes overlap, with results generally showing the occurrence of 
transcriptional repression (Nagalakshmi et al., 2008, Gagneur et al., 2009). 
From this it is possible to hypothesize that the patterns of AEI that we have 
identified in C. albicans could be due to uneven overlapping of alleles; where 
one allele overlaps, and therefore undergoes transcriptional repression, 
whereas the other allele does not overlap, and therefore expression is 
unaffected. This is seen in mice for the imprinted Mest locus (MacIsaac et al., 
2011) as described in section 3.1.2.2.  
 
To address this question, firstly the numbers of overlapping genes across each 
chromosome were identified and compared to the numbers of genes with AEI 
across each chromosome as discussed in section 3.3.2.1. In total, 5.89% of all 
features were found to overlap with their neighbouring open reading frame. Of 
these overlapping features, 20.15% were not ORFs. This figure is similar to that 
found in the human genome, where 1316 pairs of overlapping genes were 
identified, which is approximately 7% of all genes (Veeramachaneni et al., 
2004). The frequency of overlapping features across each chromosome 
appears to be random, as seen in Table 3.8. Statistical analysis shows that 
chromosome 1 has significantly less overlapping features than expected based 
on overall distribution across the genome (Chi-square test, 1 d.f., p < 0.001; 
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Table 3.9). Whereas chromosomes 3 and 7 and the mitochondrial genome have 
significantly more overlapping features than expected (Chi-square test, 1 d.f., p 
= 0.001, p = 0.02, p < 0.001 respectively; Table 3.9). Importantly, there are no 
similarities in the frequency of overlapping features and the frequency of genes 
with allelic expression imbalance on each chromosome (see Table 3.7) 
suggesting that overlapping is unlikely to be causally linked to allelic expression 
imbalance. 
 
Table 3.9 Percentage of features in the entire C. albicans genome and in 
each chromosome which overlap 
Chromosome  Genome 1 2 3 4 5 6 7 R M 
Percentage of 
Features that 
Overlap 
5.89 3.71
1
 5.74 8.64
1
 6.39 5.45 4.99 8.74
1
 5.55 25.00
1
 
1. Frequencies that differ significantly from expected are highlighted in red 
(chi-square test, 1 d.f., p < 0.001, p = 0.001, p = 0.02 and p < 0.001 
respectively).  
 
To further support the lack of a relationship between overlap and allelic 
expression imbalance, the genes with differentially expressed alleles that 
overlap with neighbouring features were identified. Only four genes (orf19.2127, 
orf19.246, orf19.3607 and orf19.4332) were found to satisfy both of these 
criteria out of a total of 391 overlapping genes (Table 3.10), which was deemed 
as a statistically significant low amount (hypergeometric distribution, p = 0.012). 
Of these four genes, two have both alleles overlapping with the adjacent ORF, 
suggesting that transcriptional interference due to overlap of only one allele is 
not the cause of the allelic expression imbalance.  Not only does this result 
firmly reject the hypothesis that allelic expression imbalance is due to overlap of 
just one allele, it also produces a further question – why do such an 
unexpectedly small number of genes with AEI overlap with neighbouring ORFs? 
Is there a disadvantage to overlapping? If open reading frames do overlap, is 
the expression level of one gene or both genes affected as seen in other 
organisms (Nagalakshmi et al., 2008, Gagneur et al., 2009)?  
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Table 3.10 Percentage of genes with AEI and without AEI that do and do 
not overlap with the neighbouring feature.  
  Overlapping 
Feature 
Non-Overlapping 
Feature 
Allelic Expression 
Imbalance 
0.06 % 3.45 % 
No Allelic Expression 
Imbalance 
5.83 % 90.66 % 
 
To investigate this, the RPKM values obtained via RNA sequencing for a pair of 
overlapping genes were compared, via a Fisher Exact test, to assess the effect 
of overlapping on gene expression. A subset of pairs were found to have 
significantly different RPKM values, and therefore expression levels (Fisher 
exact test, p < 0.000568; Table 3.11). The remaining pairs were deemed to 
have similar expression levels. The strand which genes were on was also 
considered, with the hypothesis that overlapping genes on the same strand 
were likely to have more divergent expression levels due to transcriptional 
interference, whereas the expression levels of overlapping genes in opposite 
orientation, and therefore on opposite strands, were predicted to be unaffected 
by each other. This has previously been shown to be the case for several genes 
in C. albicans, CCT8 and TRP1 have convergent overlap with each other and 
unaffected expression levels (Gerads and Ernst, 1998), two homologs of the 
human protein erbA overlap and are based on opposite strands, with the 
expression level of one unaffected by the other (Miyajima et al., 1989), this has 
also been found to be the case for the human genes TCP1 and ACAT2 
(Shintani et al., 1999).  The results suggest that expression levels of a pair of 
genes are generally unaffected when they overlap, and the strand which the 
genes are placed has no affect upon this difference (Chi-square test, 1 d.f., p = 
0.054; Table 3.11). This result may be because such a small number of pairs of 
overlapping genes were identified on the same strand, and therefore not 
enough were present to statistically represent a difference in expression. 
However, the results do support the alternative hypothesis, with a higher 
number of overlapping genes on the same strand with similar expression levels 
(Table 3.11). Surprisingly, these findings contradict previous studies in yeast 
where gene overlap has been linked to expression differences (Nagalakshmi et 
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al., 2008, Gagneur et al., 2009), though these investigations were carried out in 
S. cerevisiae which could explain this contradiction.  
 
Table 3.11 Number of pairs of overlapping genes that have significantly 
similar or different RPKM values (expression levels) and the link to strand 
identity 
  
  
  
Expression Level 
Same Different 
Strand Same 10 3 
Opposite 36 39 
 
 
  
Page | 130  
 
3.3.2.3 Relationship Between Structural Factors and Gene Expression 
Overall gene expression levels were determined by calculating RPKM values 
using the alignment against the haploid C. albicans reference genome (Van Het 
Hoog et al., 2007). GC content, ORF length, the codon usage values, CAI and 
GCB, and the usage of the CUG codon were then compared against the RPKM 
values to identify the relationship between these structural factors and 
expression. 
 
A very weak, but significant, negative correlation is seen between GC content 
and RPKM (Figure 3.6a), and between ORF length and RPKM (Figure 3.6b) 
suggesting that expression levels decrease as GC content and ORF length 
increases (Spearman’s correlation for GC content, ρ = -0.033, p = 0.02; 
Spearman’s correlation for ORF length, ρ = -0.083, p < 0.001). The trend seen 
with ORF length conforms to the generally accepted hypothesis that shorter 
genes are more transcriptionally efficient and therefore have higher expression 
levels (Coghlan and Wolfe, 2000, Jansen and Gerstein, 2000, Marín et al., 
2003). The GC content results support previous studies which suggest that 
higher GC content in some cases causes lower expression levels (Goncalves et 
al., 2000). The exact mechanism behind this relationship is still unclear. It is 
possible that higher GC content leads to a higher melting temperature, which in 
turn slows DNA unwinding and therefore transcription. Other elements, such as 
chromatin organisation could also influence transcription rates. It has been 
demonstrated in S. cerevisiae that low GC content tracts of dA:dT are rigid and 
therefore unable to bend around and bind nucleosomes. These nucleosome 
unbound regions are then associated with increased accessibility for the 
transcriptional machinery and therefore higher gene expression (Mavrich et al., 
2008).    
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Figure 3.6 Correlation between a) average GC content of allele 1 and 2; b) average 
ORF length of allele 1 and 2; c) average GCB of allele 1 and 2; d) average CAI of allele 
1 and 2; e) average CUG count of allele 1 and allele 2 and RPKM (reads per kilobase 
per million mapped reads) on a logarithmic scale (Spearman’s correlation; a) ρ = -
0.033, p = 0.02; b) ρ = -0.083, p < 0.001; c) ρ = 0.334, p < 0.001; d) ρ = 0.011, p = 
0.439; e) ρ = -0.237, p < 0.001). Linear trend lines are shown by the black lines.  
  
d) CAI Value   b 
e ) CUG Count  b b) ORF Length  
a ) GC Content  b 
c) GCB 
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No significant correlation was found when comparing average CAI with RPKM 
values calculated from the haploid alignment (Spearman’s correlation, ρ = 
0.011, p = 0.439 – Figure 3.6d). This suggests that CAI does not reflect 
expression levels and contradicts previous studies in yeast (Coghlan and Wolfe, 
2000) and the original paper in which CAI was developed (Sharp and Li, 1987).  
However, GCB was found to have a significant positive correlation with RPKM 
(Spearman’s correlation, ρ = 0.334, p < 0.001; Figure 3.6c). In this study, a 
higher positive GCB value is associated with genes with high expression levels, 
whereas a low or negative GCB value, is associated with genes with low 
expression levels. This trend is what is expected as based on the original paper 
(Merkl, 2003) and suggests, that based on codon usage, genes with higher 
expression levels favour protein sequences which use more abundant tRNAs. 
This trend is particularly noticeable in the most highly abundant genes with 
RPKM values greater than 1000 (on a logarithmic scale) as seen in Figure 3.6c.  
   
Unusually, C. albicans and other related Candida species translate the CUG 
codon as serine instead of leucine (Ohama et al., 1993). This change occurred 
due to codon reassignment approximately 170 million years ago (Massey et al., 
2003).  This has resulted in reduced usage of the CUG codon throughout these 
species (Butler et al., 2009). Here, this theory is supported by our transcriptional 
data which shows a significant negative correlation between the number of 
CUG codons per ORF and RPKM (Spearman’s correlation, ρ = -0.237, p < 
0.001; Figure 3.6e). This demonstrates that genes with high expression have 
fewer CUG codons.  
 
3.3.2.4 The Contribution of GC Content, Gene Length and Codon Usage to 
AEI 
Following up on the observed correlations of structural factors with overall gene 
expression levels, the relationship between GC content, ORF length, codon 
usage and allelic expression imbalance was assessed. Although CAI values did 
not correlate significantly with overall gene expression, the relationship with AEI 
was still assessed to ensure that no significant results were overlooked. For 
each factor, the values obtained from the allele with the lowest and highest 
expression were compared. In addition, structural factors were also assessed in 
a cohort of genes with equally expressed alleles (fold difference ≈1) (Appendix I 
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Table II). This ensures that any trends observed were specific to genes with 
allelic expression imbalance.  
 
GC content, GCB, CAI and CUG usage did not differ significantly between the 
alleles with lower and higher allele expression (two sample t-test, p = 0.76 – 
Figure 3.7a; two sample t-test, p = 0.83 – Figure 3.7c; two sample t-test, p = 
0.20 – Figure 3.7d; two sample t-test, p = 0.32 – Figure 3.7e). The case was the 
same for alleles with equal expression (two sample t-test, p = 0.94 – Figure 
3.8a; two sample t-test, 0.97 – Figure 3.8c; two sample t-test, p = 0.73 – Figure 
3.8d; two sample t-test, p = 0.94 – Figure 3.8e). These results indicate that 
despite the overall correlation with gene expression, GC content and codon 
usage are unlikely to have a role in regulation of AEI. Following on from the 
overall gene expression results, CAI is also ruled out from directly influencing 
allelic expression imbalance. This is supportive of the results found by Muzzey 
et al. (2014) who show that CAI does not have a role in allelic expression 
imbalance at the translational level in C. albicans.  
 
Although CAI and CUG usage did not differ significantly between the alleles, the 
mean difference in CAI and CUG usage (0.015 ± 0.023, 0.705 ± 1.70) is 
significantly larger in genes with AEI than genes with equal expression (0.005 ± 
0.012, 0.124 ± 0.558) (two-sample t-test, p < 0.001 – Figure 3.9d and 3.9e). 
This suggests that although CAI and CUG usage in differentially expressed 
alleles do not follow the overall expression trend, it may still have an important 
role.   
 
Surprisingly analysis of genes with AEI indicates that the ORF length of the 
allele with lowest expression is significantly shorter than the allele with higher 
expression (two sample t-test, p = 0.008; Figure 3.7b). This directly contradicts 
the results found when correlating ORF length with overall gene expression and 
the results found in previous studies in the yeast Saccharomyces cerevisiae 
(Coghlan and Wolfe, 2000, Jansen and Gerstein, 2000, Marín et al., 2003). This 
relationship is not seen in genes with equal allele expression, where no 
significant difference is observed between the ORF length of alleles (two 
sample t-test, p = 0.81 – Figure 3.8b). This suggests that the result is specific to 
the gene set with allelic expression imbalance. A possible explanation for this  
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Figure 3.7. Histograms showing the distribution of a) GC content; b) allele length (after logarithmic transformation); c) GCB value; d) CAI value and e) 
CUG count of alleles with lower and higher expression from the genes with allelic expression imbalance. No significant differences were found for GC 
content (two sample t-test, p = 0.76), GCB values (two sample t-test, p = 0.83), CAI values (two sample t-test, p = 0.20) nor CUG count (two sample t-
test, p = 0.32). The allele with lowest expression was found to have a significantly shorter length than the allele with higher expression (two sample t-
test, p = 0.008). Black lines represent fitted distribution assuming normal distribution. 
  
L
o
w
e
s
t 
E
x
p
re
s
s
io
n
 
H
ig
h
e
s
t 
E
x
p
re
s
s
io
n
 
a b c d e 
GC content ORF length GCB CAI CUG Count 
Page | 135  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.8. Histograms showing the distribution of a) GC content; b) allele length (after logarithmic transformation); c) the GCB value; d) the CAI value 
and e) the CUG count of allele one and allele two from the gene set of alleles with equal expression. No significant differences were found for GC 
content (two sample t-test, p = 0.94), ORF length (two sample t-test, p = 0.81), GCB values (two sample t-test, p = 0.97), CAI values (two sample t-
test, p = 0.73) nor CUG count (two sample t-test, p = 0.94). Black lines represent fitted distribution based assuming a normal distribution. 
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Figure 3.9. Histograms showing the distribution of a) differences in allele GC content; b) fold difference in allele length; c) differences in GCB; d) 
differences in CAI and e) differences in CUG count between genes with AEI (blue) and equally expressed alleles (red). A significantly larger variance 
in the data-set is observed for genes with AEI with each measure (F-test, p < 0.001). The difference in CAI and CUG count is significantly larger in 
genes with AEI (two sample t-test, p < 0.001). Black lines represent the fit to a normal distribution.  
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observation is that longer genes have been shown to be more “sequenceable” 
as more fragments are produced and therefore sequenced. This gives the 
impression that longer genes (or alleles) have higher expression levels, and it 
has been found that this difference in expression is not corrected for sufficiently 
by using RPKM (Bullard et al., 2010a).  
 
Another possible explanation may be found when looking at the relationship 
between differences in these structural factors and the percentage protein 
identities calculated in section 3.3.1.4. For all five factors, the difference in GC 
content, GCB, CAI and CUG usage and the fold difference in ORF length, there 
is a significantly larger variance in differentially expressed alleles when 
compared to equally expressed alleles (F-test, p < 0.001 in each case; Figure 
3.9). In the case of GC content, ORF length, CAI and CUG usage, a strong 
negative correlation is observed between this difference and percentage protein 
identity (Spearman’s correlation, ρ = -0.630, p < 0.001; Spearman’s correlation, 
p = -0.814, p < 0.001; Spearman’s correlation, ρ = -0.533, p < 0.001; 
Spearman’s correlation, ρ = -0.527, p < 0.001; Figure 3.10). This suggests that 
as the difference in GC content, length and codon usage increases, the 
percentage protein identity decreases, and therefore the alleles may become 
more functionally distinct. A positive correlation is also observed between the 
fold difference in length and the difference in GC content, CAI and in CUG 
usage (Spearman’s correlation, ρ = 0.560, p < 0.001; Spearman’s correlation, ρ 
= 0.481, p < 0.001; Spearman’s correlation, ρ = 0.456; Figure 3.11). It can be 
inferred from this that alleles with large size differences have larger changes in 
GC content and codon usage. This directly results in more non-synonymous 
substitutions. Additionally, shorter alleles could be missing functional domains 
entirely. It now remains to be investigated whether the imbalance in the allele 
expression levels is due to functional divergence of the alleles caused by these 
structural differences. If so, it can be elucidated that although the difference in 
allele length contributes towards allele-specific functions, it is not the sole 
causal factor or control element behind allelic expression imbalance.  
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Figure 3.10. Correlation between a) difference in GC content; b) fold difference in allele 
length; c) difference in GCB; d) difference in CAI and e) difference in CUG count with 
percentage protein identity of alleles which are differentially (blue) and equally (red) 
expressed.  (Correlation values for all genes [Spearman’s correlation; a) ρ = -0.630, p < 
0.001; b) p = -0.814, p < 0.001; c) ρ = -0.004, p = 0.942; d) ρ = -0.533, p < 0.001; e) ρ = 
-0.527, p < 0.001]). Fitted lines represent the linear trend line, except for b) where no 
appropriate trend lines were available to represent the data.  
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Figure 3.11. Correlation between a) difference in GC content; b) difference in GCB; c) 
difference in CAI and d) difference in CUG count with fold difference in ORF length in 
genes with alleles which are differentially (blue) and equally (red) expressed.  
(Correlation values for all genes [Spearman’s correlation; a) ρ = 0.560, p < 0.001; b) p 
= 0.498, p = 0.037; c) ρ = 0.456, p < 0.001; d) ρ = 0.481, p < 0.001]). Fitted lines show 
linear trend lines.  
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3.3.3 Attempts at Expression Validation using qPCR, Restriction Enzyme 
Digests and Western Blotting 
Validation of expression levels determined through RNA sequencing has 
previously been achieved using various methods including microarrays (Marioni 
et al., 2008, Bloom et al., 2009, Esteve-Codina et al., 2011, Guida et al., 2011) 
and qPCR (Marioni et al., 2008, Nagalakshmi et al., 2008, Bloom et al., 2009, 
Bruno et al., 2010). However, validating allelic expression imbalance has added 
complications with finding a method with the required high levels of both 
specificity and sensitivity. Therefore, four methods were adopted here in an 
attempt to verify the results produced from RNA sequencing, two types of allele-
specific qPCR, allele-specific restriction enzyme digestion of cDNA, and 
western blotting using strains with individually tagged alleles.   
 
3.3.3.1 Validation using Allele-Specific qPCR and TaqMan Probes 
Allele-specific qPCR has previously been used to both identify AEI and validate 
RNA sequencing results using TaqMan Genotyping Assays-By-Design (Applied 
Biosystems) (Harries et al., 2006, Tuch et al., 2010a). In this system, a region of 
DNA around 150 – 200 bp in length is amplified. Within this region, two probes 
are designed to bind over a SNP-containing region; a probe specific to “allele 
one” and a probe specific to “allele two”. Each probe is conjugated to a 
fluorescent probe, FAM or VIC, which is released and quantified when the 
probe binds to the DNA.   
 
In this instance two genes with significant AEI were chosen for validation using 
allele-specific qPCR, VPS1 and CDC6. In total, three assays were tested for 
VPS1 and two assays for CDC6 (see Table 3.1). Initially specificity and 
efficiency of the assays were tested using a 10x fold serial dilution of genomic 
DNA, in triplicate, from the wild-type strain SC5314, where both alleles are 
expected to be detected in equal quantities, and also from heterozygous 
knockout strains, where expression of just one allele is expected to be detected. 
For each concentration of DNA, the average Ct value of each probe was 
calculated, with increasing concentrations of DNA predicted to have lower Ct 
values. Figure 3.12 demonstrates the set of graphs that would be produced 
when plotting DNA concentration against average Ct value if the specificity and 
efficiency of the probes is optimal. Of the five assays tested, none showed 
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sufficient specificity of the probes with the wrong probe being detected in at 
least one heterozygous knockout strain in each assay. Figure 3.13 shows the 
results of testing one assay as an example.  
 
 
 
Figure 3.12 Predicted plots from a TaqMan genotyping assay with optimal efficiency 
and specificity. The average Ct value of the HEX probe (blue) and FAM probe (red) is 
plotted against the Log10 DNA concentration. The HEX probe is designed to bind to 
allele one and the FAM probe is designed to bind to allele two. Plots demonstrate the 
results for genomic DNA isolated from the a) wild-type strain, b) a heterozygous 
knockout of allele one and c) a heterozygous knockout of allele two.   
0
10
20
30
40
50
-4 -3 -2 -1 0 1 2
A
ve
ra
ge
 C
t 
V
al
u
e 
Log10 DNA Concentration (ng/µl) 
Wild-type 
HEX
FAM
0
10
20
30
40
50
-4 -3 -2 -1 0 1 2
A
ve
ra
ge
 C
t 
V
al
u
e
 
Log10 DNA Concentration (ng/µl) 
Knockout of Allele 1 
HEX
FAM
0
10
20
30
40
50
-4 -3 -2 -1 0 1 2
A
ve
ra
ge
 C
t 
V
al
u
e 
Log10 DNA Concentration (ng/µl) 
Knockout of Allele 2 
HEX
FAM
a 
b 
c 
Page | 142  
 
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.13 Specificity of TaqMan genotyping assays. The average Ct value of the 
HEX probe (blue) and FAM probe (red) is plotted against the Log10 DNA concentration. 
The HEX probe is designed to bind to allele one and the FAM probe is designed to bind 
to allele two. Errors bars represent ± one standard deviation. The results shown here 
are for CDC6 assay 1 but are representative of all five assays tested. a) Wild-type 
SC5314 DNA shows approximately equal detection and efficiency of the probes when 
DNA concentrations are above 0.1 ng/µl. b) SC9, the knockout of allele one, shows 
approximately equal detection of both probes where only FAM is expected. c) SC8, the 
knockout of allele two, shows probe specificity, with only HEX detected at 
concentrations above 0.1 ng/µl.   
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Efficiency of each probe was calculated, as described in section 3.2.6.1.5, using 
the range of DNA concentrations which have a linear relationship with the 
average Ct values. This range varied from probe to probe. To calculate 
efficiency, the linear trend line was plotted, and the gradient (Δx/Δy) calculated. 
Ideally, gradients will be about -3.3, equating to an efficiency of the probe of 
around 100%. Table 3.12 shows that on average, efficiencies were either below 
what was expected, or were “too efficient” i.e. average Ct values did not 
decrease sufficiently as DNA concentrations increased. Figure 3.14 graphically 
represents the range of DNA concentrations, and subsequent linear equations, 
used to calculate the efficiencies for one assay. This was repeated for all five 
assays. Therefore, due to the lack of specificity and poor efficiencies of the 
probes tested it was decided that these assays would not be taken forward for 
use with cDNA to validate the levels of allelic expression imbalance.  
 
Table 3.12 Efficiencies of TaqMan genotyping assays 
Assay Probe Gradient1 Efficiency 
CDC6 Assay 1 FAM -3.695 86.48% 
VIC -3.8267 82.52% 
CDC6 Assay 2 FAM -4.028 77.12% 
VIC -2.785 128.59% 
VPS1 Assay 1 FAM -3.8633 81.49% 
VIC -3.677 87.05% 
VPS1 Assay 2 FAM -3.627 88.67% 
VIC -3.7677 84.25% 
VPS1 Assay 3 FAM  -3.5513 91.24% 
VIC -3.827 82.52% 
1. Calculated as (Δx/Δy). 
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Figure 3.14 Graphical representation of efficiency calculations for TaqMan genotyping 
assays. The average Ct value of the HEX probe (blue) and FAM probe (red) is plotted 
against the Log10 DNA concentrations which are in a linear range. Errors bars 
represent ± one standard deviation. Linear trend lines are plotted and gradient 
calculations shown for the CDC6 assay 1. This was repeated for all five assays. The 
FAM probe (red) has an efficiency of 86.48% and HEX probe (blue) has an efficiency of 
82.52%.  
 
3.3.3.2 Validation using Allele-Specific qPCR and SYBR® Green 
As validation proved unsuccessful using a TaqMan genotyping assay (see 
previous section), validation using allele-specific primers and a traditional qPCR 
system with SYBR® green was attempted. Here two sets of primers were 
designed, each set specific to a certain allele. During qPCR, SYBR® green 
binds to the double stranded DNA product produced from amplification of the 
cDNA from the specific primers, and the fluorescence is quantified. The 
threshold value (Ct) can then be compared for each allele and the difference in 
expression level inferred. This system does, however, rely on the efficiency of 
the primer sets being equal (Bustin et al., 2009).  
 
Allele-specific primers were designed for three genes identified by RNA 
sequencing as having significantly divergent levels in allele expression: CDC6, 
VPS1 and RBT4. Primers were designed to bind over SNP locations to ensure 
specificity, as demonstrated in Figure 3.15 (see Table 3.2 for a full list of 
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oligonucleotides tested). Computational analysis of specificity was carried out 
using BLASTn as described in section 3.2.6.1.6. Amplification of genomic DNA 
from the wild-type strain, SC5314, and appropriate heterozygous knockout 
mutants, was used to test the specificity of primer sets. Gradient PCR was used 
to optimise the annealing temperature for specificity. Figure 3.16 shows that the 
combination of CDC6-F7-1A with CDC6-R7-1A is specific for allele one of 
CDC6, as amplification only occurs with DNA from the wild-type and the 
knockout of allele two. CDC6-F7-2A with CDC6-R7-2A is specific for allele two 
of CDC6, as amplification only occurs with DNA from the wild-type and the 
knockout of allele one. This specificity for CDC6 occurs under three different 
annealing temperatures: 56.6 °C, 58.3 °C and 60.1 °C. Therefore these primer 
sets were taken forward, and tested for efficiency, with the median annealing 
temperature of 58.3 °C.  
 
Figure 3.17 shows that combining RBT4-F4-1A with RBT4-R4-1A, and RBT4-
F4-2A with RBT4-R4-2A shows specificity for RBT4 allele one and two 
respectively. This specificity for RBT4 only occurs when the annealing 
temperature is 56.6 °C. However, as the intensity of the bands is observably 
different, it can be concluded that the amplification efficiency of the primer pairs 
is not equal. Therefore use of these oligonucleotides for validation was not 
taken any further.  
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Figure 3.15 Allele specific primer locations for CDC6, VPS1 and RBT4. SNP locations are indicated by red lines. Note, not to scale. 
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Figure 3.16 Allele-specific oligonucleotide primer combinations for CDC6. Lanes 1 – 4 
contain oligonucleotide primers specific to allele 1. Lanes 5 – 8 contain oligonucleotide 
primers specific to allele 2. Expected band size 264 bp. Lanes 1 and 5 show 
amplification of wild-type DNA. Lanes 2 and 6 contain DNA from the heterozygous 
knockout of allele 1, SC9, therefore amplification only occurs with the allele 2 primers. 
Lanes 3 and 7 contain DNA from the heterozygous knockout of allele 2, SC8, therefore 
amplification only occurs with the allele 1 primers. Lanes 4 and 8 are negative controls 
with no template DNA. Annealing temperatures are a) 56.6 °C, b) 58.3 °C and c) 60.1 
°C. L denotes a 1 kb DNA ladder (Fermentas, UK).   
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Figure 3.17 Allele-specific oligonucleotide primer combinations for RBT4. Lanes 1 – 4 
contain oligonucleotide primers specific to allele 1. Lanes 5 – 8 contain oligonucleotide 
primers specific to allele 2. Expected band size 169 bp. Lanes 1 and 5 show 
amplification of wild-type DNA. Lanes 2 and 6 contain DNA from the heterozygous 
knockout of allele 1, SC3, therefore amplification only occurs with the allele 2 primers. 
Lanes 3 and 7 contain DNA from the heterozygous knockout of allele 2, SC4, therefore 
amplification only occurs with the allele 1 primers. Lanes 4 and 8 are negative controls 
with no template DNA. Annealing temperature is 56.6 °C. L denotes a 1 kb DNA ladder 
(Fermentas, UK).   
 
No combinations of the oligonucleotide primers tested were found to be specific 
for the VPS1 gene.  
 
Efficiency of the specific oligonucleotide primer combinations for CDC6 was 
tested using qPCR with SYBR® green and a range concentrations of genomic 
DNA (in triplicate) from the wild-type strain SC5314. Efficiency of the primer 
pairs was calculated using the average threshold value (Ct) for each DNA 
concentration as described in section 3.2.5.1.6. Ideal Ct values fall in the range 
of 10 – 30, and ideal efficiencies lie around 100%. Figure 3.18 shows the 
graphical representation of the efficiency calculation for the primers specific to 
allele one. Fluorescence, and therefore amplification, was detected at 
concentrations of genomic DNA over 1 ng/µl. However, the efficiency (86.7%) 
was too low for use. Figure 3.19 shows the graphical representation of the 
efficiency calculation for the primers specific to allele two. Ct values were high, 
suggesting little detection of fluorescence, and inconsistent across all 
concentrations of DNA. The efficiency of the oligonucleotides was also 
calculated at 118%. Therefore, due to the unequal and poor efficiency of the 
250 bp 
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oligonucleotide pairs, validation using allele-specific primers and SYBR® green 
was taken no further.  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.18 Graphical representation of efficiency calculations for allele-specific 
primers for CDC6 allele one. The average Ct value is plotted against the Log10 DNA 
concentrations for; a) all DNA concentrations. It can be seen here that amplification 
only occurs at DNA concentrations above 1 ng/µl; and for b) DNA concentrations which 
are in a linear range. The gradient of the line has been calculated as used to calculate 
the primer efficiencies at 86.7%. Errors bars represent ± one standard deviation.  
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Figure 3.19 Graphical representation of efficiency calculations for allele-specific 
primers for CDC6 allele two. The average Ct value is plotted against the Log10 DNA 
concentrations for; a) all DNA concentrations. It can be seen here that amplification is 
poor for all concentrations; and for b) DNA concentrations which are in a linear range. 
The gradient of the line has been calculated as used to calculate the primer efficiencies 
at 118.0%. Errors bars represent ± one standard deviation.  
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3.3.3.3 Validation using Allele-Specific Restriction Enzyme Digests 
Allele-specific restriction enzyme digests of PCR products amplified from cDNA 
were designed to verify the levels of AEI. This has previously been used to 
verify AEI identified by RNA sequencing in maize (Zhang et al., 2011). Allele-
specific restriction digests produce different sized fragments for each allele.  
The expression levels of each allele can then be inferred from the intensity of 
the bands from each allele through use of DNA gel electrophoresis.  
 
Figure 3.21 shows the results when verification was attempted for the gene 
VPS1. PCR amplification of the gene from genomic DNA or cDNA was followed 
by digestion with the enzyme HaeIII and separation of the fragments using DNA 
gel electrophoresis. Here it can be observed that digestions of PCR products 
amplified from genomic DNA of heterozygous knockouts of each allele produce 
distinct differences in band sizes (for expected sizes see Figure 3.20 and Table 
3.4). The strain containing only allele one, SC7, (lane 6) has three bands 
differing in length, 314 bp, 172 bp and 123 bp, whereas the strain containing 
only allele two, SC6, (lane 5) has a single band of around 290 bp in length. This 
is likely to be a combination of the bands at 288 bp and 295 bp in length, with 
the 26 bp band not being visible. Digestion of PCR products amplified from 
genomic DNA of the wild-type strain SC5314 (lane 4) produces a combination 
of these band sizes, although the three bands relating to allele one are clearer. 
Although the results from digestion of PCR products amplified from cDNA are 
faint (lanes 1 – 3), the pattern of bands closely resembles that of the allele two 
knockout strain, SC7. Therefore it can be suggested that allele one has a more 
intense band, and therefore higher expression, than allele two. This is 
especially evident in lane 3. RNA sequencing results indicate that VPS1 has 
significantly higher expression levels of allele one (see section 4.3.1) which is 
loosely supported by these results. However, the pattern produced from the 
wild-type DNA, where allele one and allele two are present in equal quantities, 
is indistinguishable to that produced from the heterozygous knockout strain 
containing only allele one, SC6. This is suggestive of an unequal amplification 
efficiency of the alleles in the PCR step, leading to a bias of results towards 
allele one. Further attempt at validation using restriction digests was therefore 
stopped.  
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Figure 3.20 Allele specific restriction enzyme digest locations for VPS1 PCR products. Arrows and black lines indicate the region amplified by PCR 
prior to digestion. Blue lines show restriction digestion sites. SNP locations are indicated by red lines. Allele 1 produces three fragments; 314 bp, 128 
bp and 172 bp in size. Allele 2 produces three fragments; 26 bp, 288 bp and 295 bp in size. Note, not to scale. 
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Figure 3.21 Allele-specific restriction enzyme digest of VPS1 PCR products. Lanes 1 to 
3 show digestion of PCR products amplified from three biological replicates of cDNA. 
Although faint, three distinct bands can be seen at 314 bp, 172 bp and 123 bp. Lane 4 
shows digestion of PCR products amplified from genomic DNA extracted from the wild-
type strain SC5314. Although faint, three distinct bands can be seen at 314 bp, 172 bp 
and 123 bp. Lane 5 shows digestion of PCR products amplified from genomic DNA 
extracted from a heterozygous knockout strain of allele 1, SC6. One clear band can be 
observed at approximately 290 bp. This is a combination of bands 288 bp and 295 bp 
in length. The 26 bp band is not visible. Lane 6 shows digestion of PCR products 
amplified from genomic DNA extracted from a heterozygous knockout strain of allele 2, 
SC7. Three distinct bands can be seen at 314 bp, 172 bp and 123 bp. Lane N shows a 
negative control digestion, containing all components except the PCR product. L 
denotes a 1 kb DNA ladder (Fermentas, UK).   
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3.3.3.4 Validation using Western Blotting 
As an alternative to the use of qPCR and cDNA to validate the AEI identified by 
RNA sequencing, validation using protein expression was attempted. To 
achieve this, separate strains were constructed that had each allele tagged with 
a V5-6xHIS protein tag. This enabled western blotting to be used with an Anti-
V5 antibody to compare and quantify the protein expression from each allele. 
Quantification of the actin protein was used as a loading control to normalise 
expression levels between samples. This validation was attempted for two 
genes, CDC6 and VPS1. All strains used can be found in Table 2.1. 
 
Growth rates of the tagged strains were assayed at 30 °C, as described in 
2.13.1, to ensure that the presence of the protein tag did not inhibit growth. 
Appendix I Figure 1 and Appendix I Table III show that this was the case, and 
growth was not significantly affected by the protein tag in any of the constructs 
made.  
 
To replicate the results from the RNA sequencing experiment as closely as 
possible, proteins were extracted when growth in YPD at 30 °C reached an OD 
at 600 nm equal to 1. Protein concentrations were quantified using a Bradford 
Assay before use in a Western blot. Figure 3.22 shows that this approach is not 
successful for validation of AEI. The assay was not sensitive enough to detect 
expression of CDC6 alleles with no bands seen in Figure 3.22a. Expression 
was detected for the VPS1 alleles, however the differences between the alleles 
were not strong enough to quantify the difference in protein expression levels 
and support the RNA sequencing data. Difficulties in detecting actin expression 
from the loading control with the VPS1 strains also complicate the interpretation 
of results.  
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Figure 3.22 Western blots showing protein expression of V5 tagged alleles. In all 
cases, Lane 1 represents protein extracted from the wild-type strain SC5314, which 
contains no V5-6xHis tag. a) Expression of CDC6 alleles; Lanes 1 and 2 show protein 
from the allele one tagged strains SC35 and SC36; Lanes 3 and 4 show protein from 
the allele two tagged strains SC61 and SC62. 1) Expression of V5 is undetectable with 
only faint bands present whereas 2) expression of actin is detectable across all strains. 
b) Expression of VPS1 alleles; Lanes 1 and 2 show protein from the allele one tagged 
strains SC13 and SC14; Lanes 3 and 4 show protein from the allele two tagged strains 
SC27 and SC28. 1) Expression of V5 is detected, with allele one appearing to have 
higher expression with strain SC14 and lower expression with strain 13 however 2) 
shows expression of actin is also higher in strain SC14 and lower in strain 13 
suggesting no differences in allele expression. L = BLUeye prestained protein ladder 
(Geneflow).  
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3.4 Discussion 
3.4.1 The Biological Consequence of AEI 
As Gene Ontology analysis of the genes identified with AEI revealed no 
significant patterns in predicted functionality, it can be concluded that AEI is not 
operating within a set of genes with a specific biological function or within a 
specific network. However, individual genes were identified that have virulence 
and pathogenesis related properties such as ERB1, RBT4, SMI1, TAC1, TPO3 
ALS1, RBT4, RCK2 and RFG1, amongst others. Therefore AEI may have a role 
in genes which are important during the infection process.   
 
A possible hypothesis is that these alleles which differ in expression level may 
also differ in function due to the high level of heterozygosity seen across the C. 
albicans genome. Examples of divergence in allele function are highlighted in 
section 1.4.1, and show that differences in functionality of alleles occurs in a 
wide variety of genes that all operate in distinct biological processes. To further 
support our hypothesis that AEI may be linked to differences in allele function, 
the percentage protein identity between alleles was calculated. This was found 
to be on average significantly lower in genes with AEI than in genes with equal 
allele expression, suggesting that the protein sequences of alleles with AEI are 
significantly different. This question now needs to be taken into the laboratory to 
decipher if these differences in protein sequence occur within functional 
domains, and therefore if they have biological consequences. Investigating this 
question will be addressed at length in the next chapter. 
 
It should be noted that difference in DNA sequence, which impact upon GC 
content and length, may produce bias in measurement of expression level by 
the sequencing technology. This matter is discusses further in the next section. 
Therefore the identification of AEI in a set of genes with large differences in 
DNA, and therefore protein, sequence may in fact be a false positive result due 
to bias in the sequencing technology, and that AEI may not be linked to 
functional differences in alleles at all.  
 
3.4.2 Using RNA Sequencing to Identify Allelic Expression Imbalance 
In previous studies of AEI in human T cells (Heap et al., 2010), human cancer 
cells (Tuch et al., 2010a), pig species (Esteve-Codina et al., 2011), and yellow 
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baboons (Tung et al., 2011) a haploid reference genome alongside variant 
calling has been used to identify AEI. Use of a haploid reference has, however, 
been associated with bias towards the reference genome (Stevenson et al. 
2013). RNA sequencing technologies have been used here to identify 
significant levels of allelic expression imbalance in the yeast Candida albicans 
using a diploid reference genome with quantification of reads aligning uniquely 
to each allele.  Across the genome, a total of 233 genes were identified as 
having AEI when cells were grown in YPD at 30 °C, of which 81 genes were 
identified with monoallelic expression.  
 
Little evidence had been previously obtained for the presence of AEI in C. 
albicans. However, in 2013, Muzzey et al. developed a method to calculate 
expression levels of individual alleles in C. albicans. This study developed an 
improved diploid reference genome with phasing information and this 
information was used to identify AEI in a similar manner to our approach. In a 
follow up investigation, AEI at both the transcriptional and translational level 
was investigated (Muzzey et al., 2014). However, as both studies lacked a 
measure of significance to the levels of allelic expression imbalance, there is no 
definitive list of genes with AEI from these studies that we can directly compare 
with our results. Therefore, the research carried out here presents a unique list 
of genes with significant levels of allelic expression imbalance which can be 
taken forward for various investigations, which has not previously been reported 
for C. albicans. However, it should be noted that the AEI in these genes is yet to 
be confirmed using an alternative method to RNA sequencing.  
 
RNA sequencing has distinct advantages over other existing technologies, like 
microarrays and qPCR, for identification of AEI. For example, there is no need 
for prior assumptions of coding sequences, and, now with the advancement of 
de novo transcriptome assembly algorithms, there is no need for a reference 
genome, making RNA sequencing accessible to a wider range of organisms. 
Sensitivity has also been seen to be greater when using RNA sequencing 
allowing for identification of transcripts with lower expression levels (Wang et 
al., 2009, Tuch et al., 2010a).    
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However, RNA sequencing is not a perfect method and errors occur which 
could impact upon the identification of AEI. Library preparation introduces areas 
of bias in coverage. A 3’ bias in coverage of reads is readily reported in cDNA 
fragmented libraries, like the ones used here (Wilhelm et al., 2008), which can 
be improved by using RNA fragmentation (Mortazavi et al., 2008). However, 
RNA fragmentation is depleted in reads at both transcript ends, making exact 
start and end points of transcripts unclear (Wang et al., 2009). As our method 
relies on reads which align uniquely to SNP positions, if the SNPs are localised 
to a region of deeper coverage, the level of allele expression may be skewed in 
comparison to a gene where the SNPs lie in an area of low coverage. Heap et 
al. (2010) also found that reads had a bias in aligning towards alleles in a 
forward or reverse direction and that INDELs close to SNPs contribute to bias in 
measurement of allele-specific expression. To overcome this, all SNPs within 
45 bp of an INDEL were removed in the 2010 study.  
 
As well as bias in the mapping of reads, other issues have also been identified 
when using RNA sequencing to identify AEI. Variations in the “sequenceability” 
of alleles could impact upon expression levels measured. GC-rich sequences 
tend to be preferentially sequenced under the Illumina platform and a study by 
(Bullard et al., 2010b) showed that a 5% differences in GC content conferred a 
10% difference in expression level. Therefore alleles which differ vastly in GC 
content could be false positive results in our list of genes with AEI. The results 
of our analysis of structural factors indicate that alleles with divergent allele 
expression do have a significantly larger variance in differences in GC content 
than alleles with equal expression level. Therefore could the differences in 
expression that we have observed actually be a by-product of bias within the 
sequencing technology? A recent study has developed a method of measuring 
AEI using RNA sequencing which corrects for differences in the GC content of 
alleles to account for this difference in “sequenceability” (Skelly et al., 2011), 
which could be used to overcome this problem in future investigations of AEI.  
 
Problems also occur when reads map with equal efficiency to paralogous genes 
and when reads containing mutations are mapped incorrectly (Mortazavi et al., 
2008). It has been documented that some RNA sequencing aligners such as 
TopHat and MapSplice produce both false negative and false positive results 
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due to this problem of reads which can align to multiple regions in the genome 
(Zhang et al., 2013).  These factors could lead to reads being misaligned to the 
wrong allele or gene, and impact upon the levels of AEI identified.  
 
RPKM was used here to normalise the expression levels of the alleles across 
sequencing replicates which differ in overall numbers of reads, and across 
alleles which differ in length. However, a meta-analysis of a number of RNA 
sequencing data-sets showed that normalisation using RPKM is biased by 
numerous factors including GC content as well as gene length and dinucleotide 
frequencies (Zheng et al., 2011). A similar study also confirmed that RPKM is 
biased for gene length, producing more reliable results with longer genes 
(Bullard et al., 2010a). Therefore, alleles which differ significantly in length and 
GC content are at risk of further bias in expression levels from the normalisation 
method we have used here.  
  
Systematic errors have been readily identified in all sequencing technologies. 
Particular motifs and genome locations are more prone to base-call errors, 
which occur at the initial steps of sequencing, where bases are identified using 
imaging software. Positions proceeded by GG or GGC, or sequences at the end 
of reads have been identified as particularly problematic (Nakamura et al., 
2011). These errors have been recorded to occur as frequently as once in a 
1000 base pairs and have been highlighted as problematic for studies 
investigating heterozygosity and allele-specific expression using RNA 
sequencing (Meacham et al., 2011). Although the study investigating systematic 
errors developed a software package, SysCall, to identify likely error prone 
motifs, this was designed for use with human genome sequences and it is 
outside the scope of this project to modify the software for our use.  
 
The method applied in the work presented here could still be improved by 
identifying the strand of origin for transcripts as it is currently unknown if reads 
have originated from the sense or anti-sense strand. As cases of imprinting, 
such as the example of the Mest locus (MacIsaac et al., 2011), show 
relationships between sense and anti-sense transcription, identification of 
strand origin could reveal important patterns of expression linked to AEI. 
Several methods, all with varying degrees of success, are available for strand-
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specific RNA sequencing, which fall under two classes, methods that involve 
ligation of strand-specific adaptors and methods that mark one strand of RNA or 
cDNA such as bisulfite modification (Levin et al., 2010). In C. albicans, strand-
specific RNA sequencing identified that 50% of all transcripts overlapped with 
their antisense transcript by at least one base pair (Tuch et al., 2010b), however 
it was found that some but not all antisense transcripts repress the expression 
of the sense transcript, suggesting that overlap does not necessarily result in 
repression. This further suggests that identifying strand specificity could 
increase our knowledge of the mechanisms behind AEI in C. albicans.  
 
3.4.3 The Impact of Structural Factors on AEI  
Here structural factors related to genes with AEI were investigated. These 
factors included chromosomal location, overlap with neighbouring genes, GC 
content, length and codon usage, and the results of these findings are 
discussed below. However, there are structural factors that still remain 
unanalysed in terms of AEI in C. albicans. Some of these factors are discussed 
below to indicate other factors which may be important to investigate in the 
future.    
 
3.4.3.1 Chromosomal Location 
Although evidence has previously been seen suggesting that there is a 
relationship between AEI and chromosomal location, reports are often 
contradictory. In maize, imprinted genes have been seen to cluster in location 
when compared to the frequency of genes across the entire genome (Zhang et 
al., 2011). In mice, position dependent gene silencing was also observed for the 
HoxD gene due to differences in chromosomal conformation of the alleles 
(Lonfat et al., 2013).  However studies looking at both autosomal monoallelic 
genes and genes with AEI in humans have shown that although some 
clustering of genes occurs, most genes are randomly distributed (Lo et al., 
2003, Savova et al., 2013). These differences in findings may be due to 
inconsistencies in the measure of a “gene cluster” or differences between 
species.  
 
Here, similar findings were found to those by Lo et al. (2003) and Savova et al. 
(2013). Although some individual clusters of genes with AEI were identified, the 
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patterns observed were random and infrequent. In the most part, the location of 
genes with AEI resembled the location of heterozygous genes across the 
genome. This does however support the findings of the Gene Ontology 
analysis; that AEI occurs across a random set of genes in C. albicans, with no 
underlying concerted biological mechanism. 
 
3.4.3.2 Overlapping Genes 
The extent of gene overlap in genes with allelic expression imbalance has 
previously been investigated in the yeast S. cerevisiae by Gagneur et al. (2009), 
where a total of 36 genes out of 371 with AEI were found to overlap with their 
neighbouring open reading frame, with varying patterns of expression. 
However, Gagneur found no clear mechanistic relationship between gene 
overlap and AEI. Here, only 4 genes with AEI were found to overlap suggesting 
that overlap of genes may be actively selected against in terms of AEI in C. 
albicans. However, our results also indicate that gene overlap has little impact 
on gene expression in C. albicans with a large proportion of genes which 
overlap on the same strand having similar expression levels. Therefore, it could 
be hypothesised that gene overlap is unrelated to AEI, and that such a small 
number of genes with AEI overlapping is purely coincidental. However it cannot 
be ruled out that gene overlap does contribute towards AEI at these few loci. 
 
It was also observed that the mitochondrial genome has a particularly high 
percentage of overlapping features at 25%. It has been suggested that the 
purpose of overlapping genes is to conserve space in small genomes (Iwabe 
and Miyata, 2001, Johnson and Chisholm, 2004), and as the mitochondrial 
genome originated from a small prokaryotic ancestor it could have far higher 
percentage of overlapping features to increase efficiency. This theory needs 
further investigating as the purpose of overlapping genes is often disputed, with 
the suggestion that in bacterial genomes, overlapping genes are used for 
regulation of expression (Scherbakov and Garber, 2000). Further confusion is 
added by studies showing that mitochondrial genomes in a few organisms, such 
as molluscs and nematodes, have large non-coding regions, questioning their 
efficiency (Boore, 1999). 
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3.4.3.3 GC Content, Gene Length and Codon Usage 
Despite evidence here and in previous studies indicating that GC content and 
codon usage correlate significantly with overall gene expression levels (Coghlan 
and Wolfe, 2000, Marín et al., 2003), these factors were not found to directly 
relate to levels of allelic expression imbalance. When comparisons were made 
between the structural factors of the allele with the lowest expression and the 
allele with the highest expression, no clear patterns were observed relating to 
expression. This rules out these structural factors as the direct causal 
mechanism behind the divergence in allele expression.  
 
However, when analysing allele length, it was found that the shorter allele had a 
significantly lower level of expression. It remains unclear as to whether this 
difference in length is functionally important to levels of AEI, or if it is in fact a 
bias of sequencing technologies as mentioned previously. Shorter alleles 
produce shorter fragments and are therefore sequenced less often, with this 
difference not being sufficiently accounted for through RPKM normalisation 
(Bullard et al. 2010b).  
 
Alleles of genes with AEI were found to have significantly larger variance in 
differences of structural factors than alleles with equal expression. These 
differences, especially the fold difference in allele length, had a positive and 
significant correlation with the difference in protein identity seen between 
alleles. Consequently, following on from the hypothesis that divergent allele 
expression is linked to differences in allele function, it can be suggested that 
although structural factors are not mechanistically causing the differences in 
allele expression, they are leading to differences in DNA sequences. These 
differences in DNA sequence are, in turn, leading to differences in function, and 
this is driving the difference in expression level.  
 
Again, it should be noted from previous discussions that these differences in 
structural factors being larger in genes with AEI may actually be a consequence 
of bias in the sequencing technologies. The identification of these genes as 
having significant AEI may be false positive results as differences in structural 
factors such as length and GC content can lead to differences in 
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sequenceability (Bullard et al., 2010b) and biases in normalisation (Zheng et al., 
2011), causing an over representation of the differences in expression.  
 
3.4.3.4 Structural Factors Still to Be Investigated 
Although this study has investigated a number of structural factors, there remain 
many more which could influence levels of allelic expression imbalance which 
have not been explored here.  
 
Methylation patterns have been associated with allelic expression imbalance, 
especially imprinting, as described in section 1.6.1. It has been seen in humans 
that all but one imprinted gene exhibit allele-specific methylation (Brannan and 
Bartolomei, 1999). Genome-wide analysis of methylation patterns in Candida 
albicans revealed that methylation is centred upon 150 genes, with a general 
association with environmentally cued pathways (Mishra et al., 2011). However, 
this study looked at C. albicans in a haploid sense and did not identify allele-
specific methylation patterns. Unfortunately, identifying allele-specific 
methylation through the use of whole genome bisulfite sequencing was 
unpractical for use in this study and is associated with difficulties in pairing 
SNPs with methylcytosines as described in section 1.6.1, but is an area for 
further investigation. However, when investigating the 150 methylated genes 
identified by Mishra et al. (2011) it was observed that only six of these genes 
were also identified as having allelic expression imbalance in this study. This 
suggests that allele-specific methylation patterns are unlikely to be the sole 
causal factor in differential allele expression. This reflects upon the results 
found by a study of methylation in maize where it was shown that not all 
imprinted genes have methylation differences between alleles (Zhang et al., 
2011). Nevertheless, Mishra et al. (2011) also showed that methylation patterns 
varied significantly between distinct morphological forms. Condition specific 
methylation differences could account for such few methylated genes being 
identified with AEI here, and therefore the influence of this mechanism upon AEI 
still requires further examination.  
 
Aspects of DNA packaging are also reported to contribute towards gene 
expression levels. Nucleosomes consists of a stretch of 147 bp of DNA helix 
which wrap and bend around a histone protein, with 10 – 50 bp of unwrapped 
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DNA separating individual nucleosomes (Richmond and Davey, 2003). 
Generally unbound, and therefore unoccupied, regions of DNA have greater 
access for DNA-binding proteins, and are associated with higher expression 
levels, for example centromeres are known to have low levels of gene 
expression and have a higher occupancy of nucleosomes than other stretches 
of DNA (Wyrick et al., 1999). The nucleosome-DNA interaction model has been 
constructed in S. cerevisiae using a combination of isolated nucleosome-bound 
DNA fragments and computational modelling methods (Segal et al., 2006). This 
study stated that around 50% of in vivo nucleosome organisation can be 
explained solely by sequence preferences. Different DNA sequences have 
different propensities to bend, and therefore wrap around histones. For 
instance, dinucleotide repeats of AA/TT/AT bend easily and bind to 
nucleosomes more readily. Therefore, it could be proposed that alleles which 
differ in sequence could have differing propensities towards nucleosomes, and 
therefore differing expression levels. To support this idea, it has recently been 
demonstrated in mice that alleles of an imprinted gene differ in their 3D 
chromosomal conformation; a compact structure relates to repression of the 
HoxD gene in the maternal line (Lonfat et al., 2013). In this study, insertion of 
genes into different chromosomal locations near the HoxD locus resulted in 
varying levels of imprinting, demonstrating that these differing chromosomal 
conformations result in position dependent gene silencing.  However, this theory 
of nucleosome occupancy and gene expression being dictated by DNA 
sequence and position produces interesting questions, for example, how do 
gene expression levels change under different conditions where DNA 
sequences will always remain the same?  
 
The impact of differences in the 5’-UTR sequence upon protein expression 
levels has been previously investigated in yeast. Using a constructed library of 
over 2000 mutants which differ only in the 10 bp upstream of the start codon 
and all translate to the same YFP-tagged gene, the contribution of specific 
motifs in UTRs upon protein levels were identified (Dvir et al., 2013). Motifs with 
the highest impact included the nucleotide at positions -3 to -1, with a purine at -
3 leading to an increase in protein levels; mRNA secondary structure with stable 
secondary structures leading to a decrease in protein levels; and out-of-frame 
upstream AUGs which again decrease protein levels. It should be noted that 
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this study used only a single gene with a short 5’-UTR and the observations 
made may not be applicable across all genes, but results do imply that 
differences in UTR sequence effect expression, and therefore could impact 
upon AEI. Interestingly this study demonstrates that differences in up-stream 
motifs had a much larger impact upon protein levels (4.5-fold) than mRNA 
levels (2.9-fold). Therefore this may not have been detected within our results. 
When investigating AEI at both transcriptional and translational levels in C. 
albicans, a weak but significant correlation was seen between SNPs in the 60 
bp around the start codon and the disparity in allelic expression, however this 
relationship was not deemed significant enough to fully account for the levels of 
AEI (Muzzey et al., 2014). Longer UTRs have also been associated with highly 
regulated genes both in C. albicans (Tuch et al., 2010b) and in C. parapsilosis 
(Guida et al., 2011), therefore differences in UTR lengths between alleles could 
influence allelic expression imbalance. Both of these studies identified UTR 
lengths from RNA sequencing data, and so this is an area that can be returned 
to for further investigation with our data. However, there is also contradictory 
evidence for the relationship between UTR length and expression in C. 
albicans. Since Sellam et al. (2010) demonstrated more stable transcripts have 
shorter 5’-UTRs (Sellam et al., 2010), and therefore any analysis of UTR length 
and AEI would need to be mindful of this.  
 
Differing RNA decay rates of alleles could also lead to differences in RNA 
abundance, giving the impression of differences in expression level. As RNA 
decay rates have been proposed to be regulated by sequence motifs, such as 
AU-Rich elements which modulate poly(A)-shortening rates (Vasudevan and 
Peltz, 2001), it is possible to infer that transcripts produced from different alleles 
could differ in decay rate, especially in the case of alleles which differ vastly in 
sequence. Therefore, decay rates could account for the AEI observed. It is 
possible to quantitatively measure RNA decay rates in yeast using various 
methods including in rich media with 1,10 phenanthroline and dot blotting 
(Santiago et al., 1986), and with the use of strains carrying a temperature-
sensitive mutation in RNA polymerase II (Wang et al., 2002). However, using 
these methods to identify allele expression levels requires a system, such as 
PCR, specific to each allele. As seen in the development of a validation system, 
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obtaining specificity is challenging, and would need to be optimised before 
decay rates were observed.  
 
Interestingly, RNA decay rates have also been linked to transcript lengths. In a 
study of 15 genes in S. cerevisiae it was shown that length has an inverse 
relationship with mRNA stability with longer mRNAs decaying faster (Santiago 
et al., 1986). An increase in targets for endonucleolytic cuts in longer transcripts 
was suggested as a possible mechanism for this relationship. The results 
presented here showing that gene length has a negative correlation with overall 
expression support this hypothesis. Although alleles with lower expression 
levels were were in fact found to be significantly shorter than alleles with high 
expression, this change in length and therefore possible change in RNA stability 
could still impact upon AEI. However, a more recent genome-wide study, using 
DNA microarrays and a strain with a temperature-sensitive mutation in RNA 
polymerase II, found that there was no correlation between decay rates and 
transcript lengths. Nor was there a relationship seen between decay rates and 
codon bias, ribosome density or abundance (Wang et al., 2002). Instead it was 
proposed that decay rates could be dictated by function, with groups of proteins 
seen in the same complexes or pathways having very similar decay rates. This 
included complexes such as histones, the 20S proteasome, ribosomal proteins 
and the trehalose phosphate synthase complex and pathways including energy 
metabolism enzymes and mating pheromone signal transduction pathway 
(Wang et al., 2002). Therefore if the levels of AEI seen are attributed to 
differences in allele decay rates, this could be supportive of a functional 
difference between the alleles.  
 
An idea moving away from structure of alleles is the age of the allele. In yeast, 
“younger” recently duplicated genes are thought to be less essential than older 
more conserved genes. These older genes have higher expression levels and 
appear to have more severe phenotypes when removed (Chen et al., 2012). 
This leads to the idea that the allele with higher expression level is the older 
functional copy. This is supported by the evidence that duplicated genes have a 
higher probability of being functionally compensated for, with less lethal effects 
upon removal. Through use of microarrays, it was also revealed that knocking 
out the duplicate with higher expression levels had a more severe phenotypic 
Page | 167  
 
effect than loss of the duplicate with lower expression (Gu et al., 2003). 
However, here alleles are being directly compared to duplicate genes, with the 
assumption that they have arisen by the same mechanism.  
 
3.4.4 Validation of AEI   
To validate the results produced from RNA sequencing, numerous methods 
were explored. In previous studies, allele-specific qPCR with TaqMan probes 
(Harries et al., 2006, Tuch et al., 2010a) and allele-specific restriction enzyme 
digestion (Zhang et al., 2011) have been used to both identify and validate 
levels of AEI. Use of allele-specific qPCR with SYBR® green and use of protein 
tagged alleles were also explored for their efficacy in validation. However, all 
approaches attempted encountered similar problems with specificity against 
each allele and with sufficient efficiency to achieve reproducible results. 
Validation of the levels of AEI identified by RNA sequencing, therefore, 
remained unsuccessful.   
 
An alternative method for validation of the results produced from RNA 
sequencing which was not explored is the use of the NanoString nCounter gene 
expression system (Geiss et al., 2008). This method captures and counts 
individual mRNA transcripts through the use of capture and reporter probes, 
which complementarily bind to a transcript, and a colour-coded tag which 
produces the signal. High concordance was seen between the results from 
NanoString, microarrays and TaqMan qPCR. However, there is currently no 
evidence for use of this method to identify or validate AEI, and it is unclear if the 
probes are subject to cross-hybridisation of highly similar sequences such as 
alleles.  
 
Measuring allele-specific protein expression was attempted using western blots 
and allele specific tags, but proved unsuccessful. Other protein expression 
measurement techniques is another area which could have been explored 
further. Recently, work has been published which has monitored allele-specific 
protein expression using liquid chromatography mass spectrometry. The study 
used a hybrid diploid strain of S. cerevisiae and S. bayanus, which was labelled 
with a heavy isotope, and two parental homozygous strains labelled with a light 
isotope. Comparisons were made between the ratios of variant peptides to 
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shared peptides in these strains to identify the protein allele-specific expression 
level (Khan et al., 2012). This study found that on a proteome-wide average, 
both alleles are expressed at equal expression levels. However 589 proteins in 
replicate one and 426 in replicate two were identified with protein allele-specific 
expression. A modest correlation was also found between protein allele-specific 
methods and mRNA allele-specific measurements made in the same hybrid 
species, however, the cells were grown in different conditions for both of these 
experiments, questioning the comparability. Currently, this novel method is 
unsuitable for use with Candida albicans as homozygous parental strains are 
not available for comparison against a heterozygous offspring.  
 
Measuring protein levels to validate RNA sequencing data relies upon the 
assumption that mRNA levels have a proportional relationship with protein 
levels. However evidence to contradict this assumption has been found. In E. 
coli, the protein and mRNA expression levels have been quantified 
simultaneously using an YFP protein fusion library, single molecule 
fluorescence microscopy and fluorescence in situ hybridisation. It was found 
that on a single cell level, protein and mRNA expression levels did not 
significantly correlate with each other, although this was only determined for 
137 genes with high protein expression and not across the entire genome 
(Taniguchi et al., 2010). Ribosome profiling has been recently developed to 
interrogate levels of protein abundance. This method involves isolation and 
sequencing of ribosome bound mRNA fragments (Ingolia et al., 2009). Recently 
this technique has been used to assess the relationship between allele specific 
levels of transcription and translation, for example showing that small 
divergences in allele expression levels are buffered for and not present at the 
level of translation in F1 hybrids of S. cerevisiae and S. paradoxus (Artieri and 
Fraser, 2013, McManus et al., 2014). However, assessment of allelic 
expression imbalance at the translational level in C. albicans has shown that 
allelic bias at the transcriptional and translational level showed similar 
magnitudes of bias but on a gene-by-gene basis, levels of AEI did not always 
predict levels of translational allelic bias. For example the gene CHO2 was 
shown to have equal levels of allele expression at the transcriptional level but 
was seen to favour allele two at the level of translation (Muzzey et al., 2014). 
Alternatively, other genes were seen to have a compensatory relationship 
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between transcriptional and translational bias with uneven levels of mRNA 
being corrected for by opposing uneven levels on translation (Muzzey et al., 
2014).  
 
3.4.5 Conclusion 
To conclude this chapter, genes with significant levels of AEI have been 
identified in C. albicans wild-type strain SC5314 using RNA sequencing. These 
genes were not themselves associated with specific biological functions. 
However, analysis of the structural factors associated with these alleles indicate 
significant differences in DNA sequence, which could lead to functional 
differences in proteins. Deciphering the true extent of the link between AEI and 
functional divergence will be the main focus of the following chapter.  
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Chapter 4: Investigating the 
Phenotypic Contribution of Allelic 
Expression Imbalance 
 
4.1 Introduction 
This chapter examines the functional consequences of allelic expression 
imbalance in the wild-type Candida albicans strain SC5314. The previous 
chapter used RNA sequencing to identify genes with significant divergence in 
allele expression level. Percentage protein identity comparisons indicated that 
the protein sequences of many of the differentially expressed alleles are also 
highly divergent. This has led to the hypothesis that alleles which differ in 
expression level may also have functionally distinct roles due to differences in 
protein sequence. To investigate this theory, heterozygous knockout mutants of 
each allele of a number of genes identified as having significant levels of AEI 
were constructed and phenotypically compared under a range of conditions.  
 
4.1.1 Methods of Knockout Construction 
Investigations of the phenotypic contributions of genes in C. albicans was 
initially problematic due to its diploid nature and lack of a conventional sexual 
cycle. The construction of an auxotrophic knockout strain in 1993 by Fonzi and 
Irwin opened up the possibilities of genetic manipulation in Candida albicans. 
Through targeted mutagenesis and homologous recombination, the strain CAI4 
was constructed, which lacks both alleles of the URA3 gene (Fonzi and Irwin, 
1993). This strain, and subsequent other auxotrophic marker deletion strains, 
have led to the development of various methods to “knockout” genes of interest 
via homologous recombination, constructing both heterozygous and 
homozygous strains. These methods involve targeted replacement of the gene 
of interest with an auxotrophic marker, allowing for selection of successful 
transformants. The Ura-blaster method (Figure 4.1a), as developed in 1993, 
uses a targeted cassette containing the URA3 gene and 
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Figure 4.1 Methods of constructing gene knockout strains. a) The Ura-blaster method involves use of a URA3 cassette (yellow) flanked by repeats 
(purple). Transformants that are URA+ are used to select isolates that carry the Ura-blaster cassette. Isolates that have lost the URA3 sequences 
through recombination between the repeats are counter-selected for using 5-FOA selection. This followed by a second transformation with the URA3 
cassette to remove the second allele. b) PCR-mediated transformation use a cassette containing a selectable marker flanked by 70 nucleotides of 
homologous sequence. Amplification of the cassette uses 5' and 3' primers that include short regions ( 20 nucleotides) of sequence homologous to 
the marker vector and 70 nucleotides of sequence homologous to the sites of insertion. The cassette is then used to transform Candida 
albicans strains. Sequential transformation with amplified fragments that carry the same flanking sequences and two different selectable markers is 
required to generate a homozygous deletion strain. Figure adapted from (Berman and Sudbery, 2002)   
a b 
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5-fluoro-orotic acid (5-FOA) selection to recycle and reuse the cassette to 
produce homozygous mutants (Fonzi and Irwin, 1993). Later PCR amplification 
based methods (Figure 4.1b) involve amplification of a cassettes targeted to the 
gene of interest and sequential gene knockouts with different auxotrophic 
markers such as HIS1 and ARG4 (Noble and Johnson, 2005). Other knockout 
approaches which are available for use in C. albicans include the flipper 
cassette system and the Cre-loxP system. The flipper system uses a cassette 
containing a selectable marker and a C. albicans adapted FLP gene. This 
allows for sequential deletion of the target alleles, in a similar way to the PCR 
amplification methods, but by the same cassette. After the removal of the first 
allele, the cassette is “flipped out” by the FLP gene and then reused for removal 
of the second allele. This system also allows for easy reintegration of 
sequences for complementation at the native locus. Flipper cassettes have 
been developed with various selectable markers including auxotrophic markers 
(Morschhäuser et al., 1999) and the antibiotic resistance cassette 
nourseothricin (discussed in more detail below) (Reuß et al., 2004). The Cre-
loxP system also allows for recycling of the selection cassette. Here the 
selection cassette is flanked by loxP elements which allows for removal via site-
specific recombination catalysed by the Cre recombinase enzyme (Dennison et 
al., 2005). An alternative approach to knocking out genes is knocking down 
genes, and RNAi is an approach that has been developed to achieve this. 
Expression of the target gene is reduced using small RNAs complementary to 
the target gene mRNA. Double stranded RNA then forms via complementation 
and is targeted for degradation via small interfering RNA sequences and the 
RNA-induced silencing complex (Jinek and Doudna, 2009). This system has 
been used in C. albicans to knock down the EFG1 gene involved in the 
morphological switch to hyphae (Moazeni et al., 2012). 
 
Phenotypic screening of knockout mutants allows for elucidation of gene 
function. Large-scale screening of gene function using several hundred 
homozygous and heterozygous mutants in C. albicans has been undertaken, 
identifying genes involved in infection related processes such as antifungal drug 
resistance (Xu et al., 2007) and morphological switching (Noble et al., 2010). 
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As detailed in section 1.4.1, phenotypic screening of heterozygous knockout 
strains has indicated that certain genes have divergence in allele function, 
lending support to our hypothesis that alleles with AEI may differ in function. 
Examples include, not exclusively, the adenine gene ADE2 which has one 
functional and one non-functional allele (Tsang et al., 1999), the histidine gene 
HIS4 where a single SNP renders allele 1 inactive (Gómez-Raja et al., 2008), 
the ALS9 gene which has highly divergent allele sequences with suggestions of 
functional differences (Zhao et al., 2007), the TAC1 transcription factor which 
have alleles that differ in function, impacting upon drug resistance (Coste et al., 
2006), and the CDR genes which have been shown to have alleles with differing 
pumping capabilities, again effecting susceptibility to antifungal drug treatments 
(Holmes et al., 2006). Of the genes identified with AEI in chapter three, Table 
4.1 shows that 31 have already been shown to have a phenotype of the 
heterozygous knockout mutant (in any strain, not exclusively the wild-type strain 
SC5314; information obtained from the Candida genome database 
http://candidagenome.org/ (Inglis et al., 2012)), although these studies often do 
not compare the functionality of the two alleles. 
 
Traditionally, auxotrophic markers such as the URA3 gene described above 
have been used for marker selection during the transformation process. 
However, evidence has shown that altered expression of these genes, 
especially URA3, can cause phenotypic impacts themselves, particularly with 
regards to pathogenicity (Kirsch and Whitney, 1991, Brand et al., 2004). This, 
therefore, has put phenotypic predictions obtained from these mutants into 
question. To avoid this problem, an alternative method has been adopted here 
using the antibiotic resistance cassette nourseothricin. This marker was 
developed for use in Candida albicans transformations and has been shown to 
not effect growth in the yeast or hyphal form, unlike use of the URA3 marker 
(Shen et al., 2005). Other selectable markers available for use in Candida 
albicans which avoid auxotrophic markers include a gene conferring resistance 
to the antibiotic hygromycin B (Basso et al., 2010) and a strain lacking the 
MET15 gene which grows as brown colonies on media containing lead, allowing 
for replacement of a target gene with a MET15 cassette causing white colony 
growth and simple colour selection for transformants (Viaene et al., 2000). 
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Table 4.1 Genes with AEI shown to have a heterozygous null phenotype. 
Data taken from the Candida genome database http://candidagenome.org/.  
ORF name Gene Name Strain Phenotype 
orf19.1047 ERB1 SC5314 Resistance to 5-fluorouracil, tubercidin and 
flucytosine decreased 
CAI-4 Virulence decreased (mouse model) 
orf19.1246  BWP17 Resistance to clotrimazole decreased 
orf19.1357 FCY21 SC5314 Resistance to 5-fluorouracil and flucytosine 
increased 
orf19.1440  BWP17 Invasive growth decreased 
orf19.1557  BWP17 Invasive growth decreased 
orf19.1736  BWP17 Invasive growth decreased 
orf19.1949 VPS1 CAI-8 Resistance to fluconazole decreased. 
Filamentous growth decreased 
orf19.2014 BCY1 CAI-4 Filamentous growth abnormal 
orf19.220 PIR1  Resistance to Congo red and calcofluor white 
decreased. Vegetative growth decreased. 
orf19.2268 RCK2 BWP17 Invasive growth decreased 
orf19.2521  BWP17 Invasive growth decreased 
orf19.2555 URA5 CAI-4 Virulence absent (mouse model) 
orf19.2743  BWP17 Invasive growth decreased 
orf19.2823 RFG1 CAI-4 Filamentous growth increased. Virulence 
decreased (mouse model). 
orf19.3077 VID21 BWP17 Invasive growth decreased 
orf19.3161  CAI-4 Virulence absent (mouse model) 
orf19.3188 TAC1  Resistance to fluconazole and terbinafine 
increased 
orf19.3353  BWP17 Invasive growth decreased 
orf19.3526 ITR1 BWP17 Invasive growth decreased 
orf19.3969 SLF2 SC5314 Invasive growth decreased. Colony shape 
abnormal. Germ tube formation decreased. 
orf19.4332  BWP17 Invasive growth decreased 
orf19.4737 TPO3 SC5314 Resistance to 5-fluorouracil, tubercidin and 
flucytosine decreased 
BWP17 Invasive growth decreased 
orf19.5104 LTP1 BWP17 Invasive growth decreased 
orf19.5574  BWP17 Invasive growth decreased 
orf19.5623 ARP4 SC5314 Resistance to virgineone decreased 
orf19.5741 ALS1 CAI-4 Hyphal growth decreased 
orf19.5768 SNF4 CAI-4 Filamentous growth decreased 
orf19.6202 RBT4 SC5314 Resistance to ergosterol analogs decreased 
CAI-4 Virulence decreased (mouse model) 
orf19.6630  BWP17 Invasive growth decreased 
orf19.6854 ATP1 BWP17 Invasive growth decreased 
orf19.801 TBF1 CAI-4 Virulence absent (mouse model) 
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4.1.2 Aims of this Chapter 
This chapter has three main aims to investigate the functional consequence of 
AEI: 
1. Identification of a set of target genes for heterozygous knockout 
construction. 
2. Construction and validation of heterozygous knockout strains. 
3. Phenotypic screening of heterozygous knockout strains under a range of 
general and gene specific assays.  
 
4.2 Materials and Methods 
4.2.1 Identification of Target Genes 
Genes to be used for heterozygous knockout construction were selected based 
upon three criteria: greater than 2x fold difference in RPKM value of alleles, 
more than 20 counts for the allele with the lowest expression level (except for 
the cases of monoallelic expression), and association with GO terms that are 
related to virulence and are easily screened to assess phenotypic impact – 
pathogenesis, morphology, cell cycle, metabolism and drug resistance. GO 
terms for each gene were identified using the Candida genome database 
(www.candidagenome.org) (Inglis et al., 2012).  
 
4.2.2 Heterozygous Knockout Mutant Construction 
For a full list of all heterozygous knockout mutants constructed and used in this 
study, please refer to Table 2.1. Heterozygous deletions were carried out as 
described in sections 2.8 to 2.11. 
 
4.2.3 Phenotypic Screening 
For methodology of general phenotypic assays used both here and in chapter 
five, see section 2.14. Below lists the phenotypic screens used in just this 
chapter. 
 
4.2.3.1 Biofilm Production 
The ability of a strain to form a biofilm was measured using a 96-well plate 
assay. Cells were grown overnight in 10 ml of YNB + 50 mM glucose (0.67% 
(w/v) yeast nitrogen base, 0.9% (w/v) glucose). This media has previously been 
shown to promote growth of biofilms (Hawser and Douglas, 1994). Cells were 
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pelleted at 4000 rpm for five minutes, washed twice in 20 ml of PBS, and 
resuspended at a concentration of 1 x 107 cells/ml using a haemocytometer. 
100 µl of cells were added to a well of the 96-well plate. Individual strains were 
inoculated in a minimum of technical triplicate. Cells were left to adhere to the 
plate at 37 °C for 90 minutes. Non-adherent cells were washed off twice with 
150 µl of PBS. 100 µl of YNB + 50 mM glucose was then added and plates 
were incubated at 37 °C for 24 or 48 hours.  
 
Biofilm formation was measured using an XTT assay, where the solution turns 
increasingly red with increasing metabolic activity of mitochondrial 
dehydrogenase (Chandra et al., 2012). Fresh XTT/menadione solutions were 
prepared on the day of the assay (10 ml of 0.5 mg/ml XTT and 1 µl of 10 mM 
menadione). Spent media was removed from the wells leaving the biofilm 
behind. Unbound cells were removed by washing twice with 150 µl of PBS. 100 
µl of the XTT/menadione solution was added to each well, followed by 
incubation in the dark at 37 °C for two hours. The optical density at 490 nm was 
then measured using a spectrophotometer (Bio-Rad iMark Microplate Reader). 
Measurements were statistically compared using an ANOVA followed by a 
Dunnett’s post-hoc test.   
 
4.2.3.2 Antifungal Resistance during Biofilm Formation 
The protocol for measuring antifungal resistance of biofilms was based on a 
method by Nett et al. (2011). To summarise, cells were grown overnight in 5 ml 
of YPD at 30 °C, 180 rpm. Cell concentrations were estimated using a 
haemocytometer and diluted to a concentration of 1 x 106 cells/ml in RPMI 1640 
medium (1.04% (w/v) RPMI 1640, 3.45% (w/v) MOPS, 1.8% (w/v) glucose, pH 
7.0). 100 µl of cells were then added to the well of a 96-well plate and incubated 
at 37 °C for six hours. Wells were then washed twice with 150 µl of PBS to 
remove unbound cells. 100 µl of fresh RPMI 1640 containing the antifungal drug 
of interest was added to the well and allowed to incubate at 37 °C for 24 hours. 
Spent media was then removed and 100 µl of fresh RPMI containing the 
antifungal drug of interest was applied. The plate was then incubated at 37 °C 
for a further 24 hours and the XTT assay described in section 4.2.3.1 was used 
to measure metabolic activity.    
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Antifungal drugs and concentrations were based on those described in section 
2.14.3.  
 
4.2.3.3 Cell Cycle Analysis 
Flow cytometry was used to assess if a heterozygous knockout strain has an 
altered cell cycle distribution. For cell cycle analysis to be carried out, all cells 
need to be in the same stage of their cell cycle. To achieve this synchronisation, 
a technique involving starvation was used. This method was chosen over 
alternatives, as other forms of cell-cycle block have been associated with a 
switch to hyphae-like cell growth (Berman, 2006). Cells were grown overnight in 
10 ml of YPD at 30 °C, 180 rpm. 200 µl of cells were transferred to 5 ml of 1% 
(w/v) yeast extract and 2% (w/v) bacto-peptone and incubated overnight at 30 
°C, 180 rpm. To release all cells simultaneously, cells were spun at 2000 rpm 
for five minutes and resuspended in 5 ml of YPD. This was followed by 
incubation at 30 °C, 180 rpm. 500 µl of cells were then taken every 15 minutes 
for a total of two hours.  
 
Cell cycle distribution of the wild-type strain SC5314 was checked using flow 
cytometry prior to analysis of heterozygous knockout mutants (see Appendix I 
Figure II). This was achieved using an adapted method designed for use with 
fission yeast (Sabatinos and Forsburg, 2009) as follows: at each 15 minute 
sampling, cells were resuspended in 1 ml of ice-cold 70% ethanol whilst 
vortexing, and cooled for one hour at 4 °C. From this suspension, 300 µl was 
removed and added to 3 ml of 50 mM sodium citrate. The solution was mixed 
and cells were pelleted at 2000 rpm for five minutes. To remove contaminating 
RNA, which may affect analysis of DNA content, the cells were resuspended in 
500 µl of 50 mM sodium citrate with 0.1 mg/ml RNase A and incubated at 37 °C 
for two hours. Finally to stain the DNA, 500 µl of 50 mM sodium citrate 
containing 8 µg/ml propidium iodide was added and mixed thoroughly. Samples 
were stored in the dark at 4 °C until analysis. Samples were analysed using a 
BD FACSARIA II (Becton Dickinson, San Jose, USA) set with detector FSC E00 
at Gain 3 and detector FL2-A Voltage at 890 and Gain 2. 
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4.2.3.4 Vacuole Staining with FUN-1 Solution 
To monitor vacuole size and formation a FUN-1 stain (Molecular Probes, 
Invitrogen) was used. This assay is typically used to assay whether cells are 
alive or dead, but as a lipophilic stain it can also be used to visualise vacuoles. 
The appropriate strains were grown overnight in 5 ml of YPD at 30 °C, 180 rpm. 
200 µl were removed, pelleted at 13000 rpm for five minutes and resuspended 
in 1 ml of GH solution (2% (w/v) glucose, 10 mM sodium-HEPES, pH 7.2). 100 
µl of cells were combined with 100 µl of 50 mM FUN-1 reagent in GH solution. 
The mixture was incubated for 30 minutes in the dark at 30 °C before 
visualisation of cells with a fluorescence microscope (Leica DFC300 Fx). FUN-1 
reagent is excited at around 470 nm and emission is detected at between 500 
and 700 nm.   
 
4.2.3.5 Lipase Secretion 
To measure the amount of lipase secreted from cells, a colony halo protocol 
was used as previously described by Fu et al. (1997). Cells were grown 
overnight in 5 ml of YPD at 30 °C, 180 rpm. Cells concentrations were adjusted 
to 1 x 107 cells/ml using a haemocytometer. 5 µl of cells were spotted onto Egg 
Yolk media plates (6.5% (w/v) Sabouraud dextrose agar, 5.85% (w/v) sodium 
chloride, 0.06% (w/v) calcium chloride, 10% (v/v) egg yolk (spun at 500 rpm for 
10 minutes, supernatant used)) and incubated at 30 °C. As lipase is secreted, 
the cloudy media becomes clear and produces a halo around the colony. The 
diameter of this halo was measured every 24 hours for a total of 5 days and 
statistically compared using an ANOVA followed by a Dunnett’s post-hoc test.   
 
4.2.4 Cloning of Genes 
Cloning of RCK2 to determine allele sequences was carried out as described in 
section 2.8. 
 
4.3 Results 
4.3.1 Identification of Target Genes for Phenotypic Analysis and 
Construction of Heterozygous Knockout Mutants 
From the 233 genes identified as having significant levels of AEI in chapter 3, 
genes to be used for heterozygous knockout construction were selected based 
upon three criteria: greater than 2x fold difference in RPKM value of alleles, 
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more than 20 counts for the allele with the lowest expression level (except for 
the cases of monoallelic expression), and association with GO terms that are 
related to virulence and are easily screened to assess phenotypic impact – 
pathogenesis, morphology, cell cycle, metabolism and drug resistance. These 
strict criteria produced too small a list of genes to work with at just two genes, 
CDC6 and RBT4. Therefore genes matching with 2 out of 3 criteria were also 
included.  
 
This filter identified 11 possible gene targets for use in heterozygous knockout 
construction. Knocking out the gene RFG1 would result in interference with the 
neighbouring open reading frame, and therefore, this gene was removed from 
the list of gene targets, leaving 10 genes in total (Table 4.2). Fold differences in 
the RPKM levels of each gene are graphically represented in Figure 4.2. Of the 
10 genes selected, heterozygous knockout mutants were successfully 
constructed for both alleles of six genes, CDC6, ERB1, RBT4, RCK2, SMI1 and 
VPS1. Validation of insertion at the correct genomic location was carried out 
using PCR as described in sections 2.9 and 2.10 (Figure 4.3). Southern blotting 
was used to further validate insertion in the correct position and ensure that only 
one copy of the nourseothricin cassette had been inserted, as described in 
section 2.15 (Figure 4.4). Southern blotting was carried out for all strains except 
for RCK2 knockouts, as sequencing only identified knockouts of allele one. Due 
to the inability to produce knockouts of both alleles, there are also no 
phenotypic screens for RCK2. This is further discussed in section 4.3.3. 
 
To show that the nourseothricin cassette itself was not causing phenotypic 
differences, a control strain containing nourseothricin at the RPS1 locus was 
constructed as described in section 2.14.1. Herein, this strain is named SC12. 
This location was chosen based on evidence that replacement has no 
phenotypic contributions (Murad et al., 2000). Validation of the strain was 
carried out using PCR (Figure 4.5).  
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Table 4.2 Target Genes for Heterozygous Knockout Construction 
 
Gene Name Allele 1 Allele 2 Allele 1 
Tags 
Allele 2 
Tags 
Allele 1 RPKM 
(3 d.p.) 
Allele 2 RPKM  
(3 d.p.) 
Fold Difference in 
RPKM (3 d.p.) 
P Value 
 orf19.2051 orf19.9599 737 1908 15.840 46.483 2.935 3.55x10-12 
 orf19.3556 orf19.11040 94 0 5.863 0.000 - 7.97x10-6 
 orf19.4516 orf19.11991 175 19 21.020 2.477 8.485 3.38x10-12 
 orf19.5095 orf19.12561 468 1 21.456 0.044 491.344 1.79x10-19 
CDC6 orf19.5242 orf19.12707 49 199 9.450 26.730 2.830 1.92x10-7 
ERB1 orf19.1047 orf19.8649 80 2 6.177 0.148 41.739 4.01x10-6 
RBT4 orf19.6202 orf19.13583 23 312 3.713 50.963 13.727 2.60x10-34 
RCK2 orf19.2268 orf19.9808 139 1192 14.091 121.551 8.626 4.13x10-68 
SMI1 orf19.5058 orf19.12525 216 0 22.524 0.000 - 1.18x10-20 
VPS1 orf19.1949 orf19.9505 1723 633 147.921 55.058 2.687 1.39x10-28 
- Indicates that expression levels for one allele were below the detectable limit and therefore the fold difference could not be calculated. 
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Figure 4.2 Average differences in allele expression of target genes. Errors bars ± one standard deviation. Blue shows “allele one” and red shows 
“allele two”. a) orf19.2051, b) orf19.3556, c) orf19.4516, d) orf19.5095, e) CDC6, f) ERB1, g) RBT4, h) RCK2, i) SMI1 and j) VPS1.  
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Figure 4.3 PCR validations of heterozygous knockout mutants. L = 1 kb DNA ladder (Fermentas, UK). N = negative control containing no DNA. SC3, 
SC4 and SC5 = RBT4 knockouts with a band expected at 557 bp. SC6, SC7, SC16, SC17, SC18 and SC32 = VPS1 knockouts with a band expected 
at 590 bp. SC8, SC9 and SC10 = CDC6 knockouts with a band expected at 525 bp. SC30 and SC33 = SMI1 knockouts with a band expected at 607 
bp. SC34, SC44, SC45, SC51, SC52, SC55, SC54 and SC55 = RCK2 knockouts with a band expected at 581 bp. SC42, SC46, SC47, SC48, SC49 
and SC56 = ERB1 knockouts with a band expected at 627 bp.   
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Figure 4.4 Southern blotting validations of heterozygous knockout mutants using a 
hybridisation probe against the NAT1 sequence. L = 1 kb DNA ladder (Fermentas, UK). 
SC5314 = negative control containing untransformed wild-type DNA. N = negative 
control containing all reaction components except DNA. SC3, SC4 and SC5 = RBT4 
heterozygous knockouts showing a single band at 3635 bp. SC8, SC9 and SC10 = 
CDC6 heterozygous knockouts showing a single band around 7000 bp, this is higher 
than expected but may be due to errors in the reference sequence used to design the 
digests. SC6, SC7, SC16, SC17, SC18 and SC32 = VPS1 heterozygous knockouts 
with a single band at 2951 bp. SC30 and SC33 = SMI1 heterozygous knockouts with a 
single band at 4588 bp. SC42, SC46, SC47, SC48, SC49 and SC56 = ERB1 
heterozygous knockouts showing a single band at 2573 bp.  
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Figure 4.5 PCR validation of control strain SC12 with NAT1 cassette integrated at 
RPS1. L = 1 kb DNA ladder (Fermentas, UK). N = negative control containing no DNA. 
SC12 shows a band at approximately 1500 bp as expected.  
 
4.3.2 Phenotypic Screening of Heterozygous Knockout Mutants 
Five standard phenotypic tests, which are related to the infection process, were 
undertaken on the heterozygous knockout mutants of all genes to elucidate any 
general defects in function.  Phenotypic assays included growth rate at 30 °C 
and 37 °C (for methods see section 2.14.2), induction of hyphae with foetal calf 
serum (for methods see section 2.14.5), an adhesion assay using buccal 
epithelial cells (for methods see section 2.14.6), a virulence assay using a 
Galleria mellonella infection model (for methods see section 2.14.7), and 
resistance to the antifungal compounds fluconazole, 5-flucytosine and 
amphotericin B (for methods see section 2.14.3). These assays were 
accompanied by phenotypic tests specific for the gene in question based upon 
the findings of previous published work.   
 
4.3.2.1 CDC6 Phenotypic Screening 
CDC6 forms part of the DNA pre-replication subunit and is expressed during the 
M/G1 phase of the cell cycle (Cote et al., 2009). Work in S. cerevisiae has 
shown that CDC6 is essential for DNA replication, with a role in origin firing and 
establishment of the pre-replication complex (Cocker et al., 1996). Deletion 
leads to an accumulation of cells in S phase (Yu et al., 2006) due to a lack of 
initiation of replication. Over-expression has demonstrated a block in M phase 
suggesting that CDC6 also has a checkpoint role to ensure completion of the S 
phase before progression in the cell cycle (Bueno and Russell, 1992). 
Therefore, based on these previous studies, the heterozygous knockout 
L SC12 N 
1000bp 
1500bp 
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mutants of CDC6 were analysed for any cell cycle malfunctions using flow 
cytometry as described in section 4.2.3.3.  
 
Figure 4.6k shows that all three mutants, two knockouts of allele 1 and one 
knockout of allele 2, have a shift in their profile when compared to the wild-type 
strain SC5314 and the NAT1 control strain SC12. There are a number of 
interesting points that can be made from this observation. All strains have two 
peaks, one representing a DNA content of 2n and one representing a DNA 
content of 4n, indicative of no block in the cell cycle at the S phase as is 
observed with S. cerevisiae CDC6 knockout. However the shift in profiles 
suggests that all three CDC6 heterozygous knockout mutants may be tetraploid, 
and in fact the peaks represent a DNA content of 4n and 8n, with cell separation 
defects being unlikely as appearance under the microscope is normal. 
Comparative genome hybridisation is an assay that could use in the future to 
confirm the ploidy of all chromosomes. Despite this phenotypic variation, the 
alleles themselves do not indicate a difference in function. 
 
Mutants of CDC6 in S. cerevisiae have also shown abnormal cellular 
morphology (Hartwell et al., 1973) and an abnormal growth rate at 37 °C 
(Detweiler and Li, 1997). These phenotypes, however, have been shown to be 
unaffected in the C. albicans CDC6 heterozygous knockout mutants with growth 
rates comparable to the wild-type strain SC5314 at both 30 °C and 37 °C (see 
Table 4.3 and Figures 4.6a and 4.6b), with only a minimal statistically significant 
increase in end-point optical density for SC9 at 30 °C, one isolate lacking allele 
one. However, this difference is also observed for the control strain SC12 
containing NAT1 at the RPS1 locus, suggesting that the difference is not due to 
the loss of the allele. 
 
Other phenotypic assays also indicated no differences between the 
heterozygous knockout strains and the wild-type strain SC5314. All strains 
adhered to buccal epithelial cells (two sample t-test, d.f. = 2, p > 0.05; Figure 
4.6c-e), all strains were able to switch to the hyphal growth form (Figure 4.6f), 
and all strains had comparable virulence using a Galleria mellonella infection 
model (Kaplan-Meier test, d.f. = 4, p > 0.05),  
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Table 4.3 Average generation times, times to maximum inflection and end-
point optical densities of CDC6 heterozygous knockout mutants at 30 °C 
and 37 °C (± one standard deviation)  
Growth Curve 
(from Figure 4.6) 
Strain Generation 
Time (mins) 
Time to 
Maximum 
Inflection (mins) 
End-Point Optical 
Density (OD at 650 
nm) 
a) 30 °C SC5314 117.23 ± 36.54 306.69 ± 28.29 1.22 ± 0.17 
SC12 124.92 ± 59.84 326.20 ± 34.27 1.39* ± 0.20 
Allele 1 knockout SC9 106.63 ± 14.98 310.19 ± 31.17 1.45* ± 0.15 
SC10 114.53 ± 20.35 332.50 ± 29.75 1.34 ± 0.20 
Allele 2 knockout SC8 112.31 ± 15.55 321.30 ± 37.09 1.37 ± 0.17 
b) 37 ° C SC5314 120.53 ± 29.04 448.58 ± 56.94 0.80 ± 0.23 
SC12 135.60 ± 28.20 449.75 ± 91.35 0.98 ± 0.19 
Allele 1 knockout SC9 127.23 ± 23.74 465.85 ± 79.12 0.76 ± 0.46 
SC10 144.61 ± 36.91 455.70 ± 61.44 0.64 ± 0.30 
Allele 2 knockout SC8 141.81 ± 35.88 429.92 ± 51.80 0.89 ± 0.23 
* Significantly different measurements from SC5314, identified by ANOVA 
followed by post-hoc analysis using a Dunnett’s test, at p < 0.05, are 
annotated with an asterisk. 
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Figure 4.6 Phenotypic assays of CDC6 heterozygous knockout mutants. SC5314 = wild-type strain (blue). SC12 = control strain with NAT cassette at 
RPS1 locus (red). SC9 and SC10 = knockout of “allele one” (yellow) and SC8 = knockout of “allele two” (green).  
 
  
 
 
 
 
 
 
 
 
 
a) Growth rate at 30 °C. b) Growth rate at 37 °C.  
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c) Percentage of BECs adhered to C. albicans cells. d) Number of C. albicans cells per BEC. e) Number of C. albicans cells per BECs (with cells 
adhered). Error bars = ± one standard deviation.  
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g) Galleria mellonella virulence 
assay at a cell concentration of 
2 x 107 cells/ml.  
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h) Growth in response to fluconazole. Concentrations range from 0 – 1024 µg/ml. Blue = 
OD at 595 nm at 24 hours. Red = OD at 595 nm at 48 hours. Error bars = ± one standard 
deviation.  
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i) Growth in response to 5-flucytosine. Concentrations range from 0 – 1024 µg/ml. Blue = 
OD at 595 nm at 24 hours. Red = OD at 595 nm at 48 hours. Error bars = ± one standard 
deviation.  
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j) Growth in response to amphotericin b. Concentrations range from 0 – 1024 µg/ml. Blue = 
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deviation.  
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4.3.2.2 ERB1 Phenotypic Screening 
The function of C. albicans gene ERB1 is yet to be fully characterised, however, 
based upon orthology to the S. cerevisiae gene ERB1, predictions have been 
made for its involvement in synthesis of ribosomal subunits (Pestov et al., 
2001). Observations of tagged protein levels have been shown that ERB1 levels 
are reduced during the transition to hyphae (Lee et al., 2005). However, our 
results show that heterozygous knockout mutants of this gene have normal 
morphology both in the yeast and hyphal forms (Figure 4.7f). Large scale 
genome-wide studies have shown that heterozygous null mutants of ERB1 have 
reduced resistance to a range of antifungal drugs including 5-flucytosine, 5-
fluorouracil and tubercidin (Xu et al., 2007). Conversely, our results have shown 
a normal response of heterozygous knockout mutants to 5-flucytosine (Figure 
4.7i) and the other antifungal compound amphotericin B (Figure 4.7j). However, 
in growth in fluconazole, all knockout mutants demonstrated a slight increased 
sensitivity at 48 hours (Figure 4.7h). A TET-down ERB1 repressive strain has 
shown attenuation of virulence in a murine infection model (Becker et al., 2010), 
but virulence of heterozygous knockout mutants, using a Galleria mellonella 
model, has been shown to be largely unaffected (Figure 4.7g). Some significant 
differences for strains SC48 and SC56, both knockouts of allele 2, were 
observed at 2 x 107 cells/ml (Kaplan-Meier, d.f. = 1, p = 0.048 and 0.004 
respectively). However this difference was not observed at the other two cell 
concentrations and the third isolate of this strain, SC47, also shows no 
significant differences. To be sure that this difference was not significant, a total 
of eight biological replicates were carried out for these strains.  
Other generic phenotypic screens also suggest that the alleles of ERB1 do not 
differ in function. Growth at both 30 and 37 °C shows no significant differences 
in growth (ANOVA, p > 0.05; Figure 4.7a, Figure 4.7b, Table 4.4). And adhesion 
to buccal epithelial cells was comparable to the wild-type strain SC3514 for all 
three measures taken (Student’s t test, d.f. = 2, p > 0.05; Figures 4.7c – e). 
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Table 4.4 Average generation times, times to maximum inflection and end-
point optical densities of ERB1 heterozygous knockout mutants at 30 °C 
and 37 °C (± one standard deviation) 
Growth Curve 
(from Figure 4.7) 
Strain Generation 
Time (mins) 
Time to 
Maximum 
Inflection (mins) 
End-Point Optical 
Density (OD at 650 
nm) 
a) 30 °C SC5314 115.34 ± 9.88 325.06 ± 16.25 1.37 ± 0.15 
SC12 118.63 ± 8.37 328.13 ± 7.19 1.32 ± 0.09 
Allele 1 knockout SC42 117.94 ± 8.02 328.56 ± 11.45 1.35 ± 0.10 
SC46 111.24 ± 9.44 328.13 ± 10.54 1.38 ± 0.12 
SC49 111.64 ± 12.86 323.31 ± 11.67 1.39 ± 0.10 
Allele 2 knockout SC47 113.64 ± 9.02 328.13 ± 6.73 1.30 ± 0.11 
SC48 121.45 ± 6.00 312.81 ± 7.19 1.40 ± 0.03 
SC56 127.34 ± 13.85 321.50 ± 8.43 1.31 ± 0.02 
b) 37 ° C SC5314 54.86 ± 19.52 315.00 ± 33.44 1.20 ± 0.23 
SC12 60.35 ± 17.66 310.92 ± 30.40 1.38 ± 0.14 
Allele 1 knockout SC42 52.85 ± 21.37 314.96 ± 38.00 1.34 ± 0.16 
SC46 55.04 ± 15.89 302.17 ± 27.61 1.38 ± 0.16 
SC49 58.32 ± 13.02 294.54 ± 28.80 1.42* ± 0.11 
Allele 2 knockout SC47 65.07 ± 10.04 294.86 ± 29.96 1.42* ± 0.09 
SC48 61.66 ± 14.10 301.58 ± 25.63 1.27 ± 0.20 
SC56 59.57 ± 20.07 305.67 ± 26.88 1.32 ± 0.14 
* Significantly different measurements from SC5314, identified by ANOVA 
followed by post-hoc analysis using a Dunnett’s test, at p < 0.05, are 
annotated with an asterisk. 
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Figure 4.7 Phenotypic assays of ERB1 heterozygous knockout mutants. SC5314 = wild-type strain (blue). SC12 = control strain with NAT cassette at 
RPS1 locus (red). SC42, SC46 and SC49 = knockout of “allele one” (yellow) and SC47, SC48 and SC56 = knockout of “allele two” (green).  
 
 
 
 
 
 
 
 
 
 
a) Growth rate at 30 °C and b) Growth rate at 37 °C   
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c) Percentage of BECs adhered to C. albicans cells. d) Number of C. albicans cells per BEC. e) Number of C. albicans cells per BECs (with cells 
adhered). Error bars = ± one standard deviation.  
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assay at a cell concentration of 
2 x 107 cells/ml.  
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h) Growth in response to fluconazole. Concentrations range from 0 – 1024 µg/ml. Blue = OD 
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deviation.  
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i) Growth in response to 5-flucytosine. Concentrations range from 0 – 1024 µg/ml. Blue = 
OD at 595 nm at 24 hours. Red = OD at 595 nm at 48 hours. Error bars = ± one standard 
deviation.  
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j) Growth in response to amphotericin b. Concentrations range from 0 – 1024 µg/ml. Blue = 
OD at 595 nm at 24 hours. Red = OD at 595 nm at 48 hours. Error bars = ± one standard 
deviation.  
 
Page | 202  
 
4.3.2.3 RBT4 Phenotypic Screening 
The gene RBT4 has been associated with the transition from the yeast to 
hyphal form, and is named due to negative regulation by the gene Tup1. Tup1 
is a transcription factor which represses the switch of C. albicans cells from 
yeast to hyphal form. Deletion of Tup1 induces the expression of RBT4 and the 
switch to hyphal form (Braun et al., 2000). Homozygous knockout strains of 
RBT4 have been shown to have no differences in morphology or growth rate 
(Jackson et al., 2007, Noble et al., 2010), which is supported by our growth 
curve results as seen in Figures 4.8a and 4.8b and Table 4.5 (ANOVA, p > 
0.05). However, knockout strains have been found to have reduced infectivity in 
BALB/c mice during both disseminated infection (Noble et al., 2010) and 
corneal inflammation (Braun et al., 2000, Jackson et al., 2007). Conversely, 
here it is shown that heterozygous knockout mutants have no reduction in 
infectivity in a Galleria mellonella infection model (Kaplan-Meier test, d.f. = 4, p 
> 0.05; Figure 4.8g). During corneal infection with the RBT4 deletion strain, it 
was also observed that only yeast cells were present, whereas many hyphal 
cells were seen during wild-type infection. The results here indicate that 
induction of hyphae is also unaffected in heterozygous knockout mutants 
(Figure 4.8f).  
 
Screening in other phenotypic assays indicated no difference in function 
between the alleles of RBT4. All heterozygous knockout mutants showed 
similar capabilities as the wild-type strain to adhere to buccal epithelial cells for 
all three measures taken (Student t-test, d.f. = 2, p > 0.05; Figure 4.8c-e). All 
strains also showed no evidence of resistance or susceptibility to the antifungal 
drug treatments (Figure 4.8i-j). All three heterozygous knockout strains showed 
a marginal increase in growth in fluconazole at 48 hours when compared to the 
wild-type strain SC5314 and the control strain SC12 (Figure 4.8h), however this 
slight difference can most likely be accounted for by inter-plate variability.  
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Table 4.5 Average generation times, times to maximum inflection and end-
point optical densities of RBT4 heterozygous knockout mutants at 30 °C 
and 37 °C (± one standard deviation) 
Growth Curve 
(from Figure 
4.8) 
Strain Generation 
Time (mins) 
Time to 
Maximum 
Inflection (mins) 
End-Point Optical 
Density (OD at 650 
nm) 
a) 30 °C SC5314 117.23 ± 36.54 306.69 ± 28.29 1.22 ± 0.17 
SC12 124.92 ± 59.84 326.20 ± 34.27 1.39* ± 0.20 
Allele 1 KO SC3 111.08 ± 17.51 311.50 ± 25.62 1.29 ± 0.15 
Allele 2 KO SC4 115.00 ± 19.22 322.00 ± 68.55 1.40* ± 0.14 
SC5 106.10 ± 18.54 310.41 ± 24.17 1.35 ± 0.16 
b) 37 °C SC5314 120.53 ± 29.04 448.58 ± 56.94 0.80 ± 0.23 
SC12 135.60 ± 28.20 449.75 ± 91.35 0.98 ± 0.19 
Allele 1 KO SC3 120.41 ± 18.63 461.71 ± 65.50 0.98 ± 0.34 
Allele 2 KO SC4 130.30 ± 25.66 415.33 ± 41.04 0.75 ± 0.28 
SC5 120.76 ± 17.52 404.83 ± 43.00 0.92 ± 0.26 
* Significantly different measurements from SC5314, identified by ANOVA 
followed by post-hoc analysis using a Dunnett’s test, at p < 0.05, are 
annotated with an asterisk.  
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Figure 4.8 Phenotypic assays of RBT4 heterozygous knockout mutants. SC5314 = wild-type strain (blue). SC12 = control strain with NAT cassette at 
RPS1 locus (red). SC3 = knockout of “allele one” (yellow) and SC4 and SC5 = knockout of “allele two” (green).  
 
 
 
 
 
 
 
 
 
 
 
 
a) Growth rate at 30 °C. b) Growth rate at 37 °C.  
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c) Percentage of BECs adhered to C. albicans cells. d) Number of C. albicans cells per BEC. e) Number of C. albicans cells per BECs (with cells 
adhered). Error bars = ± one standard deviation.  
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f) Induction of hyphae. Strains 
were exposed to 5% foetal calf 
serum and incubated at 37 °C. 
Figures shows cells at 120 
minutes however samples were 
taken every 15 minutes. Scale 
bar = 10 µm.  
 
g) Galleria mellonella virulence 
assay at a cell concentration of 
2 x 107 cells/ml.  
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h) Growth in response to fluconazole. Concentrations range from 0 – 1024 µg/ml. Blue = OD 
at 595 nm at 24 hours. Red = OD at 595 nm at 48 hours. Error bars = ± one standard 
deviation.  
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i) Growth in response to 5-flucytosine. Concentrations range from 0 – 1024 µg/ml. Blue = 
OD at 595 nm at 24 hours. Red = OD at 595 nm at 48 hours. Error bars = ± one standard 
deviation.  
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j) Growth in response to amphotericin b. Concentrations range from 0 – 1024 µg/ml. Blue = 
OD at 595 nm at 24 hours. Red = OD at 595 nm at 48 hours. Error bars = ± one standard 
deviation.  
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4.3.2.4 SMI1 Phenotypic Screening 
SMI1 is a gene involved in cell wall biosynthesis which appears to interact with 
the β-1,3-glucan synthase FKS1 (Nett et al., 2011). Homozygous deletion of the 
gene results in reduced biofilm antifungal resistance when exposed to 
fluconazole, amphotericin B and anidulafungin, as well as reduced β-1,3-glucan 
in the biofilm matrix, a thinner biofilm cell wall, and an increased susceptibility to 
calcofluor white stress. A heterozygous knockout strain also demonstrated the 
reduction in β-1,3-glucan but to a lesser extent. However growth rate, biofilm 
growth and virulence phenotypes were all unaffected by removal of SMI1 (Nett 
et al., 2011).  
 
Phenotypic screening of heterozygous knockout mutants here also shows that 
growth rate (ANOVA, p > 0.05; Figures 4.9a and 4.9b; Table 4.5), virulence 
(Kaplan-Meier test, d.f. = 3; Figure 4.9g) and biofilm formation (ANOVA, p > 
0.05; Figure 4.9k) are not altered significantly by removal of a copy of SMI1. 
Exposure of biofilms to the antifungal drugs fluconazole, 5-flucytosine and 
amphotericin B also showed no significant differences between heterozygous 
knockout mutants and the wild-type strain SC5314 (Figure 4.9l). However, both 
SC30 and SC33 appear to have a higher growth rate than SC5314 when 
exposed to all concentrations of amphotericin B (Figure 4.9l3). This results is 
surprising, and the opposite as to what is seen in the homozygous knockout 
strain (Nett et al., 2011).  
 
Investigations in the S. cerevisiae homolog of SMI1 have also shown that gene 
knockouts have reduced β-glucan (Hong et al., 1994, Dague et al., 2010), 
reduced cell wall elasticity, increased mannan and chitin (Dague et al., 2010), 
increased sensitivity to caspofungin (Markovich et al., 2004), increased 
sensitivity to SDS and cercosporamide (Hong et al., 1994), increased sensitivity 
to ethanol (Dudley et al., 2005, van Voorst et al., 2006, Yoshikawa et al., 2009), 
and increased sensitivity to the antifungal drug hygromycin B and the stress 
condition calcium chloride (Dudley et al., 2005). 
 
Based upon these observations, growth of the heterozygous knockout mutants 
was monitored under a range of conditions, including SDS, ethanol, calcium 
chloride, hygromycin B and calcofluor white. Figure 4.9m shows that under all of 
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the conditions tested, there is no significant sensitivity of any of the mutants 
when compared to the wild-type strain SC5314, however SC33, the knockout of 
allele one shows a very minimal sensitivity to SDS and ethanol with reduced 
growth and colony size at the lowest cell concentration. It is difficult to infer from 
the results here whether there is a minor functional difference in the alleles or if 
this observation is due to uneven plating of the strains with the replicator.    
 
A possible assay that may have indicated phenotypic differences between the 
heterozygous knockout strains of each allele, but has not been included in this 
investigation, is the measurement of β-glucan. The methodology for this assay, 
as previously seen in (Hong et al., 1994, Dague et al., 2010), was not available 
for use here, but is something that could be investigated as part of further work.  
 
Results of other phenotypic assays indicate no functional differences between 
the alleles of SMI1. All heterozygous knockout strains had comparable 
adhesion to buccal epithelial cells to the wild-type strain for all three measures 
taken (student’s t-test, d.f. = 2, p > 0.05; Figures 4.9c-e). All strains were able to 
switch from the yeast to hyphal form (Figure 4.9f). Growth under exposure to 
the antifungal drug treatments fluconazole (Figure 4.9h), 5-flucytosine (Figure 
4.9i) and amphotericin B (Figure 4.9j) is comparable for all strains at both 24 
and 48 hours. 
 
Table 4.6 Average generation times, times to maximum inflection and end-
point optical densities of SMI1 heterozygous knockout mutants at 30 °C 
and 37 °C (± one standard deviation) 
Growth Curve 
(from Figure 4.9) 
Strain Generation 
Time (mins) 
Time to 
Maximum 
Inflection (mins) 
End-Point Optical 
Density (OD at 650 
nm) 
a) 30 °C SC5314 127.49 ± 38.30 344.75 ± 80.57 1.48 ± 0.18 
SC12 123.68 ± 34.77 357.00 ± 43.54 1.49 ± 0.11 
Allele 1 knockout SC33 118.29 ± 31.14 306.54 ± 28.53 1.50 ± 0.12 
Allele 2 knockout SC30 121.59 ± 30.46 322.88 ± 21.01 1.47 ± 0.11 
b) 37 ° C SC5314 108.28 ± 36.15 258.13 ± 77.11 1.43 ± 0.21 
SC12 116.43 ± 31.22 304.06 ± 123.98 1.46 ± 0.16 
Allele 1 knockout SC33 87.36 ± 52.91 240.19 ± 38.97 1.48 ± 0.16 
Allele 2 knockout SC30 98.47 ± 48.64 228.44 ± 28.13 1.40 ± 0.12 
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Figure 4.9 Phenotypic assays of SMI1 heterozygous knockout mutants. SC5314 = wild-type strain (blue). SC12 = control strain with NAT cassette at 
RPS1 locus (red). SC33 = knockout of “allele one” (yellow) and SC30 = knockout of “allele two” (green).  
 
 
 
 
 
 
 
 
 
 
 
 
 
a) Growth rate at 30 °C. b) Growth rate at 37 °C.  
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c) Percentage of BECs adhered to C. albicans cells. d) Number of C. albicans cells per BEC. e) Number of C. albicans cells per BECs (with cells 
adhered). Error bars = ± one standard deviation.  
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SC12 - RPS1 
h) Growth in response to fluconazole. Concentrations range from 0 – 1024 µg/ml. Blue = OD 
at 595 nm at 24 hours. Red = OD at 595 nm at 48 hours. Error bars = ± one standard 
deviation.  
 
Page | 216  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
0
0.5
1
1.5
2
0 1 2 4 8
1
6
3
2
6
4
1
2
8
2
5
6
5
1
2
1
0
2
4
O
D
 a
t 
5
9
5
 n
m
 
Concentration (µg/ml) 
SC5314 
0
0.5
1
1.5
2
0 1 2 4 8
1
6
3
2
6
4
1
2
8
2
5
6
5
1
2
1
0
2
4
O
D
 a
t 
5
9
5
 n
m
 
Concentration (µg\ml) 
SC30 - Allele 2 KO 
0
0.5
1
1.5
2
0 1 2 4 8
1
6
3
2
6
4
1
2
8
2
5
6
5
1
2
1
0
2
4
O
D
 a
t 
5
9
5
 n
m
 
Concentration (µg\ml) 
SC33 - Allele 1 KO 
0
0.5
1
1.5
2
0 1 2 4 8
1
6
3
2
6
4
1
2
8
2
5
6
5
1
2
1
0
2
4
O
D
 a
t 
5
9
5
 n
m
 
Concentration (µg/ml) 
SC12 - RPS1 
i) Growth in response to 5-flucytosine. Concentrations range from 0 – 1024 µg/ml. Blue = 
OD at 595 nm at 24 hours. Red = OD at 595 nm at 48 hours. Error bars = ± one standard 
deviation.  
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k) Biofilm production. Representative results for the 24 hour time point shown here. 
Error bars represent ± one standard deviation.  
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j) Growth in response to amphotericin b. Concentrations range from 0 – 1024 µg/ml. Blue = 
OD at 595 nm at 24 hours. Red = OD at 595 nm at 48 hours. Error bars = ± one standard 
deviation.  
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l) Biofilm production under exposure to antifungal drug treatments at a range of 
concentrations from 0 to 1024 µg/ml. 1) fluconazole, 2) 5-flucytosine and 3) 
amphotericin B. Error bars represent ± one standard deviation.  
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m) Growth under stress conditions. Cells are plated in tenfold dilution from 1 x 107 
cells/ml to 1 x 103 cells/ml. Growth on YPD as a control compared to growth on YPD + 
0.1% SDS, 6% ethanol, 0.5 M calcium chloride, 100 mg/ml hygromycin B and 40 µg/ml 
calcofluor white. 
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4.3.2.5 VPS1 Phenotypic Screening 
In C. albicans, the gene VPS1 encodes a dynamin-like GTPase. This gene has 
been well characterised and has been found to functionally complement the 
VPS1 gene in S. cerevisiae (Bernardo et al., 2008). From this it has been 
inferred that C. albicans VPS1 is involved in the sorting of vacuolar proteins.  As 
an essential gene, the function has been tested using a conditional mutant 
under control of a tetracycline-regulatable promoter. This mutant was found to 
have normal growth rates, and a normal response to flucytosine and 
amphotericin B but was hyper-sensitive to the antifungal drug fluconazole, had 
abnormal vacuolar morphology, defects in filamentation and biofilm formation, 
and have a decrease in secretion of extracellular proteases such as aspartyl 
proteinases and lipase.  (Bernardo et al., 2008).  
 
Interestingly, VPS1 has not been found to be essential in S. cerevisiae. 
Removal of the gene has been associated with numerous phenotypic effects, 
some of which are similar to those seen in C. albicans, including mis-sorting of 
the vacuolar protein carboxypeptidase Y, abnormal fragmented vacuolar 
morphology (Peters et al., 2004, Yu and Cai, 2004, Bernardo et al., 2008) which 
is a classical phenotype of VPS genes, a decrease in number and increase in 
size of peroxisomes (Hoepfner et al., 2001, Kuravi et al., 2006, Vizeacoumar et 
al., 2006), an increase in the time taken to internalise endocytic vesicles (Yu 
and Cai, 2004, Nannapaneni et al., 2010, Rooij et al., 2010) suggestive of a role 
in invagination, disruption of the actin cytoskeleton (Yu and Cai, 2004, 
Nannapaneni et al., 2010) although normal actin has also been observed in 
similar mutants (Hoepfner et al., 2001), a delay in cytokinesis (Hoepfner et al., 
2001), and a defect in Golgi protein retention (Wilsbach and Payne, 1993, 
Nothwehr et al., 1996).  
 
From these previous studies, the VPS1 heterozygous knockout mutants 
constructed here were screened for a number of phenotypic defects. However, 
unlike the results found by Bernardo et al. (2008), the response of these strains 
to growth in fluconazole was less striking, with justSC7, a single isolate lacking 
allele two, which had increased sensitivity at 24 hours (Figure 4.10h). This is 
supported by growth on solid agar containing 64 µg/ml fluconazole (Figure 
4.10k) The ability to form hyphae was also shown to be normal in these 
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heterozygous mutants (Figure 4.10f). Lipase secretion did not significantly differ 
between mutants (ANOVA, p > 0.05; Figure 4.10l), nor did the strains abilities to 
form biofilms (ANOVA, p > 0.05; Figure 4.10m). Vacuole morphology, as 
indicated by FUN-1 staining (detailed in section 4.2.3.4) shows that the 
knockout strains of allele two; SC7, SC18 and SC32; all have a larger vacuole 
than the wild-type strain. However this is also the case for strain SC17, a 
knockout of allele one (Figure 4.10n). 
 
Despite some isolates showing significant differences in growth rate 
measurements at 30 °C, upon observation of the figure, the biological 
significance of these differences are not apparent (ANOVA followed by 
Dunnett’s test, p < 0.05; Figure 4.10a and Table 4.7). Growth rates were found 
to not differ significantly at 37 °C (ANOVA, p > 0.05; Figure 4.10b and Table 
4.7), with the exception of the strain SC7, the knockout of VPS1 allele two, 
which has a significantly longer generation time and longer time to maximum 
inflection. However, the other two isolates of this allele knockout, SC18 and 
SC32, appear to have growth rates comparable to the wild-type strain. 
 
Results of other phenotypic assays indicate no functional differences between 
the alleles of VPS1. The ability to adhere to buccal epithelial cells was not 
significantly different for any of the heterozygous knockout mutants for any of 
the three measures taken (student t-test, p > 0.05; Figures 4.10c-e), suggesting 
that the alleles of VPS1 do not have a functional role in adhesion. Virulence 
using the Galleria mellonella infection model showed that none of the 
heterozygous mutants were attenuated significantly for virulence (Kaplan-Meier 
test, d.f. = 7, p > 0.05; Figure 4.10g). Growth after exposure to the antifungal 
drug amphotericin B did not differ between all strains (Figure 4.10j) and the 
response to 5-flucytosine was generally comparable for all isolates lacking allele 
one. However, strains lacking allele two differed in their response to 5-
flucytosine considerably with SC7 showing reduced sensitivity at 48 hours and 
SC18 and SC32 showing increased sensitivity at 48 (Figure 4.10i). However, as 
growth on solid agar containing 32 µg/ml 5-flucytosine shows that at 48 hours 
only SC7 has increased sensitivity (Figure 4.10k), these differences are likely to 
be accounted for by inter-plate variation in the assay used. 
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Table 4.7 Average Generation Times, Times to Maximum Inflection and 
End-Point Optical Densities of VPS1 Heterozygous Knockout Mutants at 
30 °C and 37 °C (± one standard deviation) 
Growth Curve 
(from Figure 
4.10) 
Strain Generation 
Time (mins) 
Time to 
Maximum 
Inflection (mins) 
End-Point Optical 
Density (OD at 650 
nm) 
a) 30 °C SC5314 119.74 ± 30.63 280.88 ± 49.69 1.38 ± 0.27 
SC12 124.74 ± 50.20 304.96 ± 48.06 1.50 ± 0.24 
Allele 1 KO SC6 109.06 ± 16.80 263.96 ± 55.37 1.48 ± 0.20 
SC16 122.11 ± 15.54 247.63 ± 28.11 1.68* ± 0.07 
SC17 116.11 ± 18.26 245.44 ± 20.36 1.58 ± 0.19 
Allele 2 KO SC7 140.92 ± 27.49 336.44* ± 57.62 1.49 ± 0.16 
SC18 109.52 ± 25.32 232.75 ± 50.65 1.71* ± 0.07 
SC32 132.81 ± 9.19 215.69* ± 51.78 1.70* ± 0.09 
b) 37 °C SC5314 103.37 ± 28.92 367.35 ± 115.90 1.12 ± 0.41 
SC12 116.83 ± 30.55  388.35 ± 125.48 1.25 ± 0.33 
Allele 1 KO SC6 104.22 ± 44.59 347.93 ± 110.93 1.16 ± 0.41 
SC16 94.85 ± 27.38 308.29 ± 151.98 1.39 ± 0.13 
SC17 94.98 ± 30.46 290.21 ± 87.96 1.29 ± 0.21 
Allele 2 KO SC7 153.62* ± 37.86 488.48* ± 150.63 0.98 ± 0.36 
SC18 85.46 ± 27.03 286.13 ± 106.79 1.44* ± 0.15 
SC32 91.71 ± 32.16 282.63 ± 110.53 1.45* ± 0.16 
* Significantly different measurements from SC5314, identified by ANOVA 
followed by post-hoc analysis using a Dunnett’s test, at p < 0.05, are 
annotated with an asterisk.  
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Figure 4.10 Phenotypic assays of VPS1 heterozygous knockout mutants. SC5314 = wild-type strain (blue). SC12 = control strain with NAT cassette at 
RPS1 locus (red). SC6, SC16 and SC17 = knockout of “allele one” (yellow) and SC7, SC18 and SC32 = knockout of “allele two” (green).  
 
  
 
 
 
 
 
 
 
 
 
a) Growth rate at 30 °C. b) Growth rate at 37 °C.  
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c) Percentage of BECs adhered to C. albicans cells. d) Number of C. albicans cells per BEC. e) Number of C. albicans cells per BECs (with cells 
adhered). Error bars = ± one standard deviation.  
  
0.0%
10.0%
20.0%
30.0%
40.0%
50.0%
60.0%
70.0%
80.0%
90.0%
100.0%
P
e
rc
e
n
ta
ge
 o
f 
B
EC
s 
ad
h
e
re
d
 t
o
 C
. a
lb
ic
a
n
s 
ce
lls
 
SC5314
SC12 - SC5314 RPS1-1
RPS1-2::NAT1
SC6 - SC5314 VPS1-
1::NAT1 VPS1-2
SC7 - SC5314 VPS1-1
VPS1-2::NAT1
SC16 - SC5314 VPS1-
1::NAT1 VPS1-2
SC17 - SC5314 VPS1-
1::NAT1 VPS1-2
SC18 - SC5314 VPS1-1
VPS1-2::NAT1
SC32 - SC5314 VPS1-1
VPS1-2::NAT1
0.00
1.00
2.00
3.00
4.00
5.00
6.00
7.00
8.00
C
. a
lb
ic
a
n
s 
ce
lls
 p
e
r 
B
EC
 
SC5314
SC12 - SC5314 RPS1-1
RPS1-2::NAT1
SC6 - SC5314 VPS1-
1::NAT1 VPS1-2
SC7 - SC5314 VPS1-1
VPS1-2::NAT1
SC16 - SC5314 VPS1-
1::NAT1 VPS1-2
SC17 - SC5314 VPS1-
1::NAT1 VPS1-2
SC18 - SC5314 VPS1-1
VPS1-2::NAT1
SC32 - SC5314 VPS1-1
VPS1-2::NAT1
0.00
1.00
2.00
3.00
4.00
5.00
6.00
7.00
8.00
C
. a
lb
ic
a
n
s 
ce
ll 
p
e
r 
B
EC
 (
w
it
h
 c
e
lls
 a
d
h
e
re
d
) 
SC5314
SC12 - SC5314 RPS1-1
RPS1-2::NAT1
SC6 - SC5314 VPS1-
1::NAT1 VPS1-2
SC7 - SC5314 VPS1-1
VPS1-2::NAT1
SC16 - SC5314 VPS1-
1::NAT1 VPS1-2
SC17 - SC5314 VPS1-
1::NAT1 VPS1-2
SC18 - SC5314 VPS1-1
VPS1-2::NAT1
SC32 - SC5314 VPS1-1
VPS1-2::NAT1
c d e 
Page | 225  
 
 
  
 
  
  
 
 
 
 
 
 
  
 
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
0 0.5 1 1.5 2 2.5 3
P
e
rc
e
n
ta
ge
 s
u
rv
iv
al
 
Days 
PBS
SC5314
SC5314 RPS1-1 RPS1-2::CIp10-NAT1
SC6 - SC5314 VPS1-1::NAT1 VPS1-2
SC7 - SC5314 VPS1-1 VPS1-2::NAT1
SC16 - SC5314 VPS1-1::NAT1 VPS1-2
SC17 - SC5314 VPS1-1::NAT1 VPS1-2
SC18 - SC5314 VPS1-1 VPS1-2::NAT1
SC32 - SC5314 VPS1-1 VPS1-2::NAT1
SC5314 
f 
SC12 – RPS1 SC6 – Allele 1 KO SC16 – Allele 1 KO 
SC17 – Allele 1 KO SC7 – Allele 2 KO SC18 – Allele 2 KO SC32 – Allele 2 KO 
g 
f) Induction of hyphae. Strains 
were exposed to 5% foetal calf 
serum and incubated at 37 °C. 
Figures shows cells at 120 
minutes however samples were 
taken every 15 minutes. Scale 
bar = 10 µm.  
 
g) Galleria mellonella virulence 
assay at a cell concentration of 
2 x 107 cells/ml.  
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h) Growth in response to fluconazole. Concentrations range from 0 – 1024 µg/ml. Blue = 
OD at 595 nm at 24 hours. Red = OD at 595 nm at 48 hours. Error bars = ± one standard 
deviation. 
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i) Growth in response to 5-flucytosine. Concentrations range from 0 – 1024 µg/ml. Blue = 
OD at 595 nm at 24 hours. Red = OD at 595 nm at 48 hours. Error bars = ± one standard 
deviation. 
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j) Growth in response to amphotericin b. Concentrations range from 0 – 1024 µg/ml. Blue = 
OD at 595 nm at 24 hours. Red = OD at 595 nm at 48 hours. Error bars = ± one standard 
deviation. 
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k) Growth on YPD + 64 µg/ml fluconazole agar plates at 24 hours and YPD + 32 µg/ml 
5-flucytosine agar plates at 48 hours. YPD agar is present as a control. Cell 
concentrations range in tenfold dilutions from 1 x 107 to 1 x 103 cells/ml. 
 
 
k Cell Conc. 
SC6 – Allele 1 KO 
SC5314 
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l) Lipase secretion analyses. Representative results for four strains shown here. Halos produced by degradation of egg yolk agar after 7 days for 1) 
SC5314, 2) SC12, 3) SC6 and 4) SC7. 5) Measurements of the halo diameters every 24 hours. Error bars represent ± one standard deviation.  
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m) Biofilm production. Representative results for four strains at $the 24 hour time point 
shown here. Error bars represent ± one standard deviation.  
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n) Vacuole morphology. Right hand side shows vacuole morphology using FUN-1 
staining, visualised using fluorescence microscopy with excitation at 470 nm to 590 nm. 
Left hand side shows the corresponding bright field image. Scale bar = 10 µm. 
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4.3.2.6 Phenotypic Screening Summary 
Table 4.8 summarises the results for all of the phenotypic screening carried out 
in this chapter.  
 
Table 4.8 Summary of phenotypic screening. Strains with significant 
results are highlighted with arrows indicating the direction of the results.  
GENE CDC6 ERB1 RBT4 SMI1 VPS1 
ALLELE KO 1 2 1 2 1 2 1 2 1 2 
Growth at 30 
°C 
Generation 
Time 
 
Endpoint 
Density 
 
Time to 
Maximum 
Inflection 
 
 
 
 
 
↑SC9  
↑SC12 
     
 
 
 
 
↑SC4 
↑SC12 
   
 
 
 
 
↑SC16  
 
 
 
 
 
 
↑SC18 
↑SC32  
 
↑SC7  
↓SC32  
Growth at 37 
°C 
Generation 
Time 
 
Endpoint 
Density 
 
Time to 
Maximum 
Inflection 
   
 
 
 
 
↑SC49  
 
 
 
 
 
↑SC47  
      
 
↑SC7  
 
 
↑SC18 
↑SC32  
 
↑SC7  
 
Adhesion           
Hyphal 
Induction 
          
Virulence (at  
2 x 107 
cells/ml) 
   ↓SC48 
↓SC56  
      
Sensitivity to 
Fluconazole 
  ↑All at 48 hours ↓All 48 hours    ↑SC7 at 
24 
hours 
Sensitivity to 
5-Flucytosine 
(liquid) 
         ↓SC7  
↑SC18 
↑SC32 
at 48  
hours 
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Sensitivity to 
5-flucytosine 
(agar) 
         ↑SC7 at 
48 
hours 
Sensitivity to 
Amphotericin 
B 
          
Cell Cycle 
(DNA content) 
↑All          
Biofilm           
Biofilm + 
Fluconazole 
          
Biofilm + 5-
Flucytosine 
          
Biofilm + 
Amphotericin 
B 
      ↑All growth   
Sensitivity to 
EtOH and 
SDS 
      ↑SC33     
Lipase 
Secretion 
          
Vacuole Size         ↑SC17  ↑SC7 
↑SC18 
↑SC32  
 
 
4.3.3 Errors in the Reference Genome 
From the construction of heterozygous knockout mutants, two unusual 
observations were made. Upon sequence confirmation of the VPS1 
heterozygous knockout mutants, it was noted that five of the SNPs in the 
reference genome do not exist, and after construction of nine strains, only allele 
one knockouts were produced for the gene RCK2.  
 
These observations were followed up using sequencing methods to compare 
the gene sequences of VPS1 and RCK2 to the reference genome. As 
heterozygous knockout mutants of both alleles were available for VPS1, 
sequencing of the gene was carried out by colony PCR amplification of the 
entire length of the gene in six sections from strains SC6 and SC7 (see section 
2.11, and for oligonucleotides used see Table 2.7). Samples were sent for 
Sanger sequencing (see section 2.12) and results were aligned against the 
reference genome, downloaded from the Candida genome database 
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(http://www.candidagenome.org/) (Inglis et al., 2012). Results confirmed that of 
the 20 SNPs in the reference genome, five do not exist (Appendix I Figure III). 
The remaining 15 SNPs only lead to synonymous amino acid changes. 
Therefore the protein sequences of the two alleles do not differ. Consequently, 
the unusual phenotypic results seen when screening the knockout strains of 
allele two, such as the larger vacuole size, are likely to be due to secondary 
mutations elsewhere in the strains and not due to a difference in function of the 
two alleles. However as the chitin synthesis gene CHS7 has been shown to 
have identical allele sequences with functional differences due to disparity in 
expression level (Sanz et al. 2007), functional differences between the alleles of 
VPS1 cannot be ruled out. 
 
A different method was adopted for RCK2 as only knockouts of allele one were 
obtained. PCR amplification and sequencing of the wild-type strain SC5314, 
similar to sequencing VPS1 in SC6 and SC7, would produce unclear 
sequencing results with two peaks at SNP locations, and sequencing of the 
allele one knockout strains would not confirm the sequence of the missing 
allele. Therefore a conventional cloning technique was used, as described in 
section 2.8. To summarise, the gene sequence for RCK2 was amplified using 
colony PCR from the wild-type strain SC5314, with the assumption that both 
alleles would amplify with equal efficiency. These PCR fragments were ligated 
into a pGEM-T easy vector and transformed into E. coli cells. Only the 
sequence from one allele is ligated and transformed into a single E. coli cell. 
Positive transformants were selected based on disruption of the LacZ operon 
and antibiotic resistance. Allele sequences were then amplified via PCR and 
sent for conventional Sanger sequencing, with a probability of 0.5 that the 
sequence is allele one and 0.5 that the sequence is allele two. All seven 
positive transformations came back matching the sequence for allele two. 
Based on the probability of 0.5 that the sequence is allele two, the probability 
that all seven strains contained allele two equates to: 
 
0.5
7 
= 7.8125 x 10-3 
 
With such a small probability of this occurring by chance, and all of the 
heterozygous knockout strains matching the sequence for allele two 
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(suggesting that allele one had been removed), it is sensible to assume that 
RCK2 is in fact a homozygous gene with an identical sequence for both alleles,  
matching that of allele two (Appendix I Figure IV).  
 
4.4 Discussion 
4.4.1 Is AEI Linked to Functional Differences of Alleles? 
The functional consequences of AEI have been investigated here through use 
of heterozygous knockout mutant strains. From the list of genes with AEI 
identified in chapter three, potential targets for knockout construction were 
initially selected based upon a 2x fold difference in allele expression, a 
minimum allele count of 20 and a pathogenesis-related function. Genes 
matching 2 out of 3 of these criteria were selected. Heterozygous knockouts of 
both alleles were produced for five genes. Phenotypic screening under a wide 
range of general and gene-specific conditions indicated that in most cases the 
alleles are not functionally distinct, with no sets of heterozygous knockout 
mutants showing segregation of phenotypic differences from each other or from 
the wild-type strain SC5314. This is with the exception of VPS1 which showed 
some phenotypic differences of some strains, such as a decreased growth rate 
of SC7 at 37 °C (Figure 4.10b) and unusual vacuolar morphology of a number 
of strains (Figure 4.10n). However, due to the sequencing results showing that 
VPS1 alleles in fact translate to two identical proteins, and with the 
inconsistencies in the phenotypes of identical isolates, it is unlikely that these 
phenotypes are due to functional differences in the alleles and are in fact a 
consequence of secondary mutations elsewhere in the genome. However 
functional differences cannot be firmly ruled out, as differences in function due 
solely to expression levels of identical sequences have been observed in the 
past, as is the case for the previously mentioned gene CHS7 (Sanz et al., 
2007). 
 
Initially this could suggest that AEI is not linked to function, and is present for 
another purpose which is currently unclear. However, this cannot be claimed 
with 100% confidence. Of the heterozygous knockout mutants constructed, 
phenotypic tests were selected based upon pathogenesis related functions or 
phenotypes identified in previous studies. There is a chance that the alleles do 
differ in function, but the right phenotypic tests to demonstrate this were not 
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used. For example, it was not practical to test if the β-glucan amounts in the cell 
wall of the SMI1 mutants differed even though it had been shown to be reduced 
in mutants previously (Hong et al., 1994, Dague et al., 2010). To increase the 
chances of identifying the most suitable conditions to show differences in allele 
function, strains could be tested using a high-throughput screen testing an 
extensive number of conditions such as the screen used by Homann et al. 
(2009) testing a transcription factor knockout library on 55 conditions (Homann 
et al., 2009). However, this type of investigation was also not feasible during 
this project but is an area that could be followed in the future. The next chapter 
will discuss the use of RNA sequencing data collected from C. albicans under 
different conditions to identify if AEI is condition specific, and therefore identify 
possible conditions to assay to demonstrate differences in allele function. Of the 
233 genes identified with AEI in chapter three, functional contributions of the 
alleles were only investigated for five genes. Attempts were made to knockout 
two other genes, RCK2 and orf19.2051, however RCK2 was later identified as 
homozygous and no successful strains were ever obtained for orf19.2051 
despite numerous attempts at transformation. It could also be the case that if 
further heterozygous knockout mutants were made, functional differences in the 
alleles will be identified. Again, this is an area for further investigation. 
 
Variability in the phenotypic assays used is unlikely to be masking phenotypic 
differences in the heterozygous knockout mutants, but is something should be 
highlighted from this investigation. Although biological, and often technical, 
replicates were used for all assays, high levels of variance are still observed. 
This is particularly clear in measures of growth in response to the antifungal 
compounds fluconazole and 5-flucytosine, where large error bars are present. 
Strains were assayed in 96 well plates with two strains per plate. Clear inter 
plate variation is also observed suggesting false positive interpretations of 
functional differences between strains, as can be seen for the knockout strains 
of the gene VPS1 when grown in 5-flucytosine (Figure 4.10i). The adhesion 
assay using buccal epithelial cells shows considerable variability between the 
“adhesiveness” of BECs on samples taken on different days. For example, the 
average percentage of BECs adhered to wild-type C. albicans cells is 44% in 
the assay using CDC6 knockouts and 94.9% in the assay using VPS1 
knockouts. This should be considered when comparing results from across 
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studies. The survival rates of the wax moth larvae used for the virulence assay 
often varied between batches. Although using three separate cell 
concentrations aimed to account for this, some Galleria did die in the PBS 
control suggesting that death by natural causes may have some minor impacts 
upon results.  
 
Another possible explanation as to why no phenotypic differences were seen in 
the heterozygous knockout mutants is that when one allele is removed, the 
other allele increases expression levels to compensate for the loss. Functional 
redundancy is observed within C. albicans, especially with regards to gene 
families, where removal of one gene is compensated for by other genes. This 
has been reported for the phosphatase gene PTC6 (Yu et al., 2010), the 
mannosyltransferase MNN1 gene family (Bates et al., 2013), and ALS genes 
ALS2 and ALS4 (Zhao et al., 2005). Due to a lack of a method which verifies 
allele-specific expression, as discussed in chapter three, it was not possible to 
assess if allele expression levels were altered in knockouts and if a mechanism 
of functional redundancy occurs.  
 
As demonstrated by sequencing of VPS1 and RCK2, errors are present in the 
diploid reference genome suggesting that some genes are incorrectly annotated 
as heterozygous. This directly impacts upon the initial identification of genes 
with AEI, as measurements of allele expression are based upon reads which 
align to SNP positions. If these SNPs are errors, reads will be aligning to the 
incorrect position in the genome, producing incorrect allele counts. In the future, 
it would be beneficial to verify the heterozygosity of all of the genes identified as 
having significant levels of AEI to show that the AEI is not a false positive due to 
incorrect alignment of reads at sequencing errors. Alternatively, re-alignment of 
reads to the recently published phased diploid reference genome may also 
improve estimations of AEI (Muzzey et al., 2013). Within this paper, evidence 
was shown that the reliability of AEI measurements were significantly improved 
using the new reference genome.    
 
4.4.2 Conclusion 
To conclude, the functional consequences of AEI are still unclear after 
phenotypic screening of heterozygous knockout mutants. Although no functional 
Page | 239  
 
differences in alleles were identified here, the correct conditions or gene to 
show this may have been overlooked. Conversely, AEI may not be linked to 
function and could in fact be due to errors in the initial identification of genes 
with AEI due to errors in the reference genome. However, sequencing errors 
were not present during verification of all heterozygous knockout strains and 
therefore this cannot explain the lack of functional differences in all cases. 
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Chapter 5: AEI in Different Growth 
Conditions 
 
5.1 Introduction 
The identification of allelic expression imbalance in chapter three and the 
subsequent investigations of the functional consequences associated with this 
phenomenon in chapter four have so far been based upon a single RNA 
sequencing data-set. However, changes in gene expression due to a shift in 
growth conditions occurs readily in C. albicans (Enjalbert et al., 2003, Bensen et 
al., 2004, Fradin et al., 2005, Biswas et al., 2007, Nobile et al., 2012, Tierney et 
al., 2012). Therefore it would be sensible to infer that levels of AEI may also be 
responsive to the growth environment. Identification of changes in AEI 
responses may therefore shed some light upon the functional purpose of AEI 
itself. To investigate this hypothesis, RNA sequencing data-sets obtained from 
C. albicans grown under different conditions were examined from both in house 
experiments and public databases. A computational pipeline was developed to 
identify levels of AEI from this data, and the condition-specific response of AEI 
was investigated. Heterozygous knockout mutants of genes indicating condition 
specific allelic expression responses were then phenotypically screened to 
further investigate the functional impact of allelic expression imbalance.  
 
5.1.1 Condition-Specific Gene Expression in Candida albicans 
Extensive evidence is present to demonstrate that Candida albicans gene 
expression levels alter in response to environmental cues. As discussed in 
section 1.1.1, a complex network of signalling pathways centred on the MAPK 
pathway and the cAMP pathway are responsible for the up-regulation of hypha 
specific genes leading to the morphological switch from a yeast to a hyphal form 
following exposure to a number of different growth conditions (Biswas et al., 
2007). The genome-wide transcriptional response of this morphological 
transition has been elucidated through use of microarrays, which identified key 
genes involved in this response (Nantel et al., 2002). Additionally, six key 
regulator genes have been identified in the control of biofilm formation, which 
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consequently alter the expression level of approximately 1000 genes (Nobile et 
al., 2012), as discussed in section 1.1.4.   
 
As well as morphological transitions, gene expression levels in C. albicans have 
shown to be altered under growth in differing environments, especially those 
inducing a stress response. A shift in temperature from 23 °C to 37 °C induces 
the expression of heat shock proteins HSP12, HSP70, HSP78 and HSP104 
(Enjalbert et al., 2003). Hyperosmotic stress causes an increase in the 
expression of ENA1, GPP1 and GPD2 to protect the cell from increases in ionic 
strength (Enjalbert et al., 2003). Both acidic and alkaline pH induce changes in 
gene expression, with 514 genes having been identified as pH responsive 
(Bensen et al., 2004). Oxidative stress leads to an increase in expression of the 
glutathione reductase TTR1 and the thioredoxin gene TRX1 (Enjalbert et al., 
2003). A core set of stress response genes, which alter their transcriptional 
profile under osmotic, heavy metal and oxidative stress, have also been 
identified (Enjalbert et al., 2006). Growth of the closely related species C. 
parapsilosis under hypoxic conditions has been associated with an increase in 
expression of genes involved with ergosterol biosynthesis and carbohydrate 
metabolism, and a decrease in expression of genes involved in cellular 
respiration and the tricarboxylic acid cycle (Guida et al., 2011). However, the 
most comprehensive investigation of the condition-specific transcriptional 
response in C. albicans was published by Bruno et al. in 2010. Here RNA 
sequencing was used to identify the gene expression patterns of the wild-type 
strain SC5314 when grown under nine different conditions, including hypha 
specific conditions, oxidative stress, nitrosative stress and cell wall damaging 
conditions. The results were taken forward and used to identify novel transcripts 
which are regulated in a condition specific manner, and used to uncover novel 
functions and pathways of previously annotated genes (Bruno et al., 2010). 
 
The transcriptional response under conditions closely resembling in vivo 
infections have also demonstrated that gene expression levels respond to 
environmental cues that would occur naturally. For example, 545 genes have 
been found to alter expression levels when cells are co-cultured with mouse 
dendritic cells (Tierney et al., 2012), upon phagocytosis by mammalian dendritic 
cells, gene expression shifts to increase gluconeogenic growth and fatty acid 
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degradation (Lorenz et al., 2004, Fernández-Arenas et al., 2007), and 
resistance to fungal clearance by neutrophils requires gene expression profiles 
that resemble growth in carbohydrate starvation, nitrosative and oxidative stress 
conditions (Fradin et al., 2005, Miramón et al., 2012).  
 
Although condition-specific shifts in AEI are yet to be reported, it is sensible to 
infer from the above examples that this could occur during growth both under in 
vitro conditions and during the infection process.  
 
5.1.2 Computational Tools Available for Identifying AEI 
The identification of AEI from RNA sequencing data in chapter three used the 
software package CLCBio software (www.clcibio.com). However this is a closed 
source software package, which is no longer available for use in this project. 
Therefore a new computational tool to identify AEI needed to be devised. 
Various different software packages have been previously developed to identify 
levels of AEI using RNA sequencing data. However, most of these programmes 
are designed for use with human sequencing data, a haploid reference genome, 
or full genomes for both parental strains in the case of diploid hybrid offspring, 
most of which are unavailable for Candida albicans (Rozowsky et al. 2011; 
Turro et al. 2011; Krueger, 2012; Pandey et al. 2013). Although a haploid 
reference genome is available for C. albicans, significant biases have been 
observed when identifying AEI using this methodology (Degner et al., 2009, 
Stevenson et al., 2013) as discussed in section 3.1. 
 
As mentioned above, it has been reported that bias can occur when mapping 
reads against a haploid reference genome with an unequal success rate of read 
mapping producing a skewed number of reads towards the reference 
(Stevenson et al., 2013). The software package Allim (Allelic imbalance metre) 
(Pandey et al., 2013) has been developed to overcome this mapping bias by 
initially constructing a polymorphism-aware reference genome, then mapping 
bias is estimated using a sequence-specific simulation tool, followed by a G-test 
which corrects the alignment for this bias (Pandey et al., 2013). Unfortunately, 
this software was not suitable for use here as it assumes the diploid strain is a 
hybrid of two parental strains and therefore requires full genome or 
transcriptome data (with full phasing) of both parents.  
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AlleleSeq has been developed for use with the human reference genome and 
also aims to overcome mapping bias seen when using a haploid reference 
genome (Rozowsky et al., 2011). In a similar way to Allim, Alleleseq constructs 
a “personal” diploid reference genome, with maternal and paternal haplotypes. 
This is achieved using fully phased variant information obtained from the 1000 
genomes consortium alongside “equivalence maps” listing base-pair locations 
for both parental genomes. Reads are then aligned against the maternal and 
paternal haplotypes and quantified at SNP locations to give allele-specific 
counts (Rozowsky et al., 2011). Again, this level of phased variant information is 
unavailable for C. albicans, and equivalence maps are not available as there 
are not two separate parental genomes, making Alleleseq unsuitable for use 
here. 
 
MMSEQ aims to identify haplotype specific isoforms and takes a similar 
approach to Allim and Alleleseq, but includes an initial alignment of RNA 
sequencing reads against a haploid reference genome using TopHat (Turro et 
al., 2011). Variants are then called from this alignment and phased using 
population level genotype data before editing of the reference genome into a 
haplotype specific reference and realignment of the reads to this reference 
using Bowtie (Turro et al., 2011). As this software uses a haploid reference with 
variant calling, it is subjected to the mapping biases mentioned above. 
Additionally, population level genotype data is unavailable for Candida albicans 
and therefore, for these reasons, MMSEQ was not suitable for use in this 
investigation.  
 
The final piece of computational software available is ASAP (Allele-specific 
alignment pipeline). ASAP has been developed for identification of allele-
specific expression in heterozygous individuals where reads are aligned to two 
separate haploid reference genomes (Krueger, 2012). As only one reference 
genome is available for C. albicans, this software is also unsuitable for use. 
 
Due to these reasons, development of a new computational pipeline is detailed 
in this chapter to identify AEI in Candida albicans using alignment against the 
diploid reference genome and avoiding the use of variant calling. This pipeline 
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can then be applied to a number of RNA sequencing data-sets to evaluate if 
AEI changes in response to environmental cues. 
 
5.1.3 Aims of this Chapter 
This chapter aims to achieve three research objectives: 
1. Development of a computational pipeline to identify AEI from RNA 
sequencing data. 
2. Use of RNA sequencing data to identify how AEI changes in a condition-
specific manner. 
3. Construction and phenotypic screening of heterozygous knockout 
mutants to further investigate the functional consequence of AEI.   
 
5.2 Materials and Methods 
5.2.1 Computational Pipeline 
The computational pipeline developed here works around a modified version of 
standard RNA sequencing analysis. Figure 5.1 details the pipeline in a step-by-
step manner. Initially, the analysis was repeated on the data-set collected in 
chapter three (see section 3.2.1 for methodology) to compare computational 
analyses. 
 
Raw sequencing reads were filtered to improve quality, removing sequencing 
adaptors and bases with a phred value of less than 20 using the software 
Fastq-mcf (Aronesty, 2011). Filtered reads were then aligned against the diploid 
reference genome (Jones et al., 2004) (indexed using BWA index (Li and 
Durbin, 2009)) using Bowtie (Langmead et al., 2009). To replicate the original 
CLCBio analysis as closely as possible, parameters were set to allow up to two 
mismatches (see section 3.2.1.4).  
 
Bowtie was selected as the alignment software for a number of reasons. Due to 
an algorithm that combines the Burrows-Wheeler transformation and a suffix 
array, Bowtie converts the reference genome to an FM-index. This transforms 
large reference genomes to a manageable size, increasing the efficiency of 
short-read mapping (Berger et al., 2013). Bowtie is also adopted by the allele-
specific software MMSEQ (Turro et al., 2011) and has been used in previous 
studies identifying AEI (Li et al., 2012), including the investigations of AEI in 
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Candida albicans (as discussed in section 1.8) (Muzzey et al., 2013, Muzzey et 
al., 2014) 
 
Alignments were then converted from SAM to BAM file formats and sorted using 
the SAMTools package (Li et al., 2009). The numbers of reads aligned at every 
base-pair location throughout the genome were then identified using SAMTools 
mpileup (Li et al., 2009).  
 
To quantify allele-specific expression levels, reads aligning at SNP locations 
were quantified. To achieve this, all of the SNP locations were first identified 
using a custom Perl script (Appendix II.II), which takes the list of allele pairs and 
the diploid reference genome as the input. Alignments of each allele pair for a 
gene were carried out using MUSCLE (Edgar, 2004) and SNP locations were 
recorded. Only SNP locations were used and INDEL locations were ignored to 
prevent a bias in genes identified with AEI that differ in length. This is discussed 
in more detail in section 5.3.1. The mpileup file listing all of the reads across the 
genome was then filtered to list just the reads at SNP locations using a custom 
Perl script written with the help of Paul O’Neill (Appendix II.III). Again, a custom 
Perl script (Appendix II.IV) was used to total the number of reads aligned to 
each allele.  
 
From here, three statistical measures were implemented to identify genes with 
significant levels of AEI. Three tests were chosen to ensure that the pipeline 
was stringent and the number of false positive results are minimal. The choice 
to use multiple statistical tests also reflects the lack of consistency in methods 
which identify AEI as discussed in section 1.5.2. Raw allele counts of each gene 
were paired using a custom Perl script (Appendix II.V) and then statistically 
analysed using DESeq (Anders and Huber, 2010) implemented in R (The R 
Foundation for Statistical Computing, 2010). DESeq works on the assumption of 
an underlying negative binomial distribution and has been shown to be a 
powerful tool for analysing differential expression (Anders and Huber, 2010). 
Alleles of a single gene with a p value of less than 3.67107 x 10-5 (set using 
Bonferroni correction) were identified as having statistically significant allelic 
expression imbalance.  
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To reproduce the original analysis, raw counts for each allele were also 
normalised to RPKM values (reads per kilobase per million mapped reads) 
(Mortazavi et al., 2008) using a custom Perl script (Appendix II.VI). RPKM 
values for each gene were paired using a custom Perl script (Appendix II.V) and 
statistically compared in two ways: to replicate the original analysis, a Fisher’s 
Exact test was used, and to replicate previous investigations of AEI a chi-
square test was used (Gregg et al., 2010, Tuch et al., 2010a, Zhang et al., 
2011). In both cases, alleles of a single gene with a p value of less than 
3.67107 x 10-5 (set using Bonferroni correction) were identified as having 
statistically significant allelic expression imbalance.  
 
Only genes identified as having significant levels of AEI by all three statistical 
tests and within all replicates of the experiment were taken forward as genes 
with AEI.  
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Figure 5.1 Computational pipeline devised to identify allelic expression imbalance from 
RNA sequencing data.  
  
Total unique reads for each allele – Custom Perl Script (Appendix II.IV) 
Next Generation Sequencing  
Align against diploid reference genome – Bowtie 
Total reads at every location in genome – SAMtools mpileup 
Compare allele counts 
of a gene – DESeq 
Reverse Primer 
Normalise allele counts to RPKM – 
Custom Perl Script (Appendix II.VI) 
Compare allele 
RPKMs of a gene 
-Chi Squared 
Conversion of alignment to BAM and sorting – SAMtools view and SAMtools sort  
Remove adaptors and Trim – Fastq-mcf 
Select reads at SNP locations – Custom Perl Script (Appendix II.III) 
Compare allele 
RPKMs of a gene 
–Fisher Exact 
Test 
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5.2.2 Acquisition of RNA Sequencing Data from Cells Grown Under 
Different Conditions 
To assess if condition specific patterns of allelic expression imbalance occur, 
RNA sequencing data-sets from C. albicans grown under different conditions 
was obtained and analysed with the pipeline described above.  
 
5.2.2.1 Data from Bruno et al. (2010) 
As described in section 5.1.1, Bruno et al. (2010) carried out RNA sequencing 
on C. albicans grown under different conditions. Methodologies describing 
sample preparation and sequencing can be found in Bruno et al. (2010). It is 
important to note, that in the Bruno et al. study, short read, 30 bp single end 
sequencing was carried out using an Illumina GAII sequencer. The raw 
sequencing reads for this paper were downloaded from the NCBI Sequence 
Read Archive (http://www.ncbi.nlm.nih.gov/Traces/sra/sra.cgi) under the 
accession number SRA020929. Table 5.1 details the runs downloaded and 
analysed for each condition. If more than one run was available for a replicate, 
these were concatenated into a single file before processing via the 
computational pipeline.  
 
5.2.2.2 Data from Co-Culture of C. albicans with Streptococcus gordonii 
In collaboration with Professor Howard Jenkinson and Dr. Lindsay Dutton from 
the University of Bristol, RNA samples were collected from C. albicans hyphae 
co-cultured with the oral bacterium Streptococcus gordonii. Interactions 
between these species are often observed in vivo during oral candidiasis 
infections (Wright et al., 2013). RNA samples were taken in triplicate from C. 
albicans cell harvests grown under three conditions: alone in hypha-inducing 
conditions (37 °C in glucose) for two hours, in hypha-inducing conditions (37 °C 
with glucose) for two hours before co-culture with S. gordonii for one hour in a 
2:1 ratio, and in hypha-inducing conditions (37 °C with glucose) for two hours 
before culture alone in S. gordonii media for one hour. 
 
Total RNA was extracted using the RNeasy Mini Kit (Qiagen) according to the 
manufacturer’s instructions for yeast, using mechanical disruption and including 
on-column DNase digestion using RNase-free DNase (Qiagen). RNA 
concentration and quality was quantified using a NanoDrop Spectrophotometer 
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and formaldehyde agarose gel electrophoresis (see section 3.2.6.1.3). 
Ribosomal RNA was depleted using a RiboZero Magnetic Gold Kit (Epicentre) 
and Illumina sequencing libraries were prepared using ScriptSeq v2 (Epicentre). 
The quality and quantity of each library was analysed using an Agilent 2100 
Bioanalyser (samples prepared according to the manufacturer’s instructions). 
100 bp paired-end sequencing was then performed using the Illumina 
HiSeq2500 platform in high output mode using Truseq v3 reagents (Illumina).   
 
Table 5.1 Sequencing Runs Downloaded and Analysed from the Bruno et 
al. (2010) paper 
Condition Replicate Run Number 
YPD Replicate 1 SRR060099 
SRR060100 
SRR060101 
Replicate 2 SRR060102 
SRR060124 
SRR060125 
SRR060126 
Hyphae Inducing (YPD + 10% 
foetal calf serum) 
Replicate 1 SRR060087 
SRR060088 
Replicate 2 SRR060089 
SRR060090 
SRR060091 
SRR060092 
Tissue Culture Media pH 4 (M199 
pH 4) 
Replicate 1 SRR060127 
Replicate 2 SRR060128 
Tissue Culture Media pH 8 (M199 
pH 8) 
Replicate 1 SRR060129 
Replicate 2 SRR060130 
High Oxidative Stress (YPD + 5 
mM Hydrogen Peroxide) 
Replicate 1 SRR060131 
Replicate 2 SRR060134 
Low Oxidative Stress (YPD + 0.5 
mM Hydrogen Peroxide) 
Replicate 1 SRR060135 
Replicate 2 SRR060136 
No Oxidative Stress Control 
(YPD) 
Replicate 1 SRR060143 
Replicate 2 SRR060144 
Cell Wall Damaging (YPD + 100 
µg/ml Congo Red) 
Replicate 1 SRR060146 
Replicate 2 SRR060145 
No Cell Wall Damage Control 
(YPD) 
Replicate 1 SRR060148 
Replicate 2 SRR060147 
Nitrosative Stress (YPD + 1 mM 
Dipropylenetriamine Nonoate 
dissolved in 10 mM NaOH) 
Replicate 1 SRR063952 
Replicate 2 SRR063953 
No Nitrosative Stress Control 
(YPD + 10 mM NaOH) 
Replicate 1 SRR063986 
Replicate 2 SRR063987 
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5.2.3 Calculation of Allele Lengths 
Allele lengths were obtained from the ‘Chromosomal Features File’ available 
from the Candida genome database (www.candidagenome.org) (Inglis et al., 
2012) for “allele one” and calculated manually for “allele two” based on 
chromosomal coordinates. 
 
5.2.4 Gene Ontology (GO) Analysis 
Analysis for over representation of Gene Ontology (GO) terms within genes 
identified to have AEI was carried out using “CGD GO Term Finder” at the 
Candida genome database (www.candidagenome.org) (Inglis et al., 2012). Lists 
of GO terms were created using “CGD Gene Ontology Slim Mapper” also 
available from the Candida genome database.  
 
5.2.5 Calculating Differences in Promoter Sequences 
As in chapter three, the promoter regions of differentially expressed alleles were 
compared to assess if differences in this region were linked to differences in 
expression. As promoter sequences in C. albicans are currently undefined, the 
1000 bp of DNA sequence upstream of each allele were downloaded from the 
Candida Genome Database (www.candidagenome.org) (Inglis et al., 2012). If 
the neighbouring open reading frames were within the 1000 bp upstream, the 
sequence up to the neighbouring ORF was taken. Promoter sequences of each 
pair of alleles of a gene were aligned used ClustalW 
(http://www.genome.jp/tools/clustalw/) (Kyoto University Bioinformatics Center, 
2010) and sequences were recorded as different if one of more SNPs or 
INDELs were observed. The probability of observing SNPs across a region of 
1000 bp was calculated based upon the observed average level of 
heterozygosity across the genome of one SNP in every 237 bp (Jones et al., 
2004). The observed and expected number of promoter sequences with SNPs 
was compared statistically using a chi-square test.  
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5.2.6 Identification of Genes with Uneven Changes in Allele Expression 
Levels between Growth Conditions 
Despite a lack of significant AEI, as determined by the statistical tests described 
in section 5.2.1, for some genes the ratio of allele one expression to allele two 
expression will differ significantly when growth conditions change. To identify 
these genes where the growth condition causes a change in expression of one 
allele greater than the change in the other allele, the fold difference in RPKM 
values (see section 5.2.1) of each allele between conditions was calculated for 
every gene, for 16 different condition comparisons taken from the analysis of 
the Bruno et al. (2010) data (Table 5.2). The Log10 fold change in allele one 
expression level was then plotted against the Log10 fold change in allele two 
expression level for each comparison and linear trend lines were fitted. The 
equation of the linear trend line was used to calculate the predicted y values. 
Any genes where the observed y value was greater than two standard 
deviations away from the predicted y value were identified as having a 
significantly larger change in one allele expression than the other allele between 
those growth conditions. To identify genes which frequently have a disparity in 
the fold difference of alleles between conditions, the frequency of genes 
identified as significant for each condition comparison was calculated and 
multiplied for each gene to give a significance measure. All genes with p < 1.95 
x 10-4, as determined by Bonferroni correction for multiple comparisons, were 
identified as having alleles whose changes in expression levels differ 
significantly in response to a change in growth condition.    
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Table 5.2 Condition Comparisons Used to Identify Genes with Uneven 
Differences in Allele Expression Levels between Conditions 
Condition One Condition Two 
YPD Serum 
YPD Congo Red 
YPD No Congo Red (YPD) 
Congo Red No Congo Red (YPD) 
YPD  High Oxidative Stress 
YPD Low Oxidative Stress 
High Oxidative Stress Low Oxidative Stress 
YPD No Oxidative Stress (YPD) 
Low Oxidative Stress No Oxidative Stress (YPD) 
High Oxidative Stress No Oxidative Stress (YPD) 
YPD M199 pH 4 
YPD M199 pH 8 
M199 pH 4  M199 pH 8 
YPD Nitrosative Stress 
YPD  No Nitrosative Stress (YPD + NaOH) 
Nitrosative Stress No Nitrosative Stress (YPD + NaOH) 
    
5.2.7 Heterozygous Knockout Mutant Construction 
Heterozygous knockout mutants of ADH2, GPX1, RPS7A and orf19.5648 were 
constructed as described in sections 2.8 to 2.11. For a full list of strains refer to 
Table 2.1.  
 
5.2.8 Phenotypic Screening 
For the methods describing general phenotypic assays used here and in 
chapter four, see section 2.14. Listed below are the phenotypic screens used in 
just this chapter. 
 
5.2.8.1 Growth with Ethanol as the Sole Carbon Source 
Conditions for the growth of ADH2 heterozygous knockout strains on solid 
media containing ethanol as the sole carbon source is detailed in section 
2.14.4. 
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For growth in liquid media, the growth rate of ADH2 heterozygous knockout 
strains in ethanol as the sole carbon source was measured using a liquid assay 
in a 96-well plate format. A single colony of the appropriate strain was grown 
overnight in either 10 ml of YPD or 10 ml of YPE (2% (w/v) Bacto-peptone, 2% 
(v/v) ethanol, 1% (w/v) yeast extract) at 30 °C, 180 rpm. 10 µl of this culture was 
taken and diluted into 1 ml of fresh YPE. 100 µl of the cell suspension was then 
transferred to a single well of a 96 well plate. Each strain was plated in technical 
quadruplicate and sterile YPE was used as a control. The experiment was then 
carried out in biological duplicate.  
 
Optical density at 650 nm was measured every 3½ minutes using a kinetic read 
microplate spectrophotometer held at 30 °C for a total of 48 hours (Molecular 
Devices VersaMax Microplate Reader). Plates were shaken for three minutes in 
between reads.  
 
5.2.9 Cloning of Genes 
Cloning of RPS7A and orf19.5648 to confirm allele sequence polymorphisms 
was carried out as described in section 2.8. 
 
5.3 Results 
5.3.1 Comparison of Computational Pipelines 
To assess the validity of the computational pipeline designed to identify AEI, the 
RNA sequencing data collected in chapter three was reanalysed with the new 
pipeline (see section 5.2.1) and the results were compared. Initially, the 
computational pipeline totalled reads for each allele at both SNP and INDEL 
locations. In total, 175 genes were identified as having significant AEI from all 
three statistical tests in all three replicates. However 168 of these genes 
showed a difference in the length of the alleles, with 159 of these genes 
showing higher expression levels of the longer allele. Although gene length has 
been shown to impact upon expression levels (as discussed in chapter three), 
the relationship is well established as being the opposite of what is shown here, 
with the shorter genes showing increased transcriptional efficiency and higher 
expression levels (Coghlan and Wolfe, 2000, Jansen and Gerstein, 2000, Marín 
et al., 2003). Therefore, it is proposed that although allele counts are 
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normalised for length using RPKM, the pipeline devised has biases surrounding 
alleles which differ in length, producing a high number of false positive results. 
Biases for length during the sequencing process which are not sufficiently 
corrected for using RPKM have been previously reported (Bullard et al. 2010). 
This may be due to the bias seen in cDNA library preparation which leads to a 
higher coverage of reads at the 3’ end of a transcript (as discussed in section 
3.4.3.4) (Wilhelm et al., 2008), with alleles that differ in length at the 3’ end 
being the most susceptible to this bias.  
 
To correct for this, the pipeline was revised and reads aligning at INDEL 
locations were removed from the allele specific counts. This may lead to some 
false negative results, missing genes with AEI which only differ in length. 
However, alleles which just differ in length are more likely to be a consequence 
of annotation errors during the construction of the reference genome, making 
screening these genes out of the identification for AEI advantageous.  
 
Repeating the analysis of the RNA sequencing data collected in chapter three, 
using the SNP locations alone, identified 24 genes with AEI from replicate one, 
29 genes with AEI from replicate two and 26 genes with AEI from replicate 
three. Of these genes, a total of 21 were identified in all three replicates (Figure 
5.2 and Table 5.3). Two thirds (14) of these genes were also identified in the 
analysis carried out in chapter three, including RCK2 and RBT4 which were 
taken forward for heterozygous knockout construction in chapter 4. Length 
differences between the alleles were also closer to what was expected with 9 of 
the 21 genes differing in length, of which only 4 showed higher expression of 
the longer allele, against the trend that has been previously observed in yeast.   
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Figure 5.2 Number of genes identified with AEI using the new computational pipeline.  
A total of 21 genes with AEI were identified in C. albicans cells grown in YPD at 30 °C 
from the three RNA sequencing replicates isolated in chapter three. 
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Table 5.3 Genes identified with AEI in C. albicans cells grown in YPD at 30 °C using the new computational pipeline. Counts and 
RPKM values for each replicate are detailed. 
Allele 1 Count 
Replicate 1 
Count 
Replicate 2 
Count 
Replicate 3 
RPKM  
Replicate 1 
RPKM 
Replicate 2 
RPKM 
Replicate 3 
Allele 2 Count  
Replicate 1 
Count 
Replicate  2 
Count 
Replicate 3 
RPKM 
Replicate 1 
RPKM 
Replicate 2 
RPKM 
Replicate  3 
Average Fold 
Difference 
orf19.10681 66 134 123 4.58 7.53 7.51 orf19.3171 556 655 666 38.54 36.82 40.66 6.24 
orf19.11687 26887 45984 46492 1578.35 2188.57 2403.68 orf19.4212 124 352 294 7.20 16.57 15.03 170.44 
orf19.11957 1480 1296 928 159.37 113.14 88.01 orf19.4476 97 137 149 10.23 11.72 13.84 10.53 
orf19.12579 525 356 233 54.75 30.10 21.40 orf19.5113 1 1 0 0.10 0.08 0.00 - 
orf19.13093 41 70 38 7.50 10.38 6.12 orf19.5648 2789 3256 2761 500.04 473.30 435.97 61.17 
orf19.13163 255 380 299 7.36 8.89 7.60 orf19.5741 2782 4509 4031 80.30 105.51 102.47 12.09 
orf19.13213 2526 2750 1882 248.48 219.32 163.05 orf19.5791 13 5 1 1.28 0.40 0.09 875.44 
orf19.1357 19 50 34 1.34 2.86 2.12 orf19.8937 279 472 348 26.65 36.56 29.28 15.48 
orf19.13891 2 1 2 0.44 0.18 0.39 orf19.6538 284 329 282 63.03 59.20 55.12 204.00 
orf19.14144 1 3 5 0.10 0.24 0.43 orf19.6854 3327 4152 3697 169.51 171.52 165.90 938.50 
orf19.1915 0 4 1 0.00 0.21 0.06 orf19.9471 1890 2875 2806 125.53 154.81 164.13 - 
orf19.2268 47 90 68 2.90 4.50 3.69 orf19.9808 748 1287 1191 46.14 64.37 64.71 15.91 
orf19.4212 124 352 294 7.20 16.57 15.03 orf19.11689 1144 1117 1326 66.62 52.74 68.01 5.65 
orf19.4213 12 13 32 0.70 0.61 1.64 orf19.11689 1144 1117 1326 66.62 52.74 68.01 74.23 
orf19.465 919 1782 1592 35.51 55.82 54.17 orf19.8096 13 66 61 0.50 2.067 2.08 41.26 
orf19.4959 388 732 664 24.60 37.63 37.08 orf19.12424 3 8 7 0.19 0.41 0.39 105.23 
orf19.5602 624 575 475 35.10 26.22 23.53 orf19.13045 16 4 2 1.16 0.24 0.13 108.47 
orf19.6202 35 118 98 3.55 9.70 8.75 orf19.13583 301 806 710 30.51 66.25 63.39 7.56 
orf19.8644 214 305 307 27.52 31.80 34.77 orf19.1042 951 764 770 122.31 79.66 87.22 3.15 
orf19.9267 1955 261 289 380.50 41.19 49.53 orf19.1700 10 2 1 1.95 0.32 0.17 205.00 
orf19.9571 14641 14629 12283 984.98 797.93 727.78 orf19.2022 1142 1192 1148 103.91 87.94 92.00 8.82 
- Indicates that expression levels for one allele were below the detectable limit and therefore the fold difference could not be calculated. 
Key   Allele 1 Higher   
Allele 1 
Monoallelic   Allele 2 Higher   
Allele 2 
Monoallelic 
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Despite the analysis in chapter three identifying 233 genes with AEI, and this 
pipeline identifying only 21 genes, the high stringency of statistical tests used 
could explain this difference. Genes need to be identified as significant in all 
three statistical tests and in all three replicates in this pipeline to be considered 
as having a significant level of AEI. In the analysis in chapter three, only one 
statistical test, the Fisher Exact test, was applied to the data. When looking at 
the genes identified just by Fisher Exact test in the new pipeline, a much higher 
number is identified (69 in replicate one, 55 in replicate two and 47 in replicate 
three), accounting for some of the differences between the two analyses. The 
analysis here discounted any genes with alleles that only differed by INDELs. If 
this criteria was applied to the data from chapter three, the total number of 
significant genes is reduced to 193. Although this doesn’t solely account for the 
differences in significant genes between the two pipelines, 99 genes identified 
in chapter three contain both SNPs and INDELs, and therefore measurements 
of allelic expression may be significantly altered using the new methodology. 
Although the high stringency of statistical tests here may be losing some genes 
as false negatives, it can increase the certainty of the genes that have been 
identified as having real disparities in allele expression levels. 
 
5.3.2 Identification of Condition Specific AEI 
Condition specific allelic expression imbalance was investigated by applying the 
new computational pipeline to RNA sequencing data from C. albicans grown 
under different conditions including 11 conditions from Bruno et al. (2010) (see 
section 5.2.2.1) and from co-culture with the bacterial species Streptococcus 
gordonii (Jenkinson, personal communication, see section 5.2.2.2). Genes 
identified as having significant levels of AEI from analysis of both data-sets are 
listed in Table 5.4 and Table 5.5 respectively. In each case, a comparison to the 
analysis of the wild-type strain SC5314, as detailed in section 5.3.1, is made. 
Genes are defined as monoallelic if the read count for all three replicates of one 
allele is less than five, and the other allele is more than five. In the re-analysis of 
the data from chapter three, four genes were defined as monoallelic, and a 
further two genes had very low expression (<10 counts) of one allele.  
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Table 5.4 Genes identified with AEI from RNA sequencing data obtained from Bruno et al. (2010). Numbers indicate fold 
difference in RPKM values (to 2 d.p.), with dashes present where one replicate has an RPKM value equal to zero.  
Allele 1 Allele 2 
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orf19.1048 orf19.8650      20.83   6.77    
orf19.10681 orf19.3171 6.24            
orf19.10952 orf19.3448   -   - 295.00 - - -  - 
orf19.11687 orf19.4212 170.44        91.18   64.23 
orf19.11957 orf19.4476 10.53     23.80      11.82 
orf19.11980 orf19.4504         37.44 40.24   
orf19.12237 orf19.4773           51.09  
orf19.12579 orf19.5113 - -  45.56  220.75  59.25 6.10  87.58 48.83 
orf19.12758 orf19.5299            3.23 
orf19.13093 orf19.5648 61.17  30.89 21.13  - - 268.24 59.86 29.82 34.35 52.91 
orf19.13163 orf19.5741 12.09            
orf19.13213 orf19.5791 875.44            
orf19.1357 orf19.8937 15.48            
orf19.13840 orf19.6486      14.29       
orf19.13891 orf19.6538 204.00        -    
orf19.14144 orf19.6854 938.50     - - - -   - 
orf19.1763 orf19.9332      44.97       
orf19.1915 orf19.9471 -       -    - 
orf19.2023 orf19.9571            6.38 
orf19.2023 orf19.9572            6.27 
orf19.2268 orf19.9808 15.91     11.18   39.25    
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orf19.2787 orf19.10303      187.91       
orf19.3365 orf19.10873      12.22       
orf19.4212 orf19.11689 5.65        77.65   7.67 
orf19.4213 orf19.11689 74.23  46.60 36.30  35.32  33.45 42.04 25.36 144.10 47.02 
orf19.4505 orf19.11981         49.18    
orf19.465 orf19.8096 41.26            
orf19.4959 orf19.12424 105.23            
orf19.5145 orf19.12611      17.55       
orf19.5602 orf19.13045 108.47            
orf19.6202 orf19.13583 7.56            
orf19.8644 orf19.1042 3.15            
orf19.8714 orf19.1117          47.58   
orf19.917 orf19.8532            3.23 
orf19.9267 orf19.1700 205.00 503.50 523.58 320.50 183.50 - - - -  - - 
orf19.9571 orf19.2022 8.82           4.08 
- Indicates that expression levels for one allele were below the detectable limit and therefore the fold difference could not be calculated. 
 
Key   
Allele 1 
Higher   
Allele 1 
Monoallelic   
Allele 2 
Higher   
Allele 2 
Monoallelic 
 No AEI 
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Table 5.5 Genes identified with AEI from RNA sequencing data obtained 
from co-culture with S. gordonii. Numbers indicate fold difference in 
RPKM values (to 2 d.p.), with dashes present where one replicate has an 
RPKM value equal to zero.  
Allele 1 Allele 2 
Genes from 
5.3.1 
C. albicans 
alone Co-Culture 
C. albicans in S. 
gordonii media 
orf19.11075 orf19.3593  27.19 19.41 25.48 
orf19.11087 orf19.3604  - - - 
orf19.11553 orf19.4072  175.63 - 194.72 
orf19.11972 orf19.4496  72.03 - 29.85 
orf19.11990 orf19.4515  - - - 
orf19.1219 orf19.8806  57.35 - 54.86 
orf19.13069 orf19.5624  - - - 
orf19.13093 orf19.5648 61.17 - - 1330.02 
orf19.13211 orf19.5789  13.36 12.26 11.66 
orf19.13213 orf19.5791 875.44 - - 435.75 
orf19.13289 orf19.5867  95.98 144.88 93.80 
orf19.13290 orf19.5869  24.44 17.50 14.98 
orf19.1351 orf19.8931  - - - 
orf19.1357 orf19.8937 15.48 - - - 
orf19.14178 orf19.6889  144.00 - - 
orf19.1434 orf19.9008  60.84 128.46 75.46 
orf19.1516 orf19.9091  24.55 20.94 13.38 
orf19.1556 orf19.9129  100.48 96.78 92.47 
orf19.1744 orf19.9311  20.86 38.25 19.45 
orf19.1864 orf19.9420  105.52 236.75 65.19 
orf19.2268 orf19.9808 15.91 - 796.50 851.83 
orf19.2841 orf19.10359  - - - 
orf19.3561 orf19.11045  279.30 166.00 315.31 
orf19.3776 orf19.11257  - - - 
orf19.4068 orf19.11551  40.79 45.35 56.49 
orf19.4118 orf19.11600  26.22 26.06 21.02 
orf19.4213 orf19.11689 74.23 38.54 138.29 29.12 
orf19.4488 orf19.11964  20.41 28.56 18.28 
orf19.5095 orf19.12561  - - 257.87 
orf19.6080 orf19.13499  - - - 
orf19.6346 orf19.13702  - - - 
orf19.797 orf19.8417  - - - 
orf19.807 orf19.8426  40.45 37.98 48.43 
orf19.8214 orf19.581  - - - 
orf19.841 orf19.8461  105.22 237.19 82.59 
orf19.8420 orf19.801  40.97 29.08 37.68 
orf19.8421 orf19.802  46.78 53.89 27.97 
orf19.8421 orf19.803  - 71.95 - 
orf19.8428 orf19.808  46.07 37.89 30.62 
orf19.8875 orf19.1295  36.09 22.31 38.06 
orf19.8930 orf19.1350  268.92 283.00 160.61 
orf19.8963 orf19.1383  55.84 6.32 17.95 
orf19.8963 orf19.1384  99.15 - - 
orf19.8971 orf19.1393  16.82 22.40 - 
orf19.9071 orf19.1494  - - 54.13 
orf19.9267 orf19.1700 205.00 41.23 52.75 37.93 
orf19.9315 orf19.1747  39.87 50.33 53.74 
orf19.9345 orf19.1779  - - - 
orf19.9428 orf19.1872  12.31 16.83 10.75 
orf19.9469 orf19.1913  31.13 - 38.81 
orf19.9470 orf19.1914  62.83 - 39.51 
orf19.9565 orf19.2015  24.71 36.61 26.05 
orf19.9569 orf19.2019  42.94 66.00 202.17 
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orf19.9783 orf19.2242  - - 418.00 
orf19.9806 orf19.2266  207.70 39.30 58.67 
orf19.11979 orf19.4503  13.72 13.44  
orf19.11980 orf19.4504  56.51 61.41  
orf19.11980 orf19.4505  - -  
orf19.13747 orf19.6389  - -  
orf19.7788 orf19.148  13.73 -  
orf19.10860 orf19.3352  10.02  12.82 
orf19.11037 orf19.3554  15.25  10.35 
orf19.11560 orf19.4079  62.86  101.58 
orf19.1356 orf19.8936  28.91  31.07 
orf19.1372 orf19.8952  38.81  22.41 
orf19.14144 orf19.6854 938.50 -  - 
orf19.1759 orf19.9328  19.89  16.38 
orf19.182 orf19.7812  9.60  14.93 
orf19.185 orf19.7816  44.50  39.72 
orf19.1911 orf19.9467  34.24  18.81 
orf19.1995 orf19.9547  61.06  73.21 
orf19.3189 orf19.10699  -  - 
orf19.3605 orf19.11088  -  57.50 
orf19.3733 orf19.11218  6.03  4.88 
orf19.4689 orf19.12158  -  - 
orf19.4901 orf19.12367  -  - 
orf19.5863 orf19.13285  -  - 
orf19.7836 orf19.206  21.60  18.51 
orf19.8753 orf19.1161  -  - 
orf19.11687 orf19.4212 170.44 43.18   
orf19.13909 orf19.6556  44.21   
orf19.1495 orf19.9072  -   
orf19.1782 orf19.9348  -   
orf19.2018 orf19.9568  -   
orf19.3550 orf19.11034  -   
orf19.3934 orf19.11416  9.94   
orf19.6202 orf19.13583 7.56 13.05   
orf19.9578 orf19.2030  13.61   
orf19.11233 orf19.3746   - 75.20 
orf19.11988 orf19.4513   11.78 15.82 
orf19.1915 orf19.9471 -  44.51 31.47 
orf19.2005 orf19.9556   34.90 36.17 
orf19.216 orf19.7848   40.39 33.69 
orf19.7828 orf19.198   15.80 19.56 
orf19.8414 orf19.795   50.63 30.79 
orf19.9563 orf19.2012   203.50 83.75 
orf19.11110 orf19.3627   -  
orf19.1386 orf19.8964   -  
orf19.1479 orf19.9054   56.55  
orf19.1765 orf19.9334   20.12  
orf19.220 orf19.7851   20.44  
orf19.465 orf19.8096 41.26  -  
orf19.5225 orf19.12690   11.59  
orf19.8485 orf19.866   14.10  
orf19.9825 orf19.2285   -  
orf19.1048 orf19.8650    6.67 
orf19.11254 orf19.3770    10.17 
orf19.1390 orf19.8968    8.90 
orf19.1531 orf19.9106    17.34 
orf19.1873 orf19.9429    72.50 
orf19.2116 orf19.9664    8.21 
orf19.3555 orf19.11038    6.39 
orf19.3590 orf19.11072    5.41 
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orf19.3771 orf19.11254    26.37 
orf19.4280 orf19.11756    18.28 
orf19.4506 orf19.11982    31.98 
orf19.7708 orf19.35    7.56 
orf19.8776 orf19.1185    20.22 
orf19.8951 orf19.1371    8.86 
orf19.9090 orf19.1515    20.16 
orf19.9323 orf19.1754    44.75 
orf19.9663 orf19.2115    7.03 
orf19.10681 orf19.3171 6.24    
orf19.11957 orf19.4476 10.53    
orf19.12579 orf19.5113 -    
orf19.13163 orf19.5741 12.09    
orf19.13891 orf19.6538 204.00    
orf19.4212 orf19.11689 5.65    
orf19.4959 orf19.12424 105.23    
orf19.5602 orf19.13045 108.47    
orf19.8644 orf19.1042 3.15    
orf19.9571 orf19.2022 8.82    
- Indicates that expression levels for one allele were below the detectable limit and 
therefore the fold difference could not be calculated. 
 
Key   
Allele 1 
Higher   
Allele 1 
Monoallelic   
Allele 2 
Higher   
Allele 2 
Monoallelic 
 No AEI 
 
Analysis of the data from Bruno et al. (2010) identified a small number of genes 
with AEI (27 across all 11 conditions), similar to the analysis carried out in 
section 5.3.1. Of these genes, five were monoallelic in all conditions identified 
and a further seven were identified as monoallelic in some condition but not all 
conditions. Low expression (<10 counts) of one allele was observed in three 
genes out of the seven with inconsistent monoallelism and in one gene with 
AEI. Again, this smaller than expected number may be due to the high 
stringency of statistical tests used as discussed above. Additionally, each 
condition had only two replicates, reducing the amount of data available, 
possibly impacting upon the amount of genes with AEI identified.  
 
On the other hand, a larger number of genes (123) were identified from the 
three separate conditions of the co-culture with S. gordonii experiment. 31 of 
these genes were monoallelic in all conditions and a further 12 genes were 
monoallelic in at least one but not all conditions. Of these 12, ten genes had low 
expression (<10 counts) of one allele in the other conditions and a further 20 
genes had low expression levels of one allele. The larger number of genes 
identified could be due to several reasons surrounding the sequencing process 
itself. As opposed to the analysis carried out in section 5.3.1 and carried out by 
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Bruno et al. (2010), where an Illumina GAII sequencer was used, the RNA 
sequencing for the co-culture experiment used an Illumina HiSeq2500 platform. 
This platform has been shown to produce a much higher number of reads than 
the Genome Analyser (Minoche et al., 2011). Additionally, longer 100 bp paired 
end reads were obtained for the co-culture experiment, compared to shorter 76 
bp and 30 bp reads for the in-house and Bruno et al. (2010) analyses. In all, this 
increase in the volume and length of reads gives a larger amount of data in 
which AEI may be detected, possibly explaining the larger number of genes 
identified. This has been reported to be the case for general studies 
investigating differential gene expression, where an increase in replicate 
number and sequencing depth increases statistical power (Zhang et al., 2014). 
 
Where genes have been identified in more than one condition, the allele with 
the higher level of expression remains the same and does not differ from 
condition to condition. However for some genes, such as orf19.5113, 
expression from the allele with lower levels is detected in some conditions and 
the gene is identified as monoallelic in other conditions. In other cases, the fold 
change in RPKM values is also variable between conditions, as an example 
orf19.5648 in the Bruno et al. (2010) data shows a much higher fold change 
under growth in no oxidative stress. These results suggest that in cases of 
genes with AEI, one allele has a greater functional contribution than the other, 
but this remains constant across all conditions, as opposed to the alleles having 
distinct condition-specific functions.   
  
Interestingly, few similarities in the genes identified with AEI were seen across 
similar growth conditions, such as low and high oxidative stress, or the four 
control conditions, YPD, no Congo red, no oxidative stress and no nitrosative 
stress. It is difficult to determine why this is the case, but it is possible to infer 
that although the genes with AEI do differ between growth conditions, the 
conditions themselves are unlikely to trigger this difference.  
 
5.3.3 Gene Ontology (GO) Analysis  
Despite the lack of evidence for a condition specific response in AEI, the 
functions of genes with AEI were determined using Gene Ontology analysis on 
the separate gene lists, using the GO Term Finder tool available from the 
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Candida Genome Database (www.candidagenome.org) (Inglis et al., 2012). 
This would indicate whether all genes with AEI have similar functions, or 
functions related to the growth condition. 
  
An over representation of genes involved in oxidation-reduction processes and 
activities, iron transport, and locations to the cell surface and plasma membrane 
was observed for the analysis of the genes identified in section 5.3.1 where the 
wild-type strain was grown in YPD (Table 5.6). Although, in the analysis of the 
Bruno et al. (2010) data-set, just two genes (orf19.1700 and orf19.5113) were 
identified with AEI from growth in YPD, when combining the results from all of 
the control conditions used by Bruno et al. (2010) (YPD, no Congo red, no 
oxidative stress and no nitrosative stress) similar Gene Ontology terms were 
identified as over represented (Table 5.7). Additionally, an over representation 
of genes involved in carbohydrate transport was observed.  
 
GO analysis of the genes identified in other conditions from the Bruno et al. 
(2010) experiment showed that there appears to be no condition specific roles 
of AEI. Similar processes and functions to those found in the control conditions 
above were found; metal ion binding and transport processes were identified in 
growth in serum and Congo red, oxidation and reduction processes were 
identified in growth in Congo red, high oxidative stress, nitrosative stress and 
tissue culture media (M199) at both pH 4 and pH 8, and plasma membrane 
localisation was identified in growth in nitrosative stress (Table 5.8).   
 
Conversely, GO analysis of the 123 genes identified with AEI from the three 
conditions of the co-culture experiment show over representation of different 
processes to the genes identified from Bruno et al. (2010), with functions 
involved in protein kinase and transferase activity being over represented 
(Table 5.9). Again, condition specific analysis showed no over representation of 
functions when C. albicans is cultured with S. gordonii nor when it is grown in S. 
gordonii media alone. However growth in hypha inducing conditions per se did 
identify similar functions to those identified from the Bruno et al. (2010) data-set 
with enrichment of metal ion binding (Table 5.10).  
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Taken together these results suggest that AEI does not differ in a condition 
specific manner. However, contrary to the findings of chapter three, it does 
suggest that genes with AEI may be enriched for functional roles in metal 
binding and transport, and oxidation and reduction processes. 
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Table 5.6 GO Terms enriched for genes exhibiting AEI when SC5314 is grown in YPD. GO terms identified using “CGD Gene 
Ontology Term Mapper” (www.candidagenome.org).  
 
Ontology GOID GO term Cluster 
frequency 
Background 
frequency 
Corrected 
P-value 
False discovery 
rate 
Gene(s) annotated to the term 
Process 70627 “ferrous iron import” 2 out of 22 
genes, 9.1% 
2 out of 6517 
background genes, 
0.0% 
0.0011 0.00% FET3 FET31 
97286 “iron ion import” 2 out of 22 
genes, 9.1% 
2 out of 6517 
background genes, 
0.0% 
0.0011 0.00% FET3 FET31 
15684 “ferrous iron transport” 2 out of 22 
genes, 9.1% 
3 out of 6517 
background genes, 
0.0% 
0.00331 0.00% FET3 FET31 
55085 “transmembrane transport” 7 out of 22 
genes, 31.8% 
363 out of 6517 
background genes, 
5.6% 
0.01035 1.00% POR1 FCY21 orf19.2022 FET3 
FET31 VMA11 ATP1 
34755 “iron ion transmembrane 
transport” 
2 out of 22 
genes, 9.1% 
10 out of 6517 
background genes, 
0.2% 
0.04907 8.80% FET3 FET31 
Function 
 
5507 “copper ion binding” 3 out of 22 
genes, 13.6% 
22 out of 6517 
background genes, 
0.3% 
0.00175 4.00% FET3 FET99 FET31 
16724 “oxidoreductase activity, 
oxidizing metal ions, oxygen 
as acceptor” 
2 out of 22 
genes, 9.1% 
4 out of 6517 
background genes, 
0.1% 
0.00242 4.00% FET3 FET31 
4322 “ferroxidase activity” 2 out of 22 
genes, 9.1% 
4 out of 6517 
background genes, 
0.1% 
0.00242 2.67% FET3 FET31 
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16722 “oxidoreductase activity, 
oxidizing metal ions” 
2 out of 22 
genes, 9.1% 
12 out of 6517 
background genes, 
0.2% 
0.02624 7.50% FET3 FET31 
Component 71944 “cell periphery” 10 out of 22 
genes, 45.5% 
685 out of 6517 
background genes, 
10.5% 
0.0011 0.00% POR1 FCY21 orf19.2022 FET3 
FET99 FET31 IFF9 ADH2 ALS1 ATP1 
9986 “cell surface” 6 out of 22 
genes, 27.3% 
204 out of 6517 
background genes, 
3.1% 
0.00192 0.00% RPS7A FET99 IFF9 ALS1 RBT4 ATP1 
5886 “plasma membrane” 8 out of 22 
genes, 36.4% 
475 out of 6517 
background genes, 
7.3% 
0.00392 0.67% POR1 FCY21 orf19.2022 FET3 
FET99 FET31 ADH2 ATP1 
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Table 5.7 GO terms enriched for genes exhibiting AEI when SC5314 is grown in control conditions (YPD, No Congo Red, No 
Oxidative Stress and No Nitrosative Stress) from Bruno et al (2010). GO terms identified using “CGD Gene Ontology Term 
Mapper” (www.candidagenome.org).  
 
Ontology GOID GO term Cluster 
frequency 
Background 
frequency 
Corrected 
P-value 
False 
discovery rate 
Gene(s) annotated to the term 
Process 70627 “ferrous iron import” 2 out of 14 
genes, 14.3% 
2 out of 6517 
background genes, 
0.0% 
0.00024 0.00% FET3 FET31 
97286 “iron ion import” 2 out of 14 
genes, 14.3% 
2 out of 6517 
background genes, 
0.0% 
0.00024 0.00% FET3 FET31 
15684 “ferrous iron transport” 2 out of 14 
genes, 14.3% 
3 out of 6517 
background genes, 
0.0% 
0.00072 0.00% FET3 FET31 
34755 “iron ion transmembrane 
transport” 
2 out of 14 
genes, 14.3% 
10 out of 6517 
background genes, 
0.2% 
0.01081 7.00% FET3 FET31 
55085 “transmembrane 
transport” 
5 out of 14 
genes, 35.7% 
363 out of 6517 
background genes, 
5.6% 
0.03054 11.20% orf19.2022 HGT7 FET3 FET31 ATP1 
  
6826 “iron ion transport” 2 out of 14 
genes, 14.3% 
19 out of 6517 
background genes, 
0.3% 
0.04067 11.33% FET3 FET31 
Function 5507 “copper ion binding” 3 out of 14 
genes, 21.4% 
22 out of 6517 
background genes, 
0.3% 
0.00018 0.00% FET3 FET99 FET31 
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 16724 “oxidoreductase activity, 
oxidizing metal ions, 
oxygen as acceptor” 
2 out of 14 
genes, 14.3% 
4 out of 6517 
background genes, 
0.1% 
0.00043 1.00% FET3 FET31 
4322 “ferroxidase activity” 2 out of 14 
genes, 14.3% 
4 out of 6517 
background genes, 
0.1% 
0.00043 0.67% FET3 FET31 
16722 “oxidoreductase activity, 
oxidizing metal ions” 
2 out of 14 
genes, 14.3% 
12 out of 6517 
background genes, 
0.2% 
0.00479 2.00% FET3 FET31 
5355 “glucose transmembrane 
transporter activity” 
2 out of 14 
genes, 14.3% 
19 out of 6517 
background genes, 
0.3% 
0.01232 1.60% orf19.2022 HGT7 
15149 “hexose transmembrane 
transporter activity” 
2 out of 14 
genes, 14.3% 
20 out of 6517 
background genes, 
0.3% 
0.01367 1.33% orf19.2022 HGT7 
15145 “monosaccharide 
transmembrane 
transporter activity” 
2 out of 14 
genes, 14.3% 
22 out of 6517 
background genes, 
0.3% 
0.01659 1.14% orf19.2022 HGT7 
15144 “carbohydrate 
transmembrane 
transporter activity” 
2 out of 14 
genes, 14.3% 
28 out of 6517 
background genes, 
0.4% 
0.02697 1.00% orf19.2022 HGT7 
19014
76 
“carbohydrate transporter 
activity” 
2 out of 14 
genes, 14.3% 
28 out of 6517 
background genes, 
0.4% 
0.02697 0.89% orf19.2022 HGT7 
51119 “sugar transmembrane 
transporter activity” 
2 out of 14 
genes, 14.3% 
28 out of 6517 
background genes, 
0.4% 
0.02697 0.80% orf19.2022 HGT7 
Component 5886 “plasma membrane” 7 out of 14 
genes, 50.0% 
475 out of 6517 
background genes, 
7.3% 
0.00051 0.00% orf19.2022 HGT7 FET3 FET99 FET31 
ADH2 ATP1 
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 71944 “cell periphery” 7 out of 14 
genes, 50.0% 
685 out of 6517 
background genes, 
10.5% 
0.00561 1.00% orf19.2022 HGT7 FET3 FET99 FET31 
ADH2 ATP1 
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Table 5.8 GO terms enriched for genes exhibiting AEI when SC5314 is grown in different conditions from Bruno et al (2010). GO 
terms identified using “CGD Gene Ontology Term Mapper” (www.candidagenome.org).  
 
Condition/ 
Ontology 
GOID GO term Cluster 
frequency 
Background 
frequency 
Corrected 
P-value 
False 
discovery rate 
Gene(s) annotated to the term 
Serum 
Function 5507 “copper ion binding” 2 out of 5 
genes, 40.0% 
22 out of 6517 
background genes, 
0.3% 
0.00075 2.00% FET99 FET31 
Congo Red 
Process 55114 “oxidation-reduction 
process” 
3 out of 5 
genes, 60.0% 
418 out of 6517 
background genes, 
6.4% 
0.02614 88.00% FET99 FET31 ADH2 
Function 5507 “copper ion binding” 2 out of 5 
genes, 40.0% 
22 out of 6517 
background genes, 
0.3% 
0.00075 0.00% FET99 FET31 
46914 “transition metal ion 
binding” 
3 out of 5 
genes, 60.0% 
401 out of 6517 
background genes, 
6.2% 
0.01474 8.00% FET99 FET31 ADH2 
16491 “oxidoreductase activity” 3 out of 5 
genes, 60.0% 
421 out of 6517 
background genes, 
6.5% 
0.01698 5.33% FET99 FET31 ADH2 
46872 “metal ion binding” 3 out of 5 
genes, 60.0% 
502 out of 6517 
background genes, 
7.7% 
0.02827 6.00% FET99 FET31 ADH2 
43169 “cation binding” 3 out of 5 
genes, 60.0% 
510 out of 6517 
background genes, 
7.8% 
0.02959 5.20% FET99 FET31 ADH2 
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M199 pH 4 
Process 55114 “oxidation-reduction 
process” 
4 out of 6 
genes, 66.7% 
418 out of 6517 
background genes, 
6.4% 
0.0009 14.00% orf19.1117 FET99 FET31 
orf19.4504 
Function 5507 “copper ion binding” 2 out of 6 
genes, 33.3% 
22 out of 6517 
background genes, 
0.3% 
0.00113 0.00% FET99 FET31 
16491 “oxidoreductase activity” 4 out of 6 
genes, 66.7% 
421 out of 6517 
background genes, 
6.5% 
0.00162 0.00% orf19.1117 FET99 FET31 
orf19.4504 
46914 “transition metal ion 
binding” 
3 out of 6 
genes, 50.0% 
401 out of 6517 
background genes, 
6.2% 
0.02814 4.67% FET99 FET31 orf19.4504 
M199 pH 8 
Process 
 
70627 “ferrous iron import” 2 out of 13 
genes, 15.4% 
2 out of 6517 
background genes, 
0.0% 
0.00023 4.00% FET3 FET31 
97286 “iron ion import” 2 out of 13 
genes, 15.4% 
2 out of 6517 
background genes, 
0.0% 
0.00023 2.00% FET3 FET31 
15684 “ferrous iron transport” 2 out of 13 
genes, 15.4% 
3 out of 6517 
background genes, 
0.0% 
0.0007 1.33% FET3 FET31 
34220 “ion transmembrane 
transport” 
4 out of 13 
genes, 30.8% 
116 out of 6517 
background genes, 
1.8% 
0.00385 2.00% FET3 FET31 VMA11 ATP1 
55114 “oxidation-reduction 
process” 
6 out of 13 
genes, 46.2% 
418 out of 6517 
background genes, 
6.4% 
0.00501 1.60% FET3 FET99 FET31 orf19.4504 
ADH3 ADH2 
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 6812 “cation transport” 4 out of 13 
genes, 30.8% 
145 out of 6517 
background genes, 
2.2% 
0.0092 2.33% FET3 FET31 VMA11 ATP1 
34755 “iron ion transmembrane 
transport” 
2 out of 13 
genes, 15.4% 
10 out of 6517 
background genes, 
0.2% 
0.01048 2.00% FET3 FET31 
15988 “energy coupled proton 
transmembrane transport, 
against electrochemical 
gradient” 
2 out of 13 
genes, 15.4% 
16 out of 6517 
background genes, 
0.2% 
0.02777 5.25% VMA11 ATP1 
15991 “ATP hydrolysis coupled 
proton transport” 
2 out of 13 
genes, 15.4% 
16 out of 6517 
background genes, 
0.2% 
0.02777 4.67% VMA11 ATP1 
6826 “iron ion transport” 2 out of 13 
genes, 15.4% 
19 out of 6517 
background genes, 
0.3% 
0.03944 6.20% FET3 FET31 
Function 
 
16491 “oxidoreductase activity” 7 out of 13 
genes, 53.8% 
421 out of 6517 
background genes, 
6.5% 
0.00023 0.00% IFD6 FET3 FET99 FET31 orf19.4504 
ADH3 ADH2 
5507 “copper ion binding” 3 out of 13 
genes, 23.1% 
22 out of 6517 
background genes, 
0.3% 
0.0004 0.00% FET3 FET99 FET31 
16724 “oxidoreductase activity, 
oxidizing metal ions, 
oxygen as acceptor” 
2 out of 13 
genes, 15.4% 
4 out of 6517 
background genes, 
0.1% 
0.00094 0.00% FET3 FET31 
4322 “ferroxidase activity” 2 out of 13 
genes, 15.4% 
4 out of 6517 
background genes, 
0.1% 
0.00094 0.00% FET3 FET31 
46914 “transition metal ion 
binding” 
6 out of 13 
genes, 46.2% 
401 out of 6517 
background genes, 
6.2% 
0.00266 0.80% FET3 FET99 FET31 orf19.4504 
ADH3 ADH2 
Page | 274  
 
 
 
46872 “metal ion binding” 6 out of 13 
genes, 46.2% 
502 out of 6517 
background genes, 
7.7% 
0.00936 0.67% FET3 FET99 FET31 orf19.4504 
ADH3 ADH2 
43169 “cation binding” 6 out of 13 
genes, 46.2% 
510 out of 6517 
background genes, 
7.8% 
0.01022 0.57% FET3 FET99 FET31 orf19.4504 
ADH3 ADH2 
16722 “oxidoreductase activity, 
oxidizing metal ions” 
2 out of 13 
genes, 15.4% 
12 out of 6517 
background genes, 
0.2% 
0.0103 0.50% FET3 FET31 
43167 “ion binding” 8 out of 13 
genes, 61.5% 
1140 out of 6517 
background genes, 
17.5% 
0.02061 0.44% RCK2 FET3 FET99 FET31 orf19.4504 
ADH3 ADH2 ATP1 
High Oxidative 
 
Process 55114 “oxidation-reduction 
process” 
5 out of 15 
genes, 33.3% 
418 out of 6517 
background genes, 
6.4% 
0.07621 100.00% IFR1 DAO2 FET99 FET31 ADH2 
Function 16491 “oxidoreductase activity” 6 out of 15 
genes, 40.0% 
421 out of 6517 
background genes, 
6.5% 
0.00659 6.00% IFD6 IFR1 DAO2 FET99 FET31 ADH2 
5507 “copper ion binding” 2 out of 15 
genes, 13.3% 
22 out of 6517 
background genes, 
0.3% 
0.03448 8.00% FET99 FET31 
Nitrosative 
Process 55114 “oxidation-reduction 
process” 
4 out of 6 
genes, 66.7% 
418 out of 6517 
background genes, 
6.4% 
0.00293 4.00% FET99 FET31 AOX2 ADH2 
Function 5507 “copper ion binding” 2 out of 6 
genes, 33.3% 
22 out of 6517 
background genes, 
0.3% 
0.00113 4.00% FET99 FET31 
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16491 “oxidoreductase activity” 4 out of 6 
genes, 66.7% 
421 out of 6517 
background genes, 
6.5% 
0.00162 3.00% FET99 FET31 AOX2 ADH2 
46914 “transition metal ion 
binding” 
3 out of 6 
genes, 50.0% 
401 out of 6517 
background genes, 
6.2% 
0.02814 9.33% FET99 FET31 ADH2 
Component 5886 “plasma membrane” 4 out of 6 
genes, 66.7% 
475 out of 6517 
background genes, 
7.3% 
0.00668 0.00% FET99 FET31 AOX2 ADH2 
71944 “cell periphery” 4 out of 6 
genes, 66.7% 
685 out of 6517 
background genes, 
10.5% 
0.02746 1.00% FET99 FET31 AOX2 ADH2 
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Table 5.9 GO terms enriched for genes exhibiting AEI when SC5314 is grown in hypha inducing conditions, co-cultured with S. 
gordonii and grown in S. gordonii media. GO terms identified using “CGD Gene Ontology Term Mapper” 
(www.candidagenome.org).  
 
Ontology GOID GO term Cluster 
frequency 
Background 
frequency 
Corrected 
P-value 
False 
discovery rate 
Gene(s) annotated to the term 
Function 4672 “protein kinase activity” 9 out of 130 
genes, 6.9% 
115 out of 6525 
background genes, 
1.8% 
0.03399 6.00% orf19.148/orf19.7788 orf19.1754 
orf19.2015 RCK2 orf19.35 CDC7 
orf19.3776 PKH2 MKK2 
16769 “transferase activity, 
transferring nitrogenous 
groups” 
4 out of 130 
genes, 3.1% 
21 out of 6525 
background genes, 
0.3% 
0.06694 22.00% AAT1 orf19.3771 BAT21 orf19.803 
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Table 5.10 GO terms enriched for genes exhibiting AEI when SC5314 is grown in hypha inducing conditions. GO terms 
identified using “CGD Gene Ontology Term Mapper” (www.candidagenome.org).  
 
 Ontology GOID GO term Cluster 
frequen
cy 
Background frequency Corrected 
P-value 
False 
discovery rate 
Gene(s) annotated to the term 
Function 5507 “copper ion binding” 2 out of 
10 
genes, 
20.0% 
22 out of 6525 
background genes, 0.3% 
0.00384 6.00% FET3 FET99 
46872 “metal ion binding” 5 out of 
10 
genes, 
50.0% 
502 out of 6525 
background genes, 7.7% 
0.00384 3.00% orf19.1495 orf19.2018 CAR1 FET3 
FET99 
43169 “cation binding” 5 out of 
10 
genes, 
50.0% 
510 out of 6525 
background genes, 7.8% 
0.00414 2.00% orf19.1495 orf19.2018 CAR1 FET3 
FET99 
46914 “transition metal ion 
binding” 
4 out of 
10 
genes, 
40.0% 
401 out of 6525 
background genes, 6.1% 
0.01753 8.00% orf19.2018 CAR1 FET3 FET99 
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5.3.4 Differences in Promoter Sequences 
As in chapter three, the promoter regions of the genes identified with AEI from 
the three data-sets were analysed for sequence differences to assess if 
polymorphisms in these regions are linked to differential allele expression. As 
promoter regions are currently undefined in C. albicans, the 1000 bp upstream 
of each allele of a gene (or the distance to the adjacent ORF) were compared. 
Of the 21 genes identified with AEI from repeating the analysis of chapter three, 
14 genes (66 %) differed in their upstream region by at least a single SNP. 23 of 
the 27 (85 %) genes identified from the Bruno et al. (2010) study had at least 
one polymorphism in the upstream region of the alleles. Polymorphisms were 
found in the upstream region of 100 of the 123 (82 %) genes identified with AEI 
from the co-culture experiment. Although differences in these regions were 
identified in a high number of genes, approximately a quarter of promoter 
regions were homozygous. Based upon the observed overall level of 
heterozygosity - one SNP in every 237 bp (Jones et al., 2004), the probability 
that a 1000 bp region is homozygous can be calculated as follows: 
236
237
1000
= 0.015 
 
Therefore, based on this probability, it would be expected that less than 1 
promoter region would be homozygous out of the 21 and 27 genes identified 
from the re-analysis of the data from chapter three and from the data from 
Bruno et al. (2010) respectively. Just 2 promoter regions would be expected to 
be homozygous from the 123 genes identified from the co-culture experiment. 
However, a significantly larger proportion of promoter sequences were found to 
be homozygous in all three data-sets (chi-square test, d.f. = 1, p = 3.61 x 10-34, 
p = 7 x 10-9, and p = 2.64 x 10-57 respectively). Therefore, as opposed to 
differences in promoter regions driving differences in allele expression levels, it 
can be concluded that polymorphisms in the promoter regions of these genes 
are actually selected against. Based upon the observation in chapter three that 
genes with equal allele expression also have a similar rate of polymorphisms in 
promoter regions at 78% (section 3.3.1.3) it could be suggested that 
polymorphisms in upstream regions are selected against in all genes. The 
reasoning behind this is unclear, but may be due to the pressure to maintain 
gene expression levels. It should be noted that this probability has been 
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calculated for the simplest model where 1000 bp upstream were compared for 
each in gene. In reality, upstream regions varied in length dependent upon the 
distance to the adjacent open reading frame which may impact upon this 
probability estimate.   
 
5.3.5 Identification of Genes with Differing Allele Expression Levels 
between Growth Conditions  
Some genes which have not been identified as having significant levels of allelic 
expression imbalance by the computational pipeline will still have uneven 
changes in levels of allele expression when growth conditions change. To 
identify genes where the growth condition causes a change in expression of 
one allele greater than the change in the other allele, the fold difference in 
RPKM values of each allele between conditions was calculated for every gene 
for 16 different condition comparisons taken from the analysis of the Bruno et al. 
(2010) data (as described in section 5.2.6). The Log10 fold change in allele one 
expression level was then plotted against the Log10 fold change in the allele two 
expression level for each condition comparison and linear trend lines were 
fitted. Figure 5.3 demonstrates an example of the relationship observed for the 
change in expression of alleles between growth in YPD and growth in the cell 
wall damaging agent Congo Red.  
 
The equation of the linear trend line was used to calculate the predicted y 
values. Any genes where the observed y value was greater than two standard 
deviations away from the predicted y value were identified as having a 
significantly larger change in one allele expression than the other allele between 
those growth conditions. Appendix I Table V lists all 256 genes identified as 
significant in comparisons of two conditions or more.   
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Figure 5.3 Log10 fold differences in allele expression levels between growth in YPD and 
growth in Congo Red. A linear trend line has been fitted.  
 
To identify genes which frequently have a disparity in the fold difference of 
alleles between conditions, the frequency of genes identified as significant for 
each condition comparison was calculated and multiplied by each other for each 
gene to give a significance measure. To give an example, Table 5.11 gives an 
explanation of this calculation, looking at the gene GPX1 that was identified as 
having significant disparity in the change in allele expression levels between 12 
different conditions. The probability of this occurring by chance is calculated at p 
= 3.758 x 10-17 and is therefore significantly unlikely, suggesting that the two 
alleles of this gene have different responses to the change in growth conditions. 
All genes with p < 1.95 x 10-4, as determined by Bonferroni correction for 
multiple comparisons, were identified as significant by this analysis (Appendix I 
Table VI). This list includes the gene ERB1 which was also identified as having 
significant levels of AEI in chapter three.   
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Table 5.11 Example of calculating the probability that a gene has significant differences in change of allele expression across 
multiple condition comparisons. The example here shows the results for the gene GPX1.  
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No. of Genes 
Identified as 
Significant 
56 55 55 67 60 47 49 51 53 46 55 43 47 62 57 43 
Total Number 
of Genes 
Analysed 
1265 1263 1171 1156 1269 1304 1149 1121 1276 1130 1233 1239 1112 1152 1137 1113 
Frequency of 
Significant 
Genes 
0.044 0.044 0.047 0.058 0.047 0.036 0.043 0.045 0.042 0.041 0.045 0.035 0.042 0.054 0.050 0.039 
Is GPX1 
significant in 
this 
comparison? 
Y Y Y Y Y Y Y Y Y Y Y Y N N N N 
Probability = 
3.758x10
-17
 
0.044 x 0.044 x 0.047 x 0.058 x 0.047 x 0.036 x 0.043 x 0.045 x 0.042 x 0.041 x 0.045 x 0.035 x 0.958 x 0.946 x 0.950 x 0.961 x 
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5.3.6 Target Genes for Heterozygous Knockout Construction 
From the condition-specific data compiled above, four genes were selected for 
heterozygous knockout construction with a hypothesis that these alleles are 
likely to differ in function. ADH2 was identified as having significantly higher 
expression of allele one or monoallelic expression of allele one from the re-
analysis of the data from chapter three and from seven conditions of the Bruno 
et al. (2010) study (section 5.3.2). ADH2 was also identified as having 
significant differences in the change of allele expression across nine different 
growth condition comparisons (section 5.3.5). GPX1 was not identified as 
having significant AEI but was found to have significant differences in changes 
in allele expression across 12 different condition comparisons, making it the 
most significant gene in the analysis in section 5.3.5. RPS7A was identified as 
having significantly higher expression levels of allele one or monoallelic allele 
one expression in all data-sets analysed in section 5.3.2 except from growth in 
M199 pH 4. Finally, orf19.5648 was found to have higher expression levels of 
allele two or monoallelic allele two expression in all data-sets analysed in 
section 5.3.2 except for growth in YPD and the no Congo red control from 
Bruno et al. (2010).  
 
Heterozygous knockout mutants were successfully constructed for just two of 
these four genes; ADH2 and GPX1. Only constructs lacking RPS7A allele one 
and constructs lacking orf19.5648 allele two were obtained after numerous 
transformation attempts. Due to the inability to produce knockouts of both 
alleles, there are no phenotypic screens for these genes. Reasons explaining 
this are further discussed in section 5.3.9. Validation of insertion of knockout 
cassettes at the correct genomic location was carried out using colony PCR as 
described in sections 2.9 and 2.10 (Figure 5.4). Southern blotting was used to 
further validate the ADH2 and GPX1 mutants, showing insertion in the correct 
position and that only one copy of the nourseothricin cassette had been 
inserted, as described in section 2.15 (Figure 5.5).  
 
To show that the nourseothricin cassette was not causing phenotypic 
differences, the control strain used in chapter three containing nourseothricin at 
the RPS1 locus (SC12) was used as described in section 2.14.1. 
Page | 283  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Figure 5.4 PCR validations of heterozygous knockout mutants. L = 1 kb DNA ladder (Fermentas, UK). N = negative control containing no DNA. SC66, 
SC67, SC68, SC69, SC90 and SC92 = ADH2 knockouts with a band expected at 434 bp. SC74, SC75, SC76, SC81 and SC107 = GPX1 knockouts 
with a band expected at 563 bp. SC70, SC93, SC94, SC96, SC97 and SC98 = RPS7A knockouts with a band expected at 550 bp. SC71, SC72, 
SC73, SC85, SC86, SC87, SC88, SC99, SC100, SC101 and SC102 = orf19.5648 knockouts with a band expected at 487 bp.  
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orf19.5648 
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Figure 5.5 Southern blotting validations of heterozygous knockout mutants. L = 1 kb 
DNA ladder (Fermentas, UK). SC5314 = negative control containing untransformed 
wild-type DNA. N = negative control containing all reaction components except DNA. 
SC69, SC90 and SC92 = ADH2 allele one heterozygous knockouts showing a single 
band at 7145 bp. SC66, SC67 and SC68 = ADH2 allele two heterozygous knockouts 
showing a single band at 1910 bp. SC74, SC75, SC76, SC81 and SC107 = GPX1 
heterozygous knockouts showing a single very faint band at 5342 bp.  
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5.3.7 Phenotypic Screening 
5.3.7.1 ADH2 Phenotypic Screening 
The ADH2 gene encodes an alcohol dehydrogenase which works closely with 
the related gene product of ADH1 to convert ethanol to acetaldehyde, allowing 
Candida albicans to utilise ethanol as a sole carbon source (Bertram et al., 
1996, Marttila et al., 2013). Screening of heterozygous knockout mutants using 
generic assays showed little differences between the knockout strains of either 
allele and the wild-type strain SC5314. Growth at both 30 °C and 37 °C did not 
differ significantly from the wild-type strain SC5314 for any of the measures 
taken (ANOVA, p > 0.05; Figure 5.6a, Figure 5.6b, Table 5.12). Adhesion to 
buccal epithelial cells also did not differ significantly from the wild-type strain 
SC5314 for any of the three measures taken (two sample t-test, p > 0.05, 
Figures 5.6c-e). All strains were able to switch to the hyphal form at the same 
rate as the wild-type strain SC5314 (Figure 5.6f), showing that although over 
expression of ADH2 protein has been reported in hyphae (Hernández et al., 
2004) the individual alleles are not functionally important for this morphological 
switch. Virulence of the heterozygous knockout mutants using a Galleria 
mellonella infection model was the same as the wild-type strain at all three cell 
concentrations tested (Kaplan-Meier, d.f. = 7, p > 0.05; Figure 5.6g). The 
response to growth in the antifungal compounds 5-flucytosine and amphotericin 
B does not differ from the wild-type strain SC5314 (Figure 5.6i and j). In 
response to fluconazole, SC66, SC67 and SC68, the allele two knockout 
strains, have a similar response to the wild-type strain SC5314. However, SC90 
and SC92, the allele one knockout strains, appear to have reduced recovery, 
with lower growth rates at 48 hours than SC5314, although this trend is not 
observed in the third isolate, SC69, which is also an allele one knockout strain 
(Figure 5.6h). Conversely, growth on fluconazole agar plates at 48 hours does 
not show a difference in growth for any of the heterozygous knockout strains 
(Figure 5.6m). As ADH2 has previously been observed to exhibit increased 
protein expression under exposure to the related azole ketoconazole 
(Hoehamer et al., 2010), it would be sensible to infer that the alleles may have a 
role in the response to fluconazole, however from the results gathered here, 
that role is not apparent.  
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The ADH2 gene has not been well characterised in Candida albicans, however 
the function of the closely related ADH1 gene has been investigated in yeast 
species. Saccharomyces cerevisiae alcohol dehydrogenase knockout strains 
are unable to grow on ethanol as the sole carbon source, however the C. 
albicans ADH1 gene can functionally compensate for this phenotype (Bertram 
et al., 1996). In our investigation, all strains, including the wild-type strain 
SC5314, had reduced growth when ethanol was used as the sole carbon 
source as opposed to glucose, however comparison of the growth of the strains 
demonstrated no differences. This reduced rate of growth was observed when 
overnights were cultured in both glucose and ethanol prior to experimentation 
(Figures 5.6k and l). Additionally, Bertram et al. (1996) showed that S. 
cerevisiae ADH mutants were resistant to growth on the respiratory inhibitor 
antimycin A, however it can be seen in Figure 5.6m that all heterozygous 
knockout mutants of ADH2 in C. albicans grow on antimycin A in a comparable 
manner to the wild-type strain SC5314, which is also resistant to antimycin A at 
a concentration of 1 µg/ml. Bertram et al. (1996) only observed sensitivity to 
growth on ethanol and resistance to antimycin A in S. cerevisiae knockout 
strains lacking all three alcohol dehydrogenase genes implying that a 
mechanism of functional redundancy occurs. Therefore it could hypothesised 
that in the C. albicans ADH2 heterozygous knockout mutants, the remaining 
allele or the other alcohol dehydrogenase gene ADH1 may be masking any 
functional consequences of the allele that is missing.   
 
Additionally, as GO analysis of the genes identified with AEI from the Bruno et 
al. (2010) data-set revealed an over representation of genes involved in 
oxidation-reduction processes, the ADH2 heterozygous knockout mutants were 
assayed for their growth under oxidative stress. Figure 5.6m shows that under 
all three conditions tested the knockout strains had comparable growth to the 
wild-type strain suggesting that the ADH2 alleles do not have separate functions 
in response to oxidative stress. However, as was the case for growth in ethanol, 
this could be due to functional redundancy of other alcohol dehydrogenase 
genes.   
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Table 5.12 Average generation times, times to maximum inflection and 
end-point optical densities of ADH2 heterozygous knockout mutants at 30 
°C and 37 °C (± one standard deviation) 
Growth Curve 
(from Figure 5.6) 
Strain Generation 
Time (mins) 
Time to 
Maximum 
Inflection (mins) 
End-Point Optical 
Density (OD at 650 
nm) 
a) 30 °C SC5314 115.93 ± 5.99 490.88 ± 102.58 1.25 ± 0.12 
SC12 118.90 ± 9.05 491.75 ± 132.56 1.24 ± 0.27 
Allele 1 knockouts SC69 119.51 ± 5.19 495.54 ± 76.21 1.18 ± 0.08 
SC90 123.43 ± 10.36 454.67 ± 163.52 1.23 ± 0.18 
SC92 114.45 ± 6.64 472.92 ± 65.54 1.29 ± 0.10 
Allele 2 knockouts SC66 114.13 ± 7.42 494.86 ± 158.93 1.19 ± 0.25 
SC67 116.45 ± 7.95 470.46 ± 69.03 1.27 ± 0.12 
SC68 115.78 ± 6.90 472.50 ± 162.12 1.24 ± 0.21 
b) 37 °C SC5314 91.40 ± 9.47 328.13 ± 38.81 1.16 ± 0.26 
SC12 90.12 ± 5.41 311.79 ± 23.29 1.30 ± 0.19 
Allele 1 knockouts SC69 82.63 ± 16.72 307.42 ± 58.50 1.10 ± 0.21 
SC90 96.02 ± 14.02 368.08 ± 93.34 1.27 ± 0.14 
SC92 95.21 ± 14.07 358.17 ± 120.43 1.30 ± 0.16 
Allele 2 knockouts SC66 79.75 ± 20.73 309.17 ± 37.01 1.18 ± 0.26 
SC67 91.68 ± 18.96 339.50 ± 116.15 1.25 ± 0.19 
SC68 82.61 ± 17.22 355.83 ± 104.70 1.26 ± 0.16 
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Figure 5.6 Phenotypic assays of ADH2 heterozygous knockout mutants. SC5314 = wild-type strain (blue). SC12 = control strain with NAT cassette at 
RPS1 locus (red). SC69, SC90 and SC92 = knockout of “allele one” (yellow) and SC66, SC67 and 68 = knockout of “allele two” (green).  
 
 
 
  
 
 
 
 
 
 
 
 
a) Growth rate at 30 °C. b) Growth rate at 37 °C.  
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c) Percentage of BECs adhered to C. albicans cells. d) Number of C. albicans cells per BEC. e) Number of C. albicans cells per BECs (with cells 
adhered). Error bars = ± one standard deviation.  
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Page | 291  
 
 
0
0.5
1
1.5
2
0 1 2 4 8
1
6
3
2
6
4
1
2
8
2
5
6
5
1
2
1
0
2
4
O
D
 a
t 
5
9
5
 n
m
 
Concentration (µg/ml) 
SC5314 
0
0.5
1
1.5
2
0 1 2 4 8
1
6
3
2
6
4
1
2
8
2
5
6
5
1
2
1
0
2
4
O
D
 a
t 
5
9
5
 n
m
 
Concentration (µg/ml) 
SC12 - RPS1 
0
0.5
1
1.5
2
0 1 2 4 8
1
6
3
2
6
4
1
2
8
2
5
6
5
1
2
1
0
2
4
O
D
 a
t 
5
9
5
 n
m
 
Concentration (µg/ml) 
SC66 - Allele 2 KO 
0
0.5
1
1.5
2
0 1 2 4 8
1
6
3
2
6
4
1
2
8
2
5
6
5
1
2
1
0
2
4
O
D
 a
t 
5
9
5
 n
m
 
Concentration (µg/ml) 
SC67 - Allele 2 KO 
0
0.5
1
1.5
2
0 1 2 4 8
1
6
3
2
6
4
1
2
8
2
5
6
5
1
2
1
0
2
4
O
D
 a
t 
5
9
5
 n
m
 
Concentration (µg/ml) 
SC68 - Allele 2 KO 
0
0.5
1
1.5
2
0 1 2 4 8
1
6
3
2
6
4
1
2
8
2
5
6
5
1
2
1
0
2
4
O
D
 a
t 
5
9
5
 n
m
 
Concentration (µg/ml) 
SC69 - Allele 1 KO 
0
0.5
1
1.5
2
0 1 2 4 8
1
6
3
2
6
4
1
2
8
2
5
6
5
1
2
1
0
2
4
Concentration (µg/ml) 
SC90 - Allele 1 KO 
0
0.5
1
1.5
2
0 1 2 4 8
1
6
3
2
6
4
1
2
8
2
5
6
5
1
2
1
0
2
4
O
D
 a
t 
5
9
5
 n
m
 
Concentration (µg/ml) 
 SC92 - Allele 1 KO 
h) Growth in response to fluconazole. Concentrations range from 0 – 1024 µg/ml. Blue = OD 
at 595 nm at 24 hours. Red = OD at 595 nm at 48 hours. Error bars = ± one standard 
deviation.  
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i) Growth in response to 5-flucytosine. Concentrations range from 0 – 1024 µg/ml. Blue = OD 
at 595 nm at 24 hours. Red = OD at 595 nm at 48 hours. Error bars = ± one standard 
deviation.  
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j) Growth in response to amphotericin b. Concentrations range from 0 – 1024 µg/ml. Blue = 
OD at 595 nm at 24 hours. Red = OD at 595 nm at 48 hours. Error bars = ± one standard 
deviation.  
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k) Growth with 
2% ethanol as 
the sole carbon 
source, both in 
a liquid assay 
and on agar 
plates, after 48 
hours at 30 °C 
after pre-growth 
in glucose. 
 
l) Growth with 
2% ethanol as 
the sole carbon 
source, both in 
a liquid assay 
and on agar 
plates, after 48 
hours at 30 °C 
after pre-growth 
in ethanol.  
 
Cell Conc. 
SC66 – Allele 2 KO 
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SC67 – Allele 2 KO 
SC68 – Allele 2 KO 
SC69 – Allele 1 KO 
SC90 – Allele 1 KO 
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Cell Conc. 
SC66 – Allele 2 KO 
SC5314 
SC12 – RPS1 
SC67 – Allele 2 KO 
SC68 – Allele 2 KO 
SC69 – Allele 1 KO 
SC90 – Allele 1 KO 
YPD 2 mM Hydrogen Peroxide 
50 µM Menadione 1 mM tBOOH 
Cell Conc. 
SC66 – Allele 2 KO 
SC5314 
SC12 – RPS1 
SC67 – Allele 2 KO 
SC68 – Allele 2 KO 
SC69 – Allele 1 KO 
SC90 – Allele 1 KO 
m 
SC92 – Allele 1 KO 
SC92 – Allele 1 KO 
m) Growth under stress 
conditions – YPD agar 
with 2mM hydrogen 
peroxide, 50 µM 
menadione, 1 mM tBOOH 
and 1 µg/ml antimycin A 
at 24 hours. YPD + 64 
µg/ml fluconazole agar 
plates at 48 hours   YPD 
agar alone as a control at 
24 hours. Cell 
concentrations range in 
tenfold dilutions from 1 x 
107 to 1 x 103 cells/ml. 
 
64 µg/ml Fluconazole 
1 µg/ml Antimycin A 
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5.3.7.2 GPX1 Phenotypic Screening 
The GPX1 gene in Candida albicans is currently uncharacterised but has been 
predicted to be a putative thiol peroxidase (The Candida genome database 
(Inglis et al., 2012)). Both protein and gene expression levels have been shown 
to be up-regulated in response to hydrogen peroxide (Enjalbert et al., 2006, 
Kusch et al., 2007) and gene expression levels have been shown to be up-
regulated in response to 2-amino-nonyl-6-methyoxyl-tetralin muriate, a drug 
with antifungal activity which causes high levels of endogenous reactive oxygen 
species (Liang et al., 2011). Therefore, the growth of the heterozygous 
knockout mutants was assayed under three oxidative stress conditions, 
hydrogen peroxide, menadione and tBOOH (as described in section 2.14.4). 
Figure 5.7l shows that all strains grow in a similar manner to the wild-type strain 
SC5314, suggesting that the alleles do not solely have functions in the 
response to oxidative stress.  
 
GPX1 has also been linked to the response to antifungal drug treatments, 
specifically azoles, Gpx1 protein expression levels are increased upon over 
expression of the drug transporter genes MDR1, CDR1 and CDR2 (Hoehamer 
et al., 2009), GPX1 has been shown to be differentially expressed in 
fluconazole susceptible and resistant strains (Garaizar et al., 2006), and gene 
expression has been shown to be up-regulated by TAC1 in azole resistant 
strains, the transcription factor which activates the CDR transporter genes (Liu 
et al., 2007). Interestingly, gene expression is also increased upon treatment 
with milbemycin, an ABC drug transporter inhibitor (Silva et al., 2013). Here all 
heterozygous knockout strains responded in a similar manner to the wild-type 
strain SC5314 when grown in the antifungal drugs 5-flucytosine (Figure 5.7j). 
Growth in amphotericin B shows an increased sensitivity at 48 hours for all 
strains (Figure 5.7k), however this is not supported by growth on agar plates 
containing 1 µg/ml amphotericin B (Figure 5.7l) suggesting that this observation 
is due to inter plate variability. In response to growth in fluconazole, all three 
isolates lacking allele one have a marginally reduced optical density across all 
drug concentrations at 48 hours when compared to the wild-type strain SC5314. 
On the other hand, SC81 and SC107, the heterozygous knockouts of allele 2, 
have a similar growth in fluconazole to SC5314 (Figure 5.7i). However growth at 
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48 hours on solid media containing 64 µg/ml of fluconazole does not support 
these results, with all strains growing comparably (Figure 5.7l)   
 
The results of other general phenotypic assays showed few significant 
differences between the wild-type strain SC5314 and the knockouts of either 
allele. Growth at 30 °C (Figure 5.7a) shows that all strains have a similar time to 
maximum inflection. Although statistically, all three isolates of the allele one 
knockout have a significantly higher end-point optical density (ANOVA followed 
by Dunnett’s test, p < 0.05; Table 5.13) upon observation of the graph in Figure 
5.7a the biological significance of such a difference is not immediately apparent. 
The knockout strain of allele two, SC81, also has a significantly longer 
generation time (ANOVA followed by Dunnett’s test, p < 0.05; Table 5.13). 
However, this difference is minimal and the second isolate lacking allele two 
does not have a significantly different generation time. Growth at 37 °C (Figure 
5.7b) shows that all strains have a similar generation time. SC74, a knockout of 
allele one, and SC107, a knockout of allele two, both have statistically shorter 
times to maximum inflection (ANOVA followed by Dunnett’s test, p < 0.05; Table 
5.13), however Figure 5.7b again shows that this difference is minimal. 
However, SC81, a knockout of allele two, has a highly significant reduction in 
end-point optical density (ANOVA followed by Dunnett’s test, p < 0.05; Table 
5.13). As the other isolate of an allele two knockout, SC107, did not reproduce 
this difference in end-point optical density, a third isolate was constructed 
(SC108) and the growth curve at 37 °C was repeated. This strain showed no 
difference in end-point optical density (Figure 5.7c) and therefore it can be 
concluded that the growth differences of SC81 are likely to be due to secondary 
mutations elsewhere in the genome and not due to the loss of a copy of GPX1.  
 
The ability to adhere to buccal epithelial cells did not differ significantly from the 
wild-type strain SC5314 for any of the knockouts analysed for any of the three 
measures tested (two sample t-test, p < 0.05; Figures 5.7d - f). The strains also 
did not differ in their ability to switch to hyphae (Figure 5.7g). Marginal 
differences were observed in the virulence of heterozygous knockout mutants in 
a Galleria mellonella infection model, therefore the total number of Galleria 
injected for each strain was increased to 50. Although strain SC74 (knockout of 
allele one) and SC107 (knockout of allele two) show a statistically lower 
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percentage survival than the wild-type strain SC5314 at 2 x 107 cells/ml 
(Kaplan-Meier, d.f. = 2, p = 0.001 and p = 0.039 respectively), this difference is 
not observed across other cell concentrations or across other isolates of the 
heterozygous knockout mutants, suggesting that the alleles themselves do not 
differ in their virulence. Any differences observed could be attributed to natural 
death of the Galleria mellonella used, which is reflected in the lower survival of 
the PBS control than normal in these particular assays.  
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Table 5.13 Average generation times, times to maximum inflection and 
end-point optical densities of GPX1 heterozygous knockout mutants at 30 
°C and 37 °C (± one standard deviation) 
Growth Curve 
(from Figure 5.7) 
Strain Generation 
Time (mins) 
Time to 
Maximum 
Inflection (mins) 
End-Point Optical 
Density (OD at 650 
nm) 
a) 30 °C SC5314 120.43 ± 4.67 373.41 ± 36.52 1.33 ± 0.13 
SC12 124.22 ± 9.20 336.22 ± 42.55 1.41 ± 0.10 
Allele 1 knockouts SC74 118.67 ± 6.76 336.22 ± 53.30 1.43* ± 0.05 
SC75 127.79 ± 7.09 320.25 ± 30.67 1.42* ± 0.09 
SC76 123.23 ± 9.57 331.63 ± 38.24 1.44* ± 0.06 
Allele 2 knockouts SC81 131.75* ± 8.79 346.50 ± 83.18 1.26 ± 0.12 
SC107 123.98 ± 4.98 337.75 ± 25.59 1.39 ± 0.10 
b) 37 °C SC5314 67.82 ± 14.39 318.28 ± 26.79 1.37 ± 0.18 
SC12 66.94 ± 13.58 308.44 ± 22.57 1.46 ± 0.03 
Allele 1 knockouts SC74 66.52 ± 13.49 271.47* ± 30.72 1.42 ± 0.05 
SC75 68.56 ± 20.40 306.47 ± 105.57 1.41 ± 0.06 
SC76 66.73 ± 21.67 304.72 ± 35.08 1.40 ± 0.04 
Allele 2 knockouts SC81 78.44 ± 25.05 293.75 ± 45.03 1.06* ± 0.20 
SC107 59.97 ± 21.28 270.81* ± 21.83 1.37 ± 0.21 
c) 37 °C Repeat SC5314 85.22 ± 11.14 343.58 ± 82.73 1.28 ± 0.14 
SC12 70.83 ± 19.66 289.63 ± 32.56 1.40 ± 0.07 
Allele 1 knockouts SC74 78.17 ± 20.57 312.36 ± 41.15 1.40 ± 0.04 
SC75 78.28 ± 21.37 289.33 ± 28.76 1.38 ± 0.07 
SC76 77.03 ± 15.41 325.79 ± 28.65 1.35 ± 0.11 
Allele 2 knockouts SC81 106.35 ± 61.98 353.21 ± 101.58 1.04* ± 0.40 
SC107 77.43 ± 15.12 315.29 ± 45.99 1.42 ± 0.04 
SC108 79.98 ± 12.70 306.54 ± 37.05 1.40 ± 0.05 
 * Significantly different measurements from SC5314, identified by ANOVA 
followed by post-hoc analysis using a Dunnett’s test, at p < 0.05, are 
annotated with an asterisk.  
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Figure 5.7 Phenotypic assays of GPX1 heterozygous knockout mutants. SC5314 = wild-type strain (blue). SC12 = control strain with NAT cassette at 
RPS1 locus (red). SC74, SC75 and SC76 = knockout of “allele one” (yellow) and SC81 and SC107 = knockout of “allele two” (green).  
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d) Percentage of BECs adhered to C. albicans cells. e) Number of C. albicans cells per BEC. f) Number of C. albicans cells per BECs (with cells 
adhered). Error bars = ± one standard deviation.  
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i) Growth in response to fluconazole. Concentrations range from 0 – 1024 µg/ml. Blue = OD 
at 595 nm at 24 hours. Red = OD at 595 nm at 48 hours. Error bars = ± one standard 
deviation.  
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j) Growth in response to 5-flucytosine. Concentrations range from 0 – 1024 µg/ml. Blue = 
OD at 595 nm at 24 hours. Red = OD at 595 nm at 48 hours. Error bars = ± one standard 
deviation.  
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k) Growth in response to amphotericin b. Concentrations range from 0 – 1024 µg/ml. Blue = 
OD at 595 nm at 24 hours. Red = OD at 595 nm at 48 hours. Error bars = ± one standard 
deviation.  
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Cell Conc. 
SC74 – Allele 1 KO 
SC5314 
SC12 – RPS1 
SC75 – Allele 1 KO 
SC76 – Allele 1 KO 
SC81 – Allele 2 KO 
SC107 – Allele 2 KO 
YPD 2 mM Hydrogen Peroxide 
50 µM Menadione 1 mM tBOOH 
Cell Conc. 
SC74 – Allele 1 KO 
SC5314 
SC12 – RPS1 
SC75 – Allele 1 KO 
SC76 – Allele 1 KO 
SC81 – Allele 2 KO 
SC107 – Allele 2 KO 
l 
64 µg/ml Fluconazole 
1 µg/ml Amphotericin B 
l) Growth under stress 
conditions – YPD agar 
with 2mM hydrogen 
peroxide, 50 µM 
menadione, 1 mM 
tBOOH and 1 µg/ml 
amphotericin B at 24 
hours. YPD agar with 
64 µg/ml fluconazole 
at 48 hours. YPD agar 
alone as a control. 
Cell concentrations 
range in tenfold 
dilutions from 1 x 107 
to 1 x 103 cells/ml. 
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5.3.7.3 Phenotypic Screening Summary 
Table 5.14 summarises the results for all of the phenotypic screening carried 
out in this chapter.  
 
Table 5.14 Summary of phenotypic screening. Strains with significant 
results are highlighted with arrows indicating the direction of the results.  
GENE ADH2 GPX1 
ALLELE KO 1 2 1 2 
Growth at 30 °C 
Generation Time 
Endpoint Density 
 
 
Time to Maximum Inflection 
 
 
 
 
  
 
↑SC74 
↑SC75 
↑SC76 
 
 
↑SC81 
 
Growth at 37 °C 
Generation Time 
Endpoint Density 
Time to Maximum Inflection 
   
 
 
 
 
 
↓SC81 
 
Adhesion     
Hyphal Induction     
Virulence  (at 2 x 10
7
 cells/ml)   ↓SC74 ↓SC107 
Sensitivity to Fluconazole (liquid) ↑SC90 
↑SC92 
 ↑SC74 
↑SC75 
↑SC76 
 
Sensitivity to Fluconazole (solid)     
Sensitivity to 5-Flucytosine     
Sensitivity to Amphotericin B     
Growth in Ethanol as Sole Carbon Source 
(liquid) 
↓All including 
SC5314 & SC12 
  
Growth in Ethanol as Sole Carbon Source 
(solid) 
    
Growth on Antimycin A     
Growth on Oxidative Stress     
 
5.3.8 Homozygosity of RPS7A and orf19.5648 
As was the case in chapter four for RCK2, only heterozygous knockout mutants 
of one allele were constructed for the genes RPS7A and orf19.5648, despite a 
total of eight strains being produced for RPS7A and 14 strains produced for 
orf19.5648. The probability that either allele is knocked out is equal, and is 
therefore 0.5. Therefore the probabilities that such a high number of a single 
knockout strain is made is significantly unlikely, as follows for RPS7A and 
orf19.5648: 
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RPS7A - 0.5
8 
= 3.9063 x 10
-3
 
orf19.5648 - 0.5
14 
= 6.1035 x 10
-5
 
 
This observation suggests that these genes are either homozygous or the allele 
that cannot be knocked out is essential. To confirm the heterozygosity of these 
genes conventional cloning techniques were used, as was the case for RCK2. 
This identifies if any SNPs are just a consequence of errors in the reference 
genome. The methodology used is described in section 2.8. To summarise, the 
gene sequences for both genes were amplified using colony PCR from the wild-
type strain SC5314 with the assumption that both alleles would amplify with 
equal efficiency. These PCR fragments were ligated into a pGEM-T easy vector 
and transformed into E. coli cells. Only the sequence from one allele is ligated 
and transformed per single E. coli cell. Positive transformants were selected 
based on disruption of the LacZ operon and antibiotic resistance. Allele 
sequences were then amplified via PCR and sent for conventional Sanger 
sequencing, with a probability of 0.5 that the sequence is allele one and 0.5 that 
the sequence is allele two. In both cases, all seven positive transformations 
came back matching the same sequence; allele two for RPS7A and allele one 
for orf19.5648. Based on the probability of 0.5 that the sequence is either allele, 
the probability that all seven strains contained the same allele equates to: 
0.5
7 
= 7.8125 x 10-3 
 
With such a small probability of this occurring by chance, and all of the 
heterozygous knockout strains lacking the same allele, it is sensible to assume 
that both RPS7A and orf19.5648 are in fact homozygous genes with an 
identical sequence for both alleles. RPS7A alleles match the sequence of allele 
two (Appendix I Figure V) and the majority of orf19.5648 polymorphisms match 
the sequence of allele one (Appendix I Figure VI). Therefore, any differences in 
allele expression levels observed for these genes are due to reads aligning to 
erroneous SNPs in the reference genome producing false positive levels of AEI. 
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5.4 Discussion 
This chapter has aimed to develop a new computational pipeline to identify AEI 
in Candida albicans using a diploid reference genome. From here, condition-
specific levels of AEI were investigated using RNA sequencing data obtained 
from various sources. The functional consequence of AEI were further 
investigated using the results from this analysis and phenotypic screening of 
heterozygous knockout mutants. 
 
5.4.1 Developing a Computational Pipeline to Identify AEI 
The computational pipeline developed here has been used to identify allelic 
expression imbalance using a number of RNA sequencing data-sets as follows: 
re-analysis of the RNA sequencing data from chapter three where the wild-type 
strain SC5314 was grown in rich media, growth of the wild-type strain SC5314 
under 11 different conditions as described by Bruno et al. (2010), and growth of 
SC5314 whilst being co-cultured with the oral bacterium Streptococcus gordonii. 
Variable numbers of genes were identified from analysis of each data-set with 
21 genes identified from the data from chapter three, 27 genes from analysis of 
the data from Bruno et al. (2010), and 123 genes from analysis of the three co-
culture conditions.  
 
As discussed briefly in section 5.3.2, analysis of RNA sequenced using the 
older Illumina GAII platform identified an unexpectedly small number of genes 
with AEI. It can be assumed here that the number of reads produced from this 
platform is not high enough to surpass the level of stringent statistical tests 
used. This is evident from analysis of the co-culture data-sets, where a much 
larger number of genes were identified with significant AEI. This data-set was 
sequenced using the Illumina HiSeq2500 platform, which has previously been 
shown to produce a higher number of reads than the Genome Analyser 
(Minoche et al., 2011). Evidence has been seen that supports this hypothesis, 
with greater sequencing depth leading to a greater statistical power for 
identification of differentially expressed genes (Zhang et al., 2014). For future 
use of the computational pipeline, it may be beneficial to reduce the stringency 
of the statistical testing used to reduce the number of false negative results. 
However, identifying which statistical test provides the most accurate results 
would be reliant upon an allele specific qPCR system which, as discussed in 
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chapter three, is problematic for a number of reasons already discussed 
(sections 3.4.4). Alternatively, a simulated data-set could be constructed with 
known levels of allelic expression imbalance to test for the most appropriate 
statistical measures.  
 
RPKM has previously been challenged as a poor normalisation method for RNA 
sequencing with evidence for bias against factors such as gene length and GC 
content (Bullard et al., 2010a, Zheng et al., 2011). Therefore it could be 
suggested that the statistical testing using the raw read counts and DESeq 
(Anders and Huber, 2010) may be a more appropriate method. Alternatively, a 
different normalisation technique could be applied to the data. TMM (trimmed 
mean of M) values have been shown to be a simple and effective method for 
calculating relative RNA levels which accounts for differences in total RNA 
amounts of samples (Robinson and Oshlack, 2010) which may be appropriate 
in this case as entirely unrelated RNA sequencing samples are being 
compared.  
 
Surprisingly, re-analysis of the RNA sequencing data from chapter three did not 
identify AEI in the same genes, with just 14 genes identified by both 
computational pipelines. This may also be due to the high stringency of 
statistical testing used, causing false negative results from the re-analysis of the 
data-set. Additionally this difference in the numbers of genes identified could be 
explained by differences in the computational pipeline as the original pipeline 
aligned reads to both SNPs and INDELs. It was shown here that this caused a 
bias in the results with an over representation of high expression values from 
longer alleles and therefore reads were aligned to SNP regions only.  
 
Analysis of differing growth conditions showed, surprisingly, that AEI does not 
appear to be changeable under different growth conditions with the same allele 
always showing higher allele expression for each gene. It can be hypothesised 
from this observation that expression of the favoured allele is maintained 
consistently across all conditions tested. However the fold changes in allele 
expression do differ on some occasions, indicating that the exact expression 
levels may alter dependent upon condition. This may indicate that AEI has a 
biological importance and is therefore unchanged; however if this was the case, 
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the same genes should always be identified under all conditions tested which 
was not observed. Therefore the level of noise in the RNA sequencing data may 
also be an influential factor in the results, accounting for the changing fold 
difference in expression. Due to this noise, a proportion of genes will be 
statistically likely to be identified with AEI as an artefact. The fact that the same 
gene is identified in some but not all conditions may be a consequence of bias 
skewing expression level measurements always in favour of one allele, such as 
GC content, as discussed in chapter three.  
 
Conflicting evidence to the idea that AEI is consistent is seen from the analysis 
carried out in section 5.3.5, where genes with uneven changes in allele 
expression between growth conditions were identified. Here, it suggests that 
allele expression levels are variable. Again, this could be a consequence of 
noise within the RNA sequencing, and any changes are due to natural variability 
in the sequencing process. On the other hand, there could exist two separate 
types of genes with AEI – one set where AEI remains consistent regardless of 
growth condition, and one set where AEI changes in response to the 
environment.  However some genes, such as ADH2, are present in both lists, 
reducing the likelihood of this hypothesis.  
 
The computational pipeline itself could be altered to improve the accuracy of the 
results obtained. In alleles with more than one SNP identified, a check could be 
implemented to ensure all SNPs show the same direction of allelic expression 
bias, and remove them from analysis if this is not the case. This method has 
been adopted in a study of AEI in a “super-hybrid” rice species (Zhai et al., 
2013) and was also used by Muzzey et al. (2013) in their recent identification of 
AEI in Candida albicans. Muzzey et al. (2013) also developed the methodology 
to ensure that high numbers of reads at certain positions did not skew the 
measure of AEI by determining confidence intervals using bootstrapping 
(Muzzey et al., 2013). In the follow-up investigation carried out by Muzzey et al. 
(2014) biases related to library preparation and sequencing processes were 
accounted for by comparing the coverage of allele specific regions to the 
coverage at non-specific regions, with the idea that systematic errors would 
increase the disparity between these measures (Muzzey et al., 2014). Again, 
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use of a simulated data-set with known AEI levels could be used to determine 
the impact of these changes to the pipeline.  
 
Here we have excluded alleles which differ in length as the earlier results 
showed an over representation of longer alleles with higher expression levels, 
with the assumption that this is due to the 3’ bias in library preparation (Wilhelm 
et al., 2008). Although Muzzey et al. (2013) also observed expression 
differences in alleles which differ in length in C. albicans, expression differences 
were proposed to be a consequence of nonsense-mediated decay (NMD) 
triggered by premature stop codons in the shorter allele. However the list of 
candidate genes which they investigated for NMD consisted of only 22 genes, 
of which only 73% (16/22) experienced allelic expression bias. Additionally, 
when these 16 genes are compared to the analysis here of the Bruno et al. 
(2010) YPD data-set, using the computational pipeline which includes INDELs, 
only one of these genes are identified. Therefore NMD cannot be conclusively 
proved as the causative factor of the difference in expression levels seen by 
alleles which differ in length in our re-analysis of the data from chapter three, 
where a total of 159 were found to favour the expression of the longer allele.  
 
As with the initial identification of AEI in chapter three, this methodology still 
suffers from false positive results due to errors in the reference genome. RCK2 
was identified as having significant levels of AEI from analysis of all three RNA 
sequencing data-sets despite being shown in chapter four that RCK2 is a 
homozygous gene with all SNPs being due to errors in the reference genome. 
This is also the case for RPS7A and orf19.5648, as described in section 5.3.9, 
which were identified as having significant AEI across a high number of 
conditions. For these genes, AEI is due to reads falsely aligning to SNPs in the 
reference genome which do not exist, producing false positive measurements of 
AEI. Although not practical within this study, it would be beneficial to confirm the 
heterozygosity of all genes with AEI to demonstrate the impact of errors in the 
reference genome upon this analysis. Another option to avoid these false 
positive results is to use the phased diploid reference genome of C. albicans 
which has recently been published (Muzzey et al., 2013). The investigation 
used sequencing of the wild-type strain SC5314 alongside a number of strains 
homozygous for certain genomic regions to elucidate the full phasing and 
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identify a total of 69,688 SNPs (an increase of 69% from Assembly 19). Using a 
similar computational pipeline to here, this phased genome was used as a 
reference with data from Bruno et al. (2010) to measure allele-specific 
expression levels in comparison to identification of AEI using the Assembly 19 
reference genome. The paper states that some genes were detected as false 
negative when the old Assembly 19 reference genome was used as opposed to 
the phased reference genome. Unfortunately, the phased reference genome is 
not yet available for download and therefore we are unable to elucidate the 
impact it would have upon the pipeline developed here.  
 
5.4.2 Functional Consequences of AEI 
Gene Ontology (GO) analysis of the genes identified from analysis of the 
various RNA sequencing data-sets suggests that the functions of the genes with 
AEI do not reflect the growth condition. However, when genes identified from all 
conditions were combined there was a significant over representation of genes 
involved in oxidation-reduction processes and metal binding and transport. This 
is supportive of our finding that AEI levels are consistently in favour of the same 
allele, suggesting that these genes are also involved in the same processes, 
regardless of the growth condition.  
 
To further investigate if alleles with expression imbalance differ in function, 
heterozygous knockout strains were constructed for ADH2 and GPX1 and were 
screened for phenotypic differences under a number of different conditions. 
Results of all screens indicate that the alleles themselves are not functionally 
distinct, with no assay conclusively showing clear differences between the 
knockouts and the wild-type strain SC5314. This included screening on 
oxidative stress conditions, proposed due to the over representation of 
oxidation-reduction processes in the GO analysis. Combining these results with 
those found in chapter four suggest that allelic expression imbalance is not 
linked to distinct allele functions.  
 
However, despite the over-whelming evidence suggesting AEI and allele 
function are not linked, this conclusion cannot be confirmed solely with the 
results from this analysis. Phenotypic screening may have missed the 
conditions which would identify functional differences. For example, the ADH2 
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gene has been identified to be over expressed in hypoxic growth conditions 
(Setiadi et al., 2006), an observation of particular interest as genes with AEI are 
shown to have an over representation of genes involved in oxidation-reduction 
processes. Here it was not practical to test whether the heterozygous knockout 
mutants were differentially sensitive to growth in this condition but this is 
certainly an area for further investigation. A large scale phenotypic screen could 
be used to further increase the chances of finding a condition which 
demonstrates differences in allele function as also suggested in chapter four, 
such as the screen used by Homann et al. (2009) testing a transcription factor 
knockout library on 55 conditions (Homann et al., 2009). 
 
Functional redundancy, where the phenotypic consequences of the loss of a 
gene are compensated for by other closely related genes, has already been 
observed across the ADH genes in S. cerevisiae with mutants only displaying 
phenotypes when lacking all three alcohol dehydrogenase genes (Bertram et 
al., 1996). Examples of functional redundancy have been reported in C. 
albicans genes such as the phosphatase gene PTC6 (Yu et al., 2010), the 
mannosyltransferase MNN1 gene family (Bates et al., 2013), and ALS genes 
ALS2 and ALS4 (Zhao et al., 2005). Therefore, it could be hypothesised that 
any phenotypic effects presented in our heterozygous knockout mutants are 
being compensated for either by related genes or by the remaining allele itself.    
 
A further explanation for the lack of evidence suggesting functional differences 
between the alleles could be found when looking at the protein levels. Recent 
research in C. albicans using ribosome profiling suggests that some cases of 
AEI at the transcriptional level are buffered and not present at the translational 
level (Muzzey et al., 2014). This is known as a compensatory relationship 
between transcription and translation. However, the majority of alleles with 
transcriptional allelic bias showed a reinforcing relationship at the translational 
level (Muzzey et al., 2014). Despite attempts to develop a method to monitor 
allele specific protein expression levels in chapter three, these techniques were 
shown to lack the sensitivity and precise quantification needed, and therefore 
we are unable to ascertain here that levels of AEI are present at the level of 
protein expression.  
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5.4.3 Conclusion 
To conclude, although a computational pipeline was developed to interrogate 
RNA sequencing data for evidence of allelic expression imbalance, analysis 
suggests that AEI is maintained consistently regardless of the growth conditions 
tested. The functional consequence of this AEI is yet to be elucidated, with 
further phenotypic screening of heterozygous knockout mutants shedding no 
light on the matter.   
  
Page | 316  
 
Chapter 6: Allelic Expression 
Imbalance and Candida albicans 
 
This body of work has attempted to detail the genome-wide occurrence of allelic 
expression imbalance in the pathogenic yeast Candida albicans, through the 
use of RNA sequencing and the development of a novel computational pipeline. 
The functional consequences of this phenomenon were then investigated 
through analysis of a number of RNA sequencing data-sets collected from 
Candida albicans grown under different conditions, and through targeted 
construction and phenotypic screening of heterozygous knockout strains. 
Investigations of the control mechanisms and sequence specific features driving 
the divergence in allele expression levels were also presented.  
 
6.1 Allelic Expression Imbalance and Candida albicans 
6.1.1 Identification of AEI 
Allelic expression imbalance, or AEI, is the term given to an uneven level of 
allele expression from a single gene. This can be observed either as differential 
allele expression or as monoallelic gene expression. At the onset of this 
research project, AEI was yet to be identified on a genome-wide level in 
Candida albicans despite it being a diploid organism with a publically available 
annotated reference genome.  
 
However, evidence for variability in allele expression levels has been reported 
in C. albicans on a gene-by-gene basis, suggesting that this phenomenon does 
occur under some circumstances. For example, the two alleles of the SAP2 
gene have been shown to be differentially regulated during the infection process 
due to differences in their promoter regions (Staib et al., 2002). A similar story is 
observed for the drug-resistance gene MDR1, where differences in the 
promoter regions confer differences in allele expression levels (Bruzual and 
Kumamoto, 2011).  And finally, even though the allele sequences of the chitin 
synthesis gene CHS7 are homozygous, the promoter regions have been shown 
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to differ in length directly impacting upon allele expression levels (Sanz et al., 
2007). 
 
From here, this project aimed to identify the genome-wide extent of allelic 
expression imbalance in Candida albicans. Chapter three details initial 
investigations using RNA sequencing data from the wild-type strain SC5314 
grown under optimal laboratory conditions demonstrating that 233 genes have 
significant disparities in allele expression levels. Analysis of this gene set 
suggested no common functionality or chromosomal location to genes with AEI, 
leading to the conclusion that AEI occurs in seemingly unrelated genes. The 
functional consequences of this phenomenon for individual genes were 
investigated using heterozygous knockout mutant strains and the results of 
these investigations are further discussed in section 6.2. 
 
As overall gene expression levels in Candida albicans have previously been 
shown to alter in response to the growth environment (Nantel et al., 2002, 
Enjalbert et al., 2003, Bensen et al., 2004, Enjalbert et al., 2006, Biswas et al., 
2007), in chapter five the condition specific patterns of AEI were also 
investigated. To achieve this, a novel computational pipeline was devised using 
the publically available diploid reference genome. RNA sequencing data 
published by Bruno et al. (2010) from the wild-type strain of C. albicans SC5314 
grown under various conditions was then analysed, revealing that in general, 
AEI does not appear to alter in a condition-specific manner. Table 5.4 
demonstrates this point clearly, showing that the majority of genes are identified 
in more than one growth condition, but with these conditions often being 
unrelated. For example, orf19.4212 was identified under growth in tissue culture 
media at pH 8 as well as growth in YPD under the no nitrosative stress control, 
but was not identified in tissue culture media at pH4, nor in other YPD control 
conditions. A second example shows that no genes were identified under 
growth in both oxidative stress conditions only, with all low oxidative stress 
genes also being identified under growth in YPD as a no oxidative stress control 
and other conditions. However a small number of genes do appear to have a 
condition specific response to AEI, orf19.4504 was identified in both tissue 
culture conditions only, orf19.4773 was identified under growth in nitrosative 
stress only, and orf19.6486, orf19.1763, orf19.2787, orf19.3365 and orf19.5145 
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were identified under high oxidative stress only. These few examples of genes 
do imply that there could be a very small set of condition specific responses that 
require AEI, but this needs further verification. 
 
The appearance of a number of unexpected results has opened up the novel 
computational pipeline for criticism. A distinct lack of consistency is present 
when comparing the results from similar growth conditions. Growth under YPD 
alone was used as the control for comparison to growth under stresses by 
Bruno et al. (2010) and was therefore analysed on three separate occasions. 
On each occasion, different genes were identified as having AEI, implying that 
allele expression is varying even though the growth condition is unchanged. A 
number of explanations could account for this observation. Technical variability, 
whether as small differences in experimental protocol or during library 
preparation, could result in larger observations of change in expression levels. 
This has reportedly been the case for RNA sequencing data where coverage is 
low (McIntyre et al., 2011), which is sometimes the case for the allele specific 
counts used here. Stochastic gene expression, where expression levels of 
genes in single cells are randomly distributed across a population, could also 
account for this variability. However, although stochastic expression levels have 
previously explained variability in single cell expression studies (Raj and van 
Oudenaarden, 2008), it has not been used to describe variability across entire 
cell populations. This result could also be a consequence of the computational 
pipeline. This is made evident when comparing the results from growth in YPD 
by Bruno et al. (2010), where just two genes are identified with AEI, to the re-
analysis of the RNA sequencing data from chapter 3 also from growth in YPD, 
where 21 genes with AEI are identified. The pipeline devised here appears to 
be sensitive to both read length and replicate number, with the study by Bruno 
et al. (2010) using shorter 36 bp reads and just two biological replicates 
identifying a far smaller number of genes with AEI. The results of the co-
infection study further compound this point with the identification of a much 
higher number of 123 genes from the use of longer 100 bp paired end reads 
and three biological replicates. To support these findings, an investigation into 
the most appropriate method for identification of differentially expressed genes 
has shown that increasing both replicate number and sequencing depth leads to 
an increase in statistical power and an increase in identification of differential 
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expression when using the existing software packages DESeq, Cuffdiff and 
edgeR (Zhang et al., 2014).  
 
The sensitivity to read length and replicate number is likely to be due in part to 
the high stringency of the statistical testing used by the computational pipeline. 
An increase in reads (and therefore allele counts) allows for more genes to pass 
all three statistical tests. This stringency can also explain why such a small 
number of genes with AEI are identified, as discussed in chapter 5. A number of 
statistical tests were chosen due to a lack of consistency in current 
investigations of AEI, with no apparent “best” statistical method. To overcome 
this, further validation of the computational methodology is needed. Due to the 
lack of success in developing a wet-lab method for validation of AEI, the most 
appropriate way forward could lie in the use of a simulated RNA sequencing 
data-set with known disparities in allelic expression imbalance which can be 
used to identify which statistical tests produce the most accurate results.  
 
To further explain the point of inconsistencies in results from growth in similar 
experimental conditions, the RPKM normalisation technique used here has 
been previously highlighted as unsuitable for use when comparing RNA 
sequencing results across unrelated studies, as normalising for total read 
number calculates proportions of expression. If one gene is greatly increased in 
expression in a sample compared to others, the remaining genes will also 
appear to have reduced expression in this sample (Robinson and Oshlack, 
2010). Therefore an alternative normalisation method, such as TMM as 
mentioned in section 5.4.1, may be more appropriate in this study. Additionally, 
RPKM has shown to be biased both by read length and GC content (Bullard et 
al., 2010a, Zheng et al., 2011). As the results of the analysis of structural factors 
in genes with AEI in chapter three show that both gene length and GC content 
have a significantly larger variance in genes with differentially expressed alleles, 
it is possible to suggest that any differences in expression are in fact due to the 
biases of the normalisation technique. Software which identifies differential 
expression through use of raw counts, such as DESeq (used here in chapter 5) 
and edgeR (Robinson et al., 2010) may therefore be more appropriate for use 
with calculations of AEI. A recent comparison of software for identification of 
differentially expressed genes showed that edgeR out-performs DESeq and 
Page | 320  
 
Cuffdiff, a package based around RPKM normalisation, for detecting true 
positive results but may be subjected to a high number of false positive results 
(Zhang et al., 2014).   
 
Another observation of concern is the lack of consistency between the 
computational analyses of the same data-set carried out in chapter 3 and 
chapter 5, with just 14 genes identified both times. The differences in these 
results are discussed in chapter five, and are likely to be due to both the higher 
stringency of statistical testing as well as the removal of reads aligning to 
INDELs in the latter analysis. INDELs were removed in this analysis as reads 
aligning in these regions were leading to a distinct bias for identification of 
genes with AEI from alleles that differ in length. This bias due to differing allele 
length has not previously been reported in other studies of allelic expression 
imbalance, but is something that future investigations of AEI should take into 
consideration.  
 
During the course of this investigation, evidence for genome-wide levels of 
allelic expression imbalance in Candida albicans was published by Muzzey et 
al. in 2013 and 2014. The initial investigation by Muzzey et al. (2013) focused 
around the development of a diploid reference genome with improved phasing 
information. The phased reference genome was then used for identification of 
allelic expression imbalance in combination with a similar computational 
pipeline to the one devised here. Unfortunately, as no statistical measures were 
applied to compare the expression of each allele, this study does not have a 
definitive list of genes with significant allelic expression imbalance against which 
our results can be compared. However, the methodology used by Muzzey et al. 
(2013) does indicate areas for improvement of the pipeline used here. Muzzey 
et al. (2013) included screening for the directionality of imbalance across SNPs 
of a single gene ensuring that all “SNP windows” favour expression of the same 
allele and included bootstrapping to produce a confidence interval in the fold 
change measurement to ensure that extreme counts at individual SNPs do not 
skew results. Implementing these steps into the pipeline constructed here may 
help to remove any false positive results. Muzzey et al. (2013) also highlighted 
that use of the improved phased reference genome is more sensitive for 
identification of AEI, using orf19.3556 as an example gene which is detected as 
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having AEI with the new reference but not with the old diploid reference genome 
published by Jones et al., (2004). Differences in the sensitivity could be 
accounted for by the differences in SNP numbers between the two reference 
genomes. The new phased genome increases the SNP number from 54858 to 
69688. Additionally, only 75% of the original SNPs could be corroborated by the 
new reference genome, with the statement that many locations were falsely 
identified as heterozygous in the original reference due to low coverage. This 
supports the findings found in this investigation where a number of genes 
identified with significant AEI were subsequently found to be homozygous 
through cloning and sequencing of the alleles. Use of the new phased reference 
genome alongside the pipeline constructed here will aid in improving the 
accuracy of the results obtained, as currently reads will be falsely aligned to 
SNPs that don’t exist and will be missed from SNPs that are lacking from the 
original assembly. However, this reference genome is not yet publically 
available for use.  
 
This study differs from previous investigations of allelic expression imbalance 
through the use of a diploid reference genome. Investigations in other species 
have taken the approach of using a haploid reference genome alongside variant 
calling. However, this method has been associated with a significant intrinsic 
bias, with reads tending to map to the reference allele as opposed to the 
“alternate” allele (Degner et al., 2009, Stevenson et al., 2013) and is also 
dependent upon accurate identification of SNPs. Use of a diploid reference 
genome here has aimed to overcome these issues. Similar approaches have 
been adopted by the software packages Allim (Pandey et al., 2013), Alleleseq 
(Rozowsky et al., 2011) and MMSEQ (Turro et al., 2011), however these 
methods are often designed for use with human samples or with diploid 
offspring where full parental reference genomes are available. Use of the 
approach developed here, alongside aspects of the methodology from Muzzey 
et al. (2013), could allow for unbiased and accurate identification of allelic 
expression imbalance in any species with a diploid reference genome. Although 
that number of species is currently limited to humans, C. albicans and the giant 
panda, there are clear possibilities for use with manually constructed diploid 
references inferred from variant calling. Recent work into Drosophila show that 
although improvements can be made for use of a haploid reference genome, 
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using high quality SNP calling directly from the RNA sequencing data, small 
biases towards the reference genome still occurred (Quinn et al., 2014). 
Therefore use of a diploid reference genome, or a similar approach, are likely to 
be the more reliable avenue for future investigations into allelic expression 
imbalance.   
 
As well as issues surrounding statistical testing and false negative results, 
inherent bias caused by the sequencing process itself may also produce errors 
in identification of allelic expression imbalance, as discussed in section 3.4.2. 
Errors have been observed which are dependent upon the library preparation 
method, with cDNA fragmentation leading to a higher coverage of reads at the 
3’ end of transcripts (Wilhelm et al., 2008) and RNA fragmentation methods 
causing depletion of coverage at either transcript end (Wang et al., 2009). As 
cDNA fragmentation was used both in chapter 3 and by Bruno et al. (2010), this 
source of bias is a possible explanation for the results seen in chapter 5 where 
false positive results are obtained when mapping to both SNPs and INDELs. 
Alleles which have insertions in the 3’ region are likely to have a much higher 
number of reads, causing a skew in the calculation of AEI towards that allele. 
This bias needs to be accounted for in future experiments. Removing reads 
mapping to INDELs, as has been done here, may lead to false negative results 
from genes which have only INDELs and no SNPs. Therefore, use of RNA 
fragmentation for the sequencing library preparation may be a more suitable 
option to overcome this issue.  
 
GC rich regions have been shown to be more “sequenceable” by Illumina 
technologies than regions of low GC content (Bullard et al., 2010b)  with a 5% 
difference in GC content conferring as much as a 10% difference in reported 
expression level. As AEI identification is based around differences in allele 
sequences, GC content is likely to differ, even if only slightly. This observation 
was made in chapter three, where genes with AEI were seen to have a 
significantly larger difference in GC content than equally expressed genes. 
However, when this data is reanalysed, excluding all alleles which differ in 
length, i.e. which have INDELs, the difference in GC content is reduced from 
0.80 to 0.27, a number far more comparable to the equally expressed alleles 
which have an average GC content difference of 0.24. Therefore GC content 
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bias may be less problematic with the novel computational pipeline which 
excludes INDELs. However, if a pipeline using INDEL information is developed 
in the future, GC content bias could be accounted for using a method which 
models expected expression change due to GC content and then corrects for 
this difference in AEI estimations, similar to that developed by Skelly et al. 
(2010) in a study of allele specific expression in hybrid diploid yeast.  
 
Finally, systematic errors in the base calling during sequencing have also been 
shown to cause potential errors in identification of AEI, with certain base pair 
motifs frequently sequenced incorrectly (Meacham et al., 2011). Currently, this 
is an unavoidable issue in computational analysis of AEI, but is something that 
all researchers in this field should be aware of.  
 
6.1.2 Future Advancements in Identification of AEI 
Advances in analysis and quantification of RNA are leading the way for possible 
future methods for improved identification of AEI. The most recent advance in 
sequencing technology is the advent of single-cell RNA sequencing methods, 
such as Smart-seq. Studies have suggested that although a gene may appear 
to have allelic expression imbalance at the level of the cell population, individual 
cells may deviate from this expression pattern (Levesque et al., 2013), making 
single cell technologies important for identifying this difference. The Smart-seq 
system has been used to identify monoallelic gene expression in 
preimplantation embryos of mice, showing that allele selection appears to be 
random and dynamic (Deng et al., 2014). However, using this methodology to 
identify levels of AEI is still problematic, as around 60% of all polyadenylated 
RNA species are lost in the preparation protocol.   
 
Recently, a study has showed that modification of RNA FISH (fluorescence in 
situ hybridisation) can be used to detect single nucleotide differences and 
quantify allele expression at a single cell level. This paper developed 
oligonucleotide probes to enable them to be specific. In the past longer probes 
have been needed to have enough binding energy, but this then leads to 
mismatched binding over SNPs. In this study, a “toehold probe” was used. This 
has a 28 bp stretch of single stranded DNA including the SNP of interest, 
followed by a stretch of double stranded “mask” oligonucleotides. The single 
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stranded region is short enough to confer specificity, and then the mask region 
binds and increases the binding energy (Levesque et al., 2013).  
 
Improvements have also been seen in the statistical analysis of AEI using RNA 
sequencing data. A hierarchical Bayesian model has been shown, using a yeast 
hybrid model, to be more powerful and to produce results with more relevant 
biological inference than a standard binomial test assuming equal allele 
expression. (Skelly et al., 2011). These results were demonstrated across two 
different sequencing platforms with high levels of reproducibility and specified 
false discovery rates. A distinct advantage of this method is that it accounts for 
variability in levels of AEI across SNPs within a single gene, which may be seen 
in cases of allele-specific splicing or alternative transcription start sites. A 
fundamental question raised in this study is that with enough sequencing depth 
and precision it may be possible to show that every single gene has some level 
of AEI, therefore what level of AEI is biologically significant?  
 
As all methods investigating allelic expression imbalance are reliant upon 
known locations of SNPs, the quality of the reference genome used is the 
biggest challenge faced by researchers in this field. Improved variant calling to 
increase the reliability of SNPs is essential. Quinn et al. (2014) show that this is 
possible through use of SNP calling directly from the RNA sequencing data, but 
further improvements in this area are still needed. Better phasing of sequence 
information, as demonstrated by Muzzey et al. (2013), will also aid in improving 
the reliability of results particularly where it can be shown that all SNPs of a 
gene favour the expression of the same allele. With the recent advancements in 
long read sequencing from single molecule technologies, such as the PacBio 
and MinION, better phasing information for reference genomes should be 
achievable in the near future.  
 
6.2 The Functional Impact of AEI and the Lack Thereof  
6.2.1 Is AEI linked to Differences in Allele Function 
A key hypothesis which was investigated in this piece of work was the theory 
that allelic expression imbalance is linked to differences in allele function. This 
hypothesis is supported by previous studies in genes in C. albicans, such as 
MDR1 (Bruzual and Kumamoto, 2011) and CHS7 (Sanz et al., 2007), that link 
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divergent allele expression to function as discussed in section 1.8. 
Investigations of percentage protein identity in chapter three also further support 
this idea, showing that genes with AEI had a significantly lower percentage 
protein identity (Figure 3.3), suggesting significant divergence in sequence. 
However, genes with significant sequence differences are also more 
susceptible to the sequencing biases discussed in section 6.1.1. Therefore the 
differences in protein identity observed could actually be a consequence of an 
over-representation of genes with sequence differences during the identification 
of allelic expression imbalance.  
 
Identification of over-represented or under-represented Gene Ontology terms in 
the gene sets generally suggests that there is no common functionality between 
genes with AEI. Interestingly, GO analysis of the significant genes identified 
from different RNA data-sets identified different significant functions and 
processes. In chapter three, no functions, processes or components were found 
to be over represented. However, re-analysis of the RNA data-set in chapter 
five revealed an over representation of genes involved in oxidation-reduction 
processes and activities, iron transport, and locations on the cell surface and 
plasma membrane (Table 5.6). Table 5.8 shows that differences in growth 
condition do not impact upon Gene Ontology patterns, with genes involved in 
metal ion binding and transport processes, oxidation and reduction processes 
and plasma membrane localisation identified across a number of conditions. 
Conversely, analysis of the genes identified in the co-culture RNA data-set 
show over-representation of functions including protein kinase, transferase and 
transaminase activities (Table 5.9). Overall this suggests that genes with AEI 
are not involved in a single biological process and functional consequences of 
differences in allele expression need to be investigated on a gene-by-gene 
basis. The lack of consistency between results from different data-sets again 
highlights the issues in the methodology as discussed in section 6.1.1.  
 
The functional consequences of AEI in individual genes were therefore 
investigated through use of phenotypic screening of heterozygous knockout 
mutants. Genes were selected from both computational analyses performed 
(chapter three and chapter five). Although minor differences were seen for a 
number of assays in certain strains of some genes (summarised in Tables 4.8 
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and 5.13), taken together these results strongly suggest that allelic expression 
imbalance is not linked to functional differences in the alleles. Yet functional 
differences of alleles have previously been linked to allele expression in 
Candida albicans for a number of genes. The chitin synthesis gene CHS7 has 
homozygous alleles with polymorphisms in the promoter regions. A 
heterozygous knockout strain containing just the allele with the shorter promoter 
had similar characteristics to the wild-type whereas a knockout strain with only 
the allele with the long promoter suffered from reduced chitin synthesis and 
moderate morphological differences during hyphal growth (Sanz et al., 2007). A 
similar story is seen with the efflux transporter gene MDR1, where 
polymorphisms in upstream regions are linked to differences in allele 
expression. This has important clinical ramifications, since homozygosity of the 
allele with higher expression is linked to levels of antifungal resistance in 
fluconazole resistant strains (Bruzual and Kumamoto, 2011). 
 
Although a wide range of both general and gene specific phenotypic assays 
were used here, it is possible that the conditions which indicate functional 
differences between alleles have been missed. For practical reasons, a number 
of gene specific assays were not carried out here which may have revealed 
disparities in allele function. For example, the VPS1 gene has been shown to be 
involved in sorting of the vacuolar protein carboxypeptidase Y in 
Saccharomyces cerevisiae (Peters et al., 2004, Bernardo et al., 2008). A lack of 
availability of an antibody against the C. albicans carboxypeptidase Y protein 
means that the assay indicating defective sorting cannot be used with the 
heterozygous knockout mutants constructed here. Use of high throughput 
technologies, such as robotics which plate arrays of yeast strains, could also be 
used to intensively screen the heterozygous knockout strains on a large number 
of in vitro conditions over a short period in time, such as was used for the 
screening of the transcription factor library by Homann et al. (2009). A further 
avenue for investigation is use of in vivo assays such as growth in the presence 
of macrophages or neutrophils, or virulence assays using a murine model. 
However, regardless of the number of assays used, a lack of evidence 
supporting differences in allele function does not rule out the possibility entirely.   
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With a lack of a validation technique for allelic expression imbalance, such as 
allele-specific qPCR, or an unlimited amount of RNA sequencing data, it is 
currently not possible to determine to what extent allele expression levels are 
changing within the heterozygous knockout mutants. It is possible that when 
one allele is removed, the other alters expression to compensate for the loss or 
other genes that show functional redundancy compensate. Functional 
redundancy of genes has been seen in homozygous knockout strains such as 
for the adhesion genes ALS2 and ALS4, where removal of ALS2 showed 
increased expression of ALS4 and vice versa through RT-PCR (Zhao et al., 
2005). Therefore it can be suggested that a compensatory increase in 
expression could also occur for alleles. If this is the case for the heterozygous 
knockout strains, this could be an explanation for the lack of evidence for 
functional divergence of alleles.  
 
The results of large scale screening of heterozygous knockout mutants suggest 
that the product of a single allele can be functionally important, and removal of 
an allele is not always compensated for. Screening on 35 different inhibitory 
compounds by Xu et al. (2007) demonstrated that haploinsufficiency readily 
occurs and the lack of an allele can lead to increased sensitivity to a number of 
chemicals. However, it cannot be demonstrated from studies such as this 
whether the alleles are functionally distinct or if phenotypes of heterozygous 
knockouts are due to gene dosage effects. Surprisingly, when comparing the 
genes recorded as having heterozygous phenotypes on the Candida genome 
database (www.candidagenome.org) to the genes identified with AEI in chapter 
three, 31 were identified on both lists (Table 4.1), but a further 932 genes with 
heterozygous phenotypes did not have AEI. 202 genes with AEI were also not 
identified as having haploinsufficient phenotypes. The study by Hickman et al. 
(2013) presenting haploid strains of C. albicans also highlights the functional 
significance of single alleles. Haploid strains and homozygous diploids were 
observed to have reduced fitness suggesting that the presence of both alleles is 
important.  
 
Although it cannot be concluded with certainty, the results of the study 
presented are surprisingly indicative of little linkage between allele function and 
expression level in C. albicans. This is also reflected in previous studies of AEI 
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in other species, which have readily identified the genome-wide extent of allele 
expression imbalance but have not made any inferences regarding the 
functional consequences. Imprinting, however, is an important exception to this 
with the functional impact of single allele expression, and often the loss of 
imprinting, commonly reported upon in higher eukaryotic species. For example 
loss of imprinting at the H19/Igf2 locus resulting in biallelic expression has been 
seen in many cancer types (Feinberg, 1993), and a complete switch in 
monoallelic expression at this locus has been observed in oral squamous cell 
carcinoma (OSCC) (Tuch et al., 2010a). In this investigation, a number of genes 
were identified as having monoallelic expression from the analysis of all data-
sets. Two of these genes, RPS7A and orf19.5648, were shown to be 
homozygous in section 5.3.8, but heterozygous knockout mutants of one 
monoallelic gene, SMI1, were successfully constructed in chapter three showing 
that not all monoallelic genes are a consequence of errors in the reference 
genome. For future experiments, it may be worthwhile to make these 
monoallelic genes the focus of functional investigations in Candida albicans to 
identify processes similar to imprinting.  
 
Lack of evidence for functional differences between alleles with expression 
imbalance could also be due to a lack of expression differences at the protein 
level. An experiment using single molecule fluorescence microscopy and 
fluorescence in situ hybridisation found that protein and mRNA levels did not 
significantly correlate for 137 genes in E. coli (Taniguchi et al., 2010),  and 
importantly ribosome profiling in C. albicans has also demonstrated that levels 
of AEI are not always present at the translational level (Muzzey et al., 2014). 
Although attempts were made to validate the allele specific protein expression 
levels in chapter three, through the use of western blotting, the techniques were 
insufficiently quantitative to give a clear measure of imbalance. In future, 
developing a quantitative technique to measure absolute allele specific protein 
abundance would be advantageous to this work. A possible system is QconCAT 
technology, which uses internal standards formed from concatamers of tryptic 
peptides as controls during mass spectrometry analysis (Pratt et al., 2006). 
However, this method is yet to be used to quantify protein products of individual 
alleles.  
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6.2.1 Why Did AEI Arise? 
If allelic expression imbalance is not due to functional divergence between 
alleles, then why might it occur? One possible explanation relates to gene 
dosage effects. Tuch et al. (2010a) demonstrated in OSCC tissue that 
increasing allele copy numbers leads to an increase in allelic expression 
imbalance. It is possible to hypothesize that genes with AEI, especially 
monoallelic genes, may have finely tuned expression levels to prevent 
detrimental amounts of protein being present in the cell. Therefore, construction 
and phenotypic screening of over-expression strains in C. albicans may reveal a 
link between gene dosage effects and allelic expression imbalance. Attempts 
were begun in this area, with the aim to replace the upstream region of the 
monoallelic gene RPS7A (see section 5.3.6) with the upstream region of the 
highly expressed ENO1 gene, however RPS7A was subsequently shown to in 
fact be a homozygous gene with polymorphisms being due to errors in the 
reference genome (see section 5.3.8).  A further idea linked to gene dosage is 
that gene gain is a form of quantitative neofunctionalisation; where gain in gene 
dosage has no qualitative new function, but presence of an extra copy confers a 
fitness advantage (Scannell et al., 2007). However if this was the case, 
phenotypic defects should have been observed in the heterozygous knockout 
strains due to a reduction in expression of one allele.  
 
It is also possible that AEI in Candida albicans has no functional consequence 
and has arisen, as of yet, through unknown mechanisms. One possible 
mechanism is that during situations where selective pressures are reduced, 
loss-of-function mutations can occur and accumulate in the population via 
genetic drift. This is known as the “local neutrality hypothesis”. A heterozygous 
diploid individual therefore masks these loss-of-function alleles by retaining the 
functional copy (Zörgö et al., 2012). However, functional differences between 
heterozygous knockout mutants would still be expected in this case. Then 
again, if areas of aneuploidy have arisen in the knockout mutants, extra allele 
copies could also be masking any phenotypes. Acquisition of genome changes 
have been observed in laboratory strains that have undergone molecular 
manipulations (Abbey et al., 2011), and therefore using an assay such a 
comparative genome hybridisation to verify the copy number of chromosomes 
in the heterozygous knockout strains would aid in ruling out this scenario.  A 
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final possible explanation for AEI returns to the idea of stochastic gene 
expression, as mentioned in section 6.1.1, where allele expression levels in 
cells are variable due to natural levels of “noise”.  
 
6.2.2 The Medical Importance of AEI 
Although functional differences of alleles have not been linked to AEI here in 
Candida albicans, examples of the impact of AEI upon human health have been 
reported previously, reminding us of the importance of gaining a better 
understanding of this phenomenon. As discussed in section 1.7, allelic 
expression imbalance has been implicated as a causative factor in a number of 
human cancers. AEI in the BRCA1 gene have been shown to be increased in 
familial breast cancer patients (Chen et al., 2008), the H19/Igf2 locus has been 
associated with various types of cancer (Feinberg, 1993, Tuch et al., 2010a), 
and colorectal cancer-specific AEI has been shown to occur in B cells (Lee et 
al., 2013). Imprinting associated congenital disorders in humans such as 
Prader-Willi, Angelman, Beckwith-Wiedemann and Silver-Russell syndromes 
also occur. 
 
Exploiting AEI for use in treatment of human disease is also being considered. 
Allele-specific gene silencing by RNAi has been investigated for use against the 
hepatitis B virus. The technique claims to have the potential to suppress the 
“disease-causing” allele whilst leaving the wild-type allele expression intact 
(Teng et al., 2011). This work is still in the rudimentary stages of development, 
and in fact found that the allele-specific siRNA targeted the wrong allele through 
unknown mechanisms, but demonstrates the potential of allele specific 
treatments.  
 
6.2.3 Future Avenues to Investigate the Functional Impact of AEI 
If genes with AEI do have functional differences between the alleles, each allele 
will be under distinct evolutionary pressures. Generally, evolutionary pressures 
on proteins are quantified by measuring the ratio of substitution rates at non-
synonymous and synonymous sites (dN/dS). This is calculated using divergent 
sequences where sequences under adaptive evolution produce dN/dS > 1 
(Nielsen and Yang, 2003). However it has be found that dN/dS does not follow 
the same relationship in sequences sampled from a single population 
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(Kryazhimskiy and Plotkin, 2008) making it inappropriate, in our case, to 
measure the evolutionary pressures on separate alleles within a species. 
However, if an alternative measure of evolutionary pressure could be devised, it 
may be possible to infer if alleles are functional distinct due to the presence or 
lack of evolutionary pressures.  
 
This study focused upon a single isolate of Candida albicans, the wild-type 
strain SC5314. Clinical isolates have been shown to differ in allele sequences 
and levels of heterozygosity. For example, across 60 isolates, 11 different 
alleles were found for the elongation factor 3 gene EF3. These alleles were 
found to be present in a total of 16 different combinations (Bretagne et al., 
1997). A clinical investigation of 204 isolates of Candida albicans obtained from 
HIV patients, non HIV patients and healthy individuals using restriction fragment 
length polymorphisms revealed 66 different genotypes, with samples from 
healthy individuals showing the highest level of heterogeneity (Xu et al., 1999). 
Therefore it is possible to hypothesize that the genome-wide extent of allelic 
expression imbalance may differ between isolates. Ideally, repeating RNA 
sequencing on a large number of clinical isolates with differing characteristics, 
such as virulence or antifungal resistance, could link AEI to functionality, either 
showing that the genome-wide extent, or AEI in single genes, is commonly 
associated with certain traits. Additionally, a study such as this could also 
indicate if certain combinations of alleles are favoured at the population level or 
linked to differing phenotypes. Practically, if a validation technique for allelic 
expression imbalance, such as qPCR, can be achieved, using this on a subset 
of genes within clinical isolates may also reveal useful information.  
 
6.3 What are the Control Mechanisms of AEI in C. albicans? 
A key question that was touched upon in this study is what are the control 
mechanisms behind AEI? Chapter three details an analysis of the correlations 
between structural factors and allelic expression imbalance. Previous 
investigations have shown that factors such as GC content and length can 
impact upon gene expression levels (Coghlan and Wolfe, 2000, Goncalves et 
al., 2000, Jansen and Gerstein, 2000, Marín et al., 2003, Urrutia and Hurst, 
2003, Versteeg et al., 2003). Here, gene length was the only factor identified 
which differed significantly between alleles with differential expression. 
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However, it was found that the longer allele had significantly higher expression 
levels (Figure 3.7). This observation goes against previous findings in S. 
cerevisiae which have suggested that shorter alleles have higher expression 
levels as they are more transcriptionally efficient (Coghlan and Wolfe, 2000, 
Jansen and Gerstein, 2000, Marín et al., 2003). During the development of the 
computational pipeline in chapter five, the same observation was made with 
longer alleles showing higher expression levels. However, the majority of genes 
with AEI were seen to differ in length, and therefore this observation was 
deemed a bias in the computational pipeline likely to be due to uneven 
coverage of reads at the 3’ end of transcripts (Wilhelm et al., 2008). 
 
A further observation made in chapter three is that genes with allelic expression 
imbalance have a significantly larger variance in structural factors than genes 
with equal allele expression. As opposed to these structural factors influencing 
expression levels, these variations indicate that sequencing bias, as discussed 
in section 6.1.1., could be impacting upon the process of identifying genes with 
AEI, and that these differences in structural factors should be accounted for.  
 
Any study investigating the control of expression levels will need to consider 
variability in cis- factors, such as promoter regions, as a possible causative 
factor and their interaction with trans-acting factors such as transcription factors. 
In terms of AEI, a significant correlation has previously been observed between 
polymorphism density and levels of AEI on a genome-wide scale (Gagneur et 
al., 2009). Single gene studies in C. albicans have also shown that variability in 
promoter regions are linked to allele expression differences in the genes CHS7 
(Sanz et al., 2007) and MDR1 (Bruzual and Kumamoto, 2011). Despite this, 
analysis of the upstream regions of genes with AEI, both in chapter three and 
chapter five, showed that only 75% of genes with AEI have polymorphisms in 
this region. As not all genes with AEI have upstream polymorphisms, cis- 
factors can be ruled out as the sole driving force behind differential allele 
expression. Additionally as a similar rate of polymorphism was also observed in 
the upstream regions of genes with equal allele expression and with 
calculations based upon the average rate of heterozygosity, these findings 
suggest that polymorphisms are actually selected against in upstream regions 
of all genes. To better quantify the exact influence of cis- factors, use of the 
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knockout library of transcription factors (Homann et al., 2009), alongside RNA 
sequencing or allele-specific qPCR, could identify where cis- factors are 
influencing AEI and identify which transcription factors are linked to this 
process, possibly leading to elucidation of the signalling pathways driving these 
expression levels.   
  
As discussed in section 1.6.1. methylation has been shown to be a causative 
factor in allelic expression imbalance, especially in imprinted genes such as 
H19/Igf2 (Hou and Corces, 2011) and Mest (MacIsaac et al., 2011). In Candida 
albicans, genome-wide analysis revealed that 150 genes have methylation 
patterns (Mishra et al., 2011). Comparison of these genes to those identified 
with allelic expression imbalance in chapter three revealed that only six genes 
with AEI are methylated, suggesting that methylation is also not the driving 
force behind differences in allele expression. However, the study by Mishra et 
al. (2011) only identified methylation in terms of the haploid genome and did not 
identify allele-specific methylation patterns. Use of genome-wide bisulfite 
sequencing, such as that used by Lister et al. (2008) in Arabidopsis thaliana, 
alongside similar methodology to that used here could identify genome-wide 
allele-specific methylation patterns. Techniques such as this have previously 
been seen to be problematic as methylcytosines occur at a higher frequency 
than SNPs, leading to difficulties in assigning methylation to alleles. 
Nevertheless, with the advent of long read sequencing technologies, such as 
the PacBio and MinIon, efforts can be made to overcome these issues.     
 
Sections 1.6.2 and 3.4.3.4 also detail alternative control mechanisms that could 
be investigated in future investigations into the causative factors behind allelic 
expression imbalance including chromosomal interactions, chromatin structure, 
untranslated regions and the influence of asynchronous replication. These 
factors have previously been linked to gene expression or allelic expression 
imbalance but are yet to be investigated in allelic expression imbalance in 
Candida albicans.  
 
The focus in this study has been upon possible control mechanisms at the 
transcriptional stage, however levels of AEI may also be impacted upon by 
post-transcriptional mechanisms such as differing rates in RNA decay. As 
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discussed in section 3.4.3.4, RNA decay rates have been shown to be 
influenced by sequence motifs and structural factors such as AU rich elements 
(Vasudevan and Peltz, 2001) and gene length (Santiago et al., 1986).  
Therefore the presence of polymorphisms in alleles could leads to differences in 
poly(A)-shortening rates or RNA secondary structure, in turn leading to 
differences in decay rates. Development of existing methods which measure 
RNA decay, such as use of 1,10 phenanthroline, to enable identification of allele 
specific rates is needed to identify the contribution of post-transcriptional factors 
upon levels of AEI.  
 
6.4 Concluding Remarks 
To summarise this body of work, RNA sequencing data has been used with a 
number of computational pipelines to identify the genome-wide extent of allelic 
expression imbalance in Candida albicans. The functional consequences of AEI 
were then investigated through phenotypic screening of heterozygous knockout 
mutants. Attempts at developing a validation system to support the results from 
the RNA sequencing were made and investigations into the possible control 
mechanisms driving the differences in expression levels were touched upon.  
 
Results suggest that AEI is widespread in Candida albicans, with no clear link to 
a single biological process and no clear response to changes in growth 
conditions. However, errors due to false negative results and biases in the 
sequencing process should be considered during any interpretation of results. 
Phenotypic screening of heterozygous knockout mutants suggests that there is 
no link between allelic expression imbalance and divergent allele function in 
Candida albicans; nonetheless the possibility cannot be ruled out. Further high 
throughput phenotypic screening and the development of a validation technique 
which can quantify allele redundancy will help to confirm or reject this 
hypothesis. The control mechanisms behind allelic expression imbalance are 
still unclear, and further investigations are still needed in this area. 
 
Together, this piece of work presents a novel investigation into the functional 
consequences of allelic expression imbalance in Candida albicans. Although no 
strong conclusions can be made regarding the functional importance, advances 
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into the understanding of gene expression mechanisms in this medically 
important pathogen have been made.  
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Appendix I 
 
Table Ia. Expression data for genes with allelic expression imbalance  
Average RPKM values represent the average normalised allele expression 
levels of three replicates. The fold difference in RPKM values for allele 1 and 2 
is calculated. P values were calculated using Fisher’s Exact Test. Colours show 
relativity of values with green representing the lowest value and red 
representing the highest value. 
 
CA 
name
1
 
SC 
ortholog
2
 
Allele 1 Allele 2 
Allele 1 
Average 
RPKM 
Allele 2 
Average 
RPKM 
Fold 
Diff 
P-value 
Total 
Tags 
(Haploid) 
 
TFP1 orf19.1680 orf19.9249 0.32 397.96 1258.03 0 5280 
  
orf19.3224 orf19.10734 0.40 890.88 2206.98 0 137 
RPS7A RPS7A orf19.1700 orf19.9267 4.16 1241.96 298.33 0 14540 
VMA11 TFP3 orf19.6538 orf19.13891 547.06 7.89 69.30 0 4850 
RPL24A RPL24A orf19.3789 orf19.11269 693.76 4665.36 6.72 0 975 
  
orf19.5648 orf19.13093 740.85 25.95 28.55 0 5926 
CHT2 CTS1 orf19.3895 orf19.11376 5204.49 1403.44 3.71 0 469 
ATP1 ATP1 orf19.6854 orf19.14144 5231.12 0.69 7574.02 0 3040 
MPP1 MPP1 orf19.1915 orf19.9471 0.39 296.35 752.15 1.3E-272 915 
  
orf19.5062 orf19.12528 0.56 185.96 331.87 2.2E-168 1337 
  
orf19.5128 orf19.12593 168.34 0.65 260.05 1.5E-144 1392 
ARO8 ARO8 orf19.2098 orf19.9645 159.47 0.15 1097.28 3.8E-141 2050 
POR1 POR1 orf19.1042 orf19.8644 648.59 225.68 2.87 2.5E-132 595 
BAT21 BAT2 orf19.797 orf19.8416 389.36 85.89 4.53 4.4E-132 15265 
 
SCS2 orf19.1212 orf19.8800 145.77 0.80 182.66 1.5E-124 2684 
VID21 EAF1 orf19.3077 orf19.10589 230.53 24.90 9.26 1.1E-121 641 
 
CYC8 orf19.4959 orf19.12424 143.02 3.74 38.24 1.8E-108 5924 
IFF9 MUC1 orf19.465 orf19.8096 120.59 0.73 164.59 7.8E-103 1589 
  
orf19.1537 orf19.9111 24.24 183.54 7.57 1.21E-95 1976 
MSN5 MSN5 orf19.2665 orf19.10182 0.17 100.81 586.10 9.48E-92 3500 
ECM1 ECM1 orf19.5299 orf19.12758 252.02 62.31 4.04 1.24E-77 1971 
PDX3 PDX3 orf19.550 orf19.8185 131.19 11.04 11.89 4.84E-77 4813 
SSK2 SSK2 orf19.3775 orf19.11257 14.69 132.21 9.00 4.64E-75 1220 
FAV3 
 
orf19.1914 orf19.9470 0.12 78.90 648.51 7.16E-74 3436 
FCY21 FCY2 orf19.1357 orf19.8937 28.74 160.07 5.57 2.01E-70 3670 
 
DMA1 orf19.1185 orf19.8776 162.26 27.08 5.99 7.27E-69 317 
RCK2 RCK2 orf19.2268 orf19.9808 14.09 121.55 8.63 4.13E-68 33930 
  
orf19.233 orf19.7863 366.79 142.58 2.57 1.38E-63 182 
CAR1 CAR1 orf19.3934 orf19.11416 401.62 166.11 2.42 1.22E-62 3877 
RPS23A 
RPS23B|
RPS23A 
orf19.6253 orf19.13632 75.16 2.89 26.05 9.28E-54 135 
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NCL1 orf19.518 orf19.8149 63.26 0.54 116.29 7.81E-53 4983 
ACH1 ACH1 orf19.3171 orf19.10681 136.91 26.33 5.20 9.72E-53 147 
  
orf19.3191 orf19.10702 28.52 129.70 4.55 1.97E-49 6211 
BCY1 BCY1 orf19.2014 orf19.9565 79.65 218.15 2.74 1.16E-48 335 
 
PET127 orf19.2309 orf19.9845 7.07 77.94 11.02 1.42E-48 1697 
  
orf19.1266 orf19.8852 17.41 102.03 5.86 6.75E-47 735 
 
MED7 orf19.232 orf19.7862 81.95 8.10 10.12 4.55E-46 676 
 
MRPL11 orf19.3797 orf19.11278 116.77 268.87 2.30 1.13E-45 1264 
 
SDH4 orf19.4468 orf19.11949 162.97 333.89 2.05 5.08E-45 6937 
MSS4 MSS4 orf19.3153 orf19.10663 14.50 89.93 6.20 2.62E-43 3232 
TIF4631 TIF4631 orf19.3599 orf19.11082 226.99 87.54 2.59 2.16E-40 7226 
 
BBC1 orf19.2791 orf19.10309 93.51 17.16 5.45 3.75E-38 3179 
DAO2 
 
orf19.3365 orf19.10873 30.27 114.17 3.77 1.54E-37 78 
PGA57 HPF1 orf19.4689 orf19.12158 3.29 53.36 16.20 3.59E-37 667 
 
NUP84 orf19.1298 orf19.8878 58.84 4.48 13.13 7.68E-37 2346 
IDP2 IDP2 orf19.3733 orf19.11217 108.49 25.00 4.34 1.48E-36 1013 
 
SIP5 orf19.2458 orf19.9994 53.38 3.40 15.69 4.16E-35 20060 
 
YGR12W orf19.5574 orf19.13020 57.87 4.87 11.88 1.87E-34 1179 
RBT4 PRY1 orf19.6202 orf19.13583 3.71 50.96 13.73 2.6E-34 2261 
 
PAT1 orf19.3792 orf19.11271 278.52 130.90 2.13 4.38E-34 247 
 
YLL7C orf19.5147 orf19.12613 13.32 72.02 5.41 7.36E-32 3541 
POL5 POL5 orf19.5597 orf19.13042 6.78 55.67 8.21 2.15E-31 109 
ALS1 FLO9 orf19.5741 orf19.13163 37.95 0.95 39.81 1.75E-29 180 
VPS1 VPS1 orf19.1949 orf19.9505 147.92 55.06 2.69 1.39E-28 9898 
  
orf19.3644 orf19.11128 40.23 1.91 21.02 3.02E-28 35 
 
RPH1 orf19.2743 orf19.10257 25.29 89.67 3.55 4.52E-28 39699 
 
YLR137W orf19.1557 orf19.9130 49.63 5.03 9.88 5.69E-28 14012 
 
YPR147C orf19.4398 orf19.11876 18.86 76.49 4.06 4.34E-27 47 
  
orf19.1953 orf19.9508 30.66 94.26 3.07 3.07E-25 816 
 
WSC4 orf19.254 orf19.7886 88.64 179.98 2.03 1.55E-24 323 
  
orf19.3353 orf19.10861 65.90 147.65 2.24 1.7E-24 295 
ITR1 ITR2 orf19.3526 orf19.11009 41.62 3.99 10.43 2.88E-24 3304 
ILV6 ILV6 orf19.4650 orf19.12119 37.62 102.13 2.72 3.34E-23 265 
  
orf19.1383 orf19.8963 3.95 37.57 9.51 1.06E-22 3404 
 
ESF2 orf19.3161 orf19.10670 150.19 65.50 2.29 2.62E-22 18391 
 
PKH3 orf19.1196 orf19.8787 1.46 28.88 19.83 4.81E-22 44 
SNF4 SNF4 orf19.5768 orf19.13191 63.02 136.36 2.16 2.33E-21 16777 
 
PNP1 orf19.317 orf19.7949 48.67 114.63 2.35 5.04E-21 621 
  
orf19.803 orf19.8421 98.26 34.78 2.83 6.05E-21 908 
  
orf19.4770 orf19.12233 3.53 33.95 9.62 1.59E-20 1226 
 
RLM1 orf19.5626 orf19.13071 1.65 27.82 16.86 6.53E-20 70 
 
DEF1 orf19.3773 orf19.11255 31.36 85.22 2.72 8.25E-20 6433 
 
RPO31 orf19.3103 orf19.10615 23.35 0.47 49.75 1.08E-19 104 
 
SVL3 orf19.1948 orf19.9504 52.77 11.25 4.69 1.39E-19 882 
 
OSH2 orf19.5095 orf19.12561 21.46 0.04 491.34 1.79E-19 1662 
 
YAP181 orf19.4184 orf19.11660 54.33 12.50 4.35 6.33E-19 227 
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orf19.6894 orf19.14182 66.60 134.77 2.02 1.87E-18 10274 
  
orf19.1938 orf19.9493 0.26 20.77 81.23 2.72E-18 913 
  
orf19.4952 orf19.12417 31.11 3.79 8.21 7.42E-17 5075 
WSC1 SLG1 orf19.5867 orf19.13289 3.58 28.97 8.09 1.28E-16 828 
 
BFA1 orf19.6080 orf19.13499 17.85 0.13 133.51 1.61E-16 1154 
 
CYK3 orf19.6242 orf19.13620 29.33 75.27 2.57 2.25E-16 2956 
  
orf19.2742 orf19.10256 35.50 84.51 2.38 2.51E-16 3105 
TAC1 HAL9 orf19.3188 orf19.10698 9.60 41.66 4.34 2.56E-16 946 
 
NSG2 orf19.273 orf19.7905 6.70 35.30 5.27 4.52E-16 958 
TBF1 TBF1 orf19.801 orf19.8420 45.73 97.22 2.13 2.53E-15 2354 
OCA1 OCA1 orf19.1762 orf19.9331 25.31 2.31 10.94 2.94E-15 343 
  
orf19.4068 orf19.11551 20.48 59.13 2.89 3.04E-15 3979 
EMC9 NNF2 orf19.1907 orf19.9463 17.85 0.41 43.83 4.45E-15 425 
 
EDC3 orf19.6858 orf19.14148 22.65 1.71 13.24 5.57E-15 2408 
  
orf19.2381 orf19.9917 32.18 5.37 6.00 6.89E-15 728 
PWP1 PWP1 orf19.4640 orf19.12110 0.88 18.79 21.39 3.15E-14 885 
  
orf19.5624 orf19.13069 0.76 17.26 22.81 4.2E-14 7499 
TPO3 TPO2 orf19.4737 orf19.12199 6.00 30.43 5.07 1.29E-13 62 
 
MRD1 orf19.1646 orf19.9215 1.35 18.61 13.80 2.62E-13 10859 
 
MPD1 orf19.3920 orf19.11402 37.51 8.87 4.23 4.2E-13 1026 
 
BUD17 orf19.3411 orf19.10914 50.53 15.95 3.17 4.75E-13 41 
PIR1 PIR1 orf19.220 orf19.7851 25.18 62.30 2.47 5.84E-13 706 
PGA45 PLB2 orf19.2451 orf19.9987 103.68 50.33 2.06 9.56E-13 7345 
 
CYK3 orf19.6240 orf19.13620 34.67 75.27 2.17 1.45E-12 1929 
UGA1 UGA1 orf19.802 orf19.8421 9.07 34.78 3.83 1.86E-12 72 
 
PMU1 orf19.5103 orf19.12569 3.53 23.37 6.62 2.46E-12 173 
 
NBA1 orf19.4349 orf19.11826 66.45 26.28 2.53 2.58E-12 386 
 
MET7 orf19.4516 orf19.11991 21.02 2.48 8.49 3.38E-12 1953 
 
MUC1 orf19.2051 orf19.9599 15.84 46.48 2.93 3.55E-12 1908 
 
RKR1 orf19.1219 orf19.8806 0.45 13.52 30.20 5.34E-12 51450 
APE3 APE3 orf19.3591 orf19.11073 37.45 9.99 3.75 9.12E-12 221 
 
PSD2 orf19.3954 orf19.11436 31.06 6.97 4.46 1.24E-11 947 
ARP4 ARP4 orf19.5623 orf19.13069 1.60 17.26 10.78 2.09E-11 859 
ECM25 ECM25 orf19.4958 orf19.12423 16.87 1.46 11.59 2.73E-11 2372 
 
HOS4 orf19.4728 orf19.12191 15.51 43.90 2.83 3.11E-11 3006 
 
NAF1 orf19.494 orf19.8124 25.22 58.26 2.31 4.5E-11 530 
PUS4 PUS4 orf19.1954 orf19.9509 82.70 38.92 2.12 5.5E-11 1004 
  
orf19.3372 orf19.10880 15.97 43.77 2.74 9.07E-11 3178 
 
YOR246C orf19.3352 orf19.10860 5.19 24.36 4.70 1.75E-10 1588 
 
YNL168C orf19.2184 orf19.9730 20.60 50.13 2.43 2.2E-10 1498 
 
COX1 orf19.3167 orf19.10676 7.26 28.02 3.86 2.66E-10 4012 
 
AST2 orf19.3706 orf19.11190 46.99 17.50 2.69 4.85E-10 10803 
HGT1 HXT11 orf19.4527 orf19.12002 36.98 11.58 3.19 6.57E-10 933 
OYE23 OYE2 orf19.3433 orf19.10937 23.90 4.97 4.81 9.35E-10 4418 
 
AGA1 orf19.6556 orf19.13909 17.79 2.21 8.05 1.01E-09 394 
 
MOT3 orf19.2724 orf19.10239 75.94 36.92 2.06 1.19E-09 1288 
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VMA7 VMA7 orf19.806 orf19.8424 15.20 40.11 2.64 1.89E-09 1198 
RFG1 ROX1 orf19.2823 orf19.10341 21.86 49.53 2.27 2.78E-09 1393 
  
orf19.6235 orf19.13615 76.19 37.98 2.01 2.97E-09 1212 
  
orf19.6351 orf19.13708 14.42 1.33 10.80 3.41E-09 6181 
  
orf19.2521 orf19.10057 0.93 12.48 13.45 6.76E-09 389 
  
orf19.1736 orf19.9304 29.98 9.05 3.31 8.43E-09 3666 
 
AVO1 orf19.5221 orf19.12688 2.44 15.72 6.43 9.02E-09 4225 
 
HOT13 orf19.6555 orf19.13908 1.68 13.26 7.88 3.01E-08 286 
ATS1 ATS1 orf19.6399 orf19.13757 19.25 43.23 2.25 3.16E-08 771 
  
orf19.3448 orf19.10952 25.33 7.04 3.60 3.39E-08 4064 
 
YIL18W orf19.246 orf19.7876 5.45 20.05 3.68 1.15E-07 195 
  
orf19.5843 orf19.13265 14.17 2.02 7.01 1.2E-07 617 
CDC6 CDC6 orf19.5242 orf19.12707 9.45 26.73 2.83 1.92E-07 8162 
 
ESBP6 orf19.4337 orf19.11813 8.25 23.57 2.86 9.97E-07 2303 
 
SWI3 orf19.4488 orf19.11964 7.06 21.39 3.03 1.1E-06 2327 
  
orf19.3524 orf19.11006 20.03 40.83 2.04 1.19E-06 1028 
 
YMR86W orf19.1246 orf19.8830 15.27 34.08 2.23 1.4E-06 523 
HIT1 HIT1 orf19.2723 orf19.10238 45.50 21.71 2.10 1.85E-06 396 
IFD6 YPL88W orf19.1048 orf19.8650 16.48 4.02 4.10 2.37E-06 30548 
 
YOR251C orf19.1356 orf19.8936 24.51 8.83 2.78 2.93E-06 517 
  
orf19.195 orf19.7825 7.77 0.44 17.61 3.18E-06 2128 
 
ERF2 orf19.4466 orf19.11946 6.36 19.27 3.03 3.37E-06 168 
MTR1 MTR1 orf19.1119 orf19.8716 19.94 5.98 3.33 3.6E-06 4803 
 
ECM18 orf19.310 orf19.7943 16.77 4.46 3.76 3.63E-06 586 
ERB1 ERB1 orf19.1047 orf19.8649 6.18 0.15 41.74 4.01E-06 487 
 
SEC59 orf19.261 orf19.7893 41.03 19.43 2.11 4.69E-06 2359 
 
IFH1 orf19.4282 orf19.11758 18.02 36.67 2.04 4.74E-06 450 
 
SPS19 orf19.3684 orf19.11168 7.38 20.72 2.81 5.27E-06 344 
SSP96 FMO1 orf19.5145 orf19.12610 5.54 17.50 3.16 6.69E-06 146 
 
RPM2 orf19.48 orf19.7710 2.80 12.19 4.36 7.26E-06 7957 
1. Candida albicans name according to the Candida genome database 
(www.candidagenome.org). 
2. Saccharomyces cerevisiae ortholog as given by the Candida genome 
database (www.candidagenome.org). 
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Table Ib. Expression data for genes with monoallelic expression 
Average RPKM values represent the average normalised allele expression 
levels of three replicates. The fold difference in RPKM values for allele 1 and 2 
is calculated. P values were calculated using Fisher’s Exact Test. Colours show 
relativity of values with green representing the lowest value and red 
representing the highest value. 
 
CA 
name
1 
SC 
ortholog
2
 
Allele 1 Allele 2 
Allele 1 
Average 
RPKM 
Allele 2 
Average 
RPKM 
P-value 
Total 
Tags 
(Haploid) 
RPL2B 
RPL2B 
|RPL2A 
orf19.4632 orf19.12102 4584.12 0.00 0 39871 
RIB3 RIB3 orf19.5228 orf19.12693 0.00 391.31 0 867 
YDJ1 YDJ1 orf19.506 orf19.8136 0.00 1368.57 0 899 
  
orf19.1151 orf19.8744 0.00 186.15 5.3E-173 2041 
  
orf19.1152 orf19.8744 0.00 186.15 5.3E-173 2946 
 
ZRC1 orf19.1536 orf19.9111 0.00 183.54 7.8E-171 1976 
 
NRD1 orf19.581 orf19.8212 172.60 0.00 9.7E-153 12924 
  
orf19.1997 orf19.9548 0.00 149.85 1.2E-139 227 
SES1 SES1 orf19.269 orf19.7901 0.00 149.50 2.5E-139 49 
  
orf19.3776 orf19.11257 0.00 132.21 2.8E-123 571 
BMT6 
 
orf19.5602 orf19.13045 134.90 0.00 1.2E-119 2806 
  
orf19.6389 orf19.13747 0.00 89.19 1.93E-83 37352 
SGD1 SGD1 orf19.4363 orf19.11841 93.72 0.00 2.97E-83 4875 
RPN4 RPN4 orf19.1069 orf19.8671 77.47 0.00 7.86E-69 1688 
 
BCP1 orf19.6346 orf19.13702 73.50 0.00 2.72E-65 935 
HSP12 HSP12 orf19.3160 orf19.10669 71.26 0.00 1.61E-63 2334 
 
YLR14W orf19.6630 orf19.13952 0.00 65.67 1.59E-61 416 
 
TES1 orf19.4122 orf19.11604 67.79 0.00 2.87E-60 1294 
  
orf19.1437 orf19.9011 67.22 0.00 5.68E-60 760 
  
orf19.1637 orf19.9205 57.19 0.00 4.55E-51 1988 
 
ALF1 orf19.2828 orf19.10346 55.11 0.00 5.55E-49 489 
 
PKR1 orf19.2378 orf19.9914 53.48 0.00 1.73E-47 918 
  
orf19.2053 orf19.9599 0.00 46.48 1.27E-43 524 
  
orf19.2731 orf19.10245 48.73 0.00 1.34E-43 311 
 
TVP38 orf19.5534 orf19.12980 45.62 0.00 5.9E-41 966 
 
PCP1 orf19.1643 orf19.9211 41.93 0.00 1.01E-37 3253 
 
NUP145 orf19.748 orf19.8368 41.03 0.00 7.67E-37 1111 
SAC3 SAC3 orf19.1555 orf19.9129 0.00 35.66 9.57E-34 192 
LTP1 LTP1 orf19.5104 orf19.12570 34.65 0.00 2.96E-31 1928 
 
GPI1 orf19.3996 orf19.11479 30.42 0.00 1.97E-27 860 
  
orf19.1230 orf19.8815 0.00 23.99 6.06E-23 2116 
 
YNL134C orf19.2124 orf19.9672 0.00 23.34 2.51E-22 13000 
  
orf19.4749 orf19.12211 24.42 0.00 3.95E-22 1051 
SMI1 SMI1 orf19.5058 orf19.12525 22.52 0.00 1.18E-20 7010 
  
orf19.2913 orf19.10430 0.00 20.99 3.63E-20 862 
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BNA2 orf19.583 orf19.8215 19.25 0.00 1.06E-17 3873 
  
orf19.1440 orf19.9014 18.93 0.00 2.09E-17 600 
 
BET1 orf19.1386 orf19.8964 17.39 0.00 6.27E-16 695 
 
ALG3 orf19.1092 orf19.8693 0.00 15.22 6.4E-15 292 
 
NIC96 orf19.2002 orf19.9553 0.00 14.71 2.65E-14 1242 
URA5 URA5 orf19.2555 orf19.10087 0.00 14.53 2.65E-14 296 
 
EXO84 orf19.135 orf19.7779 15.22 0.00 3.75E-14 1136 
 
SFL1 orf19.3969 orf19.11452 0.00 13.84 1.1E-13 190 
  
orf19.4332 orf19.11806 0.00 12.90 9.25E-13 11567 
 
BNA6 orf19.5054 orf19.12521 13.45 0.00 2.25E-12 1420 
  
orf19.2522 orf19.10057 0.00 12.48 3.83E-12 244 
SNX4 SNX4 orf19.1990 orf19.9541 13.15 0.00 4.45E-12 456 
  
orf19.2127 orf19.9674 0.00 12.07 7.79E-12 129359 
PHM7 PHM7 orf19.2170 orf19.9716 11.09 0.00 2.7E-10 10826 
CHS6 CHS6 orf19.5155 orf19.12622 10.23 0.00 1.06E-09 2008 
  
orf19.4138 orf19.11613 0.00 9.36 2.29E-09 1034 
PLD1 SPO14 orf19.1161 orf19.8753 9.45 0.00 8.29E-09 11203 
  
orf19.4469 orf19.11950 0.00 8.61 9.49E-09 578 
  
orf19.4470 orf19.11950 0.00 8.61 9.49E-09 22276 
  
orf19.3189 orf19.10699 9.10 0.00 1.65E-08 24 
PPT1 PPT1 orf19.1673 orf19.9242 0.00 8.20 1.93E-08 96 
 
MUC1 orf19.1725 orf19.9293 8.23 0.00 6.49E-08 996 
  
orf19.5150 orf19.12615 0.00 7.77 8E-08 886 
 
RSM25 orf19.4751 orf19.12213 7.68 0.00 2.56E-07 1600 
  
orf19.4880 orf19.12344 0.00 7.03 3.31E-07 265 
SSY1 SSY1 orf19.814 orf19.8434 0.00 6.54 6.74E-07 842 
SEO1 SEO1 orf19.700 orf19.8319 0.00 6.55 6.74E-07 10617 
 
HIR2 orf19.4295 orf19.11771 0.00 6.16 2.79E-06 203 
  
orf19.1694 orf19.9261 0.00 5.87 2.79E-06 6544 
 
KAP14 orf19.3556 orf19.11039 5.86 0.00 7.97E-06 4151 
AYR2 AYR1 orf19.5615 orf19.13059 5.91 0.00 7.97E-06 377 
  
orf19.479 orf19.8109 0.00 5.24 1.16E-05 3890 
DAL4 FUR4 orf19.313 orf19.7944 5.22 0.00 3.16E-05 755 
 
ASG1 orf19.1497 orf19.9073 0.00 4.35 9.74E-05 3057 
ECM21 CSR2 orf19.4887 orf19.12351 4.55 0.00 0.000125 281 
  
orf19.3079 orf19.10592 0.00 3.95 0.000198 4309 
 
ATG3 orf19.6020 orf19.13441 4.23 0.00 0.00025 99 
STR2 STR2 orf19.1033 orf19.8635 4.39 0.00 0.00025 1243 
RPN6 RPN6 orf19.1299 orf19.8879 0.00 3.55 0.000404 114 
SUL2 SUL1 orf19.2738 orf19.10252 0.00 3.24 0.000821 1927 
IFM1 IFM1 orf19.5167 orf19.12634 3.29 0.00 0.001979 2993 
IFC1 OPT2 orf19.3746 orf19.11231 0.00 2.69 0.003401 3203 
 
BIR1 orf19.643 orf19.8257 0.00 2.86 0.003401 4452 
 
ECM18 orf19.3607 orf19.11090 0.00 2.19 0.00692 2260 
GDH2 GDH2 orf19.2192 orf19.9738 0.00 1.62 0.028657 5470 
MDN1 MDN1 orf19.4697 orf19.12167 1.07 0.00 0.25022 10695 
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1. Candida albicans name according to the Candida genome database 
(www.candidagenome.org). 
2. Saccharomyces cerevisiae ortholog as given by the Candida genome 
database (www.candidagenome.org). 
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Table II. Expression data for genes with equally expressed alleles  
210 genes with fold difference in allele expression closest to 1.00. Average 
RPKM values represent the average normalised allele expression levels of 
three replicates. The fold difference in RPKM values for allele 1 and 2 is 
calculated. P values were calculated using Fisher’s Exact Test. Colours show 
relativity of values with green representing the lowest value and red 
representing the highest value. 
 
CA 
name
1
 
SC 
ortholog
2
 
Allele 1 Allele 2 
Allele 1 
Average 
RPKM 
Allele 2 
Average 
RPKM 
Fold 
Diff 
P-value 
Total 
Tags 
(Haploid) 
GLN1 GLN1 orf19.646 orf19.8260 550.68 581.50 1.06 0.01 36819 
 
YKR16W orf19.4396 orf19.11874 192.08 207.26 1.08 0.06 21919 
EFT2 
EFT1| 
EFT2 
orf19.5788 orf19.13210 1555.37 1446.37 1.08 0.07 426666 
SMD3 SMD3 orf19.4146 orf19.11622 240.43 251.47 1.05 0.13 1068 
 
MRPS28 orf19.2520 orf19.10056 239.63 249.63 1.04 0.15 8380 
TRP4 TRP4 orf19.3099 orf19.10611 172.25 182.00 1.06 0.15 6815 
 
YKR7W orf19.4246 orf19.11721 223.60 233.28 1.04 0.16 7962 
 
YKL27W orf19.2115 orf19.9663 245.95 255.86 1.04 0.16 11984 
 
TOM6 orf19.1650 orf19.9219 922.65 923.36 1.00 0.19 3683 
  
orf19.5547 orf19.12993 767.38 768.02 1.00 0.23 4671 
ADO1 ADO1 orf19.5591 orf19.13037 119.30 126.09 1.06 0.24 7578 
 
YER152C orf19.1180 orf19.8771 128.14 133.29 1.04 0.30 2800 
 
ADH7 orf19.5517 orf19.12963 72.32 77.21 1.07 0.30 3183 
SNF1 SNF1 orf19.1936 orf19.9491 47.72 51.22 1.07 0.35 6870 
  
orf19.1872 orf19.9428 1247.29 1230.02 1.01 0.38 19524 
  
orf19.1873 orf19.9429 766.30 721.79 1.06 0.39 5473 
NAM2 NAM2 orf19.5705 orf19.13128 48.32 51.66 1.07 0.39 2766 
 
PEX7 orf19.89 orf19.7735 49.89 53.49 1.07 0.39 1485 
SEC24 SEC24 orf19.4732 orf19.12194 100.53 104.32 1.04 0.40 22513 
CTA8 HSF1 orf19.4775 orf19.12238 59.21 62.55 1.06 0.40 3864 
HAS1 HAS1 orf19.3962 orf19.11444 66.37 69.25 1.04 0.43 12300 
 
DCP1 orf19.423 orf19.8053 84.62 87.58 1.04 0.45 1171 
ARO1 ARO1 orf19.4704 orf19.12175 42.22 44.91 1.06 0.46 21105 
SEC2 SEC2 orf19.5526 orf19.12972 42.81 45.41 1.06 0.46 738 
SPT2 SPT2 orf19.422 orf19.8052 46.90 49.63 1.06 0.48 3438 
 
YML131W orf19.3139 orf19.10651 31.98 34.30 1.07 0.48 1214 
 
CCT4 orf19.2720 orf19.10235 106.73 108.70 1.02 0.50 10315 
 
YLH47|M
DM38 
orf19.3321 orf19.10831 60.06 62.23 1.04 0.50 7940 
 
RFC5 orf19.2029 orf19.9577 44.15 46.24 1.05 0.50 1854 
  
orf19.2022 orf19.9571 346.53 344.69 1.01 0.52 8416 
 
MTL1 orf19.520 orf19.8151 33.14 34.98 1.06 0.53 1217 
 
VTI1 orf19.337 orf19.7970 26.76 28.69 1.07 0.53 471 
 
BUD2 orf19.2934 orf19.10451 113.28 114.94 1.01 0.54 866 
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ZUO1 ZUO1 orf19.2709 orf19.10224 205.33 205.37 1.00 0.55 24121 
 
YJR1C orf19.3929 orf19.11411 45.56 47.58 1.04 0.55 1719 
 
 
orf19.3871 orf19.11352 29.53 31.40 1.06 0.56 160 
NMD3 NMD3 orf19.706 orf19.8325 101.66 102.90 1.01 0.57 10177 
 
GCS1 orf19.3683 orf19.11167 19.87 21.37 1.08 0.59 1823 
NAB3 NAB3 orf19.5530 orf19.12976 76.52 78.16 1.02 0.61 7643 
ERG11 ERG11 orf19.922 orf19.8538 54.34 55.73 1.03 0.62 5129 
 
LAS17 orf19.9 orf19.7682 32.31 33.50 1.04 0.62 753 
 
RPO21 orf19.177 orf19.7810 0.49 0.52 1.06 0.62 290 
 
RSM26 orf19.3938 orf19.11420 105.15 105.62 1.00 0.63 2992 
 
LHP1 orf19.2795 orf19.10313 393.82 387.85 1.02 0.63 5124 
DUT1 DUT1 orf19.3322 orf19.10832 322.33 304.37 1.06 0.63 5446 
 
YGR21W orf19.805 orf19.8423 16.90 18.25 1.08 0.63 3325 
CPP1 MSG5 orf19.4866 orf19.12330 26.27 27.79 1.06 0.64 1072 
SEC12 SED4 orf19.3409 orf19.10912 80.77 81.48 1.01 0.65 6604 
 
KRI1 orf19.1609 orf19.9177 38.87 40.07 1.03 0.65 3586 
PSP1 YLR177W orf19.671 orf19.8288 20.96 21.95 1.05 0.66 2087 
 
CNE1 orf19.5300 orf19.12759 13.07 13.89 1.06 0.66 1266 
 
YOR52C orf19.5813 orf19.13235 13.99 14.99 1.07 0.67 824 
MNN2 MNN2 orf19.2347 orf19.9883 63.35 63.96 1.01 0.68 3620 
 
YEL43W orf19.985 orf19.8600 23.51 24.77 1.05 0.68 2751 
  
orf19.1351 orf19.8931 52.11 52.57 1.01 0.69 686 
 
CTF4 orf19.6247 orf19.13625 24.96 26.02 1.04 0.69 2124 
 
SWD3 orf19.3457 orf19.10961 16.64 17.77 1.07 0.69 446 
  
orf19.4245 orf19.11720 40.75 41.36 1.01 0.70 720 
  
orf19.5598 orf19.13042 54.86 55.67 1.01 0.70 1372 
 
NAB3 orf19.1961 orf19.9516 96.82 96.68 1.00 0.71 2331 
  
orf19.4639 orf19.12108 29.06 29.74 1.02 0.71 719 
 
SEC16 orf19.4346 orf19.11823 30.67 31.30 1.02 0.71 8855 
 
DHR2 orf19.107 orf19.7754 59.60 55.19 1.08 0.71 2166 
PDC2 PDC2 orf19.4863 orf19.12327 21.05 21.83 1.04 0.72 1616 
 
SGN1 orf19.1389 orf19.8967 718.73 686.77 1.05 0.72 8254 
ADE13 ADE13 orf19.3870 orf19.11351 187.91 177.63 1.06 0.72 7437 
 
NPA3 orf19.6463 orf19.13821 50.44 50.75 1.01 0.73 2905 
DOT4 UBP1 orf19.3370 orf19.10877 67.34 67.82 1.01 0.73 3494 
REG1 REG1 orf19.2005 orf19.9556 56.22 56.65 1.01 0.74 6523 
 
PRE4 orf19.4230 orf19.11705 295.88 290.75 1.02 0.74 8162 
  
orf19.4860 orf19.12323 24.40 25.08 1.03 0.74 156 
 
YPR45C orf19.6271 orf19.13650 12.99 13.58 1.04 0.74 2706 
ENG1 DSE4 orf19.3066 orf19.10584 13.23 14.12 1.07 0.74 5695 
GZF3 GZF3 orf19.2842 orf19.10361 75.52 70.68 1.07 0.74 3600 
IPP1 IPP1 orf19.3590 orf19.11072 1348.28 1293.37 1.04 0.75 39645 
 
YKR43C orf19.2202 orf19.9748 1.46 1.57 1.08 0.75 22 
TOP1 TOP1 orf19.96 orf19.7742 62.47 62.44 1.00 0.76 3613 
GAD1 GAD1 orf19.1153 orf19.8745 16.18 17.08 1.06 0.76 3926 
  
orf19.4250 orf19.11725 45.17 41.76 1.08 0.76 436 
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orf19.6855 orf19.14145 30.32 30.63 1.01 0.77 2163 
 
TGL4 orf19.1504 orf19.9080 18.10 18.71 1.03 0.77 979 
 
CMK2 orf19.1754 orf19.9323 1.81 1.88 1.04 0.77 1034 
  
orf19.2547 orf19.10081 7.63 8.19 1.07 0.77 804 
RMS1 SET7 orf19.2654 orf19.10177 35.47 35.67 1.01 0.78 1257 
 
YIL11W orf19.4760 orf19.12224 18.45 19.16 1.04 0.78 663 
 
PEX25 orf19.5575 orf19.13021 8.08 8.57 1.06 0.78 515 
 
SGO1 orf19.3550 orf19.11034 36.93 34.48 1.07 0.78 1041 
INT1 BUD4 orf19.4257 orf19.11733 36.81 34.08 1.08 0.78 6035 
PIF1 PIF1 orf19.6133 orf19.13552 59.19 59.14 1.00 0.79 4636 
  
orf19.551 orf19.8186 20.15 20.28 1.01 0.79 3244 
SMC1 SMC1 orf19.262 orf19.7895 8.64 9.22 1.07 0.79 762 
 
PRM5 orf19.3535 orf19.11019 39.31 36.61 1.07 0.79 3890 
 
YGR54W orf19.2930 orf19.10447 9.18 8.47 1.08 0.79 7446 
 
POP1 orf19.2404 orf19.9941 66.03 65.71 1.00 0.80 1623 
  
orf19.5539 orf19.12985 2.48 2.55 1.03 0.80 160 
  
orf19.1130 orf19.8723 9.57 10.10 1.05 0.80 975 
 
DUG1 orf19.3915 orf19.11397 92.49 86.87 1.06 0.80 11959 
CDC3 CDC3 orf19.1055 orf19.8657 101.11 95.26 1.06 0.80 5712 
ASR1 HPF1 orf19.2344 orf19.9880 2.48 2.68 1.08 0.80 373 
 
YLR253W orf19.4144 orf19.11620 25.76 26.02 1.01 0.81 921 
SLD1 
 
orf19.260 orf19.7892 26.63 27.05 1.02 0.81 812 
 
RIB2 orf19.2788 orf19.10304 11.25 11.56 1.03 0.81 273 
  
orf19.1841 orf19.9399 2.62 2.83 1.08 0.81 43 
 
YGR15C orf19.5704 orf19.13127 28.47 28.83 1.01 0.82 1803 
  
orf19.4117 orf19.11598 3.14 3.30 1.05 0.82 251 
 
FAP1 orf19.3722 orf19.11206 54.01 50.61 1.07 0.82 6026 
  
orf19.4703 orf19.12172 15.04 15.43 1.03 0.83 659 
RIM21 RIM21 orf19.3176 orf19.10686 13.53 14.16 1.05 0.83 950 
KRR1 KRR1 orf19.661 orf19.8277 3.36 3.64 1.08 0.83 2295 
 
SQS1 orf19.2400 orf19.9936 16.98 17.38 1.02 0.84 1031 
 
RNT1 orf19.3796 orf19.11277 67.51 64.01 1.05 0.84 2540 
ERG8 ERG8 orf19.4606 orf19.12076 146.71 139.64 1.05 0.84 4750 
MUC1 YBR18W orf19.4183 orf19.11659 15.90 14.77 1.08 0.84 2922 
 
YDR333C orf19.1864 orf19.9420 17.09 15.77 1.08 0.84 3351 
 
COP1 orf19.1672 orf19.9241 41.85 39.22 1.07 0.85 7050 
 
JJJ1 orf19.2399 orf19.9935 22.61 22.53 1.00 0.86 549 
ULP2 ULP1 orf19.4353 orf19.11831 20.82 20.59 1.01 0.86 510 
RAD51 RAD51 orf19.3752 orf19.11236 50.50 50.07 1.01 0.86 3469 
 
OMS1 orf19.1300 orf19.8880 5.47 5.60 1.02 0.86 936 
RPS1 RPS1B orf19.3002 orf19.10520 4399.64 4259.88 1.03 0.86 135595 
  
orf19.1505 orf19.9081 5.48 5.78 1.05 0.86 334 
 
ELP6 orf19.4701 orf19.12171 5.50 5.78 1.05 0.86 81 
PMI1 PMI4 orf19.1390 orf19.8968 204.01 195.03 1.05 0.86 7859 
CDC2 CDC2 orf19.122 orf19.7769 5.56 5.85 1.05 0.87 2351 
PGA49 INO8 orf19.4404 orf19.11882 5.76 6.05 1.05 0.87 221 
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MET13 YMR295C orf19.2887 orf19.10405 24.88 23.47 1.06 0.87 590 
 
HOS4 orf19.3726 orf19.11210 7.44 7.52 1.01 0.88 882 
MRF1 ETR1 orf19.1149 orf19.8742 7.83 7.90 1.01 0.88 397 
 
RNH1 orf19.5614 orf19.13057 29.77 29.47 1.01 0.88 1629 
ALD5 ALD5 orf19.5806 orf19.13228 128.27 125.47 1.02 0.88 89708 
ORC1 ORC1 orf19.3000 orf19.10518 7.07 7.40 1.05 0.88 3597 
 
CDC8 orf19.1137 orf19.8730 37.28 37.15 1.00 0.89 358 
SSD1 SSD1 orf19.3959 orf19.11441 34.30 34.00 1.01 0.89 10334 
 
YMR134
W 
orf19.3804 orf19.11285 35.35 34.89 1.01 0.89 493 
PRN3 
 
orf19.2462 orf19.9999 8.99 9.17 1.02 0.89 351 
FLO8 SNF5 orf19.1093 orf19.8695 8.41 8.63 1.03 0.89 7247 
SHM1 SHM1 orf19.1342 orf19.8922 311.08 302.51 1.03 0.89 16510 
 
YIA6 orf19.1393 orf19.8971 36.91 35.14 1.05 0.89 1229 
 
SYN8 orf19.2411 orf19.9949 8.62 8.11 1.06 0.89 346 
PRC3 PRC1 orf19.2474 orf19.10011 35.00 33.02 1.06 0.89 1513 
 
FYV7 orf19.4143 orf19.11619 37.31 35.25 1.06 0.89 822 
GIN1 MRC1 orf19.658 orf19.8274 8.84 9.46 1.07 0.89 2110 
 
SNA4 orf19.3606 orf19.11089 9.97 10.15 1.02 0.90 523 
HEM1 HEM1 orf19.2601 orf19.10132 43.77 42.97 1.02 0.90 6615 
HSP14 HPS14 orf19.6387 orf19.13747 91.45 89.19 1.03 0.90 10432 
DQD1 
 
orf19.2283 orf19.9823 97.77 93.47 1.05 0.90 3210 
  
orf19.752 orf19.8372 51.02 50.03 1.02 0.91 939 
  
orf19.4195 orf19.11672 14.52 13.72 1.06 0.91 70 
ROD1 ROG3 orf19.1509 orf19.9084 19.02 18.09 1.05 0.92 2089 
TPK1 TPK2 orf19.4892 orf19.12357 17.77 16.70 1.06 0.92 897 
 
YLL23C orf19.1054 orf19.8656 19.15 18.02 1.06 0.92 853 
TPO5 TPO5 orf19.151 orf19.7792 19.11 18.97 1.01 0.93 764 
FAV2 WSC3 orf19.1120 orf19.8718 21.27 20.98 1.01 0.93 172 
 
PUF2 orf19.921 orf19.8536 25.05 24.68 1.01 0.93 1161 
  
orf19.1625 orf19.9193 575.05 553.65 1.04 0.93 4211 
CMP1 CMP2 orf19.6033 orf19.13454 20.97 19.52 1.07 0.93 2888 
  
orf19.4171 orf19.11647 29.00 28.73 1.01 0.94 1494 
 
IES2 orf19.3604 orf19.11087 29.18 28.61 1.02 0.94 945 
PUP3 PUP3 orf19.1336 orf19.8916 117.28 114.28 1.03 0.94 2970 
 
YMR74C orf19.713 orf19.8332 249.17 241.91 1.03 0.94 2087 
 
YKR7W orf19.449 orf19.8079 27.17 25.83 1.05 0.94 610 
 
RPB2 orf19.3349 orf19.10857 31.28 29.71 1.05 0.94 18386 
CLN3 CLN3 orf19.1960 orf19.9515 34.04 32.46 1.05 0.94 1377 
 
BNA3 orf19.597 orf19.8229 31.14 29.27 1.06 0.94 9570 
  
orf19.1556 orf19.9129 36.34 35.66 1.02 0.95 1701 
RBF1 DEF1 orf19.5558 orf19.13004 36.90 36.23 1.02 0.95 4381 
 
YNL193W orf19.686 orf19.8304 46.76 45.58 1.03 0.95 2045 
 
DAP1 orf19.1034 orf19.8636 46.80 44.68 1.05 0.95 463 
 
YDL119C orf19.1804 orf19.9370 60.50 58.83 1.03 0.96 1258 
 
YPL247C orf19.384 orf19.8014 60.04 57.31 1.05 0.96 3747 
 
MRPL23 orf19.3348 orf19.10856 383.83 371.61 1.03 0.97 4973 
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PHR2 GAS1 orf19.6081 orf19.13500 175.11 168.77 1.04 0.98 39120 
IRA2 IRA2 orf19.5219 orf19.12686 0.63 0.64 1.00 1.00 1591 
  
orf19.3894 orf19.11375 5.95 5.98 1.00 1.00 390 
 
OTU1 orf19.2933 orf19.10450 6.69 6.70 1.00 1.00 315 
  
orf19.332 orf19.7954 10.27 10.31 1.00 1.00 4 
  
orf19.322 orf19.7954 0.99 0.98 1.01 1.00 4 
 
VMA5 orf19.2166 orf19.9712 2.02 2.00 1.01 1.00 330 
 
WSC4 orf19.6277 orf19.13656 2.20 2.17 1.01 1.00 84 
GCS1 GSH1 orf19.5059 orf19.12526 4.53 4.57 1.01 1.00 1357 
SFL1 SFL1 orf19.454 orf19.8085 8.01 8.08 1.01 1.00 6643 
 
CST26 orf19.137 orf19.7781 8.59 8.67 1.01 1.00 283 
 
YDR286C orf19.319 orf19.7951 11.57 11.46 1.01 1.00 757 
 
DEF1 orf19.4643 orf19.12113 1.04 1.01 1.02 1.00 1549 
  
orf19.1301 orf19.8881 1.11 1.09 1.02 1.00 709 
 
JIP4 orf19.3213 orf19.10725 1.61 1.64 1.02 1.00 1180 
  
orf19.4783 orf19.12247 1.83 1.87 1.02 1.00 85 
 
SIN4 orf19.1343 orf19.8923 2.10 2.15 1.02 1.00 1521 
 
GEM1 orf19.6016 orf19.13437 8.34 8.20 1.02 1.00 594 
 
MSL1 orf19.4748 orf19.12210 10.62 10.38 1.02 1.00 50 
  
orf19.247 orf19.7878 15.07 14.77 1.02 1.00 272 
 
LIN1 orf19.2368 orf19.9904 2.64 2.55 1.03 1.00 427 
 
SEC23 orf19.1638 orf19.9206 5.66 5.50 1.03 1.00 481 
ARP8 ARP8 orf19.3359 orf19.10867 8.15 7.88 1.03 1.00 2000 
 
CSR1 orf19.5711 orf19.13134 10.53 10.23 1.03 1.00 2009 
 
ENT2 orf19.6309 orf19.13686 13.23 12.83 1.03 1.00 2282 
 
CUS2 orf19.5767 orf19.13190 14.03 13.58 1.03 1.00 343 
HEM14 HEM14 orf19.4747 orf19.12209 17.79 17.35 1.03 1.00 511 
PEX3 PEX3 orf19.4426 orf19.11904 22.41 21.78 1.03 1.00 849 
 
RLF2 orf19.2739 orf19.10253 23.85 23.07 1.03 1.00 983 
TCO89 CBK1 orf19.761 orf19.8381 24.61 23.96 1.03 1.00 2203 
  
orf19.1384 orf19.8963 38.79 37.57 1.03 1.00 1033 
 
FSH3 orf19.3921 orf19.11403 42.59 41.47 1.03 1.00 3612 
BZZ1 BZZ1 orf19.1699 orf19.9266 51.41 49.80 1.03 1.00 2090 
NOT3 NOT3 orf19.2012 orf19.9563 56.33 54.43 1.03 1.00 4269 
 
YCR9C orf19.1394 orf19.8972 85.60 82.85 1.03 1.00 1042 
FAB1 FAB1 orf19.1513 orf19.9088 0.34 0.35 1.04 1.00 1458 
 
SPT1 orf19.2361 orf19.9897 8.82 8.50 1.04 1.00 498 
 
COY1 orf19.841 orf19.8461 58.28 56.25 1.04 1.00 2942 
 
PPA1 orf19.4954 orf19.12419 101.30 97.70 1.04 1.00 2435 
  
orf19.419 orf19.8049 0.09 0.10 1.05 1.00 14 
  
orf19.1863 orf19.9419 0.30 0.28 1.05 1.00 6 
ALG8 ALG8 orf19.1659 orf19.9228 0.69 0.72 1.05 1.00 380 
IST2 IST2 orf19.2792 orf19.10310 0.76 0.72 1.05 1.00 1658 
  
orf19.2822 orf19.10340 0.84 0.80 1.05 1.00 26 
 
RRF1 orf19.477 orf19.8108 1.26 1.19 1.05 1.00 794 
 
PUT3 orf19.6203 orf19.13584 2.19 2.08 1.05 1.00 2511 
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HRD1 orf19.719 orf19.8338 14.27 13.59 1.05 1.00 1579 
 
DEF1 orf19.1368 orf19.8948 2.93 2.75 1.06 1.00 196 
 
CTS2 orf19.4984 orf19.12451 4.60 4.34 1.06 1.00 435 
VPS41 VPS41 orf19.4858 orf19.12321 10.27 9.66 1.06 1.00 696 
 
RRN1 orf19.718 orf19.8337 1.34 1.26 1.07 1.00 890 
  
orf19.5151 orf19.12617 1.89 2.03 1.07 1.00 907 
TFC4 TFC4 orf19.274 orf19.7906 1.98 2.13 1.07 1.00 990 
GPI13 GPI13 orf19.832 orf19.8452 2.23 2.39 1.07 1.00 761 
  
orf19.194 orf19.7824 2.52 2.69 1.07 1.00 133 
  
orf19.4742 orf19.12204 3.67 3.42 1.07 1.00 92 
DAC1 
 
orf19.2157 orf19.9704 11.79 11.04 1.07 1.00 383 
 
HST1 orf19.4761 orf19.12225 3.31 3.06 1.08 1.00 824 
  
orf19.1496 orf19.9073 4.71 4.35 1.08 1.00 298 
 
ZRG17 orf19.3769 orf19.11253 11.06 10.26 1.08 1.00 526 
 
ENT2 orf19.1444 orf19.9019 11.74 10.88 1.08 1.00 3776 
MP65 SCW1 orf19.1779 orf19.9345 3885.73 4173.17 1.07 6.27E-17 1026 
1. Candida albicans name according to the Candida genome database 
(www.candidagenome.org). 
2. Saccharomyces cerevisiae ortholog as given by the Candida genome 
database (www.candidagenome.org). 
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Figure I Growth curves of V5 tagged strains at 30 °C 
a) CDC6 and b) VPS1 tagged strains. Allele 1 strains are shown in yellow and 
allele 2 strains are shown in green. 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
0
8
0
.5
1
6
1
2
4
1
.5
3
2
2
4
0
2
.5
4
8
3
5
6
3
.5
6
4
4
7
2
4
.5
8
0
5
8
8
5
.5
9
6
6
1
0
4
6
.5
1
1
2
7
1
2
0
7
.5
1
2
8
8
1
3
6
8
.5
O
p
ti
ca
l D
e
n
si
ty
 a
t 
6
5
0
 n
m
 
Time (mins) 
CDC6 V5 tagged strains 
Blank
SC5314
SC35 - CDC6-1-V5-6xHis-NAT1 CDC6-2
SC36 - CDC6-1-V5-6xHis-NAT1 CDC6-2
SC61 - CDC6-1 CDC6-2-V5-6xHis-NAT1
SC62 - CDC6-1 CDC6-2-V5-6xHis-NAT1
a 
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
0
8
4
1
6
8
2
5
2
3
3
6
4
2
0
5
0
4
5
8
8
6
7
2
7
5
6
8
4
0
9
2
4
1
0
0
8
1
0
9
2
1
1
7
6
1
2
6
0
1
3
4
4
1
4
2
8
O
p
ti
ca
l D
e
n
si
ty
 a
t 
6
5
0
 n
m
 
Time (mins) 
VPS1 V5 tagged strains 
Blank
SC5314
SC13 - VPS1-1-V5-6xHis-NAT1 VPS1-2
SC14 - VPS1-1-V5-6xHis-NAT1 VPS1-2
SC27 - VPS1-1 VPS1-2-V5-6xHis-NAT1
SC28 - VPS1-1 VPS1-2-V5-6xHis-NAT1
b 
Page | 350  
 
Table III Average generation times, times to maximum inflection and end-
point optical densities of V5 tagged strains at 30 °C 
(± one standard deviation) 
 
Growth Curve 
(from Figure I) 
Strain Generation 
Time (mins) 
Time to Maximum 
Inflection (mins) 
End-Point Optical 
Density (OD at 650 nm) 
 a) CDC6 SC5314 97.37 ± 6.58 326.38 ± 7.21 1.32 ± 0.12 
Allele 1 SC35 124.97 ± 53.47 311.50 ± 33.20 1.32 ± 0.05 
SC36 116.84 ± 39.05 317.63 ± 35.62 1.37 ± 0.17 
Allele 2 SC61 93.03 ± 4.70 322.00 ± 0.00 1.34 ± 0.18 
SC62 94.10 ± 5.40 326.38 ± 13.21 1.41 ± 0.16 
b) VPS1 SC5314 110.96 ± 6.11 217.88 ± 4.40 1.32 ± 0.19 
Allele 1  SC13 112.85 ± 4.16 211.75 ± 2.02 1.28 ± 0.17 
SC14 111.44 ± 3.07 227.50* ± 4.04 1.20 ± 0.02 
Allele 2 SC27 122.66* ± 13.36 203.88* ± 4.40 1.29 ± 0.15 
SC28 116.34 ± 4.66 213.50 ± 4.95 1.22 ± 0.01 
* Significantly different measurements from SC5314, identified by ANOVA 
followed by post-hoc analysis using a Dunnett’s test, at p < 0.05, are 
annotated with an asterisk.  
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Figure II Cell cycle distribution of wild-type strain SC5314 demonstrating 
cell cycle synchronisation by starvation 
Samples taken every 15 minutes and analysed as described in section 4.2.3.3.  
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Figure III Corrected sequence of VPS1 alleles 
Erroneous SNPs in the reference genome are highlighted in red, all of which 
match allele one. 
 
orf19.1949|VPS1   ATGGATGAGACATTGATTGCCACCATTAACAAATTACAAGATGCATTGGCTCCTTTAGGT 
orf19.9505|VPS1   ATGGATGAGACATTGATTGCCACCATTAACAAATTACAAGATGCATTGGCTCCTTTAGGG 
                  ***********************************************************  
 
orf19.1949|VPS1   GGAGGGTCATCCTCGCCAGTAGATTTGCCTCAAATCACTGTTGTTGGATCCCAATCCAGT 
orf19.9505|VPS1   GGAGGATCATCCTCGCCAGTAGATTTGCCTCAAATCACTGTTGTTGGATCCCAATCCAGT 
                  ***** ****************************************************** 
 
orf19.1949|VPS1   GGTAAATCGTCAGTATTGGAAAATGTTGTTGGTAGAGACTTTTTACCTAGAGGAACAGGT 
orf19.9505|VPS1   GGTAAATCGTCAGTATTGGAAAATGTTGTTGGTAGAGACTTTTTACCTAGAGGAACAGGT 
                  ************************************************************ 
 
orf19.1949|VPS1   ATTGTTACCAGAAGGCCCTTGGTTTTACAATTAATCAACAGAAGACCAAGCAAGGATTTG 
orf19.9505|VPS1   ATTGTTACCAGAAGGCCCTTGGTTTTACAATTAATCAACAGAAGACCAAGCAAGGATTTG 
                  ************************************************************ 
 
orf19.1949|VPS1   AAGAAAGCTAATGATTTGGTTGATGTTAATGCTTCAGAAAGCACAGGTGGTCAATCAGAA 
orf19.9505|VPS1   AAGAAAGCTAATGATTTGGTTGATGTTAATGCTTCAGAAAGCACAGGTGGTCAATCAGAA 
                  ************************************************************ 
 
orf19.1949|VPS1   AATAATGCTGATGAATGGGGTGAATTTTTGCATTTGCCAGGGAAAAAGTTTTTCAATTTT 
orf19.9505|VPS1   AATAATGCTGATGAATGGGGTGAATTTTTGCATTTGCCGGGGAAAAAGTTTTTCAATTTT 
                  ************************************** ********************* 
 
orf19.1949|VPS1   GAAGATATCAGAAACGAAATTGTTAGAGAAACTGATGCCAAAACAGGTAAGAATTTGGGT 
orf19.9505|VPS1   GAAGATATCAGAAACGAAATTGTTAGAGAAACTGATGCCAAAACAGGTAAGAATTTGGGT 
                  ************************************************************ 
 
orf19.1949|VPS1   ATTTCACCAGTGCCAATCAATTTGAGAATTTACTCTCCTCACGTTTTAACGTTAACTTTA 
orf19.9505|VPS1   ATTTCACCAGTGCCAATCAATTTGAGAATTTACTCTCCTCACGTTTTAACGTTAACTTTA 
                  ************************************************************ 
 
orf19.1949|VPS1   GTTGATTTACCAGGGTTGACAAAAGTCCCCGTTGGTGATCAGCCCAAAGATATTGAAAGG 
orf19.9505|VPS1   GTTGATTTACCAGGGTTGACAAAAGTCCCCGTTGGTGATCAGCCCAAAGATATTGAAAGA 
                  ***********************************************************  
 
orf19.1949|VPS1   CAAATCAAAGATATGATTATGAAATTTATTTCCAAGCCTAACGCCATTATCTTGTCTGTC 
orf19.9505|VPS1   CAAATCAAAGATATGATTATGAAATTTATTTCTAAGCCTAACGCCATTATCTTGTCTGTC 
                  ******************************** *************************** 
 
orf19.1949|VPS1   AACGCTGCTAATACGGATTTGGCTAATTCAGATGGGTTGAAATTAGCAAGAGAAGTTGAC 
orf19.9505|VPS1   AACGCTGCTAATACAGATTTGGCCAATTCAGATGGGTTGAAATTAGCAAGAGAAGTTGAC 
                  ************** ******** ************************************ 
 
orf19.1949|VPS1   CCTGAAGGTGCAAGAACAATTGGTGTTTTAACCAAAGTGGATTTAATGGATCAAGGTACT 
orf19.9505|VPS1   CCTGAAGGTGCAAGAACAATTGGTGTTTTAACCAAAGTGGATTTAATGGATCAAGGTACT 
                  ************************************************************ 
 
orf19.1949|VPS1   GATGTTATTGACATCTTGGCTGGACGTGTCATCCCATTGAGATTTGGTTATGTTCCAGTG 
orf19.9505|VPS1   GATGTTATTGACATCTTGGCTGGACGTGTCATCCCATTGAGATTTGGTTATGTTCCAGTG 
                  ************************************************************ 
 
orf19.1949|VPS1   ATAAACAGAGGTCAAAAGGATATCGAAGCTAAGAAAACTATCAGGGACGCATTGAAAGAT 
orf19.9505|VPS1   ATAAACAGAGGTCAAAAGGATATCGAAGCTAAGAAAACTATCAGGGACGCATTGAAAGAT 
                  ************************************************************ 
 
orf19.1949|VPS1   GAAAGAAACTTTTTTGAAAATCACCCATCATACAGAGCCAAAGCCCAATTCTGTGGTACG 
orf19.9505|VPS1   GAAAGAAACTTTTTTGAAAATCACCCATCATACAGAGCCAAAGCCCAATTCTGTGGTACT 
                  ***********************************************************  
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orf19.1949|VPS1   CCTTACTTGGCCAAGAAATTGAATGGTATTTTGTTGCACCACATCAAGAGTACTTTACCT 
orf19.9505|VPS1   CCTTACTTGGCCAAGAAATTGAATGGTATTTTGGTGCACCACATCAAGAGTACTTTACCT 
                  ********************************* ************************** 
 
orf19.1949|VPS1   GACATCAAGATGAGAATCGAACATTCATTGAAGAAATACCAACAGGAATTATCAATGCTT 
orf19.9505|VPS1   GACATCAAGATGAGAATTGAGCATTCATTGAAGAAGTATCACCAAGAATTATCAATGCTT 
                  ***************** ** ************** ** ** ** *************** 
 
orf19.1949|VPS1   GACCAGAAATGGCCGAATCTCCTGCATCAATTGCATTGAGTATGATCACTAATTTCTCC 
orf19.9505|VPS1   GACCTGAAATGCCTGAGCCTCCTGCATCAATTGCATTGAGTATGACCACTAATTTCTCC 
                  **** ****** * **  *************************** ************* 
 
orf19.1949|VPS1   AAAGATTACACTGGCATCTTAGATGGTGAATCCAAAGAATTGAGCTCACAAGAATTGAGT 
orf19.9505|VPS1   AAAGATTACACTGGCATCTTAGATGGTGAATCCAAAGAATTGAGCTCACAAGAATTGAGT 
                  ************************************************************ 
 
orf19.1949|VPS1   GGTGGTGCCCGTATTTCCTTTGTGTTTCATGAAATTTTCAAGAATGGGGTTAATGCCATT 
orf19.9505|VPS1   GGTGGTGCCCGTATTTCCTTTGTGTTTCATGAAATTTTCAAGAATGGGGTTAATGCCATT 
                  ************************************************************ 
 
orf19.1949|VPS1   GATCCATTTGATCAAATTAAAGATGCTGATATTAGAACTATTATGCATAATACCTCTGGG 
orf19.9505|VPS1   GATCCATTTGATCAAATTAAAGATGCTGATATTAGAACTATTATGCATAATACCTCTGGG 
                  ************************************************************ 
 
orf19.1949|VPS1   TCGGCACCCTCGTTGTTTGTCGGTACCCAAGCTTTCGAGGTGTTGGTAAGACAACAAATC 
orf19.9505|VPS1   TCGGCACCCTCGTTGTTTGTCGGTACCCAAGCTTTCGAGGTGTTGGTAAGACAACAAATC 
                  ************************************************************ 
 
orf19.1949|VPS1   AAAAGATTGGAAGAACCTTCTATCAGATGTATCAATTTAATTTTCGATGAGTTAGTCAGA 
orf19.9505|VPS1   AAAAGATTGGAAGAACCTTCTATCAGATGTATCAATTTAATTTTCGATGAGTTAGTCAGA 
                  ************************************************************ 
 
orf19.1949|VPS1   ATTTTATCACAAATTATTAGTCAACCACAATATTCAAGATACCCCGGTTTGAAAGAGCAA 
orf19.9505|VPS1   ATTTTATCACAAATTATTAGTCAACCACAATATTCAAGATACCCCGGTTTGAAAGAGCAA 
                  ************************************************************ 
 
orf19.1949|VPS1   TTGTCTCAGAATTTCATTTTATACTTGAGAGATTTGTTGATTCCAACCACTGAGTTTGTC 
orf19.9505|VPS1   TTGTCTCAGAATTTCATTTTATACTTGAGAGATTTGTTGATTCCAACCACTGAGTTTGTC 
                  ************************************************************ 
 
orf19.1949|VPS1   AATGATATAATTCAAGCTGAGGAGACATATGTTAACACTGCTCATCCAGATTTGTTGAAG 
orf19.9505|VPS1   AATGATATAATTCAAGCTGAGGAGACATATGTTAACACTGCTCATCCAGATTTGTTGAAG 
                  ************************************************************ 
 
orf19.1949|VPS1   GGGACACAAGCAATGTCTATTGTGGAAGAGAAGTTCCATCCAAAGCCACAAGTTGCTGTT 
orf19.9505|VPS1   GGGACACAAGCAATGTCTATTGTGGAAGAGAAGTTCCATCCAAAGCCACAAGTTGCTGTT 
                  ************************************************************ 
 
orf19.1949|VPS1   GATCCTAAGACTGGTAAACCATTGCCGCCAAGTCAACAACCAGCACAAGCCACATCACCT 
orf19.9505|VPS1   GATCCTAAGACTGGTAAACCATTGCCGCCAAGTCAACAACCAGCACAAGCCACATCACCT 
                  ************************************************************ 
 
orf19.1949|VPS1   AAACCAGAAGATGGGTCATCTAATGGATTCTTTGGTGGATTCTTTTCTAGCAAAAACAAA 
orf19.9505|VPS1   AAACCAGAAGATGGGTCATCTAATGGATTCTTTGGTGGATTCTTTTCTAGCAAAAACAAA 
                  ************************************************************ 
 
orf19.1949|VPS1   AAGAGATTACAACAAATGGAAGCCCCACCTCCAGTATTGAGAGCCACAGGTACTATGAGT 
orf19.9505|VPS1   AAGAGATTACAACAAATGGAAGCCCCACCTCCAGTATTGAGAGCCACAGGTACTATGAGT 
                  ************************************************************ 
 
orf19.1949|VPS1   GAAAGAGAAACTATGGAAACCGAAGTTATCAAATTATTGATTTCTTCATACTATAATATT 
orf19.9505|VPS1   GAAAGAGAAACTATGGAAACCGAAGTTATCAAATTATTGATTTCTTCATACTATAATATT 
                  ************************************************************ 
 
orf19.1949|VPS1   GTTAAGCGTACTGTTGGTGATGTTGTTCCTAAAGCTATTATGTTGAAATTGATCAACAAA 
orf19.9505|VPS1   GTTAAGCGTACTGTTGGTGATGTTGTTCCTAAAGCTATTATGTTGAAATTGATCAACAAA 
                  ************************************************************ 
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orf19.1949|VPS1   TCCAAGGATGAGATCCAAAAGACTTTATTGGAAAAGTTGTACAGCAGTCCAGACTTGGAT 
orf19.9505|VPS1   TCCAAGGATGAGATCCAAAAGACTTTATTGGAAAAGTTGTACAGCAGTCCAGACTTGGAT 
                  ************************************************************ 
 
orf19.1949|VPS1   GATTTGGTTAAGGAAAATGAGCTTACTGTTCAAAAGAGAAAGGAATGTGTTAGAATGGTT 
orf19.9505|VPS1   GATTTGGTTAAGGAAAATGAGCTTACTGTTCAAAAGAGAAAGGAATGTGTTAGAATGGTT 
                  ************************************************************ 
 
orf19.1949|VPS1   GAGGTGTTGAGAAATGCTAGTGAAATTGTTTCTAGTGTTTAG 
orf19.9505|VPS1   GAGGTGTTGAGAAATGCTAGTGAAATTGTTTCTAGTGTTTAG 
                  ******************************************  
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Figure IV Corrected sequence of RCK2 alleles  
Erroneous SNPs in the reference genome are highlighted in red, all of which 
match allele two.  
 
orf19.2268|RCK2   ATGTTTGAGAATCTCAAAGCTTTTATTCGACATGGGAAGCAAGCCAATGATATGAAAAGA 
orf19.9808|RCK2   ATGTTTGAGAATCTCAAAGCTTTTATTCGACATGGGAAGCAAGCCAATGATATGAAAAGA 
                  ************************************************************ 
 
orf19.2268|RCK2   AAGCAACAACAGCAGCCACAGCAATATCAACAACCATTTAGTACTGCTACTGCCAATGAA 
orf19.9808|RCK2   AAGCAACAACAGCAGCCACAGCAATATCAACAACCATTTAGTACTGCTACTGCCAATGAA 
                  ************************************************************ 
 
orf19.2268|RCK2   AATCCATTTCAACAAGCTTCCAACGAAACTCCAGACAGTATCAATGTTATTACCCCCAAC 
orf19.9808|RCK2   AATCCATTTCAACAAGCTTCCAACGAAACTCCAGACAGTATCAATGTTATTACCCCCAAC 
                  ************************************************************ 
 
orf19.2268|RCK2   GATATCATAAATGAATACCAACAACCAGATCAAGAACCACAACAATACTATCCCCAACAA 
orf19.9808|RCK2   GATATCATAAATGAATACCAACAACCAGATCAAGAACCACAACAATACTATCCCCAACAA 
                  ************************************************************ 
 
orf19.2268|RCK2   CAACAACAACAACAAGACCCATATCAACAGGAAACCCAATTCCAGCAACAGCAACAAGGA 
orf19.9808|RCK2   CAACAACAACAACAAGACCCATATCAACAGGAAACCCAATTCCAGCAACAGCAACAAGGA 
                  ************************************************************ 
 
orf19.2268|RCK2   GTGTATACCAACTATAATCAATCCGATGTTACCCTCAATGACAAAAACGCAGATTACAAT 
orf19.9808|RCK2   GTGTATACCAACTATAATCAATCCGATGTTACCCTCAATGACAAAAACGCAGATTACAAT 
                  ************************************************************ 
 
orf19.2268|RCK2   AGAGTAGCGCTGCAACTTGTTGAAGAAGAGAATGAACAGAGAAAAAAATCTGTCAAATAT 
orf19.9808|RCK2   AGAGTAGCGCTGCAACTTGTTGAAGAAGAGAATGAACAGAGAAAAAAATCTGTCAAATAT 
                  ************************************************************ 
 
orf19.2268|RCK2   CCAAACTTGGAAAATTATCAAATATTAGACCAAATGGGTGAAGGTGCTTTTTCCGTTGTT 
orf19.9808|RCK2   CCAAACTTGGAAAATTATCAAATATTAGACCAAATGGGTGAAGGTGCTTTTTCCGTTGTT 
                  ************************************************************ 
 
orf19.2268|RCK2   TATAAAGCCAAACACTTGTCGACTGGCAAAGAAGTTGCCGTCAAGATTTTGCGCAAGTTT 
orf19.9808|RCK2   TATAAAGCCAAACACTTGTCGACTGGCAAAGAAGTTGCCGTCAAGATTTTGCGCAAGTTT 
                  ************************************************************ 
 
orf19.2268|RCK2   CAAATGGACCAAGCTCAGAAACAGGCCGTACTAAAAGAAGTTACTATTATGAGGCAGTTG 
orf19.9808|RCK2   CAAATGGACCAAGCTCAGAAACAGGCCGTACTAAAAGAAGTTACTATTATGAGGCAGTTG 
                  ************************************************************ 
 
orf19.2268|RCK2   GACCACCCAAATATTGTTAGATTTATTAAATTTATCGACTCCCCAACATACTATTATATT 
orf19.9808|RCK2   GACCACCCAAATATTGTTAGATTTATTAAATTTATCGACTCCCCAACATACTATTATATT 
                  ************************************************************ 
 
orf19.2268|RCK2   GTCCAAGAATTAGTTCCTGGTGGTGAAATCTTCACTATGATTGTGAAGTATACTTATCTT 
orf19.9808|RCK2   GTCCAAGAATTAGTTCCTGGTGGTGAAATCTTCACTATGATTGTGAAGTATACTTATCTT 
                  ************************************************************ 
 
orf19.2268|RCK2   TCTGAAGATTTATCACGTTGGGTGATTACTCAAATTGCTCATGCAATAAGATATTTACAT 
orf19.9808|RCK2   TCTGAAGATTTATCACGTTGGGTGATTACTCAAATTGCTCATGCAATAAGATATTTACAT 
                  ************************************************************ 
 
orf19.2268|RCK2   GAAGAGGTTGGTATTGTCCACCGTGACATTAAGCCAGAAAATTTATTGTATGTACCTATT 
orf19.9808|RCK2   GAAGAGGTTGGTATTGTCCACCGTGACATTAAGCCAGAAAATTTATTGTATGTACCTATT 
                  ************************************************************ 
 
orf19.2268|RCK2   GACTTGAAGCCAAGTGCCAATCCTATATCGAAATTGAGAAAATCCGATGACCCAAACACT 
orf19.9808|RCK2   GACTTGAAGCCAAGTGCCAATCCTATATCGAAATTGAGAAAATCCGATGACCCAAACACT 
                  ************************************************************ 
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orf19.2268|RCK2   AAATTAGATGAAGGTGAGTTTGTGAATGGGGTTGGAGGTGGTGGAATTGGGACAGTTAAA 
orf19.9808|RCK2   AAATTAGATGAAGGTGAGTTTGTGAATGGGGTTGGAGGTGGTGGAATTGGGACAGTTAAA 
                  ************************************************************ 
 
orf19.2268|RCK2   TTAGCAGATTTTGGATTATCGAAACAAATATGGGAACATAACACCAAAACACCCTGTGGT 
orf19.9808|RCK2   TTAGCAGATTTTGGATTATCGAAACAAATATGGGAACATAACACCAAAACACCCTGTGGT 
                  ************************************************************ 
orf19.2268|RCK2   ACAGTTGGGTATACTGCTCCAGAAATTGTTCGTGATGAGCGCTATTCAAAAGAAGTTGAC 
orf19.9808|RCK2   ACAGTTGGGTATACTGCTCCAGAAATTGTTCGTGATGAGCGCTATTCAAAAGAAGTTGAC 
                  ************************************************************ 
 
orf19.2268|RCK2   ATGTGGGCGTTAGGATGTGTATTGTATACATTGTTATGTGGATTTCCACCGTTTTACGAT 
orf19.9808|RCK2   ATGTGGGCGTTAGGATGTGTATTGTATACATTGTTATGTGGATTTCCACCGTTTTACGAT 
                  ************************************************************ 
 
orf19.2268|RCK2   GAAAGAATCGAAACATTGACTGAAAAAGTTGCCAAAGGTGAATTTACATTTTTGAAACCA 
orf19.9808|RCK2   GAAAGAATCGAAACATTGACTGAAAAAGTTGCCAAAGGTGAATTTACATTTTTGAAACCA 
                  ************************************************************ 
 
orf19.2268|RCK2   TGGTGGGACGAAATAAGTGACGGAGCCAAGAATTGTGTTGGTAGGTTGTTGACTGTGGAC 
orf19.9808|RCK2   TGGTGGGACGAAATAAGTGACGGAGCCAAGAATTGTGTTGGTAGGTTGTTGACTGTGGAC 
                  ************************************************************ 
 
orf19.2268|RCK2   CCAAAAAAGAGGTACACAATTGACGAGTTTTTGCAAGACCCTTGGATGCAAAAAACTTCT 
orf19.9808|RCK2   CCAAAAAAGAGGTACACAATTGACGAGTTTTTGCAAGACCCTTGGATGCAAAAAACTTCT 
                  ************************************************************ 
 
orf19.2268|RCK2   CTTAGTCAGCAACCACAGATTCCAATACCTGTTACTAACCAATACCCACCAGCTACAAAA 
orf19.9808|RCK2   CTTAGTCAGCAACCACAGATTCCAATACCTGTTACTAACCAATACCCACCAGCTACAAAA 
                  ************************************************************ 
 
orf19.2268|RCK2   GTTGCTCATCCTATACAAGTTGCCAATAATAGATACTCCAAGAAGTTTAGATCTACCAAT 
orf19.9808|RCK2   GTTGCTCATCCTATACAAGTTGCCAATAATAGATACTCCAAGAAGTTTAGATCTACCAAT 
                  ************************************************************ 
 
orf19.2268|RCK2   TCTGATTTATATTCTCCTGCAGCTGTTGCTTGGCGCGTTGCCTTTGATATATCTACAGCC 
orf19.9808|RCK2   TCTGATTTATATTCTCCTGCAGCTGTTGCTTTGCGTGATGCCTTTGATATATCTACAGCT 
                  ******************************* *** * *********************  
 
orf19.2268|RCK2   GACCGCCGTATGGGGGATGGGGCTGCTTTGCAAACTAAAAAGCAAGCCCCAATTGCCGGT 
orf19.9808|RCK2   GTTCACCGTATGGGTGAAGAAGCTGCTTTGCAAACTAAAAAGCAAGCCCCAATTGAAGGT 
                  *  * ********* ** *  **********************************  *** 
 
orf19.2268|RCK2   TTGATTGAAGAAGAAGAAGAAGAGCACGAAGAAACAGTTACTAAGGACGGCAGAGTTGTA 
orf19.9808|RCK2   TTGATTGAAGAAGAAGAAGAAGAGCACGAAGAAACAGTTACTAAGGATGGCAGAGTTGTA 
                  *********************************************** ************ 
 
orf19.2268|RCK2   CAGGATACCTACAACCAAGTCCCAAGAACTCATCGTCATAGACATCATTTGAAAAATAAC 
orf19.9808|RCK2   CAGGATACCTACAACCAAGTCCTAAGAACTCATCGTCATAGACATCATTTGAAAAATAAC 
                  ********************** ************************************* 
 
orf19.2268|RCK2   AACAATCCAAACGCTTTTGATTTGAATCTTGGAGGTGCATCGATAATAGAACGGAGAAAG 
orf19.9808|RCK2   AACAATCCAAACGCTTTTGATTTGAATCTTGGAGGTGCATCGATAATAGAACGGAGAAAG 
                  ************************************************************ 
 
orf19.2268|RCK2   AACAAACAGATTCCTATTCAAAGCAGCTAG 
orf19.9808|RCK2   AACAAACAGATTCCTATTCAAAGCAGCTAG 
                  ****************************** 
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Table IV ORFs with significant difference between the fold difference in 
expression of alleles in more than two conditions 
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allele1                 
orf19.7732 1 1 1 0 0 1 0 1 0 1 1 1 1 1 1 1 
orf19.1265 0 1 1 0 0 1 1 1 0 0 0 1 1 1 1 1 
orf19.1945 0 1 1 1 1 1 0 1 0 0 0 0 1 0 1 1 
orf19.5863 1 1 1 1 0 1 0 0 0 0 0 0 1 1 1 1 
orf19.4135 0 1 1 1 0 0 1 1 0 0 1 0 0 1 1 1 
orf19.12579 0 1 0 0 0 1 0 1 0 0 1 1 1 1 1 1 
orf19.10016 0 0 0 1 1 0 1 0 1 0 1 0 1 1 1 1 
orf19.11836 1 1 0 0 0 1 0 1 1 0 1 0 0 1 1 0 
orf19.9253 0 1 1 1 0 1 1 1 0 0 0 1 0 0 1 0 
orf19.131 0 0 0 0 0 1 0 0 0 1 1 1 1 1 1 1 
orf19.3643 0 0 0 1 1 0 0 0 0 0 1 1 0 1 1 1 
orf19.877 0 0 0 0 0 0 0 0 0 1 1 1 1 1 1 1 
orf19.6350 0 0 0 0 1 0 0 0 0 0 1 1 1 1 1 1 
orf19.2382 1 1 1 0 0 1 0 0 0 0 0 0 1 1 0 1 
orf19.11233 0 1 1 1 1 1 1 0 1 0 0 0 0 0 0 0 
orf19.5602 0 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 
orf19.9178 0 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 
orf19.9142 0 1 1 1 1 1 0 0 0 1 0 0 0 0 0 0 
orf19.8485 0 0 0 1 1 1 0 0 0 1 0 0 0 1 1 0 
orf19.2413 0 0 0 1 1 0 1 0 0 1 1 0 0 0 0 1 
orf19.4706 1 1 0 1 0 0 0 0 1 1 0 1 0 0 0 0 
orf19.3395 0 1 1 0 0 0 0 0 0 0 1 1 0 0 1 1 
orf19.12697 0 0 0 0 0 0 1 0 1 0 1 1 0 0 1 1 
orf19.136 0 1 1 0 0 1 0 0 0 1 0 0 0 1 0 1 
orf19.5548 0 1 0 0 0 1 0 0 0 0 0 0 1 1 1 1 
orf19.9419 0 0 0 0 0 0 0 0 0 0 1 1 1 1 1 1 
orf19.1122 0 0 0 0 0 0 0 0 0 0 1 1 1 1 1 1 
orf19.723 0 0 0 0 0 1 0 1 1 0 0 0 1 1 1 0 
orf19.11750 0 0 1 0 0 1 0 1 0 0 0 1 0 1 1 0 
orf19.2445 0 1 0 1 0 0 0 0 0 1 0 0 1 0 1 0 
orf19.4635 1 0 0 1 0 0 0 0 1 0 0 1 1 0 0 0 
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orf19.12995 1 0 0 1 1 0 0 0 0 0 0 0 1 1 0 0 
orf19.11980 2 1 0 1 1 0 0 0 0 0 0 0 0 0 0 0 
orf19.11687 0 0 0 0 0 1 1 1 1 0 0 1 0 0 0 0 
orf19.13026 1 1 0 0 0 1 0 1 1 0 0 0 0 0 0 0 
orf19.9331 0 1 1 0 0 1 0 1 0 0 0 0 0 1 0 0 
orf19.1479 0 1 1 0 0 1 0 1 1 0 0 0 0 0 0 0 
orf19.2124 1 0 1 0 1 1 1 0 0 0 0 0 0 0 0 0 
orf19.4250 1 0 1 0 1 0 1 0 0 0 1 0 0 0 0 0 
orf19.12237 1 0 1 0 1 0 1 0 0 0 1 0 0 0 0 0 
orf19.1048 0 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 
orf19.2787 0 1 1 1 1 0 1 0 0 0 0 0 0 0 0 0 
orf19.1763 0 1 1 1 1 0 0 0 1 0 0 0 0 0 0 0 
orf19.11071 0 0 0 1 0 0 0 0 0 0 1 0 0 1 1 1 
orf19.13747 0 0 0 0 0 0 0 0 0 0 1 0 1 1 1 1 
orf19.13150 0 0 0 0 0 0 0 0 0 0 1 0 1 1 1 1 
orf19.8307 0 1 1 0 0 0 0 0 0 0 1 0 1 0 0 1 
orf19.2841 0 0 0 0 0 0 0 1 1 0 1 1 0 0 0 1 
orf19.1990 0 0 0 0 0 0 0 0 0 1 1 1 0 1 0 1 
orf19.10252 0 0 0 0 0 1 1 0 0 0 0 0 1 1 0 1 
orf19.6143 0 0 0 0 0 0 0 1 0 0 0 1 1 0 1 1 
orf19.14149 0 0 0 0 0 0 0 0 0 0 0 1 1 1 1 1 
orf19.4067 0 0 0 0 0 0 0 0 0 0 1 1 0 1 1 1 
orf19.2789 0 0 0 0 0 1 0 0 0 0 0 1 0 1 1 1 
orf19.11220 0 0 0 0 0 1 0 0 0 0 1 1 1 0 0 0 
orf19.1930 0 0 0 0 0 0 0 0 0 0 0 1 1 0 1 1 
orf19.13192 0 0 0 0 0 0 0 0 0 0 0 1 1 0 1 1 
orf19.13076 0 1 0 0 0 1 0 1 1 0 0 0 0 0 0 0 
orf19.12331 0 1 0 1 0 0 0 1 0 0 0 0 1 0 0 0 
orf19.5859 0 1 1 0 0 0 0 1 0 0 0 0 1 0 0 0 
orf19.2018 0 1 0 0 0 0 0 1 0 0 0 0 1 0 1 0 
orf19.8395 0 0 0 1 0 1 0 0 0 1 0 0 0 1 0 0 
orf19.12344 0 1 0 1 0 1 1 0 0 0 0 0 0 0 0 0 
orf19.12240 0 0 0 1 1 0 0 0 0 0 0 0 1 1 0 0 
orf19.5302 1 0 0 0 1 0 0 0 0 1 0 0 0 0 1 0 
orf19.3080 1 0 1 0 1 0 0 0 0 0 0 0 0 0 1 0 
orf19.9488 0 0 0 0 1 0 0 0 0 0 1 0 0 1 0 1 
orf19.11762 0 0 0 0 0 0 0 0 0 0 1 0 1 1 1 0 
orf19.9930 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 1 
orf19.7889 0 0 0 0 0 0 0 0 0 0 1 0 0 1 1 1 
orf19.5231 0 0 0 0 0 0 0 0 0 0 1 0 0 1 1 1 
orf19.4527 1 0 1 0 1 0 0 1 0 0 0 0 0 0 0 0 
orf19.10974 1 0 1 0 0 0 0 1 1 0 0 0 0 0 0 0 
orf19.8714 0 0 1 0 0 0 0 0 0 1 1 1 0 0 0 0 
orf19.11816 0 0 1 0 0 0 0 0 0 1 0 0 0 0 1 1 
orf19.7954 0 0 1 0 1 1 1 0 0 0 0 0 0 0 0 0 
orf19.3727 0 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 
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orf19.12265 0 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 
orf19.13289 0 0 0 0 0 1 1 0 0 1 0 0 0 0 0 0 
orf19.13448 1 0 0 0 0 0 1 0 0 1 0 0 0 0 0 0 
orf19.13062 1 0 0 0 0 0 1 0 0 1 0 0 0 0 0 0 
orf19.13024 0 0 0 1 1 0 0 0 0 0 0 0 0 1 0 0 
orf19.1736 0 0 0 1 1 0 1 0 0 0 0 0 0 0 0 0 
orf19.14132 0 0 0 1 1 1 0 0 0 0 0 0 0 0 0 0 
orf19.4983 1 0 0 1 0 0 0 0 0 1 0 0 0 0 0 0 
orf19.3788 1 0 0 1 0 0 0 0 1 0 0 0 0 0 0 0 
orf19.1862 0 0 0 1 0 0 0 0 0 1 0 0 0 0 0 1 
orf19.1557 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 1 
orf19.793 1 0 0 0 1 0 0 0 1 0 0 0 0 0 0 0 
orf19.4678 0 0 1 0 1 0 0 0 1 0 0 0 0 0 0 0 
orf19.4212 0 0 0 0 0 0 1 1 1 0 0 0 0 0 0 0 
orf19.12346 0 0 1 0 0 0 0 1 1 0 0 0 0 0 0 0 
orf19.3803 0 0 1 0 1 0 0 0 0 0 0 0 1 0 0 0 
orf19.8421 1 0 2 0 0 0 0 0 0 0 0 0 0 0 0 0 
orf19.10682 1 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 
orf19.1133 1 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 
orf19.11827 1 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 
orf19.5535 1 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 
orf19.3869 1 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 
orf19.11912 0 0 0 1 0 0 1 0 0 0 0 0 0 1 0 0 
orf19.11559 0 0 0 0 0 0 0 0 0 1 0 0 0 1 1 0 
orf19.8882 0 0 0 0 0 0 0 0 0 1 0 0 1 1 0 0 
orf19.4169 0 1 0 0 0 0 0 0 0 1 0 0 0 1 0 0 
orf19.5520 0 0 0 0 0 0 0 0 0 0 1 0 0 1 0 1 
orf19.12024 0 1 0 0 0 0 0 0 0 0 0 0 0 1 0 1 
orf19.10206 0 0 0 0 0 0 0 1 0 1 0 0 0 0 0 1 
orf19.8949 0 0 0 0 0 0 0 1 0 0 1 0 0 0 1 0 
orf19.193 0 1 0 0 0 0 0 1 0 0 0 0 0 0 1 0 
orf19.1148 0 0 0 0 0 0 0 0 0 0 1 0 0 0 1 1 
orf19.4972 0 0 0 0 0 0 0 0 0 0 0 0 1 0 1 1 
orf19.11726 0 0 0 0 0 0 0 0 0 0 0 1 0 0 1 1 
orf19.10952 0 0 0 0 0 0 0 0 0 1 1 0 0 0 1 0 
orf19.13909 0 0 1 0 0 0 0 1 0 0 1 0 0 0 0 0 
orf19.9554 0 0 0 0 0 0 1 0 0 1 1 0 0 0 0 0 
orf19.13616 0 0 0 0 0 0 1 0 0 0 1 0 1 0 0 0 
orf19.125 0 1 1 0 0 0 0 0 0 0 0 0 0 0 1 0 
orf19.4063 0 1 1 0 0 0 0 0 0 0 1 0 0 0 0 0 
orf19.6487 0 1 1 0 0 0 0 0 0 0 0 1 0 0 0 0 
orf19.532 0 1 1 0 0 0 0 0 0 0 0 1 0 0 0 0 
orf19.97 0 0 1 1 1 0 0 0 0 0 0 0 0 0 0 0 
orf19.113 0 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 
orf19.11957 0 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 
orf19.9088 0 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 
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orf19.251 0 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 
orf19.9403 0 1 0 1 0 1 0 0 0 0 0 0 0 0 0 0 
orf19.132 1 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 
orf19.8878 1 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 
orf19.2751 1 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 
orf19.12170 1 0 0 0 0 1 0 0 1 0 0 0 0 0 0 0 
orf19.13175 0 0 0 0 0 1 1 0 0 0 0 0 1 0 0 0 
orf19.1915 0 0 0 0 0 1 1 0 0 0 0 0 0 1 0 0 
orf19.4737 0 0 0 0 0 1 0 1 0 0 0 0 0 1 0 0 
orf19.9825 0 0 0 0 0 1 1 1 0 0 0 0 0 0 0 0 
orf19.11943 0 0 0 0 0 1 1 1 0 0 0 0 0 0 0 0 
orf19.5095 0 0 0 0 0 0 0 1 0 0 0 1 0 1 0 0 
orf19.1933 0 0 0 0 0 0 0 1 0 0 0 1 0 1 0 0 
orf19.9715 0 0 0 0 0 0 0 0 0 0 0 1 0 1 1 0 
orf19.8649 0 0 0 0 0 0 0 1 0 0 0 1 0 0 1 0 
orf19.13034 0 0 0 0 0 0 0 1 0 0 0 1 0 0 1 0 
orf19.9115 0 0 0 1 0 0 0 0 0 0 0 1 1 0 0 0 
orf19.8652 0 0 0 0 0 0 0 0 1 0 0 1 1 0 0 0 
orf19.11844 0 0 0 0 0 0 0 0 0 1 0 0 0 0 1 0 
orf19.10368 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 1 
orf19.11256 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 1 
orf19.13163 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 1 
orf19.1529 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 1 
orf19.3940 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 1 
orf19.3894 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 1 
orf19.11189 0 0 1 0 0 0 0 1 0 0 0 0 0 0 0 0 
orf19.1373 0 0 1 0 0 1 0 0 0 0 0 0 0 0 0 0 
orf19.4690 0 0 1 0 0 0 0 0 0 0 0 0 0 0 1 0 
orf19.13840 0 0 1 0 0 0 0 0 0 0 0 0 0 0 1 0 
orf19.10182 0 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 
orf19.11469 0 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 
orf19.290 0 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 
orf19.258 0 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 
orf19.12529 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 
orf19.4117 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 1 
orf19.10147 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 1 
orf19.5616 0 0 0 0 1 0 0 0 0 0 0 0 0 1 0 0 
orf19.4691 0 0 1 0 0 0 0 0 0 0 0 0 0 1 0 0 
orf19.12355 0 0 0 0 0 1 0 1 0 0 0 0 0 0 0 0 
orf19.7718 0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 
orf19.10881 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 
orf19.4607 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 
orf19.4901 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 
orf19.4689 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 
orf19.6923 0 0 1 0 0 0 0 0 0 1 0 0 0 0 0 0 
orf19.3460 0 0 1 0 0 0 0 0 0 1 0 0 0 0 0 0 
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orf19.8707 0 1 0 0 0 0 0 0 0 1 0 0 0 0 0 0 
orf19.805 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 
orf19.3158 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 
orf19.10399 0 0 0 0 0 0 1 0 0 0 0 1 0 0 0 0 
orf19.2468 0 0 0 0 0 0 0 0 0 0 0 1 0 1 0 0 
orf19.11253 0 0 0 0 0 0 0 1 0 0 0 1 0 0 0 0 
orf19.3526 0 0 0 0 0 0 0 1 0 0 0 1 0 0 0 0 
orf19.12007 0 0 0 0 0 0 0 1 0 0 0 1 0 0 0 0 
orf19.454 0 0 0 0 0 0 0 0 0 1 0 1 0 0 0 0 
orf19.1258 0 0 0 0 0 0 0 0 0 1 0 1 0 0 0 0 
orf19.8753 0 0 0 0 0 1 0 0 0 0 0 1 0 0 0 0 
orf19.7705 0 0 0 0 1 0 0 0 0 0 0 1 0 0 0 0 
orf19.11244 0 0 0 0 1 0 0 0 0 0 0 1 0 0 0 0 
orf19.1532 0 0 0 1 0 0 1 0 0 0 0 0 0 0 0 0 
orf19.10860 0 0 0 1 0 0 1 0 0 0 0 0 0 0 0 0 
orf19.1570 0 0 0 1 0 0 0 0 0 0 0 0 0 1 0 0 
orf19.728 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 1 
orf19.13019 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 
orf19.13065 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 
orf19.2781 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 
orf19.317 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 
orf19.3781 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 
orf19.3801 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 
orf19.8768 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 
orf19.6464 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 
orf19.8737 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 
orf19.11139 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 
orf19.2907 0 0 0 1 0 0 0 0 1 0 0 0 0 0 0 0 
orf19.10676 0 0 0 0 0 0 0 0 1 1 0 0 0 0 0 0 
orf19.3623 0 0 0 0 0 0 0 0 1 1 0 0 0 0 0 0 
orf19.13908 0 0 0 0 0 0 0 0 1 1 0 0 0 0 0 0 
orf19.465 0 0 0 0 0 0 1 0 1 0 0 0 0 0 0 0 
orf19.10004 0 0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 
orf19.10973 0 0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 
orf19.12171 0 0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 
orf19.1351 0 0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 
orf19.14177 0 0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 
orf19.8319 0 0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 
orf19.9012 0 0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 
orf19.8389 0 0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 
orf19.10584 0 0 0 0 0 0 0 0 1 0 0 1 0 0 0 0 
orf19.11402 0 0 0 0 0 0 0 0 1 0 0 1 0 0 0 0 
orf19.12400 0 0 0 0 0 0 0 0 1 0 0 1 0 0 0 0 
orf19.13250 0 0 0 0 0 0 0 0 1 0 0 1 0 0 0 0 
orf19.2381 0 0 0 0 0 0 0 0 1 0 0 1 0 0 0 0 
orf19.7861 0 0 0 0 0 0 0 0 1 0 0 1 0 0 0 0 
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orf19.6272 0 0 0 0 0 0 0 0 1 0 0 1 0 0 0 0 
orf19.11254 1 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 
orf19.1139 1 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 
orf19.124 1 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 
orf19.2746 1 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 
orf19.1308 1 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 
orf19.2928 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 
orf19.3535 1 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 
orf19.13615 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 
orf19.7895 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 
orf19.4470 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 
orf19.8267 1 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 
orf19.2006 1 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 
orf19.9382 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
orf19.9312 1 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 
orf19.11219 1 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 
orf19.10259 0 0 0 0 0 1 0 0 0 0 0 0 1 0 0 0 
orf19.2649 0 0 0 0 0 0 0 1 0 0 0 0 1 0 0 0 
orf19.4770 1 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 
orf19.5606 0 0 0 0 0 0 0 0 0 0 1 0 1 0 0 0 
orf19.7803 0 0 0 0 0 0 0 0 1 0 0 0 1 0 0 0 
orf19.12337 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 
orf19.9891 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 
orf19.4438 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 
orf19.10196 0 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 
orf19.11110 0 0 0 0 0 0 0 1 0 0 1 0 0 0 0 0 
orf19.1356 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 1 
orf19.477 0 0 0 0 0 0 0 0 0 0 1 0 0 0 1 0 
orf19.12970 0 0 0 0 0 0 0 0 0 0 1 0 0 0 1 0 
orf19.5518 0 0 1 0 0 0 0 0 0 0 1 0 0 0 0 0 
orf19.7688 0 0 0 0 0 0 0 0 0 1 1 0 0 0 0 0 
orf19.1120 0 0 0 0 0 0 0 0 0 1 1 0 0 0 0 0 
orf19.9748 0 0 0 0 1 0 0 0 0 0 1 0 0 0 0 0 
orf19.10310 0 0 0 0 0 0 1 0 0 0 1 0 0 0 0 0 
orf19.9706 0 0 0 0 0 0 1 0 0 0 1 0 0 0 0 0 
orf19.6014 0 0 0 0 0 0 1 0 0 0 1 0 0 0 0 0 
orf19.3170 0 0 0 0 0 0 1 0 0 0 1 0 0 0 0 0 
orf19.153 0 0 0 0 0 0 1 0 0 0 1 0 0 0 0 0 
orf19.13614 0 0 0 0 0 0 1 0 0 0 1 0 0 0 0 0 
orf19.12432 0 0 0 0 0 0 1 0 0 0 1 0 0 0 0 0 
orf19.10657 0 0 0 0 0 0 1 0 0 0 1 0 0 0 0 0 
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Table V Genes with significant disparities in fold difference of allele levels 
over a significant number of condition comparisons 
P value calculated as described in section 5.2.6. 
 
Gene 
Name Allele 1 Allele 2 
Number of 
Comparisons 
where Gene 
is Significant P value 
GPX1 orf19.87 orf19.7732 12 3.76E-17 
 
orf19.1265 orf19.8850 10 2.33E-14 
ADH2 orf19.5113 orf19.12579 9 4.00E-13 
UGA4 orf19.2479 orf19.10016 9 4.70E-13 
 
orf19.5863 orf19.13285 9 6.17E-13 
AUR1 orf19.1945 orf19.9500 9 7.36E-13 
PRC2 orf19.4135 orf19.11612 9 8.57E-13 
 
orf19.131 orf19.7777 8 6.13E-12 
 
orf19.4358 orf19.11836 8 9.26E-12 
 
orf19.1684 orf19.9253 8 1.57E-11 
 
orf19.877 orf19.8496 7 1.38E-10 
 
orf19.6350 orf19.13707 7 2.02E-10 
 
orf19.2382 orf19.9918 7 2.34E-10 
 
orf19.3643 orf19.11126 7 3.07E-10 
IFC1 orf19.3746 orf19.11233 7 3.48E-10 
BCR1 orf19.723 orf19.8342 6 3.54E-09 
 
orf19.4706 orf19.12177 6 3.60E-09 
CSI2 orf19.5232 orf19.12697 6 3.66E-09 
 
orf19.1863 orf19.9419 6 3.83E-09 
 
orf19.1122 orf19.8720 6 3.83E-09 
LYS14 orf19.5548 orf19.12994 6 4.15E-09 
 
orf19.2413 orf19.9951 6 4.89E-09 
 
orf19.136 orf19.7780 6 5.30E-09 
RAD32 orf19.866 orf19.8485 6 5.34E-09 
 
orf19.3395 orf19.10898 6 6.25E-09 
PUT1 orf19.4274 orf19.11750 6 6.29E-09 
UTP22 orf19.1569 orf19.9142 6 7.05E-09 
 
orf19.1610 orf19.9178 6 8.65E-09 
BMT6 orf19.5602 orf19.13045 6 8.65E-09 
NIP1 orf19.4635 orf19.12105 5 7.60E-08 
 
orf19.6143 orf19.13562 5 7.87E-08 
FET3 orf19.4211 orf19.11687 5 7.89E-08 
SNX4 orf19.1990 orf19.9541 5 7.94E-08 
SUL2 orf19.2738 orf19.10252 5 8.03E-08 
 
orf19.6859 orf19.14149 5 8.20E-08 
 
orf19.2445 orf19.9981 5 8.44E-08 
PGM2 orf19.2841 orf19.10359 5 8.53E-08 
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TEL1 orf19.5580 orf19.13026 5 8.62E-08 
HSP104 orf19.6387 orf19.13747 5 8.83E-08 
 
orf19.5728 orf19.13150 5 8.83E-08 
 
orf19.2789 orf19.10305 5 9.76E-08 
FGR18 orf19.4067 orf19.11550 5 1.02E-07 
 
orf19.5549 orf19.12995 5 1.14E-07 
PLB1 orf19.689 orf19.8307 5 1.16E-07 
 
orf19.1479 orf19.9054 5 1.25E-07 
 
orf19.2124 orf19.9672 5 1.31E-07 
SPO11 orf19.3589 orf19.11071 5 1.34E-07 
 
orf19.4250 orf19.11725 5 1.37E-07 
AOX2 orf19.4773 orf19.12237 5 1.37E-07 
OCA1 orf19.1762 orf19.9331 5 1.54E-07 
IFR1 orf19.1763 orf19.9332 5 1.77E-07 
PRY1 orf19.2787 orf19.10303 5 1.94E-07 
IFD6 orf19.1048 orf19.8650 5 1.96E-07 
 
orf19.3735 orf19.11220 4 1.63E-06 
CFL5 orf19.1930 orf19.9486 4 1.65E-06 
OPT8 orf19.5770 orf19.13192 4 1.65E-06 
PGA31 orf19.5302 orf19.12761 4 1.80E-06 
 
orf19.2394 orf19.9930 4 1.89E-06 
 
orf19.4286 orf19.11762 4 1.94E-06 
 
orf19.2018 orf19.9568 4 1.97E-06 
 
orf19.5631 orf19.13076 4 2.03E-06 
 
orf19.1117 orf19.8714 4 2.16E-06 
 
orf19.773 orf19.8395 4 2.18E-06 
 
orf19.4341 orf19.11816 4 2.25E-06 
 
orf19.257 orf19.7889 4 2.36E-06 
 
orf19.5231 orf19.12696 4 2.36E-06 
SWE1 orf19.4867 orf19.12331 4 2.41E-06 
 
orf19.3470 orf19.10974 4 2.42E-06 
DAL8 orf19.5859 orf19.13281 4 2.61E-06 
 
Orf19.4880 orf19.12344 4 2.66E-06 
CFL4 orf19.1932 orf19.9488 4 2.69E-06 
LYS143 orf19.4776 orf19.12240 4 2.69E-06 
 
orf19.3080 orf19.10592 4 3.08E-06 
 
orf19.322 orf19.7954 4 3.08E-06 
HGT1 orf19.4527 orf19.12002 4 3.17E-06 
PHO112 orf19.3727 orf19.11211 4 4.40E-06 
FTH1 orf19.4802 orf19.12265 4 4.40E-06 
 
orf19.1050 orf19.8652 3 3.15E-05 
 
orf19.1302 orf19.8882 3 3.22E-05 
 
orf19.6027 orf19.13448 3 3.25E-05 
 
orf19.5617 orf19.13062 3 3.25E-05 
WSC1 orf19.5867 orf19.13289 3 3.42E-05 
 
orf19.5752 orf19.13175 3 3.55E-05 
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HNM1 orf19.2003 orf19.9554 3 3.58E-05 
 
orf19.4700 orf19.12170 3 3.67E-05 
 
orf19.6236 orf19.13616 3 3.72E-05 
 
orf19.3448 orf19.10952 3 3.76E-05 
 
orf19.2691 orf19.10206 3 3.77E-05 
 
orf19.4972 orf19.12437 3 3.81E-05 
 
orf19.4078 orf19.11559 3 3.99E-05 
FET99 orf19.4212 orf19.11689 3 4.09E-05 
 
orf19.4983 orf19.12450 3 4.19E-05 
 
orf19.4169 orf19.11645 3 4.25E-05 
CAK1 orf19.793 orf19.8412 3 4.35E-05 
ZCF22 orf19.4251 orf19.11726 3 4.42E-05 
 
orf19.1541 orf19.9115 3 4.45E-05 
 
orf19.1862 orf19.9418 3 4.50E-05 
 
orf19.2285 orf19.9825 3 4.53E-05 
 
orf19.4463 orf19.11943 3 4.53E-05 
ERB1 orf19.1047 orf19.8649 3 4.62E-05 
 
orf19.5587 orf19.13034 3 4.62E-05 
SPC34 orf19.3788 orf19.11268 3 4.69E-05 
MPP10 orf19.1915 orf19.9471 3 4.71E-05 
 
orf19.1148 orf19.8740 3 4.76E-05 
 
orf19.2169 orf19.9715 3 4.81E-05 
 
orf19.5095 orf19.12561 3 4.95E-05 
 
orf19.1933 orf19.9489 3 4.95E-05 
 
orf19.1369 orf19.8949 3 4.98E-05 
TPO3 orf19.4737 orf19.12199 3 5.09E-05 
ASG7 orf19.5520 orf19.12966 3 5.10E-05 
 
orf19.193 orf19.7823 3 5.26E-05 
FGR38 orf19.4549 orf19.12024 3 5.38E-05 
 
orf19.4883 orf19.12346 3 5.70E-05 
NUP84 orf19.1298 orf19.8878 3 5.75E-05 
 
orf19.2751 orf19.10265 3 5.75E-05 
 
orf19.132 orf19.7778 3 5.75E-05 
MNN22 orf19.3803 orf19.11284 3 5.87E-05 
CPH1 orf19.4433 orf19.11912 3 6.02E-05 
 
orf19.1844 orf19.9403 3 6.03E-05 
 
orf19.4678 orf19.12147 3 6.31E-05 
 
orf19.6487 orf19.14137 3 6.35E-05 
RBR2 orf19.532 orf19.8165 3 6.35E-05 
 
orf19.1736 orf19.9304 3 6.40E-05 
TUS1 orf19.6842 orf19.14132 3 6.46E-05 
 
orf19.1557 orf19.9130 3 6.61E-05 
 
orf19.6556 orf19.13909 3 6.62E-05 
 
orf19.5535 orf19.12981 3 6.66E-05 
 
orf19.3869 orf19.11350 3 6.66E-05 
 
orf19.4349 orf19.11827 3 6.66E-05 
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MSB1 orf19.1133 orf19.8726 3 6.66E-05 
 
orf19.3172 orf19.10682 3 6.66E-05 
EBP1 orf19.125 orf19.7772 3 6.79E-05 
GPT1 orf19.4063 orf19.11546 3 6.84E-05 
 
orf19.4504 orf19.11980 5 7.15E-05 
 
orf19.5578 orf19.13024 3 7.20E-05 
FAB1 orf19.1513 orf19.9088 3 8.33E-05 
GLX3 orf19.251 orf19.7882 3 8.33E-05 
 
orf19.4476 orf19.11957 3 8.33E-05 
CIP1 orf19.113 orf19.7761 3 8.33E-05 
CAN1 orf19.97 orf19.7744 3 8.93E-05 
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Figure V Corrected sequence of RPS7A alleles  
Erroneous SNPs in the reference genome are highlighted in red, all of which 
match allele two. 
 
orf19.1700|RPS7A  ATGTCCTCTAAGATCTTATCAGAAAACCCAACTGAATTAGAATTAAAAGTTGCTCAAGCT 
orf19.9267|RPS7A  ATGTCCTCTAAGATCTTATCAGAAAACCCAACTGAATTAGAATTAAAAGTTGCTCAAGCT 
                  ************************************************************ 
 
orf19.1700|RPS7A  TTCGTTGATTTGGAATCTCAAGCTGATTTAAAAGCTGAATTGAGACCATTACAATTCAAA 
orf19.9267|RPS7A  TTCGTTGATTTGGAATCTCAAGCTGATTTAAAAGCTGAATTGAGACCATTACAATTCAAA 
                  ************************************************************ 
 
orf19.1700|RPS7A  TCTATCAAAGAAATTGATGTTAATGGAGGTAAAAAAGCTTTAGCTGTTTTCGTTCCACCA 
orf19.9267|RPS7A  TCTATCAAAGAAATTGATGTTAATGGAGGTAAAAAAGCTTTAGCTGTTTTCGTTCCACCA 
                  ************************************************************ 
 
orf19.1700|RPS7A  CCAAGTTTACAAGCTTACAGAAAAGTTCAAACTAGATTAACTAGAGAATTAGAAAAAAAA 
orf19.9267|RPS7A  CCAAGTTTACAAGCTTACAGAAAAGTTCAAACTAGATTAACTAGAGAATTAGAAAAAAAA 
                  ************************************************************ 
 
orf19.1700|RPS7A  TTCCCAGATAGACATGTTGTCTTTTTAGCTGAAAGAAGAATCTTACCAAAACCAGCTAGA 
orf19.9267|RPS7A  TTCCCAGATAGACATGTTGTCTTTTTAGCTGAAAGAAGAATCTTACCAAAACCAGCTAGA 
                  ************************************************************ 
 
orf19.1700|RPS7A  AAAGCTAGAAAACAGCAAAAAAGACCAAGATCAAGAACTTTGACTGCTGTTCATGATAAA 
orf19.9267|RPS7A  AAAGCTAGAAAACAACAAAAAAGACCAAGATCAAGAACTTTGACTGCTGTTCATGATAAA 
                  ************** ********************************************* 
 
orf19.1700|RPS7A  ATTTTGGAAGATTTAGTTTTCCCAACTGAAATCATTGGTAAAAGAGTTAGATACTTGGTT 
orf19.9267|RPS7A  ATTTTGGAAGATTTAGTTTTCCCAACTGAAATCATTGGTAAAAGAGTTAGATACTTGGTT 
                  ************************************************************ 
 
orf19.1700|RPS7A  GGTGGTAACAAAATCCAAAAAGTCTTGTTGGATTCTAAAGATTCAACTGCTGTTGATTAC 
orf19.9267|RPS7A  GGTGGTAACAAAATCCAAAAAGTCTTGTTGGATTCTAAAGATTCAACTGCTGTTGATTAC 
                  ************************************************************ 
 
orf19.1700|RPS7A  AAATTGGATTCTTTCCAACAATTGTACTCAAAATTGACTGGTAAACAAGTTGTTTTTGAA 
orf19.9267|RPS7A  AAATTGGATTCTTTCCAACAATTGTACTCAAAATTGACTGGTAAACAAGTTGTTTTTGAA 
                  ************************************************************ 
 
orf19.1700|RPS7A  ATCCCAGGTGAATCTCATTAG 
orf19.9267|RPS7A  ATCCCAGGTGAATCTCATTAG 
                  ********************* 
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Figure VI Corrected sequence of orf19.5648 alleles 
Erroneous SNPs in the reference genome are highlighted; blue corresponds to 
SNPS which match allele one and red corresponds to SNPS which match allele 
two. 
 
orf19.5648       ATGATAAACAGTGGTAATGGTTGTTGCTGTTGTTTTTTTCTTGCTGGTCGCCTTTCATAT 
orf19.13093      ATGATAAACAGTGGTAATGGTTGTTGCTGTTGTTTTTTTCTTGCTGGTCGCCTTTCATAT 
                 ************************************************************ 
 
orf19.5648       TTTTTTTTCAGATGTTGGCAAAAATGGACTGAAAAAAAAATCGAAAAAAAAGTTGAAAGC 
orf19.13093      TTTTTTTTCAGATGTTGGCAAAAATGGACTGAAAAAAAAATCGAAAAAAAAGTTGAAAGC 
                 ************************************************************ 
 
orf19.5648       TGCGGTCGTGTCTCATGTCCAAATCAAGCGTTATTGGAATTTTGGCTTATATTACATGAA 
orf19.13093      TGCGGTCGTGTCTCATGCCCAAATCAAGCGTTATTGGAATTTTGGCTTATATTACATGAA 
                 ***************** ****************************************** 
 
orf19.5648       AATTCTGAGAAGTTTCTCCATTCACCTTTTTCTTACAAGTACCGAAATATGTTTAGAATT 
orf19.13093      AATTCTGAGAAGTTTCTCCATTCACCTTTTTCTTACAAGTACCGAAATATGTTTAGAATT 
                 ************************************************************ 
 
orf19.5648       GTTGCCAGAGCCCCTAGGATACTCCCATATCGTCGATTTACCACTACCCCTAGCTTGAGG 
orf19.13093      GTTGCCAGAGCCCCTAGGATACTCCCATATCGTCGATTTACCACTACCCCTAGCTTGAGG 
                 ************************************************************ 
 
orf19.5648       TTTTTTGACAAAGGGCCTACTGCTGAAGAACAGGCCCAGGCATTGGAAAAGGTCAGTAAA 
orf19.13093      TTTTTTGACAAAGGGCCTACTGCTGAAGAACAGGCCCAGGCATTGGAAAAGGTCAGTAAA 
                 ************************************************************ 
 
orf19.5648       GTGGTTGCCGAAAACCCAGAGTTGTACAAGTTGATGGTTGAATTTAAACAGTTACTTGAA 
orf19.13093      GTGGTTGCCGAAAACCCAGAGTTGTACAAGTTGATGGTTGAATTCAAACAGTTACTTGAC 
                 ******************************************** **************  
 
orf19.5648       AAGAAAGGATTTGAAACCGGGGCAAAACCATCTATGACTCAAATGTTTAAATTGTTGGCC 
orf19.13093      CAGAAAGGGTTTGAATCATGGGCAATACCATCTATGACTCAAATGTTTAAATTGTTGGCC 
                  ******* ****** *  ****** ********************************** 
 
orf19.5648       GACAAAGATATCAGAGAACATGGTGCCAAATTCAAACACTTTTTGGAAACTACAGACACA 
orf19.13093      GACAAAGATATCAGAGAACATCGTGCCAAATTCAAACACTTGTTGGTGACTACAGACACA 
                 ********************* ******************* ****  ************ 
 
orf19.5648       GGACTCACTCAAAATGAGATCGCAACTGTAAGTGGTGCATT-TTTATTCAAAAATAAAGA 
orf19.13093      GGACTCACTCAAGATGAGATCGCAACTGTATATGGTGCATTATTTATTCAGACATGA--- 
                 ************ *****************  ********* ******** * ** *    
 
orf19.5648       TATTAAATAG 
orf19.13093      ---------- 
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Appendix II – Perl Scripts Written 
and Used 
 
# represents a comment  
 
II.I Script to identify frequency of CUG codons within an open reading 
frame 
#!usr/bin/perl/ 
# CUG_script.pl 
use strict; use warnings;  
 
#This programme takes a file containing the list of genes of interest and the 
fasta file with all sequences.  
#It outputs a file containing just the sequences of the genes of interest. 
 
die "not enough arguments\n" unless @ARGV == 3; 
#This bit makes an array of the genes of interest from file specified in 
command line-this needs to be a text file with one gene per line. 
 
open (GENELIST, "<$ARGV[0]") or die "error opening genenames for reading\n"; 
my @genes = ();     #declares empty array 
while (my $gene = <GENELIST>) { 
 chomp $gene; 
 push (@genes, $gene);    #adds genes to the array, one at a 
time 
} 
close GENELIST; 
my $length = @genes; 
print "Amount = $length\n";  # checking how many genes have been 
inputted 
 
my $i = 0; 
my $found = 0; 
while ($i < $length) { 
 open(IN, "<$ARGV[1]") or die "error opening sequence file for 
reading\n"; 
 open(OUT, ">>$ARGV[2].txt") or die "error creating file for reading"; 
  
while (my $line = <IN>) {  #goes through line by line 
  if ($line =~ /$genes[$i] /) { #matches genename from array 
@genes 
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   my $check =0;  #reset to 0 
   my $found ++;  #confirms match 
my $seq = <IN>; #makes $seq the new seq, overwrites 
previous. 
   while ($check == 0) { 
    my $nextline = <IN>;   #takes next line 
    if ($nextline =~ /^[ATGC]/){$seq = $seq.$nextline} 
         #adds it to utr 
else {$check +=1}  #stops it from taking 
nextline if not a 
sequence line 
   } 
   chomp $seq; 
   $seq =~ s/\s//g; 
$seq =~ s/\n//g;  #trying to get rid of spaces or 
newlines in utr sequence 
    
   my $count = 0; 
   for (my $i = 0; $i < length($seq) - 3 + 1; $i+= 3){ 
#sliding window  
    my $codon = substr($seq, $i, 3);  #extracts 3 bp 
    if ($codon eq "CTG")   {$count++} #if CUG 
+ 1 
   } 
   print OUT "$genes[$i]\t$count\n";  
  } 
 }  
 close IN; 
 close OUT;  
$i ++;  
print "$i\n"; 
} 
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II.II Script to identify all SNP locations in the genome 
#!usr/bin/perl/ 
#match_allele_sequence.pl 
use strict; use warnings; 
 
die "Insufficient Input Files\n" unless @ARGV == 2; #inputs - 1 = allele list. 
2 = sequence file.  
 
open(ALLELE, "<$ARGV[0]"); #open allele list 
while(my $line = <ALLELE>){ 
 open (SEQ, "<$ARGV[1]"); #open sequence file 
 open (OUT, ">>seq.txt");  
 chomp $line;  
 my @allele = split("\t",$line); #split allele list into array 
 my $allele1 = $allele[0]; 
 my $allele2 = $allele[1]; 
 my $seqcount = 0; 
 while (my $seq = <SEQ>){ #runs through sequence file 
  if ($seq =~ m/$allele1 /){ #if lines matches allele one 
   chomp $seq;  
   print OUT "$seq\n"; #print line name, new line 
   my $check = 0; 
   my $seq2 = <SEQ>;  
   while ($check == 0) { 
    my $nextline = <SEQ>;  #takes next line 
    if ($nextline =~ /^[ATGC]/){$seq2 = $seq2.$nextline} 
        #adds it to sequence 
else {$check +=1}  #stops it from taking 
nextline if not a 
sequence line 
   } 
   chomp $seq2;  
   $seqcount ++; 
   print OUT "$seq2\n";   #prints sequence in 
single line 
  } 
  elsif ($seq =~ m/$allele2 /){   #as above with allele 2 
   chomp $seq;  
   print OUT "$seq\n";  
   my $check = 0; 
   my $seq2 = <SEQ>;  
   while ($check == 0) { 
    my $nextline = <SEQ>;  #takes next line 
    if ($nextline =~ /^[ATGC]/){$seq2 = $seq2.$nextline} 
        #adds it to sequence 
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else {$check +=1}  #stops it from taking 
nextline if not a 
sequence line 
   } 
   chomp $seq2;  
   $seqcount ++; 
   print OUT "$seq2\n"; 
  } 
 } 
 close SEQ; 
 close OUT;  
  
if ($seqcount == 2){} #if loop to move on if the sequences have not been 
found for both alleles 
 else { 
  system("rm seq.txt");  
  next; 
 } 
   
 #print "Allele 1 $allele1\nAllele 2 $allele2\n";  
  
system("muscle -in seq.txt -out align.txt"); #run muscle using sequence 
file, outputting alignment 
 system("rm seq.txt"); # removes sequence file ready for next one.  
  
use Bio::SeqIO; #use of Bio::SeqIO to open file align.txt and split into 
ID, sequence and description   
 my $inseq = Bio::SeqIO->new('-file' => "align.txt",'-format' => 'fasta' 
) ; 
  
 my $seq_obj1 = $inseq->next_seq; 
 my $id1 = $seq_obj1->id ; 
 my $aligned_seq1 = $seq_obj1->seq ; 
 my $desc1 = $seq_obj1->description ; 
  
 my $seq_obj2 = $inseq->next_seq; 
 my $id2 = $seq_obj2->id ; 
 my $aligned_seq2 = $seq_obj2->seq ; 
 my $desc2 = $seq_obj2->description ; 
  
 #print "ID = $id1\nSEQ =$aligned_seq1\nID = $id2\nSEQ = 
$aligned_seq2\n"; 
   
 ### Iterate through the alignment and check for differences 
 my $pos_in_seq1 = 1; 
 my $pos_in_seq2 = 1; 
 foreach my $i (1 .. length($aligned_seq1)) { 
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  my $seq1char = substr($aligned_seq1, ($i-1), 1); 
  my $seq2char = substr($aligned_seq2, ($i-1), 1); 
   
  if ($seq1char eq $seq2char) { ### they are the same 
   $pos_in_seq1++; 
   $pos_in_seq2++; 
  } 
  elsif ($seq1char =~ m/^[a-z]$/i and $seq2char =~ m/^[a-z]$/i) { # 
SNP 
   print "$id1\t$pos_in_seq1\n$id2\t$pos_in_seq2\n";  
   $pos_in_seq1++; 
   $pos_in_seq2++; 
   ## record this as SNP position 
          } 
elsif ($seq1char =~ m/^[a-z]$/i and $seq2char =~ m/^\-$/) { # A 
deletion in 
sequence 2 
   #print "$id1\t$pos_in_seq1\n"; 
   $pos_in_seq1++; 
   #$snps_positions_in_seq1{$pos_in_seq1} = 1; 
  } 
elsif ($seq2char =~ m/^[a-z]$/i and $seq1char =~ m/^\-$/) { # A 
deletion in 
sequence 1 
             #print "$id2\t$pos_in_seq2\n";   
   $pos_in_seq2++; 
   #$snps_positions_in_seq2{$pos_in_seq2}; 
          } 
  else { 
   die "This should never happen!"; 
  } 
 }  
 system("rm align.txt"); # removes alignment file ready for next one.  
} 
 
close ALLELE; 
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II.III Script to filter mpileup file based upon SNP locations 
Written by Paul O’Neill 
 
#!/usr/bin/perl 
 
# takes input as contig \t pos and loads that value into specifies database 
 
use strict; 
use Getopt::Long; 
use IO::File; 
use PileupFunctions; 
 
my $usage = qq/ 
   Usage is:  
   findCandidateLOHRegions.pl 
     -mp|mp_file <mp_file> location of mp_file 
-ref|reference <ref.fasta>   # location of reference file (to map 
sequence names to ids) 
  -snp|snp_file <file containing SNPs. 
/; 
 
 
# process user options 
my ($mp_file, $snp_file, $reference); 
GetOptions ( 
 'ref=s'  => \$reference, 
 'mp=s'  => \$mp_file, 
 'snp=s'  => \$snp_file 
); 
 
 my $snp_fh = IO::File->new(); 
 open ($snp_fh, $snp_file) || die "Could not open file".$mp_file.": $!"; 
 
 # initialise feed for pileup   
 my $pf = new PileupFunctions($mp_file, $reference); 
 
 while (my $line = readline($snp_fh)) { 
  chomp $line; 
  my ($seq, $pos) = split ( /\t/, $line); 
  warn sprintf "%s\t%s\n", $seq, $pos; 
 
     if ( $pf->advance_to($seq, $pos)) { 
   $pf->count_frequencies; 
printf 
"%s\t%s\t%s\t%s\t%s\t%s\t%s\t%s\t%s\t%s\t%s\t%s\t%s\n", (  
    $seq, $pos, 
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    $pf->cov,  
    $pf->allele1, $pf->a1_fwd_cov, $pf->a1_rev_cov, $pf-
>a1_fwd_qual, $pf->a1_rev_qual, 
    $pf->allele2, $pf->a2_fwd_cov, $pf->a2_rev_cov, $pf-
>a2_fwd_qual, $pf->a2_rev_qual); 
  } else { 
   printf ("%s\t%s not found.\n", $seq, $pos); 
  } 
 
 } 
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II.IV Script to total reads aligned to each allele 
#!usr/bin/perl/ 
#allele_total.pl 
use strict; use warnings;  
 
die "Insufficient input files\n" unless @ARGV == 1; #input = shortened mpileup 
 
open(IN, "<$ARGV[0]");  
my %allele_total; #empty hash 
while(my $line = <IN>){ 
 chomp $line; 
 my @info = split("\t",$line); 
if(exists $allele_total{$info[0]} and $info[1] =~ /not found/){ #if gene 
is already in hash 
  next; 
 } 
 elsif(exists $allele_total{$info[0]} and $info[1] =~ /\d/){  
  $allele_total{$info[0]} += $info[2]; #add on the read count 
 } 
 elsif($info[1] =~ /not found/){ 
  $allele_total{$info[0]} = 0;  
 } 
 else{ 
  $allele_total{$info[0]} = $info[2];  
 } 
} 
close IN;  
 
#print hash 
open(OUT, ">>allele_total.txt"); 
foreach my $key (keys %allele_total){ 
 print OUT "$key\t$allele_total{$key}\n"; 
}  
close OUT; 
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II.V Script to match allele counts/RPKM values for each gene 
#!usr/bin/perl/ 
#match_pairs.pl 
use strict; use warnings;  
 
die "Insufficient Input files\n" unless @ARGV == 2; #Input 1 = allele pairs 
Input 2 = allele_counts 
 
open(PAIRS, "<$ARGV[0]"); 
while(my $line = <PAIRS>){ 
 chomp $line; 
 my @pairs = split("\t",$line); 
 my @pairedcount = (); 
 open(COUNTS, "<$ARGV[1]"); 
 open(OUT, ">>out_file.txt"); 
 while(my $line2 = <COUNTS>){ 
  chomp $line2; 
  my @counts = split("\t",$line2); 
  if ($pairs[0] eq $counts[0]){ 
   push(@pairedcount, $counts[0]); 
   push(@pairedcount, $counts[3]); 
  }  
  elsif ($pairs[1] eq $counts[0]){ 
   push(@pairedcount, $counts[0]); 
   push(@pairedcount, $counts[3]); 
  } 
 } 
 if (@pairedcount == 4){ 
 my $pairedcount = join("\t",@pairedcount); 
 print OUT "$pairedcount\n";  
 } 
 else{ 
 next; 
 } 
 close COUNTS; 
 close OUT; 
} 
close PAIRS; 
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II.VI Script to calculate RPKM values 
#!usr/bin/perl/ 
#rpkm.pl 
use strict; use warnings;  
 
die "Insufficient input files\n" unless @ARGV == 2; #Input 1 = allele count. 
Input 2 = lengths.  
 
open (COUNTS, "<$ARGV[0]"); 
while(my $line = <COUNTS>){ 
 chomp $line; 
 my @counts = split("\t",$line); 
 open (LENGTH, "<$ARGV[1]"); 
 while (my $line2 = <LENGTH>){ 
  chomp $line2; 
  my @lengths = split("\t",$line2); 
  open (OUT, ">>rpkm.txt");  
  if ($counts[0] eq $lengths[0]){ 
   my $top = $counts[1]/($lengths[1]/1000); 
   my $reads = total number of reads aligned/1000000;  
   my $rpkm = $top / $reads;  
  printf OUT "%s\t%d\t%d\t%e\n", $counts[0], $counts[1], 
$lengths[1], $rpkm,; 
   #print OUT "$rpkm\n"; 
   } 
 close OUT;  
 } 
}  
 
close COUNTS; 
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